



CPDD 81ST ANNUAL SCIENTIFIC MEETING PROGRAM


June 15 - 19, 2019

J.W. Marriott Hill Country Resort & Spa
San Antonio, Texas




Meeting Facilities Map


LEVEL 1



LEVEL 2



LEVEL 3



BOARD OF DIRECTORS

Margaret Haney, PhD, President	Deborah S. Hasin, PhD
Alan J. Budney, PhD, Past-President	Amy C. Janes, PhD
Elise Weerts, PhD, President-Elect	Frances R. Levin, MD
Jack Bergman, PhD, Treasurer	Geoffrey K. Mumford, PhD
Sandra D. Comer, PhD, Public Policy Officer	Beatriz A. Rocha, MD, PhD
Patrick M. Beardsley, PhD	Stacey C. Sigmon, PhD
F. Ivy Carroll, PhD	Mark A. Smith, PhD
Kathleen M. Carroll, PhD	William W. Stoops, PhD
Marilyn E. Carroll, PhD	Jennifer W. Tidey, PhD
Ziva Cooper, PhD	

EXECUTIVE OFFICER

Loretta P. Finnegan, MD

DIRECTOR, EXECUTIVE OFFICE

Ellen B. Geller, MA

SCIENTIFIC PROGRAM COMMITTEE

William W. Stoops, PhD, Chair
Kelly Dunn, PhD, Chair-Elect
Theresa Franklin, PhD
Sterling McPherson, PhD
Kevin B. Freeman, PhD
Gregory Collins, PhD
Cassie Gipson-Reichardt, PhD
Jillian Hardee, PhD
Stephen Kohut, PhD
Maria Parker, PhD, M.P.H.
Brian Kiluk, PhD
Silvia Martins, MD, PhD
Loretta P. Finnegan, MD ex officio
Ellen B. Geller, MA ex officio

Friday, June 14, 2019

PRE-MEETING SATELLITES

IN WOMAN'S CONFERENCE

**8:30 AM - 5:00 PM
Cibolo 8/9**

Saturday, June 15, 2019

ISGIDAR

**Grand Oaks RS
8:00 AM - 5:30 PM**

NIDA INTERNATIONAL FORUM

**Grand Oaks KL 8:30
AM - 4:45 PM**

NIDA GRANT-WRITING

**Grand Oaks O/P
1:00 PM - 5:00 PM**

REGISTRATION

**Conference Center
Registration Desk
1:30 PM - 5:30 PM**

OPENING RECEPTION

**Lawn (outside
Crooked Branch
Lobby Bar)
7:00 PM - 9:00 PM**

Sunday, June 16, 2019

PLENARY PROGRAM

Grand Oaks Ballroom K/L/M
8:00 - 11:00 AM

- 8:00 *Welcome* - CPDD President Meg Haney
- 8:15 Report from the National Institute on Drug Abuse: *Drug Abuse and Addiction Research: Progress, Priorities and Challenges*
Nora D. Volkow, Director, NIDA
- 8:45 Report from the National Institute on Alcohol Abuse and Alcoholism: *A Heuristic Domain Framework for Understanding the Prevention, Diagnosis, and Treatment of Alcohol Use Disorders*
George F. Koob, Director, NIAAA
- 9:15 *Presentation of the Stephen G. Holtzman Travel Award for Preclinical Investigators to Jacques D. Nguyen*
Introduction by Michael Taffe
- 9:20 *Presentation of the CPDD/NIDA Media Award to Elaine McMillon Sheldon*
Introduction by Meg Chisolm
- 9:35 *Presentation of The Martin & Toby Adler Distinguished Service Award to Charles O'Keeffe*
Introduction by Loretta Finnegan
- 9:40 *Presentation of the Joseph Cochin Young Investigator Award to Stephen Kohut*
Introduction by Scott Lukas
- 9:45 *Presentation of the Mentorship Award to Linda Cottler*
Introduction by Catherine Woodstock Striley
- 9:50 *Presentation of the Innovator Award to Bertha K. Madras*
Introduction by Loretta Finnegan
- 10:00 *Presentation of the Nathan B. Eddy Award to Maxine Stitzer*
Introduction by Eric Strain
- 10:15 Nathan B. Eddy Lecture: *My Brilliant Career: Behavioral Pharmacology, Contingency Management and More*
Maxine Stitzer, Johns Hopkins Bayview Medical Center

Sunday, June 16, 2019

POSTER SESSION I

Lunch

**Cibolo Ballroom
11:00 - 1:00 PM**

**Odd-numbered posters manned first hour; Even-numbered, second hour
Set-up time begins Saturday, 3:00 PM; Must be removed by Sunday, 2:30 PM**

OPIOIDS - HUMAN STUDIES I

- 1 *β -arrestin2 single nucleotide polymorphism associated with long-term consequences of opioid use*
K. Karavidha¹, S. Perrine¹, M. Burmeister², M. Greenwald¹, ¹Wayne State University, Detroit, MI, ²University of Michigan, Ann Arbor, MI
- 2 *The hidden harm: Child academic performance is negatively impacted by heroin-using parents*
Q. Ain¹, T. Lee¹, M. Dahar², ¹National Taiwan Normal University, Taipei, Taiwan, ²PMAS, Arid Agriculture University Rawalpindi, Pakistan
- 3 *The prevalence of heroin use, nonmedical opioid use, and associations with violent injury offending among US high school students, 1975-2016*
E. Jorgenson¹, S. Martins¹, E. Nesoff¹, C. Branas¹, T. Mielenz², ¹Columbia University, New York, NY, ²Columbia University Mailman School of Public Health, New York, NY
- 4 *Pathways into opioid use disorder (examination across three chronological cohorts)*
E. Zhang, R. Sterling, A. Rannazzisi, E. Loscalzo, Thomas Jefferson University, Philadelphia, PA
- 5 *Negative health behaviors contribute to the development of opioid use disorder*
C. Butrus¹, K. Green¹, J. Ickes¹, M. Reynolds², L. Kirisci¹, R. Tarter², ¹University of Pittsburgh School of Pharmacy, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
- 6 *Prescribing opioids as motivational incentives to promote health-related behaviors in patients*
A. Dunbar¹, E. Aston², K. Guthrie³, J. Merlin⁴, J. Champion⁵, K. Claborn¹, ¹University of Texas Dell Medical School, Austin, TX, ²Center for Alcohol and Addiction Studies, Providence, RI, ³The Miriam Hospital, Providence, RI, ⁴University of Alabama, Birmingham, AL, ⁵The University of Texas at Austin, Austin, TX
- 7 *Latent classes of opioid misuse motives across the US population*
T. Schepis¹, A. De Nadai¹, J. Ford², S. McCabe³, ¹Texas State University, San Marcos, TX, ²University of Central Florida, Orlando, FL, ³University of Michigan, Ann Arbor, MI
- 8 *Identifying opioid use disorder: Diagnosis code vs. natural language processing*
V. Zhu, L. Lenert, K. Barth, K. Simpson, H. Li, K. Brady, Medical University of South Carolina, Charleston, SC

Sunday, June 16, 2019

- 9 *A mixed-methods analysis of prevalence and motivations of kratom use in a sample of chronic opioid users*
M. Ellis, Z. Kasper, T. Cicero, Washington University, St. Louis, MO
- 10 *How to quit heroin and injection drug use – a cross-sectional study across 14 countries*
L. Maier¹, M. Barratt², J. Ferris³, A. Winstock⁴, ¹University of California San Francisco, San Francisco, CA, ²National Drug and Alcohol Research Centre, Sydney, Australia, ³University of Queensland, Brisbane, Australia, ⁴Global Drug Survey Ltd., London
- 11 *A qualitative investigation of addiction counselor experiences and perspectives on the implementation of an open-access medication-assisted treatment model*
L. Oberleitner¹, L. Madden², D. Muthulingam³, R. Marcus³, D. Oberleitner⁴, M. Beitel², D. Barry³, ¹Yale University, New Haven, CT, ²Yale University, APT Foundation, New Haven, CT, ³Yale University School of Medicine, New Haven, CT, ⁴University of Bridgeport, Bridgeport, CT
- 12 *The mind of the addiction counselor: A qualitative exploration of their social identity, perceived stigma, and work motivations*
D. Oberleitner¹, R. Marcus², M. Beitel³, D. Muthulingam², L. Oberleitner⁴, L. Madden³, D. Barry², ¹University of Bridgeport, Bridgeport, CT, ²Yale University School of Medicine, New Haven, CT, ³Yale University, APT Foundation, New Haven, CT, ⁴Yale University, New Haven, CT
- 13 *The hospitalist role to engage patients with opioid use disorder in treatment*
S. Calcaterra, University of Colorado, Aurora, CO
- 14 *Initiation of opioid agonist treatment for opioid use disorder (OUD) among hospital patients seen by a substance use disorder (SUD) consultation service*
C. Nordeck¹, J. Gryczynski¹, R. Schwartz¹, S. Mitchell¹, C. Welsh², K. O’Grady³, ¹Friends Research Institute, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD, ³University of Maryland, College Park, MD
- 15 *Same-and-next-day access improves linkage to outpatient MOUD care post-discharge*
P. Roy¹, S. Choi², R. Price¹, E. Bernstein¹, C. Cunningham³, A. Walley¹, ¹Boston University School of Medicine, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Montefiore Medical Center, Bronx, NY
- 16 *Who avoids formal treatment? Characterizing a group of opioid-dependent individuals*
S. Silverstein¹, R. Daniulaityte², R. Nahhas², R. Carlson², ¹Boonshoft School of Medicine Wright State University, Kettering, OH, ²Wright State University, Dayton, OH
- 17 *Recruitment and treatment exposure of participants with opioid use disorder in a national drug abuse trial network*
M. Lewis¹, L. Hu¹, C. Rosa², P. Wakim³, D. Blumberg¹, ¹The Emmes Corporation, Rockville, MD, ²National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD, ³The National Institutes of Health Clinical Center, Bethesda, MD

- 18 *Baseline characteristics of the population enrolled in, “comparing interventions for opioid-dependent patients presenting in medical EDs (ED-SBCM)”*
A. Regis¹, S. Meyers-Ohki¹, S. Mennenga¹, R. McCormack¹, R. Rapp², P. Greco¹, R. Glisker¹, R. Kolaric¹, M. Bogenschutz³, ¹New York University School of Medicine, New York, NY, ²Wright State University, Dayton, OH, ³New York University, New York, NY
- 19 *How long should pharmacotherapy last for the treatment of opioid use disorder? Results from a 12-month observational study*
W. Ling¹, V. Nadipelli², N. Ronquest², A. Aldridge³, C. Solem⁴, N. Peiper³, S. Learned², C. Heidbreder², ¹University of California Los Angeles, Los Angeles, CA, ²Indivior, Inc., Richmond, VA, ³RTI International, Research Triangle Park, NC, ⁴Pharmerit International, Bethesda, MD
- 20 *Long-term impact of medications for opioid use disorder on mortality and re-infection among those with infective endocarditis*
J. Suzuki¹, J. Johnson¹, M. Montgomery¹, M. Hayden², C. Price¹, J. Schnipper¹, J. Liebschutz³, R. Weiss⁴, ¹Brigham and Women’s Hospital, Boston, MA, ²Harvard Medical School, Belmont, MA, ³University of Pittsburgh, Pittsburgh, PA, ⁴McLean Hospital, Belmont, MA
- 21 *Non-drug pleasure in patients on opioid agonist treatment: Consummatory and anticipatory pleasure and the relationship to clinical and demographic characteristics*
S. Stull¹, J. Bertz¹, D. Epstein¹, L. Panlilio¹, B. Kowalczyk², P. Finan³, K. Preston⁴, ¹NIDA Intramural Research Program, Baltimore, MD, ²Hartwick College, Oneonta, NY, ³Johns Hopkins Hospital, Baltimore, MD, ⁴National Institute of Drug Abuse Intramural Research Program, Baltimore, MD
- 22 *Use of tramadol for long-term treatment of opioid dependence in resource-poor settings with regulatory hurdles for obtaining OST*
M. Varshney¹, S. Sarkar², R. Lal³, Y. Singh Balhara², ¹DM Addiction, New Delhi, India, ²National Drug Dependence Treatment Centre, New Delhi, India, ³All India Institute of Medical Sciences, New Delhi
- 23 *Dose-dependent naloxone-induced morphine withdrawal symptoms in opioid-dependent males— a double-blinded, randomized study*
L. Brandt¹, S. Weisshaar², B. Litschauer², S. Sheik-Rezaei², L. Moser², E. Kühberger³, U. Bauer³, C. Firbas², G. Gouya², M. Wolzt², G. Fischer⁴, ¹Columbia University, New York, NY, ²Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria, ³G. L. Pharma GmbH, Lannach, Austria, ⁴Medizinische Universität, Wien, Austria
- 24 *Emergency department utilization and cost comparison among people with opioid use disorder prior to, during and after opioid agonist therapy*
N. Jones¹, S. Larney², T. Dobbins², L. Degenhardt², M. Montebello², M. Shanahan², N. Gisev², ¹NDARC, UNSW, Sydney, Australia, ²National Drug and Alcohol Research Centre, Sydney, Australia

- 25 *Abstinence-contingent wage supplements to promote employment and abstinence in unemployed adults with opioid use disorder*
A. Holtyn¹, M. Arellano¹, M. Fingerhood², K. Silverman¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins Bayview Medical Center, Baltimore, MD

POLICY

- 26 *Pain town: An agent-based model of opioid policy effects in a small community*
G. Bobashev, W. Zule, J. Frank, RTI International, Research Triangle Park, NC
- 27 *Testing an epidemiologic theory of policy-shaped drug use onset curves*
B. Montgomery, J. Anthony, Michigan State University, East Lansing, MI
- 28 *Varying the timing and frequency of income assistance to reduce escalations in drug use coinciding with government payments: Results of a randomized controlled trial*
L. Richardson¹, A. Laing¹, E. Nosova², M. Milloy¹, J. Singer¹, E. Wood³, T. Kerr¹, ¹University of British Columbia, Vancouver, BC, Canada, ²BC Centre on Substance Use, Vancouver, BC, Canada, ³British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada
- 29 *A statewide pharmacy-based naloxone purchase trial in Massachusetts*
R. Pollini¹, Z. Xuan², T. Green³, A. Walley³, ¹West Virginia University, Morgantown, WV, ²Boston University School of Public Health, Boston, MA, ³Boston University School of Medicine, Boston, MA
- 30 *Mandated substance use disorder treatment for women: Associations with treatment retention*
D. Rivera¹, H. Amaro², ¹University of Southern California, Los Angeles, CA, ²Florida International University, Miami, FL
- 31 *National guidelines for long-term opioid therapy from around the world: A comparison with USA CDC national guidelines*
P. Sloan, University of Kentucky, Lexington, KY
- 32 *Trends in overdose and suicide following Florida's opioid-prescribing reform*
K. Feder, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 33 *Qualitative evaluation of a health justice partnership in inner-city Sydney, Australia*
M. Moensted¹, H. Coupland², R. Sharon³, B. White², C. Day³, ¹Discipline of Addiction Medicine, Faculty of Medicine and Health, University of Sydney, Sydney, Australia, ²Drug Health Services, Sydney Local Health District, Camperdown, Australia, ³University of Sydney, Sydney, Australia

PSYCHIATRIC COMORBIDITY

- 34 *Cigarette use, ENDS use, and co-use among persons with mental health problems in the US, 2014-2017: Will ENDS use impact the persistence of disparities in cigarette use by mental health status?*
A. Weinberger¹, J. Zhu², R. Goodwin², ¹Yeshiva University, New York, NY, ²The City University of New York, New York, NY
- 35 *Characteristics of patients with severe mental disorders who accept and decline a quitline intervention*
C. Martínez¹, A. Feliu¹, M. Ballbè¹, G. Nieva², N. Torres¹, C. Pinet³, A. Raich⁴, S. Mondon⁵, P. Bario⁵, R. Hernández-Ribas⁶, J. Vicens⁷, S. Subirà⁷, S. Costa³, J. Vilaplana⁸, L. Alastrue¹, E. Vilalta¹, E. Bruguera², J. Suelves⁹, M. Flores⁴, J. Bonet⁴, J. Guldish¹⁰, E. Fernández¹, ¹Catalan Institute of Oncology, L'Hospitalet, Spain, ²Hospital Vall d'Hebron, Barcelona, Spain, ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Althaia Xarxa Assistencial Universitària, Manresa, Spain, ⁵Hospital Clínic, Barcelona, Spain, ⁶Hospital Universitari de Bellvitge, L'Hospitalet, Spain, ⁷Hestia Duran i Reynals, L'Hospitalet, Spain, ⁸Universitat de Lleida, Lleida, Spain, ⁹Public Health Agency of Catalonia, Barcelona, Spain, ¹⁰University of California San Francisco, San Francisco, CA
- 36 *Anxiety sensitivity and smoking among Spanish-speaking Latinx adult smokers: The explanatory role of anxiety and depression*
J. Shepherd, J. Bakhshaie, M. Zvolensky, University of Houston, Houston, TX
- 37 *Impact of first episode psychosis treatment programs on heavy cannabis use among patients with psychosis*
K. Alcover¹, O. Oluwoye², L. Kriegel¹, S. McPherson³, M. McDonell², ¹Washington State University, Spokane, WA, ²Washington State University, Program of Excellence in Addictions Research, Spokane, WA, ³Washington State University, Elson S. Floyd College of Medicine, Spokane, WA
- 38 *Cannabis use disorder and its comorbidity with other mental health disorders*
M. Jacobs-Elliott¹, L. Cottler¹, A. Otufofowora², J. Ball³, A. Elliott¹, G. Nicolette¹, ¹University of Florida, Gainesville, FL, ²University of Florida, College of Public Health, Gainesville, FL, ³University of Florida, Department of Epidemiology, Gainesville, FL
- 39 *The relationship between life-time history of physical and sexual trauma with cannabis use in individuals with psychosis*
A. Bassir Nia¹, C. Mann², S. Spriggs², D. DeFransosco², C. Perkel², I. Galyunker², Y. Hurd², ¹Yale University School of Medicine, New Haven, CT, ²Icahn School of Medicine at Mount Sinai, New York, NY

Sunday, June 16, 2019

- 40 *Factors associated with recent involuntary emergency commitment due to mental illness among a cohort of people who inject drugs (PWID) in Los Angeles and San Francisco, CA*
K. Simpson¹, L. Wenger², J. Goldshear¹, A. Kral², R. Bluthenthal¹, ¹Keck School of Medicine, Los Angeles, CA, ²RTI International, San Francisco, CA
- 41 *Association of adverse childhood experiences on depression of substance abusers with comorbid medical illness recruited during hospitalization*
H. Philogene-Khalid¹, E. Cunningham¹, K. Nagayoshi¹, A. Brooks², M. Morrison¹, ¹Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ²Treatment Research Institute, Philadelphia, PA
- 42 *Consideration of substance use in compensation and pension examinations of veterans filing PTSD claims*
R. Jankowski¹, A. Black², C. Lazar², B. Brummett³, M. Rosen², ¹Department of Veterans Affairs, Leeds, MA, ²Yale University/VA Connecticut Healthcare System, New Haven, CT, ³Northampton VA Medical Center, Leeds, MA
- 43 *Risk of suicide attempts among veterans seeking pain care: Comorbid opioid use disorders and psychiatric disorders*
L. Ashrafioun, T. Bishop, P. Britton, VA VISN 2 Center of Excellence for Suicide Prevention, Canandaigua, NY
- 44 *Post-traumatic stress disorder and risk of prescription pain reliever misuse among World Trade Center Health Registry enrollees, 2015-2016*
E. Takemoto¹, R. Brackbill¹, S. Martins², M. Farfel¹, M. Jacobson¹, ¹New York City Department of Health and Mental Hygiene, New York, NY, ²Columbia University, New York, NY
- 45 *Do generous unemployment benefits moderate deaths of despair?*
E. Bruzelius¹, A. Baum², S. Martins³, ¹Columbia University Mailman School of Public Health, New York, NY, ²Arnhold Institute for Global Health, New York, NY, ³Columbia University, New York, NY
- 46 *Medical problems in women with comorbid PTSD and SUD by various substances use categories*
T. Killeen, C. Vrana, H. Feigl, M. Shaw, Medical University of South Carolina, Charleston, SC
- 47 *The prevalence of polysubstance use among psychiatric and emergency department patients in West Virginia*
J. Mahoney¹, J. Berry², L. Lander², E. Winstanley², P. Marshalek², M. Haut², S. Hodder², W. Kimble², M. Armistead², ¹West Virginia University School of Medicine, Morgantown, WV, ²West Virginia University, Morgantown, WV

Sunday, June 16, 2019

- 48 *Screening, brief intervention, and referral to treatment (SBIRT) to reduce alcohol and drug use: Results from a randomized-controlled trial in outpatient mental health clinics*
S. Spear¹, S. Glasner², R. Rawson³, C. Grella², R. Saitz⁴, M. Karno³, ¹California State University Northridge, Northridge, CA, ²University of California, Los Angeles, Los Angeles, CA, ³UCLA Integrated Substance Abuse Programs, Los Angeles, CA, ⁴Boston University School of Public Health, Boston, MA
- 49 *The relationship between post-traumatic stress disorder symptoms and alcohol problems is moderated by Criterion A, trauma type, and traumatic load in young adults*
N. Phillips, H. Lucke, M. Kelly, A. Cotton, N. Vora, C. Guillot, University of North Texas, Denton, TX
- 50 *Associations between post-traumatic stress and alcohol use and alcohol use motives among firefighters: The role of distress tolerance*
M. Zegel, A. Vujanovic, University of Houston, Houston, TX
- 51 *PTSD symptom severity and alcohol use in firefighters: The mediating role of anxiety sensitivity*
A. Lebeaut, A. Vujanovic, University of Houston, Houston, TX
- 52 *BDNF relations with and BDNF × stress interactions on symptoms of emotional disorders and associated features*
D. Poe¹, C. Guillot¹, M. Kelly¹, N. Phillips¹, T. Liang², M. Berman³, ¹University of North Texas, Denton, TX, ²Indiana University School of Medicine, Indianapolis, IN, ³Mississippi State University, Mississippi State, MS
- 53 *Purpose in life mediating the relationship between depression and problematic drinking in post-treatment among individuals with alcohol use disorders*
D. Knoblach, C. DiClemente, University of Maryland, Baltimore, MD
- 54 *Cluster B personality disorder symptoms are indirectly associated with hazardous drinking through positive alcohol expectancies*
H. Lucke¹, C. Guillot¹, M. Berman², ¹University of North Texas, Denton, TX, ²Mississippi State University, Mississippi State, MS
- 55 *Substance use disorder risk in individuals with autism spectrum disorder*
A. Yule, Partners Health Care, Boston, MA
- 56 *The relationship between hallucinogen use and cognitive empathy*
J. Armstrong¹, M. Pena¹, K. Moroney¹, C. Clark¹, K. Cropsey², ¹Wichita State University, Wichita, KS, ²University of Alabama, Birmingham, AL
- 57 *Mixed drug intake as predictor of mental health status, Bahir-Dar, north west Ethiopia*
A. Dagneu, University of Gondar, Gondar, Ethiopia

STIMULANTS

- 58 *Perspectives on stimulant use among 10- to 17- year-olds in six cities in the US*
D. Varma, P. Chaudhari, M. Johnson, K. Vaddiparti, C. Woodstock Striley, L. Cottler, University of Florida, Gainesville, FL
- 59 *Diversion of prescription stimulant drugs among 10-17-year-olds*
C. Woodstock Striley, M. Johnson, Y. Liu, N. Smith, K. Vaddiparti, L. Cottler, University of Florida, Gainesville, FL
- 60 *Past 30-day oral and non-oral prescription stimulant use and associated risk factors among youth aged 10-18 years-old*
Y. Liu, N. Smith, S. Lloyd, K. Vaddiparti, C. Woodstock Striley, L. Cottler, University of Florida, Gainesville, FL
- 61 *Differences in stimulant misuse motives between education level*
A. Peterkin, A. Haas, Palo Alto University, Palo Alto, CA
- 62 *Methamphetamine injection behaviors in Central Appalachia: Implications for rural harm reduction programs*
A. Young¹, H. Cooper², T. Green³, C. VanMeter³, ¹University of Kentucky, College of Public Health, Lexington, KY, ²Emory University, Atlanta, GA, ³University of Kentucky, Lexington, KY
- 63 *Direct relationship between family functioning and methamphetamine use among opioid injection drug users in Hanoi, Vietnam*
T. Dao¹, G. Le¹, T. Nguyen¹, T. Nguyen², L. Metsch³, D. Feaster⁴, ¹Hanoi Medical University, Hanoi, Viet Nam, ²Vietnam Ministry of Health, Hanoi, Viet Nam, ³Columbia University, New York, NY, ⁴University of Miami Miller School of Medicine, Miami, FL
- 64 *Severity of methamphetamine use among methadone patients in Vietnam: Prevalence and correlates*
G. Le¹, T. Dao¹, E. Okafor², M. Li², T. Nguyen¹, T. Nguyen³, S. Shoptaw², ¹Hanoi Medical University, Hanoi, Viet Nam, ²University of California Los Angeles, Los Angeles, CA, ³Vietnam Ministry of Health, Hanoi, Viet Nam
- 65 *Contingency management treatment for methamphetamine use disorder in Cape Town, South Africa*
E. Okafor, S. Shoptaw, University of California Los Angeles, Los Angeles, CA
- 66 *Nested case-control analysis of real world healthcare data evaluating medications to be repurposed for stimulant use disorders*
E. Hankosky¹, D. Harris¹, L. Cottler², G. Zhang¹, H. Bush¹, P. Freeman¹, J. Talbert¹, L. Dwoskin¹, ¹University of Kentucky, Lexington, KY, ²University of Florida, Gainesville, FL

Sunday, June 16, 2019

- 67 *Safety of oral lisdexamfetamine in adults with methamphetamine dependence: A dose-escalating phase-2 study*
N. Ezard¹, A. Dunlop², B. Clifford¹, R. Bruno³, K. Siefried⁴, A. Carr¹, N. Lintzeris⁵, ¹St. Vincent's Hospital / UNSW, Darlinghurst, Australia, ²Hunter New England Local Health District, Newcastle, Australia, ³University of Tasmania, Hobart, Australia, ⁴The National Centre for Clinical Research on Emerging Drugs, Sydney, Australia, ⁵South Eastern Sydney Local Health District, Surry Hills, Australia
- 68 *High-energy phosphates restoration after eight weeks of creatine supplementation in female methamphetamine users*
Y. Sung, X. Shi, L. Scholl, D. Kondo, D. Yurgelun-Todd, P. Renshaw, The University of Utah, Salt Lake City, UT
- 69 *Prevalence and correlates of problematic caffeine use in a US nationwide sample*
M. Sweeney¹, D. Weaver¹, K. Vincent², A. Arria², R. Griffiths¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Maryland, School of Public Health, College Park, MD
- 70 *Caffeine enhances sustained attention among adolescents*
R. Cooper¹, S. Lawson¹, W. Phyo¹, M. Jusko², S. Tonkin¹, A. Ziegler¹, J. Temple¹, L. Hawk¹, ¹University at Buffalo, Buffalo, NY, ²University at Buffalo, Miami, FL

THEORETICAL / COMMENTARY

- 71 *Information on the rising rates of cocaine and amphetamine interdiction, trafficking, use, and overdose deaths*
D. Carise, Recovery Centers of America & University of Pennsylvania, Conshohocken, PA
- 72 *Considerations in opioid comparator selection in epidemiology studies evaluating the effectiveness of abuse-deterrent opioids*
N. Sessler¹, R. Rodriguez¹, R. Kapil¹, S. Baldrige¹, S. Schnoll², R. Dart³, M. Bigal¹, ¹Purdue Pharma LP, Stamford, CT, ²Pinney Associates, Inc., Bethesda, MD, ³Rocky Mountain Poison & Drug Center, Denver, CO
- 73 *Examining opioid prescription patterns in safety-net clinics using electronic health records*
J. Muench, S. Bailey, D. Hartung, G. Barker, D. Wright, N. Huguet, C. Tillotson, J. O'Malley, R. Voss, M. Ukhanova, I. Chamine, Oregon Health & Science University, Portland, OR
- 74 *Family interventions addressing expressed emotions in opioid substitution therapy (OST)*
V. Singh, G. Kalojya, A. Ambekar, R. Rao, A. Mishra, National Drug Dependence Treatment Centre, New Delhi, India
- 75 *Some issues of concept, theory, and approach in research on heroin use and mood disturbances*
A. Vanderziel, J. Anthony, Michigan State University, East Lansing, MI
- 76 *Carisoprodol: Concomitant use and abuse with opioids*
G. Hawkins, N. Horner, S. Bansil, US Food and Drug Administration, Silver Spring, MD

Sunday, June 16, 2019

- 77 *Naltrexone as a novel treatment strategy for nitrous oxide use disorder*
S. Ickowicz, R. Brar, S. Nolan, University of British Columbia, Vancouver, BC, Canada
- 78 *Increasing access to naloxone: The scientific strategy needed to bring naloxone over-the-counter*
J. Ashworth¹, M. Hufford², B. Simone¹, S. Schnoll¹, E. Cone¹, A. Arthur¹, J. Pinney¹, J. Henningfield¹, ¹Pinney Associates, Inc., Bethesda, MD, ²Harm Reduction Therapeutics, Pittsburgh, PA
- 79 *Mechanisms of action of most interest to the National Institute on Drug Abuse for the potential treatment of opiate use disorder*
D. White, J. Acri, K. Rasmussen, National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD
- 80 *Pay for outcomes: How it might work in substance use disorder treatment*
D. Hodgkin¹, C. Horgan¹, D. Garnick², A. Busch³, M. Stewart², S. Reif¹, ¹Brandeis University, Heller School for Social Policy and Management, Waltham, MA, ²Brandeis University, Waltham, MA, ³Department of Health Care Policy, Harvard Medical School, Boston, MA
- 81 *Multi-site clinical trials and use of a single IRB: A case study from CTN 0067*
C. Nichols¹, L. Kunkel¹, R. Baker¹, E. Jelstrom², M. Addis³, K. Hoffman¹, D. McCarty¹, P. Korthuis¹, ¹Oregon Health & Science University, Portland, OR, ²The Emmes Corporation, Alexandria, VA, ³Kaiser Permanente Washington Health Research Institute, Seattle, WA
- 82 *Scheduling synthetic cathinone substances under the Controlled Substances Act*
K. Bonson¹, D. Chiapperino², ¹US Food and Drug Administration, Silver Spring, MD, ²U.S. Food and Drug Administration, Silver Spring, MD
- 83 *A suggestion for the design of qualification phase in human abuse potential studies*
L. Chen, US Food and Drug Administration, Silver Spring, MD
- 84 *Increasing minority participation and diversity in CPDD and ACNP meetings and membership: 2019 status and recommendations*
J. Henningfield¹, L. Brown², S. Comer³, A. Garcia-Romeu⁴, D. Hatsukami⁵, D. Furr-Holden⁶, ¹Pinney Associates, Inc., Bethesda, MD, ²START Treatment & Recovery Centers, Brooklyn, NY, ³Columbia University and NYSPI, New York, NY, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵University of Minnesota Medical School, Minneapolis, MN, ⁶Michigan State University, East Lansing, MI
- 85 *A streamlined approach to the acquisition, analysis and databasing of data from drug self-administration sessions*
H. Wetzel¹, A. Norman², ¹University of Cincinnati, Cincinnati, OH, ²University of Cincinnati, College of Medicine, Cincinnati, OH
- 86 *Considerations for the use of male and female animals in behavioral abuse potential studies during drug development*
J. Randall-Thompson, G. Hawkins, S. Calderon, D. Chiapperino, US Food and Drug Administration, Silver Spring, MD

Sunday, June 16, 2019

- 87 *Drug discrimination cannabinoid validation in the female Lister hooded rat*
S. Rowton, Covance Laboratories, Harrogate, North Yorkshire, United Kingdom

BEHAVIOR

- 88 *Ovarian hormones mediate acquisition of nicotine self-administration and accumbens glutamatergic plasticity*
J. Jackson, J. Pina, H. Ulangkaya, H. Bimonte-Nelson, C. Gipson-Reichardt, Arizona State University, Tempe, AZ
- 89 *Effects of a blueberry flavor reinforcer on nicotine self-administration in rats*
M. Palmatier¹, A. Smith¹, C. Ponder-Cepeda¹, D. Harryman¹, C. Majors¹, J. Marusich², ¹East Tennessee State University, Johnson City, TN, ²RTI International, Research Triangle Park, NC
- 90 *Investigating the sensitivity to $\alpha 4\beta 2$ compounds using nicotine drug discrimination in enriched and impoverished rats*
D. Stairs, K. Holter, W. Ramsey, M. Hamersky, Creighton University, Omaha, NE
- 91 *A novel metabotropic glutamate receptor 2 positive allosteric modulator, SBI-0069330, attenuates nicotine taking and nicotine seeking in rats*
X. Li¹, N. Cosford², G. Velicelebi², R. Gadiant², J. Hutchinson², R. Dhanya², D. Sheffler², R. Anthenelli³, ¹University of California San Diego, La Jolla, CA, ²Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, ³University of California San Diego, La Jolla
- 92 *The role of accumbens serotonin transport and GluN2B-containing NMDA receptors in nicotine relapse*
J. Jackson, J. Pina, J. McCallum, H. Ulangkaya, C. Gipson-Reichardt, Arizona State University, Tempe, AZ
- 93 *An investigation of the reinforcing potential of PN6047 by conditioned place preference testing in rats*
J. Palandri¹, D. Heal², C. Bailey¹, D. Kendall³, ¹University of Bath, Bath, United Kingdom, ²RenaSci Ltd, Nottingham, United Kingdom, ³PharmNovo AB, Kungshamn, Sweden
- 94 *A novel neuropeptide decreases opioid self-administration*
J. Kasper, K. Cunningham, J. Hommel, University of Texas Medical Branch, Galveston, TX
- 95 *Molecular mechanisms underlying incubation of morphine craving in Long Evans rats*
H. Mayberry¹, S. Downey¹, S. Bhakta¹, A. Bongiovanni¹, A. Ellis², A. Toussaint¹, M. Wimmer¹, ¹Temple University, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA
- 96 *Behavioral characterization of voluntary heroin vapor exposure in female rats*
A. Gutierrez, J. Nguyen, M. Taffe, The Scripps Research Institute, La Jolla, CA
- 97 *Development of a human Pavlovian conditioned approach paradigm*
L. Cope¹, A. Gheidi², T. Allerton¹, A. Drumheller¹, H. Khalil¹, J. Morrow¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Medical School, Ann Arbor, MI

- 98 *Development and initial validation of the TERM: A temporally extended reinforcer measure*
A. Mellis¹, W. Bickel², ¹Virginia Tech Carilion Research Institute, Roanoke, VA, ²Fralin Biomedical Research Institute at VTC, Roanoke, VA

SEX/GENDER

- 99 *Acquisition of remifentanyl self-administration: Assessing the role of sex and stress exposure in male and female rats*
D. Thorpe¹, R. Lacy², ¹Stony Brook University, Lake Grove, NY, ²Franklin and Marshall College, Lancaster, PA
- 100 *Characterization of oxycodone self-administration and withdrawal-associated negative affect in male and female rats*
S. Guha¹, N. Constantino², E. Chartoff¹, ¹McLean Hospital, Harvard Medical School, Belmont, MA, ²McLean Hospital, Belmont, MA
- 101 *An evidence-based evaluation of the possible influence of gender on results from abuse and dependence liability testing in rats*
D. Heal, J. Gosden, S. Smith, RenaSci Ltd, Nottingham, United Kingdom
- 102 *Childhood sensation-seeking and problem gambling in young adulthood: Sex matters*
N. Levy¹, C. Duarte², L. Segura³, J. Santaella-Tenorio¹, M. Okuda Benavides², M. Wall², C. Chen², M. Ramos-Olazagasti², G. Canino⁴, H. Bird⁴, S. Martins³, ¹Columbia University Mailman School of Public Health, New York, NY, ²Columbia University and NYSPI, New York, NY, ³Columbia University, New York, NY, ⁴University of Puerto Rico, San Juan, Puerto Rico
- 103 *Sex differences in subjective effects of cigarette-smoking following nicotine patch*
Y. Zakiniaez, Yale University, New Haven, CT
- 104 *Women-reported barriers and facilitators of adherence to medications for opioid use disorder*
A. Fiddian-Green, E. Evans, University of Massachusetts Amherst School of Public Health and Health Sciences, Amherst, MA
- 105 *Current unmet addiction treatment needs among reproductive-aged women*
C. Martin, A. Scialli, M. Terplan, Virginia Commonwealth University, Richmond, VA
- 106 *Unmet addiction treatment need in the US: Is there a gender difference?*
C. Martin, A. Scialli, M. Terplan, Virginia Commonwealth University, Richmond, VA
- 107 *Meta-analysis of sex differences in completed NIDA Clinical Trials Network studies*
S. Mennenga¹, S. Greenfield², D. Feaster³, M. Bogenschutz⁴, J. Rotrosen¹, ¹New York University School of Medicine, New York, NY, ²McLean Hospital, Harvard Medical School, Belmont, MA, ³University of Miami Miller School of Medicine, Miami, FL, ⁴New York University, New York, NY

Sunday, June 16, 2019

- 108 *The role of age and sex in patients on medication assisted therapy for opiate use disorder*
G. Hermes¹, R. Sinha¹, L. Madden², D. Barry¹, V. Milivojevic¹, ¹Yale University School of Medicine, New Haven, CT, ²Yale University, APT Foundation, New Haven, CT
- 109 *Sex differences in injecting drug use among newly incident users of cocaine and heroin in the US (2002-2016)*
M. Chandra¹, J. Anthony, East Lansing, MI, ¹Michigan State University, East Lansing, MI
- 110 *Time of escalation of drug use in persons dually diagnosed with opioid and cocaine dependence: Gender differences and dimensional correlates*
K. Brown, C. Chen, R. Conybeare, E. Butelman, M. Kreek, The Rockefeller University, New York, NY
- 111 *Examining the relationship between trait resilience, sex and addiction severity among individuals with opioid use disorder*
S. Martinez¹, J. Jones², D. Hien³, S. Comer¹, ¹Columbia University and NYSPI, New York, NY, ²Columbia University College of Physicians and Surgeons, New York, NY, ³Center of Alcohol Studies, Rutgers University-New Brunswick, Piscataway, NJ
- 112 *Sexual risk among substance using African Americans with a main partner*
C. McCuistian, B. Peteet, A. Burlew, B. Miller-Roenigk, University of Cincinnati, Cincinnati, OH
- 113 *Sex differences in prescription (Rx) opioid use patterns among community members in north central Florida*
M. Serdarevic, C. Woodstock Striley, K. Gurka, R. Leeman, L. Cottler, University of Florida, Gainesville, FL
- 114 *Sex differences in driving under the influence of marijuana: The role of medical and recreational marijuana use*
S. Lloyd, C. Lopez-Quintero, C. Woodstock Striley, University of Florida, Gainesville, FL

PRESIDENT'S SYMPOSIUM

**IMPACT OF TOBACCO USE ON SUBSTANCE USE
DISORDERS: MECHANISM TO EPIDEMIOLOGY**

**Grand Oaks K/L
1:00 - 2:00 PM**

Tobacco smoking associated with increased risk of cannabis relapse
Margaret Haney, Columbia University Irving Medical Center

*Tobacco use and the progression, persistence and relapse
of substance use disorders: An epidemiologic perspective*
Renee Goodwin, CUNY School of Public Health and Health Policy

From one experience to another; a molecular analysis of smoking and subsequent drug use
Amir Levine, Columbia University Irving Medical Center

Discussant - Jennifer Tidey, Brown University

LATE BREAKING I

Grand Oaks K/L
2:15 - 3:15 PM

Chair: William Stoops

- 2:15 *Association between current opioid agonist therapy use and positive urine drug screen for fentanyl*
S. Young¹, K. Hayashi², T. Kerr³, M. Milloy³, K. DeBeck⁴, E. Nosova³, E. Wood⁵, N. Fairbairn³, ¹Research in Addiction Medicine Scholars Program, Vancouver, BC, Canada, ²Simon Fraser University, Vancouver, BC, Canada, ³BC Centre on Substance Use, Vancouver, BC, Canada, ⁴British Columbia Centre on Substance Use, Vancouver, BC, Canada, ⁵British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada
- 2:20 *Injectable weekly and monthly buprenorphine in the outpatient treatment of fentanyl users with opioid use disorder (OUD)*
E. Nunes¹, S. Comer², M. Lofwall³, S. Walsh⁴, S. Peterson⁵, N. Budilovsky-Kelley⁶, F. Tiberg⁵, S. Kim⁶, ¹Columbia University and New York State Psychiatric Institute, New York, NY, ²Columbia University and NYSPI, New York, NY, ³University of Kentucky, College of Medicine, Lexington, KY, ⁴University of Kentucky, Lexington, KY, ⁵Camurus, Lund, Sweden, ⁶Braeburn, Plymouth Meeting, PA
- 2:25 *ED-initiated buprenorphine in low-resource, high-need emergency departments (NIDA CTN-0079)*
R. McCormack¹, J. Rotrosen¹, G. D'Onofrio², P. Gauthier³, D. Fiellin², L. Marsch³, E. Edelman², E. Coupet², R. Knight⁴, W. Goodman⁵, P. Novo¹, S. Farkas¹, D. Liu⁶, K. Huntley⁶, K. Hawk⁷, ¹New York University School of Medicine, New York, NY, ²Yale University School of Medicine, New Haven, CT, ³Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁴Valley Regional Hospital, Claremont, NH, ⁵Catholic Medical Center, Manchester, NH, ⁶National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD, ⁷Yale University Department of Emergency Medicine, New Haven, CT
- 2:30 *Community pharmacy-led intervention for opioid medication misuse*
G. Cochran¹, F. Craig², V. Hruschak³, A. Seybert³, A. Gordon¹, R. Tarter³, ¹University of Utah, Salt Lake City, UT, ²University of Texas, El Paso, El Paso, TX, ³University of Pittsburgh, Pittsburgh, PA
- 2:35 *Butyrylcholinesterase inhibitors exhibit efficacy in patients against-opioid induced overdose events*
A. Williams, E. Hankosky, C. Zhan, J. Talbert, University of Kentucky, Lexington, KY

Sunday, June 16, 2019

- 2:40 *A large-scale reward-related brain network abnormality in treatment-seeking prescription opioid-dependent individuals*
S. Ray¹, R. Mill¹, E. Winfield¹, M. Cole¹, D. Hien², ¹Rutgers University, Newark, NJ, ²Center of Alcohol Studies, Rutgers University-New Brunswick, Piscataway, NJ
- 2:45 *Brain reward system response to infant portraits is correlated with mother-child bonding in women with opioid use disorder*
Z. Shi¹, J. Padley², C. Aronowitz², A. Wang², A. Childress³, D. Hand⁴, D. Abatemarco⁴, D. Langleben⁵, ¹Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania Perelman School Medicine, Philadelphia, PA, ⁴Thomas Jefferson University, Philadelphia, PA, ⁵Veterans Administration, Philadelphia, PA
- 2:50 *The effects of inhaled salvinorin A on resting state functional connectivity in humans*
M. Doss¹, R. Griffiths², D. May³, M. Johnson², J. Clifton¹, F. Barrett², ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 2:55 *Sex differences in functional connectivity of large-scale neural networks and tobacco withdrawal-related states*
A. Donis¹, M. Perez Diaz², D. Ghahremani², P. Faulkner², A. Dean², G. Hellemann³, E. London², ¹UCLA, Los Angeles, CA, ²University of California Los Angeles, Los Angeles, CA, ³Semel Institute, UCLA, Los Angeles, CA
- 3:00 *Evaluation of the abuse liability of very low nicotine content cigarettes with characterization of nicotine exposure profiles in adult smokers*
N. Levy-Cooperman¹, M. Shram¹, D. Kelsh², B. Vince², E. Carmines³, ¹Altreos Research Partners Inc., Toronto, ON, Canada, ²Vince and Associates, Malvern, PA, ³Carmines Consulting, LLC, Scottsdale, AZ
- 3:05 *How and why adolescents and young adults are using different pod-type e-cigarettes*
K. McKelvey, B. Halpern-Felsher, Stanford University School of Medicine, Palo Alto, CA
- 3:10 *Smoking is associated with inflammation and increased B-cell proportion in peripheral blood in older African American smokers*
A. Andersen¹, R. Philibert¹, M. Lei², S. Beach², ¹University of Iowa, Iowa City, IA, ²University of Georgia, Athens, GA

ORAL COMMUNICATIONS 1 TEN GALLON HATS OFF TO THE VETS

**Grand Oaks M
2:15 - 3:15 PM**

Chair: Ajay Manhapra

- 2:15 *Impact of bodily pain on substance use over time among Reserve and National Guard soldiers*
B. Vest, R. Hoopsick, D. Homish, G. Homish, State University of New York at Buffalo, Buffalo, NY

Sunday, June 16, 2019

- 2:30 *Opioid use disorder and risk of homelessness nationally in the Veterans Health Administration*
A. Manhapra¹, E. Stefanovics², R. Rosenheck³, ¹Yale University School of Medicine, New Haven, CT, ²Department of Psychiatry, Yale School of Medicine, West Haven, CT, ³Yale University Department of Psychiatry, New Haven, CT
- 2:45 *Overdose events in homeless-experienced veterans: A common event in new survey data*
S. Kertesz¹, K. Riggs¹, A. Gordon², A. deRussy¹, A. Montgomery¹, S. Holmes¹, A. Jones³, E. Austin⁴, L. Gelberg⁵, S. Gabrielian⁶, A. Hoge¹, A. Varley⁴, D. Pollio⁴, J. Merlin⁷, J. Blosnich⁸, ¹Birmingham VA Medical Center, Birmingham, AL, ²University of Utah, Salt Lake City, UT, ³VA Salt Lake City Health Care System, Salt Lake City, UT, ⁴University of Alabama, Birmingham, AL, ⁵University of California, Department of Family Medicine, Los Angeles, CA, ⁶VA Greater Los Angeles Healthcare System, Los Angeles, CA, ⁷University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁸VA Pittsburgh Healthcare System, Pittsburgh, PA
- 3:00 *Psychosocial treatment reduces cost of crime among homeless veterans with substance use disorders*
E. Santa Ana¹, L. Dismuke¹, K. Lamb², K. Beavis¹, M. Ardel¹, N. Swinton-Jenkins¹, ¹Ralph H. Johnson VA Medical Center, Charleston, SC, ²Charleston VAMC, Charleston, SC

SYMPOSIUM I MINDFULNESS INTERVENTIONS IN THE TREATMENT OF MATERNAL SUBSTANCE USE

**Grand Oaks E/F
2:15 - 3:15 PM**

Chair: Karol Kaltenbach

- 2:15 *Overview of parenting quality and its relationship to comprehensive maternal substance use treatment*
K. Kaltenbach, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA
- 2:35 *Outcomes of mindfulness-based interventions in the treatment of maternal substance use*
D. Abatemarco¹, K. Kaltenbach², M. Mackenzie³, V. Short¹, M. Gannon¹, ¹Thomas Jefferson University, Philadelphia, PA, ²Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, ³University of Delaware, Newark,
- 2:55 *Predicting change in mindfulness-based outcomes: A multilevel modeling approach*
M. Mackenzie, University of Delaware, Newark, DE

Sunday, June 16, 2019

**SYMPOSIUM II
DEVELOPING AND INVESTIGATING
RODENT MODELS OF COMPULSIVE DRUG USE**

**Grand Oaks H
2:15 - 3:15 PM**

Chairs: Cody Siciliano and Erin Calipari

- 2:15 *A novel mouse model for tracking individual differences in compulsion vulnerability*
C. Siciliano, Massachusetts Institute of Technology, Cambridge, MA
- 2:35 *Cues play a critical role in addiction vulnerability in females*
E. Calipari, Vanderbilt University, Nashville, TN
- 2:55 *Withdrawal-induced escalated oxycodone self-administration is mediated by kappa opioid receptor function*
M. Taffe, The Scripps Research Institute, La Jolla, CA

**SYMPOSIUM III
PERIPHERAL MECHANISMS INVOLVED IN THE
DEVELOPMENT OF OPIOID TOLERANCES**

**Grand Oaks G
2:15 - 3:15 PM**

Chairs: William Dewey and Hamid Akbarali

- 2:15 *The guts of the opioid crisis*
H. Akbarali, Virginia Commonwealth University, Richmond, VA
- 2:35 *The role of the microbiome in morphine tolerance*
S. Roy, University of Miami, Miami, FL
- 2:55 *Morphine-mediated downregulation of miR-152 activates astrocytes via NLRP6 inflammasome signaling*
P. Periyasamy, University of Nebraska Medical Center, Omaha, NE

COFFEE BREAK

**Cibolo Ballroom
3:15 - 3:45 PM**

**ORAL COMMUNICATIONS 2
LIFTING THE FOG ON CANNABINOIDS**

**Grand Oaks
3:45 - 5:45 PM**

Chairs: Scott Lukas and Tory Spindle

- 3:45 *Pharmacological effects of AMB-FUBINACA (FUB-AMB) and related 'spice' compounds in mice lacking cannabinoid-1 receptor (CB1R) alleles*
M. Baumann¹, J. Partilla¹, T. Prisinzano², J. Fedorko¹, N. Garibay¹, ¹NIDA Intramural Research Program, Baltimore, MD, ²University of Kansas, Lawrence, KS

Sunday, June 16, 2019

- 4:00 *Are acute effects more extreme with higher-potency cannabis? A within-person comparison of marijuana and butane hash oil*
S. Okey, M. Meier, Arizona State University, Tempe, AZ
- 4:15 *Chronic cannabinoid treatment affects discrimination learning in adolescent nonhuman primates*
S. Withey¹, B. Kangas², J. Bergman³, B. Madras¹, ¹McLean Hospital, Harvard Medical School, Belmont, MA, ²Harvard Medical School, Belmont, MA, ³McLean Hospital, Belmont, MA
- 4:30 *Detection of cognitive impairment associated with cannabis intoxication via dynamic brain functional connectivity*
Y. Zhu¹, M. Sabuncu¹, J. Gilman², A. Evins², ¹Cornell University, Ithaca, NY, ²Massachusetts General Hospital-Psychiatry, Boston, MA
- 4:45 *Associations between delay discounting and measures of cannabis use frequency in a large sample of cannabis users*
M. Sofis¹, C. Stanger¹, A. Knapp², J. Borodovsky³, A. Budney², ¹Dartmouth College, Hanover, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Washington University School of Medicine, St. Louis, MO
- 5:00 *Residual impact of heavy recreational marijuana use without acute intoxication on driving performance*
M. Dahlgren¹, K. Sagar², R. Smith², A. Lambros², M. Kuppe², L. Patriarca², S. Gruber¹, ¹McLean Hospital, Harvard Medical School, Belmont, MA, ²McLean Hospital, Belmont, MA
- 5:15 *MRS metabolic profiling of marijuana users during the initial phase of abstinence*
S. Lukas¹, K. Davis², M. Kuppe³, S. Gruber¹, C. Zuo¹, ¹McLean Hospital, Harvard Medical School, Belmont, MA, ²McLean Hospital, Brain Imaging Center, Belmont, MA, ³McLean Hospital, Belmont, MA
- 5:30 *Assessment of impairment following oral and vaporized cannabis administration in infrequent cannabis users*
T. Spindle¹, M. Grabenauer², E. Martin¹, R. Vandrey¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²RTI International, Research Triangle Park, NC

ORAL COMMUNICATIONS 3 THIS IS YOUR BODY ON DRUGS: HEALTH CONSEQUENCES

**Grand Oaks M
3:45 - 5:45 PM**

Chairs: Luis Segura and William Stoops

- 3:45 *The effects of naloxone-precipitated opioid withdrawal on the parasympathetic nervous system*
J. Wai¹, C. Levin², J. Jones³, J. Kaicher⁴, S. Comer⁵, ¹Columbia University Medical Center, New York, NY, ²NYSPI, New York, NY, ³Columbia University College of Physicians and Surgeons, New York, NY, ⁴Columbia University, New York, NY, ⁵Columbia University and NYSPI, New York, NY

Sunday, June 16, 2019

- 4:00 *Nonmedical prescription opioids use, heroin use, and cardiovascular disease*
L. Segura¹, N. Levy², A. Perlmutter¹, S. Martins¹, ¹Columbia University, New York, NY,
²Columbia University Mailman School of Public Health, New York, NY
- 4:15 *Neurochemical and cardiovascular effects of alpha-ethylphenethylamine analogs found in dietary supplements*
C. Schindler¹, E. Thorndike¹, J. Partilla¹, K. Rice², M. Baumann¹, ¹NIDA Intramural Research Program, Baltimore, MD, ²National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD
- 4:30 *Relationship of cardiac health indicators to cocaine use variables*
W. Stoops¹, J. Strickland¹, J. Havens², T. Sexton¹, J. Lile², C. Rush¹, S. Smyth¹, ¹University of Kentucky, Lexington, KY, ²University of Kentucky, College of Medicine, Lexington, KY
- 4:45 *Behavioral and health consequences of cannabis and tobacco co-use among cannabis-using young adults*
C. Wong¹, E. Iverson¹, B. Conn¹, S. Mendez², E. Fedorova³, S. Lankenau⁴, ¹Children's Hospital Los Angeles, Los Angeles, CA, ²USC University Center for Excellence in Developmental Disabilities, Los Angeles, CA, ³Drexel University, Philadelphia, PA, ⁴Drexel University Dornsife School of Public Health, Philadelphia, PA
- 5:00 *Regular cannabis use is associated with adverse cardiovascular outcomes: Electronic health record findings*
T. Winhusen¹, J. Theobald¹, D. Kaelber², D. Lewis¹, ¹University of Cincinnati, Cincinnati, OH, ²MetroHealth, Shaker Heights, OH
- 5:15 *High prevalence of hypocapnia among healthy cigarette smokers*
A. Umbricht¹, D. Huggins¹, N. Schlienz², S. Reed¹, M. Velez¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²State University of New York at Buffalo, Buffalo, NY
- 5:30 *Results of implementing objective measurement of smoking status at cardiac rehabilitation*
D. Gaalema¹, P. Savage², J. Rengo², P. Ades², ¹University of Vermont, Burlington, VT, ²University of Vermont Medical Center, Burlington, VT

ORAL COMMUNICATIONS 4 SPURRING ON INNOVATION: EMERGING TX STRATEGIES

**Grand Oaks H
3:45 - 5:45 PM**

Chairs: Margaret Haney and Caitlyn Hood

- 3:45 *Influence of oxytocin on neuroendocrine and subjective response to a social stress task in cocaine-dependent men and women*
B. Sherman, N. Baker, K. Brady, J. Joseph, L. Nunn, A. McRae-Clark, Medical University of South Carolina, Charleston, SC

Sunday, June 16, 2019

- 4:00 *Predictors of neuroendocrine reactivity to social stress among smokers: Examining the roles of sex, adverse childhood experiences, and intranasal oxytocin*
C. Hood¹, R. Tomko², N. Baker², B. Tuck², J. Flanagan², M. Carpenter², K. Gray², M. Saladin², E. McClure², ¹University of Kentucky, Lexington, KY, ²Medical University of South Carolina, Charleston, SC
- 4:15 *Serum BDNF levels are associated with increased gray matter (GM) volume in the striatum and reduced GM in the prefrontal cortex and hippocampus of crack-cocaine users*
H. Oliveira¹, F. Duran¹, P. Dib Gonçalves¹, M. Serpa¹, L. de Menezes Sanchez², D. Lima², L. Valiengo¹, R. Camarini¹, I. Talib², R. Souza¹, M. Ometto³, B. Santos⁴, A. Malbergier⁴, R. Amaral³, W. Gattaz¹, H. Giroud¹, S. Nicastrì⁵, M. Zanetti¹, T. Chaim-Avancini¹, C. de Melo¹, L. Kobuti¹, M. Cavalett¹, N. Costa¹, A. Andrade⁶, G. Busatto Filho⁶, P. Jannuzzi Cunha², ¹University of São Paulo, São Paulo, Brazil, ²University of Sao Paulo Medical School, São Paulo, Brazil, ³University of São Paulo Medical School, São Paulo, ⁴University of Sao Paulo Medical School, São Paulo, ⁵Hospital Israelita Albert Einstein, São Paulo, Brazil, ⁶University of São Paulo Medical School, São Paulo, Brazil
- 4:30 *Evidence for GABA B agonists as smoking cessation aids: A placebo-controlled perfusion fMRI study*
A. Ketcherside¹, K. Jagannathan¹, N. Spilka², N. Hager¹, F. Yang¹, S. Darnley¹, H. Rao¹, T. Franklin¹, R. Wetherill¹, ¹University of Pennsylvania, Philadelphia, PA, ²The University of Pennsylvania, Philadelphia, PA
- 4:45 *In vitro and in silico illumination of an allosteric serotonin 5-HT_{2C} receptor (5-HT_{2CR}) binding site*
E. Wold, C. Wild, J. Chen, K. Pazdrak, E. Garcia, N. Anastasio, H. Chen, K. Cunningham, J. Zhou, University of Texas Medical Branch, Galveston, TX
- 5:00 *High-dose lorcaserin: Interaction with intravenous cocaine and effects on drug self-administration*
K. Grasing, J. Pirtle, K. Surineni, H. Thakur, V. Boinpelly, Kansas City VA Medical Center, Kansas City, MO
- 5:15 *Lorcaserin decreases cannabis self-administration in daily cannabis smokers following several days of abstinence*
M. Haney¹, C. Arout¹, Z. Cooper², S. Reed³, R. Foltin⁴, S. Comer⁵, F. Levin⁵, ¹Columbia University Medical Center, New York, NY, ²UCLA Cannabis Research Initiative, Los Angeles, CA, ³Columbia University, New York, NY, ⁴Columbia University Irving Medical Center, New York, NY, ⁵Columbia University and NYSPI, New York, NY
- 5:30 *Mirtazapine for methamphetamine use disorder among men and transwomen who have sex with men: A randomized placebo-controlled trial*
P. Coffin¹, G. Santos², J. Hern¹, E. Vittinghoff², J. Walker¹, T. Matheson¹, D. Santos¹, G. Colfax¹, S. Batki³, ¹San Francisco Department of Public Health, San Francisco, CA, ²University of California San Francisco, San Francisco, CA, ³San Francisco Veterans Affairs Health Care System, San Francisco, CA

Sunday, June 16, 2019

**SYMPOSIUM IV
DEVELOPMENTAL FACTORS CONTRIBUTING
TO OPIOID USE DISORDER**

**Grand Oaks I
3:45 - 5:45 PM**

Chairs: Yasmin Hurd and Junstine Larson

- 3:45 *Long-term effects of child maltreatment on risk of substance abuse and dependence*
L. Strathearn, University of Iowa, Stead Family Department of Pediatrics, Iowa City, IA
- 4:10 *Early life trauma and opioid dependence*
S. Andersen, McLean Hospital, Harvard Medical School, Belmont, MA
- 4:35 *Epigenetics and cell biology of cannabinoids in opioid addiction*
Y. Hurd, Icahn School of Medicine at Mount Sinai, New York, NY
- 5:00 *Genomic variation and epigenetic regulation in opioid use disorders*
D. Nielsen, Baylor College of Medicine, Montgomery, TX
- 5:25 *Challenges in clinical and basic research of opioid misuse vulnerability in early life*
J. Larson, Substance Abuse and Mental Health Services Administration, Rockville, MD

**SYMPOSIUM V
IN MEMORY OF NANCY PETRY—APPLICATION OF
BEHAVIOR ANALYSIS TO THE TREATMENT OF
ADDICTION: REFLECTIONS ON A SHORT CAREER**

**Grand Oaks K/L
3:45 - 5:45 PM**

Chairs: Maxine Stitzer and Kathleen Carroll

- 3:45 *Early contributions to delay discounting/behavioral economics utilizing human laboratory models*
W. Bickel, Fralin Biomedical Research Institute at VTC, Roanoke, VA
- 4:10 *Refining CM for use in non-academic clinical settings*
J. Roll, Washington State University, Spokane, WA
- 4:35 *Dissemination of CM into clinical practice*
C. Rash, University of UConn School of Medicine, Farmington, CT
- 5:00 *Application of behavior analysis to understand and treat disordered gambling*
D. Ledgerwood, Wayne State University, Detroit, MI
- 5:25 *Discussant*
K. Carroll, Yale University School of Medicine, New Haven, CT

**CPDD/NIDA PRE/POST-DOCS
NETWORKING EVENT**

**Cibolo 7-11
5:45 -7:00 PM**

All Trainees Invited

Monday, June 17, 2019

**WORKSHOP V
LEARNING TO TWEET YOURSELF RIGHT**

**Grand Oaks E/F
6:30 - 7:00 PM**

Chairs: Erin Winstanley/Chris Wolf

The perils of improperly tweating your science

**WORKSHOP I
NAVIGATING A CAREER IN ADDICTION SCIENCE**

**Grand Oaks H
7:00 - 9:00 PM**

Chairs: Denise Vidot and Cecilia Bergeria

Navigating the pre- and post-doctoral stage

C. Bergeria, Johns Hopkins University School of Medicine, Baltimore, MD

To tenure or not to tenure: Navigating as a new investigator at a research institution

D. Vidot, University of Miami, Miami, FL

Drug abuse research at a primarily undergraduate institution: Balancing the classroom and laboratory

R. Lacy, Franklin and Marshall College, Lancaster, PA

Navigating substance use disorder careers outside of academia

A. Duncan, The Pew Charitable Trusts, Washington, DC

Creating your space in and out of academia

D. Fakunle, Morgan State University, Baltimore, MD

**WORKSHOP II
EPIDEMIOLOGY AND PUBLIC HEALTH
RESEARCH METHODS**

**Grand Oaks M
7:00 - 9:00 PM**

Chairs: Howard Chilcoat and Maria Parker

Using epidemiologic methods to inform development of medications to treat addiction

H. Chilcoat, Indivior, Inc., Richmond, VA

Use of electronic medical record and medical claims data to measure abuse, misuse, addiction, overdose and death related to long-term use opioids used to treat chronic pain

A. DeVeugh-Geiss, Indivior, Inc., North Chesterfield, VA

Validation of a measure of opioid use disorder among chronic pain patients treated with opioids

D. Hasin, Columbia University, New York, NY

Emerging practices in social data stewardship for pharmacovigilance

M. Gilbert, Booz Allen Hamilton, Portland, OR

Sunday, June 16, 2019

**WORKSHOP III
25TH ANNUAL CONTINGENCY
MANAGEMENT WORKING GROUP**

**Grand Oaks K/L
7:00 - 9:00 PM**

Chairs: Diann Gaalema and August Holtyn

25th Annual Contingency Management Working Group

**WORKSHOP IV
DEEP PHENOTYPING, DRUG DEVELOPMENT
TOOLS AND -OMICS BIOSIGNATURES
FOR SUBSTANCE USE DISORDERS**

**Grand Oaks I
7:00 - 9:00 PM**

Chairs: Tatiana Ramey and F. Gerard Moeller

Deep phenotyping, drug development tools and -omics biosignatures for SUDs
T. Ramey, National Institutes of Health, Bethesda, MD

Multimodal neuroimaging probes of neurocircuit dysfunction profiles in SUD
J. Bjork, Virginia Commonwealth University, Richmond, VA

NIDA phenotyping battery
F. Moeller, Virginia Commonwealth University, Richmond, VA

The need for peripheral biomarkers defining substance use disorders
K. Bough, National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD

Monday, June 17, 2019

POSTER SESSION II

Breakfast

**Cibolo Ballroom
8:00 - 10:00 AM**

Odd-numbered posters manned first hour; Even-numbered, second hour
Set-up time begins Sunday, 3:00 PM; Must be removed by Monday 2:30 PM

CLUB DRUGS / NPS

- Drug-checking services at music festivals and events in British Columbia: A 2018 analysis of results*
K. McCrae, J. Arredondo, S. Tobias, L. Ti, K. Tupper, E. Wood, British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada
- Adulterants and altruism: A qualitative investigation of “drug checkers” in North America*
P. Acosta¹, M. Shedlin², J. Palamar¹, ¹New York University School of Medicine, New York, NY, ²New York University Rory Meyers College of Nursing, New York, NY

Monday, June 17, 2019

- 3 *A qualitative study of ketamine abuse in Thailand*
U. Perngparn¹, C. Areesantichai¹, L. Cottler², ¹Chulalongkorn University, Bangkok, Thailand, ²University of Florida, Gainesville, FL
- 4 *Probability discounting of ecstasy use by perceived purity: Effects of adulterant-related information*
S. Dolan, M. Johnson, Johns Hopkins University School of Medicine, Baltimore, MD
- 5 *Perceived negative effects and benefits of new psychoactive substances (NPS): Results of online survey among NPS users in Georgia (country)*
D. Otiashvili¹, D. Subeliani², L. Kutelia¹, A. Beselia¹, T. Mgebrishvili¹, I. Kirtadze³, ¹Addiction Research Center, Tbilisi, Georgia, ²Faculty of Arts and Science, Ilia State University, Tbilisi, Georgia, ³Ilia State University, Tbilisi, Georgia
- 6 *“Instant coffee sachet” users — A new face of new psychoactive substances in Taiwan*
L. Chen¹, T. Weng², P. Chen³, C. Kuo¹, ¹Taipei City Hospital, Taipei, Taiwan, ²Department of Emergency Medicine, National Taiwan University Hospital, Taipei, Taiwan, Taipei, Taiwan, ³Forensic and Clinical Toxicology Center, National Taiwan University, Taipei, Taiwan
- 7 *The effects of pre-encoding THC, psilocybin, and DXM on recollection and familiarity*
M. Doss¹, D. Gallo², H. de Wit², R. Griffiths³, F. Barrett³, ¹Johns Hopkins University, Baltimore, MD, ²University of Chicago, Chicago, IL, ³Johns Hopkins University School of Medicine, Baltimore, MD
- 8 *Estimating LSD- & MDMA-specific hallucinogen dependence risks*
V. Gregoire, J. Anthony, Michigan State University, East Lansing, MI
- 9 *Entactogenic effect of three cathinones*
M. Gatch, M. Forster, University of Texas Health Science Center, Fort Worth, TX
- 10 *Self-administration of α -PVP or mephedrone produces selective patterns of neuroinflammation*
J. Marusich¹, E. Gay¹, D. Stewart², B. Blough¹, ¹RTI International, Research Triangle Park, NC, ²University of North Carolina, Chapel Hill, NC
- 11 *Behavioral and physiological profiles of intravenous MDPV, methylone, and caffeine in rats*
R. Seaman Jr¹, J. San Miguel¹, A. Sulima², K. Rice², G. Collins³, ¹UT Health San Antonio, San Antonio, TX, ²National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD, ³University of Texas Health Science Center, San Antonio, TX

STIMULANTS - ANIMAL STUDIES

- 12 *Behavioral testing of nine novel cathinones*
M. Forster¹, S. Dolan², M. Gatch¹, ¹University of Texas Health Science Center, Fort Worth, TX, ²Johns Hopkins University School of Medicine, Baltimore, MD

Monday, June 17, 2019

- 13 *Compulsion zone theory explains different duration's of extinction responding with different cocaine analogues*
D. Zinani¹, H. Wetzel¹, V. Tsibulsky¹, A. Norman², ¹University of Cincinnati, Cincinnati, OH, ²University of Cincinnati, College of Medicine, Cincinnati, OH
- 14 *The effects of a recombinant humanized anti-cocaine monoclonal antibody and its Fab fragment on the urinary clearance of cocaine and metabolites in rats*
J. Marckel¹, H. Wetzel², H. Amlal², A. Norman¹, ¹University of Cincinnati, College of Medicine, Cincinnati, OH, ²University of Cincinnati, Cincinnati, OH
- 15 *The pharmacokinetics of a recombinant humanized anti-cocaine monoclonal antibody in both male and female rats*
A. Norman¹, J. Marckel¹, H. Wetzel², ¹University of Cincinnati, College of Medicine, Cincinnati, OH, ²University of Cincinnati, Cincinnati, OH
- 16 *Effects of a methamphetamine vaccine, IXT-v100, on methamphetamine-related behaviors*
C. Keller¹, A. Spence², M. Stevens³, S. Owens⁴, G. Guerin¹, N. Goeders⁵, ¹LSU Health-Shreveport, Shreveport, LA, ²Northwestern State University, Natchitoches, LA, ³InterveXion Therapeutics, Little Rock, AR, ⁴University of Arkansas for Medical Sciences, Little Rock, AR, ⁵Louisiana State University, Shreveport, LA
- 17 *Role of NR2B function in extinction consolidation following adolescent- or adult-onset methamphetamine self-administration in male and female rats*
S. Westbrook, J. Gulley, University of Illinois Urbana-Champaign, Champaign, IL
- 18 *Methamphetamine-induced vaginal lubrication*
M. Mott¹, N. Goeders², ¹LSU Health-Shreveport, Shreveport, LA, ²Louisiana State University, Shreveport, LA

THC/CANNABINOIDS

- 19 *The sigma1 receptor antagonist CM304 enhances the antinociceptive effects of morphine and the cannabinoid receptor agonist CP55,940 in mice*
S. Obeng¹, S. Intagliata², M. Mottinelli², L. Restrepo³, A. Patel¹, L. Wilson⁴, V. Taylor³, M. Reeves³, A. Pennington³, C. McCurdy¹, L. McMahon¹, T. Hiranita³, ¹University of Florida, Gainesville, FL, ²University of Florida, Department of Medicinal Chemistry, Gainesville, FL, ³University of Florida, College of Pharmacy, Gainesville, FL, ⁴University of Florida, Department of Pharmacodynamics, Gainesville, FL
- 20 *Effects of co-exposure to alcohol and delta-9-tetrahydrocannabinol (THC) during adolescence on synaptic plasticity in the prelimbic cortex in rats*
A. Banks¹, S. Kang², N. Nelson¹, N. Liang¹, J. Gulley¹, ¹University of Illinois Urbana-Champaign, Champaign, IL, ²University of Illinois, Champaign, IL
- 21 *Effects of cannabinoids on neuronal activity in mouse cerebellar cultures assessed using microelectrode array techniques*
M. Funada¹, T. Kenichi², ¹National Institute of Mental Health, Kodaira, Japan, ²National Center of Neurology and Psychiatry, Kodaira, Japan

Monday, June 17, 2019

- 22 *Influence of a low dose of pregabalin maintenance on cannabis effects and related behaviors in daily cannabis users*
J. Lile¹, J. Alcorn², H. Lon², T. Kelly¹, C. Rush², W. Stoops², M. Wesley¹, P. Westgate²,
¹University of Kentucky, College of Medicine, Lexington, KY, ²University of Kentucky, Lexington, KY
- 23 *Marijuana use frequency at college entry predicts incident prescription analgesic and stimulant misuse, cocaine use, and cigarette use during college*
B. Bugbee, A. Barrall, K. Vincent, A. Arria, University of Maryland, School of Public Health, College Park, MD
- 24 *Developmental trajectories of illicit drug use and prescription drug misuse among young adult medical cannabis patients and non-patient users in Los Angeles*
E. Fedorova¹, S. Schrage², L. Robinson¹, A. Roth¹, C. Wong³, E. Iverson³, S. Lankenau⁴,
¹Drexel University, Philadelphia, PA, ²California State University Northridge, Northridge, CA, ³Children's Hospital Los Angeles, Los Angeles, CA, ⁴Drexel University Dornsife School of Public Health, Philadelphia, PA
- 25 *Examining a quadripartite model of passion for marijuana use: Associations with consumption, consequences, craving, and satisfaction with life*
A. Davis¹, B. Arterberry², ¹Johns Hopkins University, Baltimore, MD, ²Iowa State University, Ames, IA
- 26 *Motives for cannabis use are differentially associated with severity of cannabis-use disorder and with current depression or anxiety*
L. Moran¹, S. Hertz², D. Epstein², K. Preston³, K. Phillips⁴, ¹NIDA - Center for Clinical Trials Network, Bethesda, MD, ²NIDA Intramural Research Program, Baltimore, MD, ³National Institute of Drug Abuse Intramural Research Program, Baltimore, MD, ⁴National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD
- 27 *An exploratory study of parents' experiences using medical cannabis for their children*
J. Ryan, C. Boyd, S. McCabe, University of Michigan, Ann Arbor, MI
- 28 *An online survey of medicinal cannabinoid users: Qualitative analysis of users' experiences*
A. Garcia-Romeu¹, R. Mayhugh¹, N. Schlienz², E. Martin¹, M. Bonn-Miller³, H. Jackson⁴, R. Vandrey¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²State University of New York at Buffalo, Buffalo, NY, ³University of Pennsylvania, Southmont, NC, ⁴Realm of Caring Foundation, Colorado Springs, CO
- 29 *Medical cannabis: Avenue to alleviation or path to problematic use*
K. Sagar¹, M. Dahlgren², R. Smith¹, A. Lambros¹, M. Kuppe¹, L. Patriarca¹, S. Gruber²,
¹McLean Hospital, Belmont, MA, ²McLean Hospital, Harvard Medical School, Belmont, MA
- 30 *The earliest versus later syndromes of cannabis use disorders: Incidence versus prevalence*
C. Thompson¹, K. Alcover², J. Anthony³, ¹Peds AI, Lansing, MI, ²Washington State University, Spokane, WA, ³Michigan State University, East Lansing, MI

Monday, June 17, 2019

- 31 *Racism and trauma: Examining unique effects on cannabis use among African American young adults*
S. Khazvand, T. Zapolski, Indiana University Purdue University Indianapolis, Indianapolis, IN
- 32 *Relationship between $\Delta 9$ -tetrahydrocannabinol concentration, anxiety, and depression among racially/ethnic diverse cannabis users*
D. Vidot, W. Joseph, A. Carrico, S. Roy, D. Jayaweera, University of Miami, Miami, FL
- 33 *Patterns of current drug use among past-year medical marijuana users in the US*
C. Lopez-Quintero¹, K. Alcover², ¹University of Florida, Gainesville, FL, ²Washington State University, Spokane, WA
- 34 *Clinical characteristics and health status of potential medical cannabis users in Arkansas*
L. Russell, University of Arkansas for Medical Sciences, Little Rock, AR
- 35 *Transitions into and out of medical cannabis patient status among young adults*
S. Lankenau¹, A. Kioumarsis², M. Reed², E. Fedorova², J. Ataiants¹, C. Wong³, E. Iverson³, ¹Drexel University Dornsife School of Public Health, Philadelphia, PA, ²Drexel University, Philadelphia, PA, ³Children's Hospital Los Angeles, Los Angeles, CA
- 36 *Extracting clinical documentation of patient medical cannabis use from primary care encounter notes using natural language processing*
D. Carrell, D. Cronkite, M. Shea, M. Oliver, C. Luce, K. Bradley, G. Lapham, Kaiser Permanente Washington Health Research Institute, Seattle, WA
- 37 *Medical marijuana use and trouble with the law: Does living in a state with a medical marijuana law modify the relationship?*
A. Perlmutter, L. Segura, S. Martins, P. Mauro, Columbia University, New York, NY
- 38 *Legalization of recreational cannabis in Canada: Local media analysis*
J. Sorensen, University of California San Francisco, San Francisco, CA
- 39 *Pharmacologic interventions for cannabis use disorder: A systematic review*
S. Nugent, B. Morasco, M. O'Neil, C. Ayers, M. Freeman, R. Paynter, D. Kansagara, K. Kondo, VA Portland Health Care System, Portland, OR
- 40 *Preliminary findings from a brief contingency management intervention and its effects on cannabis abstinence and relapse*
S. Wemm¹, P. Himmelstein², Z. Magin², V. Milivojevic³, S. Monlezun⁴, P. Piazza⁴, R. Sinha³, ¹Yale University, New Haven, CT, ²Yale Stress Center, Yale School of Medicine, New Haven, CT, ³Yale University School of Medicine, New Haven, CT, ⁴Aelis Farma, Neurocentre Magendie, Bordeaux, France
- 41 *A comparison between hypothetical and operant delay discounting procedures among adults enrolled in treatment for cannabis use disorder*
D. Lee, M. Johnson, R. Vandrey, Johns Hopkins University School of Medicine, Baltimore, MD

Monday, June 17, 2019

- 42 *Impact of decision-making capacities on 3-month's treatment outcome among patients treated for cannabis use disorder*
L. Jakubiec¹, F. Serre², S. Auriacombe¹, C. Denis³, S. Moriceau², M. Fatseas⁴, M. Auriacombe¹, ¹Université de Bordeaux, Bordeaux, France, ²Université de Bordeaux, Bordeaux, ³University of Pennsylvania, Philadelphia, PA, ⁴Centre Hospitalier Charles Perrens, Bordeaux, France
- 43 *Non-abstinent treatment outcomes in cannabis use disorder*
F. Levin¹, J. Mariani², D. Brooks³, C. Choi⁴, C. Basaraba⁵, M. Pavlicova⁶, ¹Columbia University and NYSPI, New York, NY, ²Columbia University and New York Psychiatric Institute, New York, NY, ³New York State Psychiatric Institute, New York, NY, ⁴Columbia University, New York, NY, ⁵NYSPI, New York, NY, ⁶Columbia University Mailman School of Public Health, New York, NY

POLYDRUG ABUSE

- 44 *The association of combined marijuana and alcohol on subjective memory complaints among persons living with HIV*
V. Joseph, Y. Wang, R. Fieo, R. Cook, University of Florida, Gainesville, FL
- 45 *Cocaine and benzodiazepine polysubstance use among illicit opioid users in New York City*
J. Manubay¹, S. Martinez², J. Jones³, S. Comer², ¹Columbia University, New York, NY, ²Columbia University and NYSPI, New York, NY, ³Columbia University College of Physicians and Surgeons, New York, NY
- 46 *National treatment admissions with opioids and benzodiazepines as drugs of abuse*
C. Arfken, M. Greenwald, Wayne State University, Detroit, MI
- 47 *Benzodiazepine use does not decrease treatment retention in a low-threshold methadone program*
K. Morford¹, F. Li², B. Zhou², E. Edelman¹, M. Stein³, J. Tetrault², ¹Yale University School of Medicine, New Haven, CT, ²Yale University, New Haven, CT, ³Boston University School of Public Health, Boston, MA
- 48 *The influence of tobacco and opioid use disorders on effort-based decisions*
M. Addicott, M. Mancino, A. Oliveto, University of Arkansas for Medical Sciences, Little Rock, AR
- 49 *Smokers with opioid use disorder may have worse drug use outcomes after varenicline than nicotine replacement*
D. Rohsenow, R. Martin, J. Tidey, Brown University, Providence, RI

Monday, June 17, 2019

- 50 *Electronic cigarette and tobacco use in individuals entering methadone or buprenorphine treatment*
S. Baldassarri¹, D. Fiellin², M. Savage, L. Madden³, M. Beitel³, L. Dhingra⁴, L. Fucito¹, D. Camenga², P. Bollampally¹, D. Barry², ¹Yale University, New Haven, CT, ²Yale University School of Medicine, New Haven, CT, ³Yale University, APT Foundation, New Haven, CT, ⁴Albert Einstein College of Medicine, Philadelphia, PA
- 51 *Item response theory analyses of DSM-5 substance use disorder criteria in French outpatient addiction clinic participants*
C. Kervran¹, D. Shmulewitz², F. Serre³, C. Denis⁴, M. Fatseas⁵, J. Daulouede⁶, D. Hasin², M. Auriacombe¹, ¹Université de Bordeaux, Bordeaux, France, ²Columbia University, New York, NY, ³Université de Bordeaux, Bordeaux, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Centre Hospitalier Charles Perrens, Bordeaux, France, ⁶Bizia Addiction Clinic, Bayonne, France

NICOTINE

- 52 *Adverse childhood experiences, impulsivity, and e-cigarette use during the transition to adulthood*
S. Shin, D. Conley, G. Ksinan Jiskrova, Virginia Commonwealth University, Richmond, VA
- 53 *E-cigarette product characteristics and frequency of smoking among young adults*
Z. Yang, J. Barrington-Trimis, University of Southern California, Los Angeles, CA
- 54 *Circadian subjective and pharmacological effects of ad libitum electronic and combustible cigarette use among dual users*
A. Harvanko, G. St.Helen, N. Benowitz, University of California San Francisco, San Francisco, CA
- 55 *Risk factors for current cigarette smoking among US college graduates*
S. Coleman, D. Gaalema, T. Nighbor, A. Kurti, J. Priest, S. Higgins, University of Vermont, Burlington, VT
- 56 *The influence of ovarian hormones on cigarette smoking behavior in the natural environment*
N. Baker¹, K. Gray¹, V. Ramakrishnan², R. Tomko¹, E. McClure¹, M. Carpenter¹, M. Saladin¹, ¹Medical University of South Carolina, Charleston, SC, ²Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC

Monday, June 17, 2019

- 57 *Smoking prevalence and trends among a US national sample of women of reproductive age in rural versus urban settings*
T. Nighbor¹, N. Doogan², M. Roberts², A. Cepeda-Benita¹, A. Kurti¹, J. Priest¹, H. Johnson¹, A. Lopez³, C. Stanton⁴, D. Gaalema¹, R. Redner⁵, M. Parker¹, D. Keith¹, A. Quisenberry⁶, S. Higgins¹, ¹University of Vermont, Burlington, VT, ²Ohio State University, Columbus, OH, ³US Army Medical Research Directorate-West, Tacoma, WA, ⁴Westat, Rockville, MD, ⁵Southern Illinois University, Carbondale, IL, ⁶Roswell Park Comprehensive Cancer Center, Buffalo, NY
- 58 *Tobacco use in a binational sample of Latino community health center (CHC) patients*
L. Gelberg¹, K. Koslov², M. Rico¹, ¹University of California, Department of Family Medicine, Los Angeles, CA, ²University of California, Los Angeles, CA
- 59 *The relationship between nicotine dependence level and DSM-V nicotine use disorder diagnosis in a diverse sample of smokers seen in primary care*
L. Harvey, L. Rodriguez, A. Wang, S. Essa, E. Absar, P. Srivastava, M. de Dios, University of Houston, Houston, TX
- 60 *Meta-analysis of the acute effects of nicotinic acetylcholine receptor stimulation on mismatch negativity*
A. Hamidovic, University of Illinois, Chicago, IL
- 61 *Modeling the effects of an acute psychological stressor on vaping lapse behavior*
I. Pericot-Valverde¹, D. Gaalema², ¹Clemson University, Greenville, SC, ²University of Vermont, Burlington, VT
- 62 *Graphic warning labels affect hypothetical purchasing behavior among smokers living with HIV*
M. Berry¹, L. Pacek², M. Johnson³, ¹University of Florida, Gainesville, FL, ²Duke University School of Medicine, Durham, ³Johns Hopkins University School of Medicine, Baltimore, MD
- 63 *Caudate reactivity to smoking cues is associated with increased response bias to monetary rewards*
E. Molokotos¹, A. Peechatka², D. Pizzagalli², A. Janes², ¹McLean Hospital, Belmont, MA, ²McLean Hospital, Harvard Medical School, Belmont, MA
- 64 *Reduced-nicotine cigarettes: Behavioral economics of operant reinforcement*
M. Johnson¹, S. Dolan¹, M. Berry², D. Cox¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Florida, Gainesville, FL
- 65 *Characterizing the malleability of cigarette product preference and consumption*
D. Davis, M. DeSarno, S. Higgins, University of Vermont, Burlington, VT
- 66 *Digital access among clients in residential addiction treatment: Potential for increasing access to smoking cessation services*
D. Yip¹, A. Maglior², N. Gubner¹, T. Le¹, J. Guydish¹, ¹University of California San Francisco, San Francisco, CA, ²Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, CA

Monday, June 17, 2019

- 67 *Reinforcer pathology and response to contingency management for smoking cessation*
A. González-Roz¹, Á. García-Pérez¹, G. Aonso-Diego¹, V. Martínez-Loredo², S. Fernandez-Artamendi³, R. Secades Villa², D. Gaalema⁴, ¹University of Oviedo, Addictive Behaviors Group, Oviedo, Spain, ²University of Oviedo, Oviedo, Spain, ³Universidad Loyola Andalucía, Seville, Spain, ⁴University of Vermont, Burlington, VT
- 68 *Electroretinogram (ERG) as a novel biomarker for dopamine release: Comparing healthy controls and cigarette smokers*
T. Lin¹, H. Lee², C. Xu³, D. Martinez², R. Girgis², S. Tsang³, E. Nunes⁴, S. Luo⁵, ¹Teachers College Columbia University, New York, NY, ²Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, NY, ³Department of Ophthalmology, Columbia University Medical Center, New York, NY, ⁴Columbia University and New York State Psychiatric Institute, New York, NY, ⁵Columbia University, New York, NY
- 69 *Changes in specific miRNAs in substance use disorders following treatment*
A. Ye¹, M. Patriquin, T. Kosten², D. Nielsen³, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Bellaire, TX, ³Baylor College of Medicine, Montgomery, TX

COCAINE

- 70 *Childhood trauma has sex-specific influences on the neural correlates of stress-induced cocaine craving*
G. James¹, Z. Alfaneq¹, B. Martins¹, A. Elton², C. Kilts¹, ¹University of Arkansas for Medical Sciences, Little Rock, AR, ²University of North Carolina, Chapel Hill, NC
- 71 *Trait impulsivity and self-exposure to non-medical cannabis and alcohol as dimensional predictors of cocaine dependence diagnosis or time of cocaine escalation*
R. Conybeare, K. Brown, C. Chen, E. Butelman, M. Kreek, The Rockefeller University, New York, NY
- 72 *A comprehensive examination of delay and probability discounting processes in cocaine use*
D. Cox¹, S. Dolan¹, P. Johnson², M. Johnson¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²California State University, Los Angeles, CA
- 73 *Exacerbating reinforcer pathology: Hurricane-associated loss increases delay discounting and demand for cocaine in cocaine users*
S. Snider¹, J. Turner², W. Bickel¹, ¹Fralin Biomedical Research Institute at VTC, Roanoke, VA, ²Virginia Tech Carilion Research Institute, Roanoke, VA

Monday, June 17, 2019

- 74 *Boredom-induced temporal discounting in cocaine users*
T. Chao¹, Y. Shaltout², M. Todman³, R. Foltin⁴, G. Bedi⁵, ¹New York State Psychiatric Institute, New York, NY, ²Columbia University Medical Center, New York, NY, ³The New School for Social Research, New York City, NY, ⁴Columbia University Irving Medical Center, New York, NY, ⁵The University of Melbourne, Parkville, Australia
- 75 *The relative contribution of behavioral economic measures in predicting cocaine severity and treatment response*
J. Yoon¹, J. Schmitz¹, S. Lane², G. San Miguel², S. Jensen¹, J. Vincent¹, A. Vujanovic³, A. Stotts¹, M. Weaver¹, A. Lin¹, R. Suchting¹, ¹University of Texas Health Science Center, Houston, TX, ²University of Texas Health Science Center, McGovern Medical School, Houston, TX, ³University of Houston, Houston, TX
- 76 *The influence of long-term cocaine use on cognitive functioning*
K. Akao¹, M. Pena¹, K. Moroney¹, C. Clark¹, K. Cropsey², ¹Wichita State University, Wichita, KS, ²University of Alabama, Birmingham, AL
- 77 *The late positive potential (LPP) as a marker of motivated attention in cocaine use disorder (CUD)*
H. Soder¹, J. Schmitz¹, C. Green¹, F. Versace², S. Lane³, ¹University of Texas Health Science Center, Houston, TX, ²MD Anderson Cancer Center, Houston, TX, ³University of Texas Health Science Center, McGovern Medical School, Houston, TX
- 78 *Elevated neutrophil to lymphocyte ratio (NLR) in cocaine use disorder as a marker of chronic inflammation*
A. Berumen¹, K. Gomez¹, M. Wardle², R. Suchting³, H. Soder³, J. Vincent³, J. Yoon³, A. Heads¹, M. Weaver³, C. Green³, J. Schmitz³, S. Lane¹, ¹University of Texas Health Science Center, McGovern Medical School, Houston, TX, ²University of Illinois, Chicago, IL, ³University of Texas Health Science Center, Houston, TX
- 79 *Associations between beliefs about research and willingness to participate in a pharmacological randomized controlled trial for the treatment of cocaine or crack-cocaine dependence*
V. Giang¹, K. Jaffe², K. Hayashi³, K. DeBeck¹, M. Milloy², L. Richardson², ¹British Columbia Centre on Substance Use, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Simon Fraser University, Vancouver, BC, Canada
- 80 *Patterns of cocaine use and posttreatment psychosocial functioning across seven randomized clinical trials*
C. Roos¹, C. Nich², C. Mun³, J. Mendonca¹, T. Babuscio¹, K. Witkiewitz⁴, K. Carroll¹, B. Kiluk¹, ¹Yale University School of Medicine, New Haven, CT, ²Yale University, New Haven, CT, ³Johns Hopkins Bayview Medical Center, Baltimore, MD, ⁴University of New Mexico, Albuquerque, NM
- 81 *Recovery capital and cocaine use in a diverse community sample*
N. Smith, L. Paz, L. Cottler, University of Florida, Gainesville, FL

OVERDOSE

- 82 *The provision of drug-checking services in the context of the fentanyl crisis: Preliminary findings on a pilot program in British Columbia, Canada*
J. Arredondo¹, K. McCrae¹, L. Ti¹, K. Tupper¹, E. Nosova², C. Grant², S. Tobias¹, E. Wood¹,
¹British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada, ²BC
Centre on Substance Use, Vancouver, BC, Canada
- 83 *Characterizing age-based differences in fentanyl risk communication using qualitative methods*
S. Bagley¹, A. Walley¹, M. Harris², S. Sampath¹, C. Gunn¹, ¹Boston University School of
Medicine, Boston, MA, ²Boston University, Boston, MA
- 84 *Fentanyl use and perceptions of suicidality: You either wake up and keep going, or you die*
C. Gunn¹, S. Bagley¹, S. Sampath¹, M. Harris², A. Walley¹, ¹Boston University School of
Medicine, Boston, MA, ²Boston University, Boston, MA
- 85 *Known and unknown exposure to fentanyl and the associated risks among people who inject drugs in Vancouver, Canada*
K. Hayashi¹, N. Fairbairn², H. Dong³, M. Milloy², K. DeBeck³, E. Wood⁴, T. Kerr², ¹Simon
Fraser University, Vancouver, BC, Canada, ²BC Centre on Substance Use, Vancouver, BC,
Canada, ³British Columbia Centre on Substance Use, Vancouver, BC, Canada, ⁴British
Columbia Centre on Substance Use, Vancouver, British Columbia, Canada
- 86 *The impact of social violence on women's utilization of housing-based overdose prevention sites: An ethnographic study during an overdose crisis in Vancouver, Canada*
A. Collins¹, J. Boyd², S. Czechaczek³, R. McNeil⁴, ¹Simon Fraser University, Vancouver,
BC, Canada, ²British Columbia Centre on Substance Use, Vancouver, BC, Canada, ³BC
Centre on Substance Use, Vancouver, BC, Canada, ⁴University of British Columbia,
Vancouver, BC, Canada
- 87 *Overdose and suicidal motivation in adults with opioid use disorder*
R. Weiss, McLean Hospital, Belmont, MA
- 88 *Mortality among people with opioid use disorder during an opioid overdose public health emergency in British Columbia, Canada*
L. Pearce¹, J. Min², M. Piske¹, C. Zhou¹, F. Homayra¹, B. Nosyk³, ¹BC Centre for
Excellence in HIV/AIDS, Vancouver, BC, Canada, ²BC Centre for Excellence in HIV/
AIDS, Vancouver, ³British Columbia Centre on Substance Use, Vancouver, BC, Canada
- 89 *Circumstances of overdose among women who inject heroin: Drug, set, and setting*
J. Ataiants, S. Lankenau, Drexel University Dornsife School of Public Health,
Philadelphia, PA

- 90 *Misclassification of opioid overdose by ambulance dispatch systems: Implications for take-home naloxone programs*
P. Dietze¹, R. Crossin², D. Scott³, K. Cantwell⁴, K. Smith⁵, D. Lubman³, ¹Burnet Institute, Melbourne, Australia, ²Monash University, Melbourne, Australia, ³Turning Point, Fitzroy, Australia, ⁴Ambulance Victoria, Doncaster, Australia, ⁵Ambulance Victoria, Doncaster, Australia
- 91 *Naloxone pharmacokinetics in humans: Novel nasal spray versus intravenous and intramuscular injection*
A. Elkashef, Insys Development Company, Inc., Chandler, AZ
- 92 *Self-reported peer buprenorphine/naloxone (Suboxone®) administration for opioid overdose reversal: A potential avenue for peer-led overdose prevention efforts in medication-assisted treatment settings*
M. Mittal¹, P. Davidson¹, E. Copulsky¹, J. Bowles², G. Hennessy¹, S. Verdugo¹, R. Harding³, T. Gaines¹, K. Wagner⁴, ¹University of California San Diego, La Jolla, CA, ²Safehouse Philadelphia, Philadelphia, PA, ³University of Nevada Reno, School of Community Health Sciences, Reno, NV, ⁴University of Nevada, Reno, NV
- 93 *Evaluation of iPad-delivered opioid overdose education among individuals with opioid use disorder*
T. Ochalek¹, K. Peck¹, K. Dunn², A. Stoner³, S. Sigmon¹, ¹University of Vermont, Burlington, VT, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³University of Rochester School of Medicine & Dentistry, Rochester, NY
- 94 *Opioid prescribing prior to heroin overdose: A national cohort study*
M. Laroche¹, P. Lagisetty², L. Lin², R. Haffajee², R. Fowler², J. Goldstick², K. Zhang³, A. Bohnert², ¹Boston University School of Medicine, Boston, MA, ²University of Michigan, Ann Arbor, MI, ³Centers for Disease Control and Prevention, Atlanta, GA
- 95 *Psychosocial correlates and treatment outcomes of methadone patients with a history of opioid overdose*
J. Ellis, J. Lister, D. Ledgerwood, M. Fodor, C. Struble, Wayne State University, Detroit, MI
- 96 *Benzodiazepine misuse in patients with substance use disorders*
R. McHugh¹, M. Griffin², N. Taghian¹, R. Geyer¹, R. Weiss¹, ¹McLean Hospital, Belmont, MA, ²McLean Hospital, Harvard Medical School, Belmont, MA

RISK, HARM REDUCTION, PREVENTION

- 97 *Drugs-violence nexus: Theory testing and health risk-factors among justice-involved Appalachian women*
G. Victor, University of Kentucky, Lexington, KY

Monday, June 17, 2019

- 98 *Effect of publicly reported cardiac surgery outcomes on rate of valve replacement in injection drug-associated and non-injection drug-associated endocarditis*
S. Kimmel¹, A. Walley¹, B. Linas¹, B. Kalesan, L. White², M. Laroche¹, ¹Boston University School of Medicine, Boston, MA, ²Boston University School of Public Health, Boston, MA
- 99 *Correlates of transactional sex among women who inject drugs: A mixed-methods study*
S. Lamb¹, S. Walters², L. Wenger³, A. Kral³, R. Bluthenthal¹, ¹Keck School of Medicine, Los Angeles, CA, ²New York University, New York, NY, ³RTI International, San Francisco, CA
- 100 *Substance use, discrimination, and HIV risk among men who have sex with men in Massachusetts*
A. Batchelder¹, M. Klevens², C. Fitch¹, S. Marquez McKetchnie³, K. Mayer⁴, C. O'Cleirigh¹, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Jamaica Plain, MA, ³Massachusetts General Hospital, Boston, MA, ⁴Harvard Medical School, Belmont, MA
- 101 *Syringe exchange uptake and HIV risk behaviors among rural people who inject drugs*
H. Surratt¹, M. Staton², A. Cowley¹, J. Otachi¹, ¹University of Kentucky, Lexington, KY, ²University of Kentucky, College of Medicine, Lexington, KY
- 102 *Risk factors associated with early injection drug use initiation among a cohort of PWID*
J. Goldshear¹, C. Page², K. Dominguez Gonzalez², A. Kral³, L. Wenger³, R. Bluthenthal¹, ¹Keck School of Medicine, Los Angeles, CA, ²University of Southern California, Los Angeles, CA, ³RTI International, San Francisco, CA
- 103 *Preliminary analyses of benefits and costs of family planning interventions for women enrolled in medication treatment for opioid use disorder*
H. Melbostad¹, D. Shepard², C. Rey¹, A. Matusiewicz¹, S. Sigmon¹, L. Macafee¹, S. Higgins¹, S. Heil¹, ¹University of Vermont, Burlington, VT, ²Brandeis University, Waltham, MA
- 104 *Adapting a family resilience intervention for families experiencing homelessness, trauma, and parental substance use disorders*
R. Ijadi-Maghsoodi¹, J. Horton², G. Ryan³, S. Kataoka⁴, P. Lester⁵, L. Gelberg⁶, ¹University of California Los Angeles, Los Angeles, CA, ²UCLA, Los Angeles, CA, ³RAND Corporation, Santa Monica, CA, ⁴Semel Institute, UCLA, Los Angeles, CA, ⁵UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, ⁶University of California, Department of Family Medicine, Los Angeles, CA
- 105 *Military spouses and longitudinal substance use: The role of marital satisfaction*
J. Kulak¹, D. Homish², G. Homish², ¹Buffalo State College, Buffalo, NY, ²State University of New York at Buffalo, Buffalo, NY

Monday, June 17, 2019

- 106 *Efforts can reduce selection bias by strengthening parental consent for child participation in a school-based drug prevention program*
T. Lee¹, S. Chang², C. Hsieh³, Y. Yang³, J. Feng³, ¹National Taiwan Normal University, Taipei, Taiwan, ²National Taiwan University Children and Family Research Center, Taipei, ³National Taiwan University Children and Family Research Center, Taipei, Taiwan
- 107 *A qualitative study on protective factors for drug use prevention among Black and Hispanic girls*
I. Opara¹, D. Lardier Jr.², R. Reid¹, P. Garcia-Reid¹, ¹Montclair State University, Montclair, NJ, ²University of New Mexico, Albuquerque, NM
- 108 *Evaluation of a drug analysis service as a harm reduction strategy in a large-scale music event in Portugal*
H. Valente¹, D. Martins¹, M. Barratt², M. Pinto³, ¹Kosmicare Association/Faculty of Sciences of Porto University, Porto, Portugal, ²National Drug and Alcohol Research Centre, Sydney, Australia, ³Faculty of Psychology and Educational Science of the Porto University, Porto, Portugal
- 109 *Persuading police to support public health in Mexico: Interactive training improves police endorsement of syringe legality*
L. Beletsky¹, J. Arredondo², P. Baker³, D. Abramovitz³, I. Artamonova³, E. Clairgue³, M. Morales³, M. Mittal³, T. Rocha³, T. Kerr⁴, A. Banuelo⁵, S. Strathdee³, J. Cepeda³, ¹Northeastern University, Boston, MA, ²British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada, ³University of California San Diego, La Jolla, CA, ⁴BC Centre on Substance Use, Vancouver, BC, Canada, ⁵Secretaría de Seguridad Pública Municipal, Tijuana, Tijuana, Mexico
- 110 *Police characteristics associated with preferences for referral of people who inject drugs to harm reduction services in Tijuana, Mexico*
P. Baker¹, E. Clairgue¹, A. Borquez¹, J. Arredondo², S. Strathdee¹, A. Vera¹, J. Cepeda¹, ¹University of California San Diego, La Jolla, CA, ²British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada
- 111 *The moral foundations of needle exchange attitudes*
N. Christie¹, E. Hsu¹, C. Iskiwitch¹, R. Iyer¹, J. Graham², B. Schwartz³, J. Monterosso¹, ¹University of Southern California, Los Angeles, CA, ²University of Utah, Salt Lake City, UT, ³Swarthmore College, Swarthmore, PA
- 112 *Police interactions and carrying naloxone among people who inject drugs*
M. Reed¹, K. Wagner², N. Tran¹, K. Brady³, J. Shinefeld³, A. Roth¹, ¹Drexel University, Philadelphia, PA, ²University of Nevada, Reno, NV, ³Philadelphia Department of Public Health, Philadelphia, PA
- 113 *Prevalence of substance misuse in a sample of primary care patients*
D. Pomm, A. Parlier-Ahmad, K. Polak, D. Svikis, Virginia Commonwealth University, Richmond, VA

Monday, June 17, 2019

- 114 *Implementing an updated “Break the Cycle” intervention to reduce initiating persons into injecting drug use in an Eastern European and a US “opioid epidemic” setting*
A. Uuskula¹, D. Des Jarlais², A. Talu¹, D. Barnes³, M. Raag¹, K. Arasteh³, G. Org¹, J. Feelemyer⁴, H. Berg⁴, S. Tross⁵, ¹University of Tartu, Tartu, Estonia, ²New York University College of Global Public Health, New York, NY, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴New York University, New York, NY, ⁵Columbia University, New York, NY
- 115 *The role of residential evictions in shaping harm amidst twin epidemics of illicit opioid and methamphetamine use: A qualitative study in Vancouver, Canada*
R. McNeil¹, T. Fleming², A. Collins³, S. Mayer², J. Boyd⁴, ¹University of British Columbia, Vancouver, BC, Canada, ²BC Centre on Substance Use, Vancouver, BC, Canada, ³Simon Fraser University, Vancouver, BC, Canada, ⁴British Columbia Centre on Substance Use, Vancouver, BC, Canada
- 116 *Contrasting trajectories of injection methamphetamine and cocaine use in a Canadian setting between 2008-2017*
P. Bach¹, L. Ti², E. Nosova¹, T. Kerr¹, K. Hayashi³, M. Milloy¹, E. Wood², N. Fairbairn¹, ¹BC Centre on Substance Use, Vancouver, BC, Canada, ²British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada, ³Simon Fraser University, Vancouver, BC, Canada
- 117 *Substance use disorder diagnosis and craving: Comparison of substance users accessing treatment and substance users in harm reduction programs*
M. Auriacombe¹, C. Kervran¹, F. Serre², C. Denis³, P. Roux⁴, M. Jauffret-Roustide⁴, L. Lalanne⁵, J. Daulouede⁶, M. Fatseas⁷, ¹Université de Bordeaux, Bordeaux, France, ²Université de Bordeaux, Bordeaux, ³University of Pennsylvania, Philadelphia, PA, ⁴Institut National de la Santé et de la Recherche Médicale, Marseille, ⁵University Hospital of Strasbourg, Strasbourg, France, ⁶Bizia Addiction Clinic, Bayonne, France, ⁷Centre Hospitalier Charles Perrens, Bordeaux, France
- 118 *Longitudinal study of treatment need perception among people with substance use disorders in the US: Low perceived need is both common and stable over time*
S. Moeller¹, J. Platt², R. Goodwin³, ¹Stony Brook University School of Medicine, Stony Brook, NY, ²Columbia University, New York, NY, ³The City University of New York, New York, NY

Monday, June 17, 2019

ORAL COMMUNICATIONS 5
READY AND RARIN' TO GO:
PRECLINICAL STIMULANT RESEARCH

Grand Oaks G
10:00 - 12:00 PM

Chairs: Cameron Davidson and Michelle Doyle

- 10:00 *Influence of drug histories on the development of high levels of MDPV self-administration*
M. Doyle¹, R. DeSantis², A. Sulima³, K. Rice³, G. Collins², ¹University of Texas Health Science Center at San Antonio, San Antonio, TX, ²University of Texas Health Science Center, San Antonio, TX, ³National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD
- 10:15 *Effects of methamphetamine isomers on d-methamphetamine self-administration and food-maintained responding in male rats*
L. Dwoskin¹, M. Bardo¹, E. Denehy¹, L. Hammerslag¹, B. Blough², J. Bergman³, S. Kohut⁴, ¹University of Kentucky, Lexington, KY, ²RTI International, Research Triangle Park, NC, ³McLean Hospital, Belmont, MA, ⁴McLean Hospital, Harvard Medical School, Belmont, MA
- 10:30 *The role of mitochondrial complexes in methamphetamine-induced vulnerability to develop Parkinson's disease*
I. Calma, A. Persons, T. Napier, Rush University Medical Center, Chicago, IL
- 10:45 *Characterization of novel allosteric modulatory effects of SRI-32743 on HIV-1 Tat protein-induced inhibition of human dopamine transporter and potentiation of cocaine reward in HIV-1 Tat transgenic mice*
J. Zhu¹, J. McLaughlin², Y. Wang³, P. Quizon⁴, S. Ananthan⁵, S. Eans², H. Stacy², M. Strauss⁴, ¹University of South Carolina, Columbia, SC, ²University of Florida, Gainesville, FL, ³College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China, ⁴Drug Discovery and Biomedical Sciences, University of South Carolina, Columbia, SC, ⁵Southern Research Institute, Birmingham, AL
- 11:00 *Periadolescence toluene exposure alters behavioral responsiveness to later ethanol or cocaine challenges in Swiss-Webster mice*
C. Davidson, M. Naddaf, D. Holcomb, J. Hannigan, S. Bowen, Wayne State University, Detroit, MI
- 11:15 *Assessing effect of nalmefene on daily 4-hr cocaine self-administration in male mice*
M. Morochnik, K. Windisch, B. Reed, M. Kreek, The Rockefeller University, New York, NY
- 11:30 *Comparing social and nonsocial influences on cocaine seeking in male rats*
L. Hammerslag, J. Beckmann, M. Bardo, University of Kentucky, Lexington, KY

Monday, June 17, 2019

- 11:45 *Shifts in the neurobiological mechanisms motivating cocaine use with the development of an addicted phenotype*
T. Nesil, A. Bakhti-Suroosh, C. Davis, W. Lynch, University of Virginia, Charlottesville, VA

ORAL COMMUNICATIONS 6 SEXUAL MINORITY HEALTH AND SUBSTANCE USE DISORDERS

**Grand Oaks M
10:00 - 12:00 PM**

Chairs: Morgan Philbin and Johannes Thrul

- 10:00 *Sensation seeking, sexual orientation, and emerging adult drug abuse*
T. Regan¹, S. Wager², H. Hahn³, B. Harris¹, S. Engler¹, J. Schueler¹, S. Fields¹, ¹Texas A&M University, College Station, TX, ²Brown University, Providence, RI, ³Ohio State University, College Station, TX
- 10:15 *Social provision, substance use and sexual orientation from a nationally representative sample of adults from NESARC-III*
E. Kahle, P. Veliz, S. McCabe, C. Boyd, University of Michigan, Ann Arbor, MI
- 10:30 *Alcohol use, dependence and abuse in sexual minority adults by sex: Evidence from a national survey, 2015-2017*
R. Peralta¹, C. Thompson², ¹University of Akron, Akron, OH, ²Peds AI, Lansing, MI
- 10:45 *Cigarette, alcohol, and cannabis use and co-use among sexual minority and non-minority young adult smokers: A daily diary study*
J. Thrul¹, N. Nguyen², L. Holmes³, P. Ling⁴, ¹Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²UCSF, San Francisco, CA, ³State University of New York at Binghamton, Vestal, NY, ⁴University of California San Francisco, San Francisco, CA
- 11:00 *Associations of sexual orientation discrimination and substance use disorders: Differences by age and gender*
R. Evans-Polce¹, P. Veliz¹, C. Boyd¹, T. Hughes², S. McCabe¹, ¹University of Michigan, Ann Arbor, MI, ²Columbia University, New York, NY
- 11:15 *State-level medical marijuana laws and marijuana use outcomes among a nationally representative lesbian, gay and bisexual individuals from 2015-2016: Gender matters*
M. Philbin¹, P. Mauro², E. Greene², S. Martins², ¹Columbia University Mailman School of Public Health, New York, NY, ²Columbia University, New York, NY
- 11:30 *Disparities in past-year blunt use and daily cigarette smoking among sexual minority adults*
E. Greene¹, P. Mauro¹, M. Philbin², N. Levy², S. Martins¹, ¹Columbia University, New York, NY, ²Columbia University Mailman School of Public Health, New York, NY

Monday, June 17, 2019

- 11:45 *Correlates of transactional sex among male people who inject drugs (PWID) in Los Angeles and San Francisco, CA*
S. Walters¹, S. Lamb², L. Wenger³, A. Kral³, R. Bluthenthal², ¹New York University, New York, NY, ²Keck School of Medicine, Los Angeles, CA, ³RTI International, San Francisco, CA

ORAL COMMUNICATIONS 7 MOMMY AND ME: PERINATAL

**Grand Oaks I
10:00 - 12:00 PM**

Chairs: Loretta Finnegan and Dennis Hand

- 10:00 *Developing a model of care for substance use in pregnancy and parenting services in Sydney, Australia*
H. Coupland¹, M. Moensted², R. Sharon³, B. White¹, S. Khanlari⁴, J. Eastwood⁴, P. Haber⁴, C. Day³, ¹Drug Health Services, Sydney Local Health District, Camperdown, Australia, ²Discipline of Addiction Medicine, Faculty of Medicine and Health, University of Sydney, Sydney, Australia, ³University of Sydney, Sydney, Australia, ⁴Sydney Local Health District, Sydney, Australia
- 10:15 *Gabapentin exposure and neonatal abstinence syndrome among methadone-exposed neonates*
D. Hand, S. Jones, E. Mann, V. Short, E. Rosenthal, C. Barber, W. Kraft, S. Adeniyi-Jones, D. Abatemarco, Thomas Jefferson University, Philadelphia, PA
- 10:30 *Alexithymia, emotional regulation strategies, and the role of traumatic experiences in prenatally cocaine-exposed young adults.*
K. Morie¹, M. Potenza², L. Mayes¹, ¹Yale University, New Haven, CT, ²Yale University School of Medicine, New Haven, CT
- 10:45 *Eat-sleep-console as a treatment for infants with neonatal abstinence syndrome*
A. Allen¹, L. Grisham², M. Bader¹, ¹University of Arizona, Tucson, AZ, ²Banner Health, Tucson, AZ
- 11:00 *Prevalence of marijuana use in pregnant women with concurrent opioid use disorder or alcohol use in pregnancy: Results from the ENRICH cohort*
L. Bakhireva, University of New Mexico, Albuquerque, NM
- 11:15 *Cigarette and cannabis use among new mothers*
O. Alshaarawy, Michigan State University, East Lansing, MI
- 11:30 *Evaluating the impact of the Affordable Care Act (ACA) on medication for addiction treatment utilization for pregnant women with opioid use disorder*
S. Choi¹, T. Johnson², C. Herrera³, M. Stein¹, ¹Boston University School of Public Health, Boston, MA, ²Boston University, Oakland, CA, ³Boston University, Boston, MA
- 11:45 *Social support and opioid use among pregnant and parenting women*
L. Paz, N. Smith, L. Cottler, University of Florida, Gainesville, FL

Monday, June 17, 2019

**SYMPOSIUM VI
EXPLORING NON-OPIOID MECHANISMS
FOR THE TREATMENT OF PAIN**

**Grand Oaks K/L
10:00 - 12:00 PM**

Chairs: David Shurtleff and Emmeline Edwards

- 10:00 *Brain imaging to assess neuroplasticity following acupuncture therapy for neuropathic pain*
V. Napadow, Harvard University, Charlestown, MA
- 10:25 *Enhancement of opioid analgesia using chemokine receptor antagonists*
S. Inan, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
- 10:50 *Shedding new light on pain management*
M. Ibrahim, University of Arizona, Tucson, AZ
- 11:15 *The role of mindfulness-based stress reduction in migraine management*
S. Burrowes, Boston University School of Public Health, Boston, MA
- 11:40 *Discussant*
D. Shurtleff, National Institutes of Health, Bethesda, MD

**SYMPOSIUM VII
PREDICTIVE MODELING IN ADDICTION:
RECENT FINDING AND IMPLICATIONS**

**Grand Oaks H
10:00 - 12:00 PM**

Chairs: Sarah Yip and Susan Whitfield-Gabrielli

- 10:00 *Classifying and characterizing nicotine use disorder using support vector machine-based classification*
R. Wetherill, University of Pennsylvania, Philadelphia, PA
- 10:25 *Multi-modal, machine-learning methods for predicting substance use initiation*
H. Garavan, University of Vermont, Burlington, VT
- 10:50 *Connectome-based predictive modelling of polysubstance use in methadone-maintained individuals*
S. Lichenstein, Yale University School of Medicine, New Haven, CT
- 11:15 *Bayesian computational adjustment of inhibitory control predicts relapse in methamphetamine dependence*
J. Stewart, Laureate Institute for Brain Research, Tulsa, OK
- 11:40 *Addiction prediction: Implications for precision medicine*
S. Whitfield-Gabrielli, Massachusetts Institute of Technology, Cambridge, MA

Monday, June 17, 2019

**ANIMAL FORUM
HOW MANY R'S DOES IT TAKE TO DO RESEARCH?**

**Grand Oaks I
12:15 - 1:15 PM**

Chairs: Mark Smith and Ziva Cooper

S. Hacker, The University of Texas Health Science Center at San Antonio, San Antonio, TX

**HUMAN RESEARCH FORUM
ETHICAL CHALLENGES RECRUITING AND
RETAINING PARTICIPANTS IN ADDICTION RESEARCH**

**Grand Oaks H
12:15 - 1:15 PM**

Chairs: Victoria Votaw and Catherine Woodstock Striley

Recruiting and retaining human participants for laboratory-based studies: Challenges and strategies

S. Walsh, University of Kentucky, Lexington, KY

Recruitment and retention of substance use disordered participants in clinical trials: Ethical and pragmatic considerations

A. Oliveto, University of Arkansas for Medical Sciences, Little Rock, AR

Recruiting and retaining adolescent and emerging adults in substance use disorder treatment trials

E. McClure, Medical University of South Carolina, Charleston, SC

Indicas, IRBs, and the Internet: Ethical considerations and recruitment strategies for social media-based cannabis use surveys

J. Borodovsky, Washington University School of Medicine, St. Louis, MO

**CPDD EARLY CAREER INVESTIGATOR
TRAVEL AWARDS LUNCHEON**

**Sunday House
12:30 - 2:00 PM**

By Invitation Only

Monday, June 17, 2019

**TOWN HALL FORUM
MEDICAL DEVICES AND SUBSTANCE USE DISORDERS:
LINKING EFFORTS FROM ACADEMIA, INDUSTRY
AND GOVERNMENT**

**Grand Oaks G
1:00 - 2:00 PM**

Chairs: Marco Pravetoni and Sean Luo

Transcranial magnetic stimulation and substance use disorders
A. Tendler, Brainsway, Jerusalem, Israel

Neuromodulation with peripheral vagal nerve
A. Miranda, Medical College of Wisconsin, Milwaukee, WI

Status of medical device development from academic efforts
J. Wai, Columbia University Medical Center, New York, NY

Overview of Food and Drug Administration regulations regarding devices for substance use disorders
P. Bom, Institute of Health Informatics, Saint Paul, MN

Discussant
S. Luo, Columbia University, New York, NY

MARIAN W. FISCHMAN AWARD LECTURE

**Grand Oaks K/L
2:00 - 3:00 PM**

Presentation of the Marian W. Fischman Award to Hendree Jones
Introduction by Michelle Lofwall

Lecture: *Following the Wisdom of Women*
Hendree Jones, UNC at Chapel Hill, Chapel Hill, NC

COFFEE BREAK

**Cibolo Ballroom
3:00 - 3:30 PM**

M.I.T. TOWN HALL

Chair: Cecilia Bergeria

**Bluebonnet
3:00 - 4:00 PM**

ORAL COMMUNICATIONS 9
EVERYTHING IS BIGGER IN TEXAS:
COMORBIDITY ISSUES

Grand Oaks H
3:30 - 4:30 PM

Chair: Brian Fairman

- 3:30 *Depression features associated with current marijuana use among youth*
B. Fairman, National Institute of Child Health and Human Development, Bethesda, MD
- 3:45 *Differences in the tryptophan system between primary and substance-induced depression*
F. Fonseca¹, J. Mestre-Pintó², A. Gomez-Gomez³, E. Papasseit⁴, C. Pérez-Mañá⁴, K. Langohr⁵, O. Valverde⁶, O. Pozo³, R. de la Torre⁷, M. Farre⁴, M. Torrens⁸, ¹Institut de Neuropsiquiatria i Addiccions, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain, ²Hospital del Mar Medical Research Institute-IMIM, Barcelona, Spain, ³Integrative Pharmacology and Systems Neuroscience Research Group, Neuroscience Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵Department of Statistics and Operations Research, Universitat Politècnica de Barcelona/Barcelonatech, Barcelona, Spain, ⁶Department of Experimental and Health Sciences, Universitat Pompeu Fabra, & Neurobiology of Behaviour Research Group, Neuroscience Research Programme. IMIM-Hospital Del Mar Research Institute, Barcelona, Spain, ⁷D'Investigacio Medica, Barcelona, Spain, ⁸Institut de Neuropsiquiatria i Addiccions, Barcelona, Spain
- 4:00 *Psychiatric comorbidity and order of condition onset among patients seeking treatment for chronic pain and opioid use disorder*
D. Barry¹, M. Beitel², C. Cutter³, D. Fiellin¹, L. Madden², N. Lipkind⁴, P. Bollampally³, R. Schottenfeld⁵, ¹Yale University School of Medicine, New Haven, CT, ²Yale University, APT Foundation, New Haven, CT, ³Yale University, New Haven, CT, ⁴APT Foundation, Inc., New Haven, CT, ⁵Howard University College of Medicine, Washington, DC
- 4:15 *Psychiatric burden of prisoners suffering from opioid use disorder and ADHD*
M. Silbernagl¹, R. Slamanig¹, M. Stegemann¹, M. Sterzer¹, L. Mayer¹, G. Fischer², ¹Medical University of Vienna, Vienna, Austria, ²Medizinische Universitat, Wien, Australia

ORAL COMMUNICATIONS 11
NOT YOUR TYPICAL TEXAS BARBECUE:
STIMULI AND CRAVING**Grand Oaks I**
3:30 - 5:15 PM

Chairs: Maylen Perez Diaz and Zhenhao Shi

- 3:30 *Withdrawal symptom severity is associated with heightened mesocorticolimbic response to drug-related stimuli in opioid use disorder*
Z. Shi¹, V. Fairchild², A. Wang², C. O'Brien³, A. Childress⁴, D. Langleben⁵, ¹Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, VA Medical Center, Philadelphia, PA, ⁴University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁵Veterans Administration, Philadelphia, PA
- 3:45 *Stress, craving and mood as predictors of early dropout from opioid agonist therapy: Clues from Ecological Momentary Assessment*
K. Preston¹, L. Panlilio², S. Stull², B. Kowalczyk³, K. Phillips⁴, J. Schroeder⁵, D. Epstein², ¹National Institute of Drug Abuse Intramural Research Program, Baltimore, MD, ²NIDA Intramural Research Program, Baltimore, MD, ³Hartwick College, Oneonta, NY, ⁴National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD, ⁵Schroeder Statistical Consulting, LLC, Ellicott City, MD
- 4:00 *Craving for opioids affects retention in treatment and adherence to antiretroviral therapy in HIV positive patients with OUD stabilized on naltrexone*
E. Krupitsky¹, E. Blokhina², E. Verbitskaya², T. Yaroslavtseva², N. Bushara³, V. Palatkin³, M. Vetrova³, D. Lioznov², S. Poole⁴, R. Gross⁴, G. Woody⁴, ¹V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, St. Petersburg, Russian Federation, ²First Pavlov State Medical University, St. Petersburg, Russian Federation, ³First Pavlov State Medical University, St. Petersburg, ⁴University of Pennsylvania, Philadelphia, PA
- 4:15 *Conditioned neural responses to methamphetamine-paired contexts*
E. Childs¹, J. Weafer², ¹University of Illinois, Chicago, IL, ²University of Chicago, Chicago, IL
- 4:30 *Temporal response in subgenual anterior cingulate cortex (sgACC) to drug salient cues: An fMRI study among meth users*
H. Ekhtiari¹, R. Kuplicki¹, M. Paulus², ¹Laureate Institute for Brain Research, Tulsa, OK, ²Tulsa 1000 Investigators, Tulsa, OK
- 4:45 *Male-female differences in the neural substrates of cigarette craving, withdrawal and relief*
M. Perez Diaz¹, D. Ghahremani¹, P. Faulkner¹, J. O'Neill², J. Alger³, E. London¹, ¹University of California Los Angeles, Los Angeles, CA, ²Semel Institute, UCLA, Los Angeles, CA, ³University of California, Los Angeles, Los Angeles, CA

Monday, June 17, 2019

- 5:00 *Influence of cannabis-related cues on concurrent monetary choice in humans*
J. Strickland¹, J. Lile², W. Stoops¹, ¹University of Kentucky, Lexington, KY, ²University of Kentucky, College of Medicine, Lexington, KY

ORAL COMMUNICATIONS 8 SYSTEMS/HEALTH SERVICES

**Grand Oaks M
3:30 - 5:30 PM**

Chairs: Trina Johnson and Maria Parker

- 3:30 *The effect of Pharmacare Plan G coverage change in British Columbia, Canada on OAT initiation and adherence*
N. Hongdilokkul¹, E. Krebs², X. Zang¹, C. Zhou¹, F. Homayra¹, J. Min², B. Nosyk³, ¹BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, ²BC Centre for Excellence in HIV/AIDS, Vancouver, ³British Columbia Centre on Substance Use, Vancouver, BC, Canada
- 3:45 *Applying the 'cascade of care' conceptualization to the current US opioid public health crisis*
M. Parker¹, A. Villanti², S. Sigmon¹, R. Rawson³, ¹University of Vermont, Burlington, VT, ²University of Vermont, Burlington, ³UCLA Integrated Substance Abuse Programs, Los Angeles, CA
- 4:00 *Impact of Affordable Care Act implementation on psychiatric treatment in outpatient substance use disorder treatment settings*
C. Shover¹, A. Abraham², T. D'Aunno³, P. Friedmann⁴, K. Humphreys¹, ¹Stanford University, Palo Alto, CA, ²University of Georgia, Athens, GA, ³Robert F. Wagner Graduate School of Public Service, New York University, New York, NY, ⁴Baystate Health, Springfield, MA
- 4:15 *Perceived impacts of the Affordable Care Act on buprenorphine treatment*
H. Knudsen, University of Kentucky, Lexington, KY
- 4:30 *Disparities in post-ACA utilization of MAT at publicly subsidized substance use treatment facilities*
T. Johnson, J. Raifman, Boston University, Oakland, CA
- 4:45 *The impact of the Affordable Care Act's young adult dependent coverage expansion on opioid overdoses in the emergency department*
E. Coupet¹, D. Polsky², R. Werner², M. Delgado², ¹Yale University School of Medicine, New Haven, CT, ²University of Pennsylvania, Philadelphia, PA
- 5:00 *Impact of opioid use disorder on hospital disposition and readmissions*
J. Zavodnick¹, M. Morley², R. Sterling², ¹Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, ²Thomas Jefferson University, Philadelphia, PA

Monday, June 17, 2019

- 5:15 *The Cornerstone Clinic at Helping Up Mission: Increasing treatment retention for homeless persons with substance use disorders*
D. Antoine¹, L. Hanks², T. Speed³, D. Huggins¹, E. Strain¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Hospital, Baltimore, MD

SYMPOSIUM IX

Grand Oaks G

**ENLARGING THE TOOLBOX: USING
PRECLINICAL DATA TO IDENTIFY NON-OPIOID
RECEPTOR TARGETS FOR MEDICATION-ASSISTED
TREATMENT OF OPIOID USE DISORDER**

3:30 - 5:30 PM

Chairs: Kurt Rasmussen and Jane Acri

- 3:30 *Serotonin receptor targets for opioid use disorder pharmacotherapy*
K. Cunningham, University of Texas Medical Branch, Galveston, TX
- 3:55 *Identifying medication targets for opioid use disorder: Redirecting the dopamine D3 receptor hypothesis*
A. Newman, NIDA Intramural Research Program, Baltimore, MD
- 4:20 *The study of gut-brain neuroendocrine pathways for the development of novel treatments for opioid (and other) use disorders: The ghrelin system*
L. Leggio, NIDA Intramural Research Program, Baltimore, MD
- 4:45 *Optimization of muscarinic M5 negative allosteric modulators for the prevention and treatment of opioid use disorder*
C. Jones, Vanderbilt University, Nashville, TN
- 5:10 *Discussant: NIDA as a catalyst for the development of new treatments for OUD*
K. Rasmussen, National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD

SYMPOSIUM VIII

Grand Oaks K/L

**WHAT PREDICTS EARLY ALCOHOL SIPPING,
CAFFEINE USE AND SCREEN MEDIA ACTIVITY IN
YOUTH? 2-YEAR FINDINGS FROM THE ADOLESCENT
BRAIN COGNITIVE DEVELOPMENT STUDY**

3:30 - 5:30 PM

Chairs: Susan Weiss and Krista Lisdahl

- 3:30 *Neurocognitive predictors of alcohol sipping and caffeine use in pre-teens: Year-two findings from the ABCD Study*
K. Lisdahl, University of Wisconsin-Milwaukee, Milwaukee, WI

Monday, June 17, 2019

- 3:55 *Externalizing correlates of early sipping*
A. Watts, University of Missouri, Columbia, MO
- 4:20 *Culture and environmental predictors of early sipping in pre-teen youth*
R. Gonzalez, Florida International University, Miami, FL
- 4:45 *Screen media activity in youth: Association with physical activity, family conflict, and sleep*
F. Breslin, Laureate Institute for Brain Research, Tulsa, OK
- 5:10 *Discussant: Overview, implications, and discussion of year- 2 findings from the ABCD Study*
S. Weiss, National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD

ORAL COMMUNICATIONS 10 RACIAL AND ETHNIC HEALTH DISPARITIES

**Grand Oaks H
4:45 - 5:45 PM**

Chairs: Devin Banks and Angela Haeny

- 4:45 *The effect of varenicline on smoking and drinking outcomes by ethnic group*
A. Haeny¹, R. Gueorguieva², A. Zweben³, S. O'Malley², ¹Yale University, New Haven, CT, ²Yale University School of Medicine, New Haven, CT, ³Columbia School of Social Work, New York, NY
- 5:00 *Differences in typologies of current substance use among African American and White high-school adolescents: A latent class analysis*
D. Banks¹, M. Bello², Q. Crichlow¹, A. Leventhal², T. Zapolski¹, ¹Indiana University Purdue University Indianapolis, Indianapolis, IN, ²University of Southern California, Los Angeles, CA
- 5:15 *Racial differences in opioid overdose training, naloxone possession, and naloxone administration among people who inject drugs (PWID)*
A. Jones¹, J. Park², S. Allen², K. Schneider¹, B. Weir³, S. Sherman³, ¹Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Hospital, Baltimore, MD
- 5:30 *Racial/ethnic and gender differences in risk for past 30- day opioid misuse: A statewide sample of the Florida juvenile justice system*
H. Pierre¹, M. Johnson², ¹University of Florida: STOMP Lab, Gainesville, FL, ²University of Florida, Gainesville, FL

Monday, June 17, 2019

FILM: HEROIN(E)

**Grand Oaks E/F
5:45 - 6:30 PM**

PRIMM-SINGLETON RECEPTION

By Invitation Only

**Wisteria
5:30 - 7:00 PM**

**NIDA INTERNATIONAL RESEARCH
POSTER SESSION**

**Grand Oaks E/F
7:00 - 9:00 PM**

Chair: Steven Gust

CPDD International Committee: Best research poster by a scientist from a low, lower middle, or upper middle-income country
C. McCoy, Comprehensive Drug Research Center, Miami, FL

2019 NIDA International Forum Abstracts

June 17, 2018–7:00 to 9:00 p.m.

Odd numbered posters manned the first hour, Even numbered, the second hour

Informational

100 Africa and Middle East Congress on Addiction: Outreach and capacity building activities in 2018

M. al'Absi¹, S. Mhamdi², M. Nakajima¹, S. Seedat³. ¹University of Minnesota, United States; ²University of Monastir, Tunisia; ³Stellenbosch University, South Africa

101 Society for Research on Nicotine and Tobacco University: Training and resources for the nicotine and tobacco research community

Mona Johnson, Society for Research on Nicotine and Tobacco, United States

102 Translating evidence into practice through drug demand reduction education programs in universities: The Kenyatta University, Kenya Experience

B. Kathungu, M. Karega. Kenyatta University, Kenya

103 The Hubert H. Humphrey Fellowship Program at Virginia Commonwealth University

J.R. Koch, R.L. Balster, W.L. Kliever, H. Ashton. Virginia Commonwealth University, United States

104 The Virginia Commonwealth University Hubert H. Humphrey Fellowship Program in Substance Abuse Prevention, Treatment, and Policy: One-year follow-up assessment

O. Leonchuk¹, J.R. Koch², R.L. Balster², W. Kliever². ¹North Carolina State University, United States; ²Virginia Commonwealth University, United States

105 Five years of cannabis legalization in Uruguay: Finding new indicators to evaluate the effects

M. Martoy. Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States; National Drug Board of Uruguay, Uruguay

106 The adaptation of the universal treatment curriculum walkthrough workshops: Philippine experience

M.I. Melgar. Ateneo de Manila University, Philippines

107 *A cross-country comparison of tobacco control policies between the United States and China*
D. Yuan^{1,2}, X. Chen¹, S. Lin¹, A. Barnes¹, J.R. Koch¹, H. Xue¹. ¹Virginia Commonwealth University, United States; ²*Southern Weekly Newspaper*, China

Basic Science

200 *Genotype-phenotype feasibility studies on khat abuse, traumatic experiences, and psychosis in Ethiopia*

K. Adorjan^{1,2,3}, Z. Mekonnen⁴, F. Tessema⁵, M. Ayana⁴, F. Degenhardt⁶, P. Hofmann^{6,7}, N. Fricker⁶, M. Widmann^{8,9}, H. Riedke^{8,9}, S. Toennes¹⁰, M. Soboka¹¹, S. Suleman¹², M. Tesfaye¹³, M. Rietschel¹⁴, E. Susser^{15,16}, M. Odenwald^{8,9}, T.G. Schulze¹, M. Mattheisen^{17,18}. ¹Institute of Psychiatric Phenomics and Genomics, Medical Center of the University of Munich, Germany; ²Department of Psychiatry and Psychotherapy, Medical Center of the University of Munich, Germany; ³Center for International Health, University of Munich, Germany; ⁴Department of Medical Laboratory Sciences and Pathology, Jimma University, Ethiopia; ⁵Department of Epidemiology, Jimma University, Ethiopia; ⁶Institute of Human Genetics, University of Bonn, Germany; ⁷Department of Genomics, Life and Brain Center, University of Bonn, Germany; ⁸Department of Psychology, University of Konstanz, Germany; ⁹Vivo international e.V., Germany; ¹⁰Department of Forensic Toxicology, Goethe University, Germany; ¹¹Department of Psychiatry, Jimma University, Ethiopia; ¹²School of Pharmacy, Faculty of Health Sciences, Jimma University Institute of Health, Ethiopia; ¹³Department of Psychiatry, St. Paul's Hospital Millennium Medical College, Ethiopia; ¹⁴Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Germany; ¹⁵Mailman School of Public Health, Columbia University, United States; ¹⁶New York State Psychiatric Institute, United States; ¹⁷Department of Psychiatry, Psychosomatics, and Psychotherapy, University of Wuerzburg, Germany; ¹⁸Department of Clinical Neuroscience, Karolinska Institutet, Sweden

201 *More extensive gray matter volume reduction in fronto-temporal areas and decision-making impairments among individuals with cocaine + alcohol use disorder than cocaine only: A voxel-based morphometric study*

P.D. Goncalves, C.V.I. de Melo, F.L.S. Duran, D.R. Lima, H.P. de Oliveira Junior, M.H. Serpa, L.M. Sanchez, P. Rosa, M. Zanetti, T. Chaim-Avancini, L.K. Ferreira, M. Cavalett, N.A. da Costa, M. Foigel, M. Ometto, A. Malbergier, R. Amaral, S. Nicastrì, A.G. de Andrade, G.F. Busatto, P.J. Cunha. Department and Institute of Psychiatry, School of Medicine, University of São Paulo, Brazil

202 *Acute effects of cannabinoids on addiction endophenotypes are moderated by genes encoding the cannabinoid receptor 1 and fatty acid amide hydrolase enzyme*

C. Hindocha^{1,2,3,6}, T.P. Freeman^{1,2,4,5}, G. Schafer¹, C. Gardner¹, M.A.P. Bloomfield^{1,2,3,6,7,8,9,10}, E. Bramon^{8,9,11}, C.J.A. Morgan^{1,12}, H.V. Curran^{1,3}. ¹Clinical Psychopharmacology Unit, Research Department of Clinical, Educational, and Health Psychology, University College London, United Kingdom; ²Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Faculty of Brain Sciences, University College London, United Kingdom; ³National Institute for Health Research Biomedical Research Centre at University College London Hospitals

and University College Hospital, United Kingdom; ⁴Department of Psychology, University of Bath, United Kingdom; ⁵National Addiction Centre, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, United Kingdom; ⁶Psychiatric Imaging Group, Medical Research Council London Institute of Medical Sciences, Hammersmith Hospital, United Kingdom; ⁷Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, United Kingdom; ⁸Division of Psychiatry, University College London, United Kingdom; ⁹Institute of Psychiatry, Psychology, and Neuroscience at King's College London, United Kingdom; ¹⁰Maudsley National Health Service Foundation Trust, United Kingdom; ¹¹Institute of Cognitive Neuroscience, University College London, United Kingdom; ¹²Psychopharmacology and Addiction Research Centre, University of Exeter, United Kingdom

203 The role of nerve growth factor gene, personality, and impulsivity in women with opioid use disorder

S-Y. Huang. Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taiwan

204 Cerebral volumetric bases of attention and working memory impairment in chronic ketamine users

C-C. Hung^{1,2}, Y-H. Liu¹, C-C. Huang³, C-S.R. Li^{4,5}, N.G. Muggleton⁶, T. Szu-Hsien Lee⁷, C.-P. Lin^{1,8}. ¹Institute of Neuroscience, National Yang Ming University, Taiwan; ²Bali Psychiatric Center, Ministry of Health and Welfare, Taiwan; ³Aging and Health Research Center, National Yang-Ming University, Taiwan; ⁴Department of Psychiatry, Yale University, United States; ⁵Department of Neuroscience, Yale University, United States; ⁶Institute of Cognitive Neuroscience, National Central University, Taiwan; ⁷Department of Health Promotion and Health Education, National Taiwan Normal University, Taiwan; ⁸Brain Research Center, National Yang-Ming University, Taiwan

205 Gas chromatography coupled to mass spectrometry (GC-MS) analysis and cytotoxicity investigations of shammah (smokeless tobacco) samples of Jazan region of Saudi Arabia reveals carcinogenic and addictive components

A. Khalid, H. Alhazmi. Smokeless Tobacco Research Group, Substance Abuse Research Centre, Jazan University, Saudi Arabia

206 Evaluation of extraction methods for the determination of cannabinoids in breast milk

R.S. Ramnarine^{1,2}, J.L. Poklis³, C.E. Wolf⁴. ¹Humphrey Fellowship Program, Virginia Commonwealth University, United States; ²Trinidad and Tobago Forensic Science Centre, Trinidad and Tobago; ³Department of Pharmacology and Toxicology, Virginia Commonwealth University, United States; ⁴Department of Pathology, Virginia Commonwealth University, United States

207 Sex differences in implicit brain connectivity of cocaine users: Opposite patterns of connectivity for males and females in resting-state functional magnetic resonance imaging

B. Sanvicente-Vieira¹, P.E. Ferreira², N. Bianchini², L. Rothmann², A. Buchweitz², A.R. Franco³, R. Grassi-Oliveira². ¹Pontificia Universidade Católica do Rio Grande do Sul (PUCRS), School of Health Sciences, Developmental Cognitive Neuroscience Lab, Brazil; ²PUCRS, Brain Institute of Rio Grande do Sul (BraIns), Brazil; ³The Nathan S. Kline Institute for Psychiatric Research, Brazil

208 *Patterns of cognitive impairment in heroin users and methamphetamine users*

W. Shen¹, J. Zhang¹, W.Cui², L. Li¹, Y. Liu¹, H. Liu¹, W. Zhou^{1,2}. ¹Ningbo Addiction Research and Treatment Center, China; ²Ningbo University School of Medicine, China

209 *Epigenetic biomarkers of drug addiction and withdrawal*

D. Soares Bispo Santos Silva, R. Spurbeck, S. Reed, A. Zmarowski. Battelle Memorial Institute, United States

210 *Repeated toluene, but not cyclohexane inhalation, induces endocrine alterations in adolescent male rats*

P. Soberanes-Chavez¹, P. de Gortari-Gallardo¹, S.L. Cruz². ¹Laboratory of Molecular Neurophysiology, National Institute of Psychiatry, Mexico; ²Department of Pharmacology, Cinvestav, Mexico

211 *Activation of trace amine-associated receptor 1 attenuates schedule-induced polydipsia in rats*

I. Sukhanov¹, A. Dorotenko¹, A. Dolgorukova¹, R.R.Gainetdinov², E.E. Zvartau¹, A.Y. Beshpalov¹. ¹First Saint Petersburg State Medical University, Russia; ²Saint Petersburg State University, Institute of Translational Biomedicine, Russia

212 *Kratom and pain tolerance*

K. Vicknasingam¹, W-T. Chooi², A.A. Rahim¹, D. Ramachandran¹, S. Ramanathan¹, D. Singh¹, H. Zainal³, M.C. Chawarski⁴. ¹Centre for Drug Research, Universiti Sains Malaysia, Malaysia; ²School of Social Sciences, Universiti Sains Malaysia, Malaysia; ³School of Pharmaceutical Sciences, Universiti Sains Malaysia, Malaysia; ⁴Yale School of Medicine, United States

213 *Effects of repeated toluene, ketamine, or MK-801 treatment on sexual behavior in adolescent male rats*

V. Violante-Soria, G. Rodríguez-Manzo, S.L.Cruz. Pharmacobiology Department, Cinvestav-Coapa, Mexico

214 *Resting state default-mode network functional connectivity correlates with glutamate+glutamine/creatine ratio of the medial prefrontal cortex in methamphetamine males: An fM-RS study*

Q. Wu^{1,2,3,4,5}, C. Qi^{1,2,3,4,5}, A. Xie⁶, Y. Liao^{1,2,3,4,5}, X.Wang^{1,2,3,4,5}, J. Tang^{1,2,3,4,5}, J. Liu⁶, W. Hao^{1,2,3,4,5}, T. Liu^{1,2,3,4,5}. ¹Department of Psychiatry, The Second Xiangya Hospital, Central South University, China; ²Mental Health Institute, The Second Xiangya Hospital, Central South University, China; ³National Clinical Research Center on Mental Disorders, China; ⁴National Technology Institute on Mental Disorders, China; ⁵Hunan Key Laboratory of Psychiatry and Mental Health, China; ⁶Department of Radiology, The People's Hospital of Hunan Province, China

215 *Role of ventral medial prefrontal cortex (vmPFC) to nucleus accumbens (NAc) shell glutamatergic projection in the heroin reward and motivation*

H. Zhu¹, M.Lai¹, X. Zhang², H. Liu¹, H. Shen², W. Zhou¹. ¹Laboratory of Behavioral Neuroscience, Ningbo Addiction Research and Treatment Center, Ningbo University School of Medicine, China; ²Zhejiang Provincial Key Laboratory of Pathophysiology, Ningbo University School of Medicine, China

Epidemiology

300 *Gender differences in stimulants use among patients in methadone maintenance treatment in Bucharest, Romania*

A.O. Abagiu^{1,2}, I.C. Fierbinteanu², A. Koulosousas², E.A. Bolocan^{1,2}, F.M. Duna¹. ¹National Institute for Infectious Diseases Prof. Dr. Matei Bals, Romania; ²Romanian Association Against AIDS, Romania

301 *Addressing prevalence and correlates among a sample of Egyptian university students who suffer from substance use disorders*

M. Abdelghani, G.S. El-Deen, M. Said, H.M. El-Gohary, U.M. Youssef, M.M. Bassiony. Psychiatry Department, College of Medicine, Zagazig University, Egypt

302 *Factors influencing indulgence in drug abuse among adolescents in selected secondary schools Akure, Ondo State*

M.O. Abiona¹, J.T. Olusegun². ¹Department of Nursing, University of Ibadan, Nigeria; ²Ondo State School of Nursing Akure, Nigeria

303 *Psychopathy and khat abuse among prisoners in the correctional institution in Jimma, Ethiopia*

Y.Y. Abyu¹, M. Soboka¹, E. Tesfaye¹, M. Abera¹, A. Mamaru¹, K. Adorjan^{2,3,4}. ¹Department of Psychiatry, Faculty of Medical Sciences, Jimma University, Ethiopia; ²Center for International Health, Ludwig-Maximilians-Universität, Germany; ³Departments of Psychiatry and Psychotherapy, Medical Center of the University of Munich, Germany; ⁴Institute of Psychiatric Phenomics and Genomics, Medical Center of the University of Munich, Germany

304 *The hidden harm: Child academic performance is negatively impacted by heroin using parents in Pakistan*

Q.U. Ain¹, M.A. Dahar¹, T. Szu-Hsien Lee². ¹Department of Education, Pir Mehr Ali Shah Arid Agriculture University Rawalpindi, Pakistan; ²Department of Health Promotion and Health Education, National Taiwan Normal University, Taiwan

305 *Access to treatment services among female drug users in Nigeria*

G.A. Akpabio, I.S. Obot. Centre for Research and Information on Substance Abuse, University of Uyo, Nigeria

306 *Involvement with the child welfare system independently associated with early injection initiation among street-involved youth who inject drugs in Vancouver, Canada*

B. Barker^{1,2}, J. Shoveller^{2,3}, H. Dong^{2,3}, T. Kerr^{2,4}, K. DeBeck^{2,5}. ¹Interdisciplinary Studies Graduate Program, University of British Columbia (UBC), Canada; ²British Columbia Centre on Substance Use, Canada; ³School of Population and Public Health, UBC, Canada; ⁴Division of AIDS, Department of Medicine, UBC, Canada; ⁵School of Public Policy, Simon Fraser University, Canada

307 *Psychiatric comorbidity among Egyptian patients with opioid use disorders attributed to tramadol*

M.M. Bassiony, U.M. Youssef, M.S. Hassan, G.S. El-Deen, M. Abdelghani, H. El-Gohari. Psychiatry Department, Faculty of Medicine, Zagazig University, Egypt

308 *Feasibility and effectiveness of an HIV education and harm reduction projection mapping intervention among crack users in Mexico City*

A. Cepeda¹, J. Frankeberger², K. Nowotny³, G. Natera-Rey⁴, A. Valdez¹. ¹University of Southern California, United States; ²University of Pittsburgh, United States; ³University of Miami, United States; ⁴National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico

309 *Exposure to environmental neurotoxins, epigenetic changes, and vulnerability to psychiatric disorders: The Consortium on Vulnerability to Externalizing Disorders and Addictions Study: Methodological issues*

A. Chakrabarti¹, V. Benegal², G. Schumann³, D. Basu⁴, S.S. Kurpad⁵, M. Krishna⁶, R.K.L. Singh⁷, R.D. Bharat², G. Barker³, M. Purushottam², S. Desrivieres³, P. Maurya¹, S. Roy¹, A. Yadav¹, S. Das¹, E. Sharma², B. Holla², N. Vaidya², Y. Zhang³. ¹Regional Occupational Health Centre–Eastern, National Institute of Occupational Health, Indian Council of Medical Research, India; ²National Institute of Mental Health and Neurosciences, India; ³Institute of Psychiatry, King's College London, United Kingdom; ⁴Postgraduate Institute of Medical Education and Research, India; ⁵St. John's Medical College, India; ⁶Holdsworth Memorial Hospital, India; ⁷Regional Institute of Medical Sciences, India

310 *Pattern of substance use and its correlates among street children in India*

B. Chatterjee, A. Dhawan, A. Ambekar, R. Bhargawa, A. Agrawal, A. Mishra, A. Chopra. National Drug Dependence Treatment Centre and Department of Psychiatry, All India Institute of Medical Sciences, India

311 *The aging journey railway, drug (De)rails and care ways in Brazil and Portugal*

M.R. dos Reis Lourenço, T.C. Bueno, J. Da Silva. Federal University of Brazil, Brazil

312 *An exploratory study on the prevalence of opiate use, abuse, and treatment in Tirana University Hospital Center*

D. Doko¹, Z. Sulaj², C. Tamasdan³. ¹Frank H. Netter M.D. School of Medicine at Quinnipiac University, University of North Haven, United States; ²Clinical Toxicology Service of Tirana University Hospital Center 'Mother Teresa', Albania; ³Pain Management Department, St. Vincent's Medical Center, United States

313 *Association of experimentation with tobacco and nicotine-containing products and current tobacco use status among youth in the United States: Findings from a 2017 national online survey*

O. El-Shahawy^{1,2,3}, K.L. Walker^{3,4}, A.M. Groom³, J.L. Hart^{3,4}. ¹New York University School of Medicine, United States; ²Ain Shams University School of Medicine, Egypt; ³American Heart Association–Dallas, Texas, United States; ⁴University of Louisville, United States

314 *Gender differences in substance use, victimization, and mental health among adolescents in specialized residential care*

S. Fernandez-Artamendi¹, A. Águila², J. Fernández del Valle², A. Bravo². ¹Department of Psychology, Universidad Loyola Andalucía, Spain; ²Family and Childhood Research Group, University of Oviedo, Spain

- 315 *Heroin use in the Mexican northern border: A qualitative and epidemiological study in field and treatment centers*
C. Fleiz¹, E. Medina-Mora¹, J. Villatoro¹, S. Cruz², M. Domínguez¹, A. Chavez³, J. Arredondo⁴, L. Pacheco³. ¹National Institute of Psychiatry Ramón de la Fuente, Mexico; ²Center for Research and Advanced Studies, Mexico; ³Prevensa-Tijuana, Mexico; ⁴School of Medicine, University of California San Diego, United States
- 316 *Emergency department admissions in Kumasi, Ghana: Prevalence of alcohol and other drug use and associated trauma*
P.K. Forson^{1,2}, G. Oduro^{1,2}, J. Bonney^{1,2}, S. Cobbold², J.S. Frimpong², C. Boyd³, R. Maio³. ¹Department of Emergency Medicine, Komfo Anokye Teaching Hospital (KATH), Ghana; ²Emergency Medicine Research Office, KATH, Ghana; ³Injury Prevention Center, University of Michigan, United States
- 317 *Impact of cocaine and/or cannabis use on markers of inflammation, monocyte activation, and intestinal permeability in patients with alcohol use disorder admitted for detoxification*
D. Fuster¹, X. García-Calvo¹, F. Bolao², P. Zuluaga¹, A. Sanvisens¹, J. Tor¹, R. Muga¹. ¹Internal Medicine Service, Hospital Universitari Germans Trias i Pujol, Spain; ²Internal Medicine Service, Hospital Universitari Bellvitge, Spain
- 318 *Understanding the role of adverse childhood experiences and life time prevalence of substance use in predicting current substance use among university students*
R. Hanif, R. Riaz. Department of Psychology, University of Karachi, Pakistan
- 319 *Predictors of baseline and recent non-fatal opioid overdose among a cohort of people who inject drugs in Melbourne, Australia*
P. Hill^{1,2}, P. Dietze^{1,2}, M. Stooze^{1,2}. ¹Behaviours and Health Risks Program, Burnet Institute, Australia; ²School of Public Health and Preventive Medicine, Monash University, Australia
- 320 *Drug and substance abuse among antenatal women in Nigeria*
N. Ibe, I.C. Chidiebere. African Youths Initiative on Crime Prevention, Nigeria
- 321 *Stigma and violence among HIV-positive people who use drugs in Ukraine*
B. Idrisov^{1,2}, J.O. Lee³, Y. Yoon³, O. Makarenko⁴, T. Kiriazova⁴, P.S. Nurius⁵, T. Flanagan⁶, J.H. Samet², K. Lunze². ¹Bashkir State Medical University, Russia; ²Boston University, United States; ³University of Southern California, United States; ⁴Ukrainian Institute for Public Health Policy, Ukraine; ⁵University of Washington, United States; ⁶Brown University, United States
- 322 *Epidemic of incident hepatitis C virus infection among injecting drug users in Rajshahi City of Bangladesh: Time is running out for massive interventions*
M.A. Kalam. Siam Health Care, Bangladesh
- 323 *Stigma associated with substance use in the Palestinian community*
H. Kharabsha. Humphrey Fellowship Program, Virginia Commonwealth University, United States; Palestinian Ministry of Health, Palestinian Territories
- 324 *The pattern of use of cannabis and a pilot run for genetic polymorphism: A prospective, exploratory cross-sectional tertiary care hospital-based study*
C. Kulkarni, A. Bavle, S. Hebbar, A. Kolandaswamy, H. Sahajanand, M.R. Prabhu. Rajarajeswari Medical College and Hospital, India

325 *Suicide risk of community ketamine users in Taiwan*

Y-C. Kuo¹, H-I. Chen², S-C. Wang^{2,3}. ¹Linsen Chinese Medicine and Kunming Branch, Taipei City Hospital, Taiwan; ²Center for Neuropsychiatric Research, National Health Research Institutes, Taiwan; ³Department of Psychiatry, Cardinal Tien Hospital, Taiwan

326 *Prevalence of HIV, hepatitis B, hepatitis C, and syphilis among crystal methamphetamine users in Indonesia*

T.P. Kusumoputri, L. Nevendorff, I. Praptoraharjo. HIV and AIDS Research Center, Atma Jaya Catholic University of Indonesia, Indonesia

327 *Factors associated with increasing cannabis use among adolescents in Chile from 2003 to 2015*

N. Libuy, A. Mundt, C. Ibáñez. Universidad de Chile, Chile

328 *Genetic characterization of HIV-1 from people who inject drugs and sexual transmission in people in Southwestern China*

Y. Ding¹, Y. Wang¹, Y. Feng¹, W. Xu¹, D. Metzger², Y. Shao¹, L. Ma¹. ¹State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, China; ²University of Pennsylvania, United States

329 *Evolution of tobacco and marijuana consumption in pregnant women's populations in Uruguay*

R. Magri¹, M. Fleming², E. Ostrender², A. Baldwin³, N. Hayes², M. Martinez¹, P. Cabral⁴. ¹Universidad de la Republica de Uruguay, Uruguay; ²Northwestern University, United States; ³United States Drug Testing Laboratories, United States; ⁴Hospital General de las Fuerzas Armadas de Uruguay, Uruguay

330 *How to quit heroin and injection drug use: A cross-sectional study across 14 countries*

L.J. Maier¹, M.J. Barratt², J.A. Ferris³, A.R. Winstock⁴. ¹University of California San Francisco, United States; ²University of New South Wales, Australia; ³University of Queensland, Australia; ⁴University College London, United Kingdom

331 *Predictors of high levels of satisfaction with opioid antagonist treatment in people who inject drugs in Ukraine: European Quality Audit of Opioid Treatment survey*

A. Meteliuk¹, L. Madden², S. Farnum², T. Fomenko¹, K. LaMonaca³, R. Marcus³, I. Pykalo⁴, Z. Islam¹, F.L. Altice³. ¹Alliance for Public Health, Ukraine; ²APT Foundation, United States; ³Yale School of Medicine, United States; ⁴Ukrainian Institute for Public Health Policy, Ukraine

332 *Diphenhydramine injection in Kyrgyz prisons: A qualitative study of a high-risk behavior with implications for harm reduction*

J.P. Meyer¹, G. Culbert², L. Azbel³, C. Bachiredy⁴, A. Kumanalieva⁵, F.L. Altice⁶. ¹AIDS Program, Yale University School of Medicine, United States; ²University of Illinois at Chicago, United States; ³London School of Tropical Hygiene and Tropical Medicine, United Kingdom; ⁴Robert Wood Johnson Clinician Scholars Program, University of Pennsylvania, United States; ⁵AIDS Foundation East-West, Kyrgyzstan; ⁶Yale AIDS Program, University of Malaya, Malaysia

333 *Irregular migration and drug use: Assessing the prevalence among identified migrant returnees in Nigeria*

I.D. Molobe¹, O. Oluwakemi². ¹Unified Initiative for a Drug Free Nigeria, Nigeria; ²Department of Community Health and Primary Care, College of Medicine, University of Lagos, Nigeria

334 *Assessing progress on HIV treatment and prevention goals in Burma (Myanmar)*

R. Myint, W.W. Lwin. Myanmar Anti-Narcotics Association, Burma (Myanmar)

335 *Heroin and amphetamine dependent individuals manifest different patterns of DSM-5 dependence symptoms*

D. Nedelchev¹, E. Psederska^{1,2}, K. Bozgunov¹, G. Vasilev¹, J. Vassileva³. ¹Bulgarian Addictions Institute, Bulgaria; ²New Bulgarian University, Bulgaria; ³Virginia Commonwealth University, United States

336 *Substance use and risky sexual behaviour among young male adults in Uyo, Nigeria*

E-U.E. Nelson, N.F. Essien. Centre for Research and Information on Substance Abuse, Nigeria

337 *The global opioid epidemic: Pattern and dynamics*

K. Niaz. United Nations Office on Drugs and Crime, Austria

338 *Smoking and quality of life among HIV-positive females at an out-patient clinic in Lagos*

A.M. Ojo, O.A. Adegbohun, O.E. Ajayi. Federal Neuro-Psychiatric Hospital, Nigeria

339 *Influence of substance use on quality of life among adolescents in Lagos*

C.C. Okonkwo, O.J. Ibiyokun, I.A. Sadiku, O.F. Ajiroto. Federal Neuro-Psychiatric Hospital, Nigeria

340 *Risk perception towards exposure to secondhand smoke from tobacco among antenatal clinic attendees in primary health care facility in Calabar, Nigeria*

U. Onukogu¹, A. Anya², O Udofia³, B.Edet¹, E. Ekpe¹. ¹Federal Neuro-Psychiatric Hospital, Nigeria; ²Federal University Gusau Zamfara, Nigeria; ³Department of Psychiatry, University of Calabar, Nigeria

341 *A comparative study of substance and non-substance abusers among Nigeria prison inmates on recidivism, psychopathy, and aggression*

F.C. Onyedibe¹, M.C.C. Onyedibe², E.E Nnadozie², M.C. Ifeagwazi². ¹Ministry of Economic Development–Uyo, Nigeria; ²Department of Psychology, University of Nigeria

342 *Substance abuse and psychotic symptoms among psychiatric patients: The moderating role of resilience*

M-C.C. Onyedibe, C.J. Aliche, M.I. Chuka. Department of Psychology, University of Nigeria–Nsukka, Nigeria

343 *Perceived negative effects and benefits of new psychoactive substances (NPS): Results of online survey among NPS users in Georgia*

D. Otiashvili¹, D. Subeliani², L. Kutelia¹, A. Beselia¹, T. Mgebrishvili¹, I. Kirtadze¹. ¹Addiction Research Centre–Alternative Georgia, Georgia; ²Faculty of Arts and Science, Ilia State University, Georgia

- 344 *Relationships between psychopathy and alexithymia in heroin, amphetamine, and polysubstance users*
E. Psederska¹, K. Bozgunov¹, D. Nedelchev¹, G. Vasilev¹, J. Vassileva². ¹Bulgarian Addictions Institute, Bulgaria; ²Departments of Psychiatry and Psychology, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, United States
- 345 *The oral cancer awareness among a sample of recovering drug addicts in Drug Rehabilitation Center, National Narcotics Board, Republic of Indonesia*
A.T.D. Putri¹, Y.S. Wimardhani². ¹Drug Rehabilitation Center, National Narcotics Board, Indonesia; ²Department of Oral Medicine, Faculty of Dentistry, Universitas Indonesia, Indonesia
- 346 *Incidence of substance use and suicidal ideation among patients reporting to psychiatric clinic of a district hospital in Sikkim, India*
T. Rai¹, S. Rasaily². ¹Sikkim Anti Drugs Unit, Department of Health, Government of Sikkim, India; ²Singtam District Hospital, India
- 347 *Reasons, consequences, and pattern of consumption of alcohol and cannabis in university students of the City Of Quito*
V.B. Rojeab-Bravo, J.A.J. Costa. Technical Secretary of Drug Use Prevention, Ecuador
- 348 *Other drug use is common in medical hospital patients willing to start alcohol use disorder medication treatment*
E. Romero-Rodriguez, S. Kim, C.A. Chen, S. Meli, D.M. Cheng, H. Lee, T. Palfai, J. Samet, R. Saitz. School of Public Health, Boston University, United States; School of Medicine, Boston University, United States; Boston Medical Center, United States
- 349 *Knowledge about opioid overdose among people who inject drugs in India and association with experience of opioid overdose: A community-based study*
R. Saini, R. Rao, A. Parmar, A.K. Mishra, A. Ambekar, A. Agrawal. National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, India
- 350 *Factors of hepatitis C virus seroconversion among clients of harm reduction programs in Ukraine*
I. Sazonova¹, T. Mykhalchuk², O. Cheshun¹, Y. Novak³, T. Saluik¹, P. Smyrnov¹. ¹ICF "Alliance for Public Health," Ukraine; ²Deloitte Ukraine, Ukraine; ³United Nations Population Fund, Ukraine
- 351 *Influence of social network on drug use among clients of methadone maintenance treatment centers in Kunming, China*
L. Shen¹, S. Assanangkornchai², W. Liu¹, L. Cai¹, F. Li³, S. Tang¹, J. Shen⁴, E.B. McNeil², V. Chongsuvivatwong². ¹School of Public Health, Kunming Medical University, China; ²Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Thailand; ³School of Basic Medical Science, Kunming Medical University, China; ⁴Yunnan Institute for Drug Abuse, Xi Shan District, China
- 352 *Psychiatric burden of prisoners suffering from opioid use disorder and attention deficit/hyperactivity disorder*
M. Silbernag, R. Slamanig, M. Stegemann, M. Sterzer, L. Mayer, G. Fischer. Medical University of Vienna, Austria

353 Effectiveness of methadone treatment and client characteristics in five regions of Burma (Myanmar)

N.M.A. Wan¹, C.S. Hlaing^{1,2}, P.W. Htun², P. Bollen², I. Tavitian-Exley^{2,3}. ¹Drug Dependency and Treatment Research Unit, Ministry of Health and Sports, Burma (Myanmar); ²World Health Organization Burma (Myanmar), Burma (Myanmar); ³Department of Infectious Disease Epidemiology, Imperial College London, United Kingdom

354 Comparison of nutritional status and food insecurity among people who inject illicit drugs, non drug users and those on methadone treatment in selected areas of Nairobi, Kenya

V. Wanjihia¹, E. Muniu¹, M. Mwangi¹, C. Mwangi², R. Mutisya¹, P. Ndemwa¹, F. Kiplamai³. ¹Kenya Medical Research Institute, Centre for Public Health Research, Kenya; ²Support for Addiction Prevention and Treatment in Africa, Kenya; ³Department of Recreation Management and Exercise Science Department, Kenyatta University, Kenya

355 Surveillance of the illicit drug cryptomarkets on the darknet

Y. Wu¹, M.H. Swahn², S.M. Strasser², E.L. Sevigny³. ¹Department of Computer Science, Georgia State University, United States; ²School of Public Health, Georgia State University, United States; ³Department of Criminal Justice and Criminology, Georgia State University, United States

356 People who inject drugs (PWID) networks of medically assisted treatment patients in Ukraine

O. Zeziulin¹, S. Dvoriak¹, K. Dumchev¹, O. Makarenko¹, T. Kiriazova¹, N. Saichuk¹, C. Latkin². ¹Ukrainian Institute on Public Health Policy, Ukraine; ²Johns Hopkins University Bloomberg School of Public Health, United States

Prevention

400 Effectiveness of provider initiative approach for smoking cessation among pregnant women in OsunState, Nigeria

A. Adelekan¹, P. Omoregie², A. Tunrayo², C. Ekerete-Udofia³. ¹University of Ibadan, Nigeria; ²Blue Gate Public Health Promotion Initiative, Nigeria; ³Centre for the Right to Health, Nigeria

401 Comparing effect of daily mobile short messages and social media messages in reducing smoking among AlAzhar University students in Gaza, Palestine

M.F. AlAfifi¹, M. Sakka², M. Shehada¹. ¹Substance Abuse Research Centre, Palestinian Territories; ²AlAzhar University, Palestinian Territories

402 Risk and protection factors associated with the consumption of alcohol, tobacco, and marijuana consumption in seventh through ninth grade students in five schools in the City of San Salvador

F. Bautista-Pérez. Universidad Tecnológica de El Salvador, El Salvador

403 Direct relationship between family functioning and methamphetamine use among opioid injection drug users in Hanoi, Vietnam

T.D. Dao¹, G.M. Le¹, T.T. Nguyen¹, T.M. Nguyen², L. Metsch³, D. Feaster⁴. ¹Hanoi Medical University, Vietnam; ²Vietnam Ministry of Health, Vietnam; ³Columbia University, United States; ⁴University of Miami Miller School of Medicine, United States

404 *Integration 3D virtual reality to develop simulation-based training system for counselors who work with adolescents abusing drugs*

J-L. Guo¹, J-Y. Liao¹, C-M. Huang². ¹Department of Health Promotion and Health Education, National Taiwan Normal University, Taiwan; ²Institute of Clinical Nursing, National Yang-Ming University, Taiwan

405 *The impact of supervised injection facility use on all-cause mortality among a cohort of people who inject drugs in Vancouver, Canada*

M.C. Kennedy¹, K. Hayashi², M-J Milloy³, E. Wood³, E. Nosova³, T. Kerr³. ¹British Columbia Centre on Substance Use, School of Population and Public Health, University of British Columbia, Canada; ²British Columbia Centre on Substance Use, Faculty of Health Sciences, Simon Fraser University, Canada; ³British Columbia Centre on Substance Use; Department of Medicine, University of British Columbia, Canada

406 *People who inject drugs and provider perspectives on factors influencing medication-assisted treatment uptake among people who inject drugs in Ukraine: Highlights from HPTN 074 study*

T. Kiriazova¹, O. Makarenko¹, I. Zaviriukha¹, R.B. Hershow², E.L. Hamilton³, K. Lancaster⁴, K. Dumchev¹, V. Go², C. Latkin⁵. ¹Ukrainian Institute on Public Health Policy, Ukraine; ²Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina–Chapel Hill, United States; ³Science Facilitation Department, FHI 360, United States; ⁴Division of Infectious Diseases, School of Medicine, University of North Carolina–Chapel Hill, United States; ⁵Department of Health, Behavior, and Society, Johns Hopkins Bloomberg School of Public Health, United States

407 *Validation of the substance use risk profile scale with Georgian substance dependent adults*

T. Kordzadze^{1,2}, J. Vassileva³. ¹Humphrey Fellowship Program, Virginia Commonwealth University, United States; ²Addiction Research and Counseling Center, Georgia; ³Departments of Psychiatry and Psychology, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, United States

408 *The persisting influence of traditional gender roles on substance use by Spanish adolescents*

S.S. Kulis¹, F.F. Marsiglia¹, C. Villalba², D. Alarcon², I. MacFadden². ¹Global Center for Applied Health Research, Arizona State University, United States; ²Universidad Pablo de Olavide, Spain

409 *A comparison of the number of inappropriately discarded syringes before and after the implementation of a syringe exchange program in Miami, Florida*

H. Levine, T. Bartholomew, V. Rea-Wilson, D.J. Arriola, G. Cardenas, D. Forrest, H. Tookes. Department of Public Health Sciences, University of Miami Miller School of Medicine, United States

410 *The Migrants' Approached Self-Learning Intervention in HIV/AIDS for Tajiks (MASLIHAT) HIV intervention for Tajik temporary migrant workers in Moscow who inject drugs*

J. Levy¹, M.E. Mackesy¹, M. Bakhromov², C. Latkin³, J. Jonbekov². ¹School of Public Health, University of Illinois at Chicago, United States; ²PRISMA Research Center, Tajikistan; ³Johns Hopkins University Bloomberg School of Public Health, United States

- 411 *Establishing screening, brief intervention, and referral to treatment (SBIRT) in China: A focus group study for the comprehensiveness, suitability, applicability, and feasibility of SBIRT*
L. Zhang¹, Z. Zhao², Y. Liu¹, W. Hao¹, N. Zhong³, M. Zhao³, V. Poznyak⁴, Y. Liao¹. ¹Mental Health Institute, the Second Xiangya Hospital of Central South University, China; ²Xinjiang Mental Health Center and Urumqi Fourth People's Hospital, China; ³Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, China; ⁴Department of Mental Health and Substance Abuse, World Health Organization, Switzerland
- 412 *Evaluation of dynamic risk assessment system for drug users in community-based drug rehabilitation program in Yuxi, China*
W. Liu¹, Y. Ma², T. Wei¹, S-H. Yang², D-L. Yang³, X. Wang⁴, Xu-bin Zhu¹. ¹Kunming Medical University, China; ²The Center for Disease Prevention and Control of Hongta District, China; ³AIDS Care China, China; ⁴Yunnan Aidun Science and Technology Company, China
- 413 *Adaptation of a risk and protective factor survey for use in South Africa*
L. Makunyane. African Youth Development Fund, South Africa; Humphrey Fellowship Program, Virginia Commonwealth University, United States
- 414 *A pilot study of Mantente REAL in Nogales, Mexico: Testing risk moderation effects*
F.F. Marsiglia¹, S. Kulis¹, H.G. Pérez², S. Ayers¹. ¹Global Center for Applied Health Research, Arizona State University, United States; ²Colegio de la Frontera, Nogales, Mexico
- 415 *Tobacco and marijuana co-use in adolescents: Differences in impulsivity and gambling behavior*
V. Martínez-Loredo, A. Grande-Gosende, A. González-Roz, S. Fernández-Artamendi, S. Weidberg, J.R. Fernández-Hermida. Department of Psychology, University of Oviedo, Spain
- 416 *Highlighting female-specific HIV and drug risk environment factors among persons who inject drugs in Nairobi, Kenya*
L.W. Mbogo¹, N.T. Ludwig-Barron^{1,2}, B. Guthrie^{1,2,3}, J. Simoni^{2,4,5}, A. Monroe-Wise⁶, D. Bukusi⁷, W. Sinkele⁸, J. Herbeck², C. Farquhar^{1,2,6}. ¹Department of Epidemiology, School of Public Health, University of Washington, United States; ²Department of Global Health, School of Public Health, University of Washington, United States; ³University of Washington Global Assistance Program–Kenya, Kenya; ⁴Department of Psychology, University of Washington, United States; ⁵Department of Gender, Women, and Sexuality Studies, University of Washington, United States; ⁶Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, United States; ⁷VCT and HIV Care, Kenyatta National Hospital, Kenya; ⁸Support for Addictions Prevention and Treatment in Africa, Kenya
- 417 *Women who use drugs left without shelter*
T. Mgebrishvili¹, A. Beselia¹, I. Kirtadze^{1,2}. ¹Addiction Research Center, Alternative Georgia, Georgia; ²Iliia State University, Georgia

418 *Assessment of mental health and perceived access to care among people who inject drugs in Athens, Greece*

G.K. Nikolopoulos¹, D. Pampaka², G. Giallourous¹, D. Evripidou¹, E. Pavlitina³, L.D. Williams⁴, D. Paraskevis⁵, M. Psychogiou⁶, V. Sypsa⁵, J. Schneider⁷, P. Smyrnov⁸, S.R. Friedman⁴, A. Hatzakis⁵, K. Pantavou¹. ¹Medical School, University of Cyprus, Cyprus; ²Cyprus International Institute for Environmental and Public Health, Cyprus University of Technology, Cyprus; ³Transmission Reduction Intervention Project–Athens site, Greece; ⁴Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Greece; ⁵Departments of Medicine and Public Health Sciences, The Chicago Center for HIV Elimination, University of Chicago, United States; ⁶Alliance for Public Health, Ukraine

419 *Adulterants of drugs and their effects on the health of drug users: A critical review*

A. Pascale^{1,2}, A. da Matta Chasin³, N. Giancotti⁴, F. Pose², M. Hynes⁵. ¹REDLA Network (Red Latinoamericana de Investigadores en Drogas), Uruguay; ²Department of Toxicology, School of Medicine, University of the Republic, Uruguay; ³Oswaldo Cruz School–São Paulo, Brazil; ⁴School of Pharmaceutical Sciences, University of São Paulo, Brazil; ⁵Inter-American Observatory on Drugs, Inter-American Drug Abuse Control Commission (CICAD), United States

420 *Factors predicting engagement with an HIV and substance abuse prevention intervention for young men living in resource-constrained communities in South Africa*

M.J. Rotheram¹, S. Rabie², J. Bantjes², S. Gordon², E. Almirol¹, J. Stewart², M. Tomlinson². ¹Department of Psychiatry and Biobehavioral Sciences, Semel Institute, University of California–Los Angeles, United States; ²Department of Psychology, Stellenbosch University, South Africa

421 *HIV testing practices and reasons for never-testing among men who have sex with men in Malaysia*

R. Shrestha¹, Z. Ni², M.M. Copenhaver³, F.L. Altice¹, S.H. Lim⁴. ¹Yale University, United States; ²Duke University, United States; ³University of Connecticut, United States; ⁴University of Malaya, Malaysia

422 *The impact of kratom (*Mitragyna Speciosa* [Korth.]) use on frequency of illicit drug use and risky HIV behaviours among poly-drug users in Malaysia*

D. Singh¹, A. Saref¹, S. Suraya², O. Grundmann³, S. Narayanan², M.T. Swogger⁴, W.C. Prozialeck⁵, E. Boyer⁶, V. Balasingam¹. ¹Centre for Drug Research, Universiti Sains Malaysia, Malaysia; ²School of Social Sciences, Universiti Sains Malaysia, Malaysia; ³Department of Medicinal Chemistry, College of Pharmacy, University of Florida, United States; ⁴Department of Psychiatry, University of Rochester Medical Center, United States; ⁵Department of Pharmacology, College of Graduate Studies, Midwestern University, United States; ⁶Department of Emergency Medicine, Brigham and Women's Hospital, Harvard Medical School, United States

423 *Healthy lifestyle screen: A positive approach for self-empowerment and resilience through health promotion among Filipino high school students*

J.M. Tamana¹, C.H. Kim². Department of Addiction Science, Sahmyook University Graduate School, South Korea

424 *Association between mental health and risk of initiating others into drug injecting in Vancouver, Canada*

J. Tirado-Muñoz¹, S. Jain², X. Sun², K. Hayashi³, M.L. Mitta¹, D. Werb^{1,4}, C. Rafful on behalf of the PRIMER study team^{1,4}. ¹Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, United States; ²Department of Family Medicine and Public Health, Biostatistics Research Center, University of California San Diego, United States; ³Department of Epidemiology and Population Health, British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Canada; ⁴Centre on Drug Policy Evaluation, St. Michael's Hospital Toronto, Canada

425 *Pattern and factors associated with intention to quit tobacco abuse in a rural community of south-eastern Nigeria*

U. Ofonakara¹, O.O. Odukoya², N. Orofuke³. ¹Federal Teaching Hospital Abakaliki, Nigeria; ²Lagos University Teaching Hospital, Nigeria; ³Delta State Primary Health Care Development Agency, Nigeria

Treatment

500 *An alternative to incarceration of drug users: A comparative study of Ghana and the United States*

D. Amankwaah. Economic Community of West African States, Nigeria

501 *Barriers to screening and treatment for HIV and hepatitis C virus among injection drug users in Colombia*

J.P. Borda¹, P.M. Herrera², G. Castaño³, S. Lopez-Guzman⁴, H. Friedman⁵, B. Tofighi⁵. ¹Facultad de Medicina Universidad von Humboldt, Colombia; ²Universidad Tecnológica de Pereira Facultad de Ciencias de la Salud, Colombia; ³Universidad CES, Colombia; ⁴Universidad del Rosario, Colombia; ⁵New York University School of Medicine, United States

502 *Dose-dependent naloxone-induced morphine withdrawal symptoms in opioid-dependent males: A double-blinded, randomized study*

L. Brandt¹, S. Weisshaar², B. Litschauer², S. Sheik-Rezai², L. Moser², E. Kühberger³, U. Bauer³, C. Firbas², G. Gouya², M. Wolzt², G. Fischer⁴. ¹Faculty of Psychology, University of Vienna, Austria; ²Department of Clinical Pharmacology, Medical University of Vienna, Austria; ³G.L. Pharma GmbH, Austria; ⁴Center for Public Health, Medical University of Vienna, Austria

503 *Treatment and care for people with drug use disorders in contact with the criminal justice system: Alternatives to conviction or punishment*

A. Busse¹, S. Pfeiffer², G. Gerra³, G. Campello¹, E. Sáenz¹, V. Lebaux², J.A. Lee². ¹Prevention, Treatment, and Rehabilitation Section, Drug Prevention and Health Branch (DHB), Division of Operations (DO), United Nations Office on Drugs and Crime (UNODC), Austria; ²Justice Section, DO, UNODC, Austria; ³DHB, DO, UNODC, Austria

504 *Variations and determinants of novel psychoactive substance use: Implications for policy and practice*

K. Higgins¹, N. O'Neill¹, L. O'Hara¹, J-A. Jordan¹, M. McCann², T. O'Neill¹, M. Clarke¹, T. O'Neill¹, A. Campbell¹. ¹Queen's University, Northern Ireland; ²University of Glasgow, Scotland

505 Adherence among HIV-positive injection drug users undergoing methadone assisted treatment

E. Chao¹, Q. Ul Ain², T. Szu-Hsien Lee¹. ¹Department of Health Promotion and Health Education, National Taiwan Normal University, Taiwan; ²Department of Education, Pir Mehr Ali Shah Arid Agriculture University, Pakistan

506 Increasing antiretroviral therapy adherence after prison release: Early findings from a randomized controlled trial of an evidence-based medication adherence intervention for HIV-infected prisoners transitioning to the community in Indonesia

G.J. Culbert^{1,2}, A. Waluyo², Z.O. Syarif³, A.B. Williams^{4,5}, J.A. Levy⁶, S.A. Freels⁷, F.A. Altice^{8,9,10}. ¹Department of Health Systems Science, College of Nursing, University of Illinois at Chicago, United States; ²Center for HIV/AIDS Nursing Research, Faculty of Nursing, University of Indonesia, Indonesia; ³Tarakan General Hospital, Indonesia; ⁴Meyers College of Nursing, New York University, United States; ⁵Yale School of Nursing, United States; ⁶Health Policy and Administration, School of Public Health, University of Illinois at Chicago, United States; ⁷Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, United States; ⁸Department of Medicine, Section of Infectious Diseases–AIDS Program, Yale University School of Medicine, United States; ⁹Department of Epidemiology of Microbial Diseases, Yale University School of Public Health, United States; ¹⁰Centre of Excellence for Research in AIDS, University of Malaya, Malaysia

507 Understanding New South Wales Long-Acting Opioids in Custody-Treatment: The UNLOC-T Study

A.J. Dunlop¹, B. White², J. Roberts³, P. Haber⁴, J. Attia⁵, C. Oldmeadow⁵, A. Searles⁵, M. Cretikos⁶, J. Mackson⁷, D. Attalla³, T. Murrell⁸, M. Doyle⁹, E. McEntyre¹⁰, L. Brown¹¹, H. Hellal³, M. Howard¹², M. Sequeira¹, N. Lintzeris¹³. ¹Hunter New England Local Health District, Australia; ²Drug Health Services, Sydney Local Health District, Australia; ³Justice Health and Forensic Mental Health Network, Australia; ⁴Sydney Local Health District, Australia; ⁵Hunter Medical Research Institute, Australia; ⁶Centre for Population Health, New South Wales (NSW) Ministry of Health, Australia; ⁷Legal and Regulatory Services, NSW Ministry of Health, Australia; ⁸Corrective Services–NSW, Australia; ⁹University of Sydney, Australia; ¹⁰Durri Aboriginal Corporation Medical Centre, Australia; ¹¹Aboriginal Health Unit, Nepean Blue Mountains Local Health District; ¹²Corrections Research Evaluation and Statistics, Australia; ¹³Drug and Alcohol Services, South Eastern Sydney Local Health District, Australia

508 Opioid addiction beliefs and attitudes of primary health care clinicians in Ukraine

M. Filippovych¹, K. La Monaca², I. Pykalo¹, L.M. Madden^{2,3}, R. Marcus², S. Farnum³, D. Barry³, S. Dvoriak¹, F.L. Altice². ¹Ukrainian Institute on Public Health Policy, Ukraine; ²Yale School of Medicine, United States; ³APT Foundation, Inc., United States

509 *Using the evidence-based model for opioid agonist treatment scale-up in Ukraine*

T. Fomenko¹, A. Meteliuk¹, L. Madden^{2,3}, S. Farnum², R. Marcus³, K. LaMonaca³, I. Pykalo⁴, M. Filippovych⁴, I.Z. Islam¹, F.L. Altice^{3,5}. ¹ICF “Alliance for Public Health,” Ukraine; ²APT Foundation, Inc., United States; ³Department of Medicine, Section of Infectious Diseases–AIDS Program, Yale University School of Medicine, United States; ⁴Ukrainian Institute on Public Health Policy, Ukraine; ⁵Department of Epidemiology of Microbial Diseases, Yale University School of Public Health, United States

510 *Differences in the tryptophan system between primary and substance induced depression*

F. Fonseca^{1,2,3}, J. Mestre-Pintó^{2,4}, A. Gomez-Gomez⁵, E. Papaseit⁶, C. Pérez-Mañá⁶, K. Langohr⁷, O. Valverde^{8,9}, O. Pozo⁵, R. de la Torre^{3,5,8}, M. Farré^{3,6}, M. Torrens^{1,2,3}. ¹Institut de Neuropsiquiatria i Addiccions, Spain; ²Hospital del Mar Medical Research Institute-IMIM, Spain; ³Universitat Autònoma Barcelona-UAB, School of Medicine, Spain; ⁴Universitat Pompeu Fabra, Spain; ⁵Integrative Pharmacology and Systems Neuroscience Research Group, Neuroscience Research Program, Hospital del Mar Medical Research Institute, Spain; ⁶Hospital Universitari Germans Trias i Pujol, Spain; ⁷Department of Statistics and Operations Research, Universitat Politècnica de Barcelona/Barcelonatech, Spain; ⁸Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Spain; ⁹Neurobiology of Behaviour Research Group, Neuroscience Research Programme, IMIM-Hospital Del Mar Research Institute, Spain

511 *Bayesian and classical meta-analysis of the effectiveness of the implementation science evidence for improving treatment outcome for adolescent patients accessing antiretroviral therapy in sub-Saharan Africa*

I. Fwemba^{1,4}, P. Govule², S. Iddi³, C. Guure¹, C. Michelo⁴, P. Musonda⁴, T. Lehane⁵, A. Yawson¹, E. Lesaffre⁶, S. Bosomprah¹. ¹Department of Biostatistics, University of Ghana, Ghana; ²Department of Epidemiology, University of Ghana, Ghana; ³Department of Statistic, University of Ghana, Ghana; ⁴Department of Epidemiology and Biostatistics, University of Zambia, Zambia; ⁵Department of Health Research Methods, Evidence, and Impact, Mc Master University, Canada; ⁶Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven University, Belgium

512 *Reinforcer pathology and response to contingency management for smoking cessation*

A. González-Roz¹, Á. García-Pérez¹, G. Aonso-Diego¹, V. Martínez-Loredo¹, S. Fernández-Artamendi², R. Secades-Villa¹, D.E. Gaalema³. ¹Department of Psychology, University of Oviedo, Spain; ²Department of Psychology, Loyola University Andalusia, Spain; ³Department of Psychiatry, University of Vermont, United States

513 *Atypical versus typical antipsychotic for the treatment of addiction: A systematic review and meta-analytic study*

S.C. Hanu. Mental Health Authority–Accra, Ghana

514 *Effects of extended abstinence on cognitive functions in tramadol dependent patients: A prospective cohort study*

S. Hassaan, A. Darwish, H. Khalifa. Department of Psychiatry, Assiut University, Egypt

515 Low dose flumazenil in the management of benzodiazepine withdrawal

G.K. Hulse^{1,2}, G.A. O'Neill^{3,4}. ¹Division of Psychiatry, University of Western Australia, Australia; ²School of Medical and Health Sciences, Edith Cowan University, Australia; ³Fresh Start Recovery Programme, Australia; ⁴GoMedical Industries, Australia

516 Gender-sensitive training for substance use disorder treatment: Results and implications of a pilot health professionals needs assessment

L. Jacobs. Psychology Department, Rhodes University, South Africa

517 Effects of cytidine-5'-diphosphate choline on brain structure and craving in methamphetamine-dependent patients

J. Kim¹, H. Jeong², S. Yoon¹, D. Yurgelun-Todd³, Y-A. Chung², J. Kim⁴, I-K.Lyoo¹, P.F. Renshaw³. ¹Ewha Brain Institute and Department of Brain and Cognitive Sciences, Ewha W. University, South Korea; ²Department of Radiology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, South Korea; ³The Brain Institute and the Department of Psychiatry, The University of Utah, United States; ⁴Ewha Brain Institute, Ewha W. University, South Korea

518 Slow release oral morphine versus methadone for the treatment of opioid use disorder: A systematic review and meta-analysis

J. Klimas^{1,2}, L. Gorfinkel¹, S. Giacomuzzi³, C. Ruckes⁴, M.E. Socías^{1,5}, N. Fairbairn^{1,5}, E. Wood^{1,5}. ¹British Columbia Centre for Substance Use, Canada; ²School of Medicine, University College Dublin, Health Sciences Centre, Ireland; ³Universitätsklinik Innsbruck-Ambulanz für Abhängigkeitserkrankungen, Austria; ⁴University Medical Center Mainz, Interdisciplinary Center Clinical Trials, Germany; ⁵Department of Medicine, University of British Columbia, Canada

519 Opportunities to improve care of Vietnamese patients with opioid use disorder by enhancing professional development of methadone treatment staff

M. Komaromy^{1,2}, N.K. Ngan³, L.M.Giang⁴. ¹Division of General Internal Medicine, Department of Medicine, University of New Mexico Health Sciences Center, United States; ²Hanoi Medical University, Vietnam; ³Center for Research and Training on Substance Abuse/HIV, Hanoi Medical University, Vietnam; ⁴Department of Global Health, Hanoi Medical University, Vietnam

520 Adapting the addiction technology transfer center model to address HIV and injection drug use in Eastern Europe, Southeast Asia, and South Africa

L. Krom¹, G. Bart², S. Becker³, D.J. Grelotti⁴, I. Koutsenok⁴, C. Kuo³, S. Larkins⁵, C. O'Connell⁶. ¹University of Missouri–Kansas City, United States; ²University of Minnesota, United States; ³Brown University, United States; ⁴University of California San Diego, United States; ⁵University of California Los Angeles, United States; ⁶Substance Abuse and Mental Health Services Administration, United States

521 Craving for opioids affects retention in treatment and adherence to antiretroviral therapy in HIV positive patients with opioid use disorder treated with naltrexone

E. Krupitsky^{1,2,3}, E. Blokhina¹, E. Zvartau¹, E. Verbitskaya¹, T. Yaroslavtseva¹, N. Bushara¹, V. Palatkin¹, M. Vetrova¹, D. Lioznov¹, S. Poole³, R. Gross³, G. Woody³. ¹First Pavlov State Medical University, Russia; ²Bekhterev National Medical Research Center for Psychiatry and Neurology, Russia; ³Perelman School of Medicine, University of Pennsylvania, United States

522 *Medication and counseling effects in opioid-dependent people who inject drugs from HPTN058*

Y-C. Ku^{1,2}, T.S-H. Lee³, L. Ma⁴, L. Fu⁵, J. Ma⁵, B. Rui⁵, L. Wei⁶, J. Huang⁷, Y. Ruan⁴, Y. Shao⁴, D.S. Metzger¹. ¹HIV Prevention Research Division, Perelman School of Medicine, University of Pennsylvania, United States; ²Crime Prevention Research Center, Ministry of Justice, Taiwan; ³Department of Health Promotion and Health Education, National Taiwan Normal University, Taiwan; ⁴National Center for AIDS Prevention and Control, China; ⁵Xinjiang Centers for Disease Control and Prevention, China; ⁶Guangxi Centers for Disease Control and Prevention, China; ⁷Heng County Centers for Disease Control and Prevention, China

523 *Group antenatal care: A prospective type I hybrid effectiveness-implementation study in rural Nepal*

L.B. Kunwar^{1,2}, P. Thapa³, S. Maru⁴. ¹Humphrey Fellowship Program, Virginia Commonwealth University, United States; ²Possible Health, Kathmandu, Nepal; ³School of Public Health and Community Medicine, University of New South Wales, Australia; ⁴Arnhold Institute for Global Health, Icahn School of Medicine at Mount Sinai, United States

524 *Feasibility and outcomes of evidence-based interventions to reduce methamphetamine use among patients on methadone maintenance therapy in Hanoi, Vietnam*

A. Nguyen¹, H. Tran¹, T. Nguyen¹, S. Shoptaw², G. Le¹. ¹Hanoi Medical University, Vietnam; ²University of California Los Angeles, United States

525 *Severity of methamphetamine use among methadone patients in Vietnam: Prevalence and correlates*

G. Le¹, T. Dao¹, T. Nguyen¹, C. Okafor², M. Li², S. Shoptaw². ¹Hanoi Medical University, Vietnam; ²University of California Los Angeles, United States

526 *The effectiveness of a smartphone application for illegal drug use prevention among at-risk adolescents*

J-Y. Liao¹, C-M. Huang², J-L. Guo¹. ¹Department of Health Promotion and Health Education, National Taiwan Normal University, Taiwan; ²Institute of Clinical Nursing, National Yang-Ming University, Taiwan

527 *Prevalence of substance abuse in prisons in Nigeria . A case study of seven prisons across the southern region of Nigeria*

N.B.C Maduka, I. Esther. Bensther Development Foundation, Nigeria

528 *Randomized controlled trial of the intervention program for adolescents who initiate the consumption of alcohol and other drugs and a family-adolescent communication component*

K.I.M. Martínez¹, M.E. Contreras-Pérez¹, E.F. Wagner². ¹Universidad Autónoma de Aguascalientes, Mexico; ²Florida International University, United States

529 *A smart electronic cigarette for smoking cessation: Using machine learning to improve treatment*

T. Modak¹, I. Saha², R. Baidya³, A. Paul³. ¹National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, India; ²Department of Computer Science, Indian Institute of Technology, India; ³Department of Information Technology, Jadavpur University, India

- 530 *Develop and systematically evaluate a child addiction severity index (Child-ASI): The CHILD Intervention for Living Drug-Free Comprehensive Assessment of Risk, Resilience, and Experience (CHILD CARRE) tool*
A.S. Momand¹, B. Morales², T. Browne³, K. O'Grady⁴, H.E. Jones¹. ¹UNC Horizons, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, United States; ²Bureau of International Narcotics and Law Enforcement Affairs, U.S. Department of State, United States; ³Rubicon Global Enterprises and Colombo Plan Secretariat, Sri Lanka; ⁴Department of Psychology, University of Maryland College Park, United States
- 531 *Motivational enhancement group therapy for cannabis use disorder co-morbidity with borderline personality disorder*
S. Momtazi. Iranian Canadian Mental Health, Canada
- 532 *Outcomes of patients with cocaine use disorders after admissions to treatment*
R. Muga¹, S. Galan¹, D. Fuster¹, M. Farré¹, P. Zuluaga¹, E. Papaseit¹, I. Rivas², A. Sanvisens¹. ¹Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Spain; ²Municipal Center for Substance Abuse Treatment, Badalona Serveis Assistencials, Spain
- 533 *Validation of the routine opioid outcome monitoring screening tool in patients prescribed opioids for chronic pain*
S. Nielsen^{1,2}, L. Picco¹, M. Middleton¹, M. Kowalski², R. Bruno^{2,3}. ¹Monash University, ¹Monash University, Australia; ²University of New South Wales, Australia; ³University of Tasmania, Australia
- 534 *Addiction, anxiety, depression, and neurosteroid or opioid dysfunction*
G. O'Neil. Fresh Start Recovery Programme, University of Western Australia, Australia
- 535 *Uptake of new hepatitis C treatments among patients in opioid substitution therapy*
I. Rivas Puy¹, A. Sanvisens², E. Faure¹, N. Espinach¹, T. Muñoz¹, M. Rubio¹, N. Salgado¹, R. Muga². ¹Mental Health and Addiction Service, Badalona Serveis Assistencials, Spain; ²Internal Medicine Service, Hospital Universitari Germans Trias i Pujol, Spain
- 536 *Assessing continuation of treatment post release for Amritsar jail inmates receiving medically assisted treatment for opioid use disorders*
K. Sharma. Punjab Police, India; Humphrey Fellowship Program, Virginia Commonwealth University, United States
- 537 *Prescription psychostimulants for treatment of cocaine and methamphetamine use disorders: A review and meta-analysis*
V. Soares Tardelli^{1,2}, A. Bisaga³, F.B. Arcadepani¹, T.M. Fidalgo¹. ¹Department of Psychiatry, Universidade Federal de São Paulo, Brazil; ²Mailman School of Public Health, Columbia University, United States; ³Division of Substance Abuse, New York State Psychiatric Institute, United States
- 538 *Antiretroviral therapy services for people who inject drugs in Myanmar*
Z.N. Soe. John Snow, Inc. Research and Training Institute, Myanmar

539 *Physician perceptions of primary care management of opioid use, HIV, and hepatitis C in Colombia: A qualitative study of clinical practices and barriers*

B. Tofighi¹, P.M.H. Gomez², J.C. Cataño³, H. Friedman¹, J.P.B. Bohigas⁴. ¹New York University School of Medicine, United States; ²Universidad Tecnológica de Pereira Facultad de Ciencias de la Salud, Colombia; ³University of Antioquia Medical School, Colombia; ⁴Facultad de Medicina, Universidad von Humboldt, Colombia

540 *Characterizing the barriers to access and utilization of HIV/AIDS and sexual health services among men who have sex with men in Nigeria*

A. Williams¹, S. Iwuagwu². ¹Rutgers University, United States; ²Center for the Right to Health, Nigeria

541 *Epitope finding on DRD2 and DRD2 antibody for further nicotine addiction vaccine development*

V. Wiwanitkit. Chulalongkorn University, Thailand; Dr DY Patil University, India; Joseph Ayo Babalola University, Nigeria

542 *The impact of the incarceration experience on the drug consumption among drug users in a Brazilian prison: Barriers and support of access to care*

N. Worcman. Psychiatrist on the Sistema Único de Saúde, Brazil; Humphrey Fellowship Program, Virginia Commonwealth University, United States

543 *Outcome of drug and alcohol dependent users after in-patient treatment and effect of follow-up outpatient counseling*

M. Yang¹, H. Ru¹, Y. Liao², T. Liu³, S. Xiao⁴. ¹Department of Drug Dependence, Shenzhen Kangning Hospital, Shenzhen Mental Health Center, Medical Department of Shenzhen University, China; ²Mental Health Institute, Second Xiangya Hospital, Central South University, China; ³Administration Department, Shenzhen Kangning Hospital, Shenzhen Mental Health Center, Medical Department of Shenzhen University, China; ⁴Department of Social Medicine, School of Public Health, Central South University, China

Monday, June 17, 2019

WORKSHOP IX

Grand Oaks K/L

USING IMPLEMENTATION SCIENCE PRINCIPLES AND INTERVENTIONS TO IMPROVE SUBSTANCE USE SERVICES LINKAGE FOR JUSTICE-INVOLVED ADOLESCENTS: FINDINGS FROM THE NIDA JJ-TRIALS COOPERATIVE AGREEMENT

7:00 - 9:00 PM

Followed by Society for Adolescent Substance Abuse Treatment Effectiveness Business Meeting

Chairs: Steven Belenko and Danica Knight

JJ-TRIALS youth: Baseline characteristics and correlates of behavioral health cascade events
G. Wasserman, Columbia University, New York, NY

Effectiveness of an implementation intervention to improve identification of substance use treatment need and referral to treatment among justice-involved youth
S. Belenko, Temple University, Philadelphia, PA

Beyond fidelity: The case for measuring and monitoring site engagement
J. Becan, Texas Christian University, Fort Worth, TX

The influence of individual and organizational characteristics on interagency service coordination between juvenile justice and behavioral health agencies
W. Welsh, Temple University, Philadelphia, PA

Discussant

T. Wiley, National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD

WORKSHOP VI

Grand Oaks M

COMMUNICATING YOUR SCIENCE

7:00 - 9:00 PM

Chairs: Margaret Chisolm and Erin Winstanley

Communicating your science

M. Chisolm¹, P. Vieira², J. Palamar³, E. Winstanley⁴, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²CSU Dominguez Hills, Carson, CA, ³New York University School of Medicine, New York, NY, ⁴West Virginia University, Morgantown, WV

Communicating science with slides is an art

B. Madras, McLean Hospital, Harvard Medical School, Belmont, MA

Secrets to great TED talks

P. Vieira, CSU Dominguez Hills, Carson, CA

Sharing your research findings to the public using press releases

J. Palamar, New York University School of Medicine, New York, NY

Monday, June 17, 2019

Science for non-scientists: Using social media to increase reach
E. Winstanley, West Virginia University, Morgantown, WV

WORKSHOP VII INTRODUCTION TO MACHINE LEARNING AND APPLICATIONS TO ADDICTION RESEARCH

**Grand Oaks H
7:00 - 9:00 PM**

Chairs: Sarah Yip and Dustin Scheinost

What is machine learning? An overview of common approaches
N. Allgaier, University of Vermont, Burlington, VT

What do I need to know? Ten simple rules for machine learning
D. Scheinost, Yale University, New Haven, CT

How do I do this? Practical application of machine learning in addiction
S. Yip, Yale University, New Haven, CT

What if I need help? Resources for incorporation of machine learning into research
J. Hardee, University of Michigan, Ann Arbor, MI

What can and cannot be learned from machine learning?
S. Grant, National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD

WORKSHOP VIII REACHING UNDERSERVED SMOKERS: NEW STRATEGIES AND HOW TO IMPLEMENT THEM

**Grand Oaks I
7:00 - 9:00 PM**

Chairs: Joy Schmitz

Using mobile dental clinics to deliver tobacco cessation treatment to rural smokers
L. Yammine, University of Texas Health Science Center, Houston, TX

Reducing tobacco smoke exposure in NICU infants' homes
A. Stotts, University of Texas Health Science Center, Houston, TX

Adherence to smoking pharmacotherapy in low income patients
K. Cropsey, University of Alabama, Birmingham, AL

Facilitating engagement in tobacco cessation treatment among smokers with low health literacy
J. Vidrine, University of Oklahoma Health Sciences Center, Oklahoma City, OK

Novel approaches to reach disadvantaged smokers with serious mental illnesses in community settings

M. Brunette, Geisel School of Medicine at Dartmouth, Lebanon, NH

Discussant

S. Higgins, University of Vermont, Burlington, VT

**WORKSHOP X
OPIOID USE DISORDER IMPACTS
DIVERSE COMMUNITIES, TOO!**

**Grand Oaks G
7:00 - 9:00 PM**

Chairs: A. Kathleen Burlew and Aimee Campbell

OUD and mental health outcomes among substance users in Puerto Rico following Hurricane Maria

V. Horigian, University of Miami, Miami, FL

The effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention among African Americans

A. Haeny, Yale University, New Haven, CT

The use of the citizen's model delivered by peer facilitators in the Black/African American church to address the opioid epidemic in Black/African American communities

A. Jordan, Yale University, New Haven, CT

Diverse perspectives on medications for opioid use disorders (MOUD): Generalizable to mainstream populations

K. Venner, University of New Mexico, Albuquerque, NM

Discussant

A. Campbell, Columbia University and New York Psychiatric Institute, New York, NY

Tuesday, June 18, 2019

2019 CPDD OUTREACH EVENT

7:30 - 11:30 AM

St. Judes Ranch for Children (SJRC). Meet in the Lobby at 7:30A.M
Preregistration is strongly encouraged. Contact Jessica Weafer,
Email: jweafer@uchicago.edu / Phone: 859-533-9878

Tuesday, June 18, 2019

MEDIA FORUM 2019
WHAT'S HOT?

Grand Oaks M
8:00 - 9:00 AM

Chairs: Margaret Chisolm and Erin Winstanley

8:00 *Welcome and overview of Media Forum and introduction of each speaker*
Margaret S. Chisolm, Johns Hopkins University, Baltimore, MD

CANNABINOIDS

8:10 *Acute oral and vaporized cannabidiol in healthy adults*
Ryan Vandrey, Johns Hopkins University, Baltimore, MD, USA

8:15 *Residual impact of heavy recreational marijuana use without acute intoxication on driving performance*
Mary (Kate) Dahlgren, Harvard University, Boston, MA, USA

8:20 *Regular cannabis use is associated with adverse cardiovascular outcomes*
Theresa Winhusen, University of Cincinnati, Cincinnati, OH, USA

OPIOIDS

8:25 *Adolescent onset marijuana use and risk for opioid misuse in an urban cohort*
Beth Reboussin, Wake Forest University, Wake Forest, NC, USA

8:30 *A longitudinal study of prescription opioid use and misuse during adolescence*
Sean McCabe, University of Michigan, Ann Arbor, MI, USA

8:35 *The geographic distribution of fentanyl-involved overdose deaths*
Elizabeth Nesoff, Columbia University, NY, NY, USA

METHAMPHETAMINE

8:40 *Mirtazapine for methamphetamine use disorder among men and transwomen who have sex with men: A randomized placebo- controlled trial*
Phillip Coffin, San Francisco Department of Public Health, San Francisco, CA, USA

8:45 *Summary of session, Q&A*
Erin L. Winstanley

Tuesday, June 18, 2019

**POLICY FORUM:
ADDRESSING THE OPIOID EPIDEMIC
IN HIGHLY IMPACTED COMMUNITIES**

**Grand Oaks K/L
9:00 - 10:30 AM**

Chairs: Sandra Comer and William Dewey

Part I HEALing Communities

Titles and speakers to be confirmed

Part II Public Policy Updates

CPDD's public policy activities and a report from Friends of NIDA

W. Dewey¹, C. O'Keeffe², ¹Virginia Commonwealth University, Richmond, VA, ²Virginia Commonwealth University, Midlothian, VA

Report from Capitol Hill: Implications for NIDA's research portfolio

E. Long, Van Scoyoc Associates, Washington, DC

**ORAL COMMUNICATIONS 12
BULLSEYE! PRECLINICAL OPIOID
USE DISORDER TARGETS**

**Grand Oaks G
10:00 - 12:00 PM**

Chairs: Christina Merritt and Dennis Sholler

10:00 *The development of novel G-protein-biased mu opioid receptor agonists as safer analgesics*

A. Alder¹, N. Shivaperumal¹, R. Crowley², S. Williamson², T. Prisinzano², B. Kivell¹,
¹Victoria University of Wellington, Wellington, New Zealand, ²University of Kansas,
Lawrence, KS

Tuesday, June 18, 2019

- 10:15 *A stable heroin hapten (6-AmHap) vaccine formulation slated for a phase 1 clinical trial induces long duration antibody titers that block the antinociceptive effects of heroin and other opioids*
G. Matyas¹, O. Torres², A. Sulima³, C. Whalen¹, Z. Beck², A. Jacobson⁴, K. Rice³, ¹Walter Reed Army Institute of Research, Silver Spring, MD, ²Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, ³National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD, ⁴National Institutes of Health, Bethesda, MD
- 10:30 *Revisiting the primary reinforcing effects of the delta-opioid receptor agonist SNC80*
E. Jutkiewicz¹, A. Matthews¹, K. Rice², ¹University of Michigan, Ann Arbor, MI, ²National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD
- 10:45 *Effects of the synthetic short-acting kappa-opioid antagonist LY2795050 in locomotor and self-grooming behaviors in male and female mice*
B. McElroy¹, E. Butelman¹, T. Prisinzano², M. Kreek¹, ¹The Rockefeller University, New York, NY, ²University of Kansas, Lawrence, KS
- 11:00 *Oxycodone self-administration is blunted during repeated administration of the 5-HT_{2C}R agonist lorcaserin*
C. Merritt¹, R. Fox¹, S. Stutz¹, F. Moeller², N. Anastasio¹, K. Cunningham¹, ¹University of Texas Medical Branch, Galveston, TX, ²Virginia Commonwealth University, Richmond, VA
- 11:15 *Nalfurafine blocks oxycodone's conditioned rewarding effects and acquisition of oxycodone self-administration in male rats*
C. Zamarripa¹, T. Patel¹, B. Williams¹, T. Prisinzano², K. Sufka³, K. Freeman¹, ¹University of Mississippi Medical Center, Jackson, MS, ²University of Kansas, Lawrence, KS, ³University of Mississippi, Mississippi, MS
- 11:30 *The 5-HT_{2A} receptor (5-HT_{2AR}) antagonist/inverse agonist pimavanserin decreases oxycodone-evoked impulsive action in male Sprague-Dawley rats*
D. Sholler, N. Anastasio, K. Cunningham, University of Texas Medical Branch, Galveston, TX
- 11:45 *Short-acting M5 negative allosteric modulator VU6008667 attenuates response to oxycodone in rats*
L. Teal, R. Gould, M. Bubser, E. Duncan, R. Matthews, D. Winder, C. Lindsley, C. Jones, Vanderbilt University, Nashville, TN

Tuesday, June 18, 2019

ORAL COMMUNICATIONS 13
KNEE-HIGH TO A GRASSHOPPER:
ADOLESCENT EPIDEMIOLOGY

Grand Oaks M
10:00 - 12:00 PM

Chairs: Micah Johnson and Kathryn Polak

- 10:00 *Trends in adolescent heroin and injection drug use vary across New York City boroughs - differences by sex and race, 2003-2017*
S. Brighthaupt, K. Schneider, R. Johnson, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 10:15 *Analyzing optimism and past 30- day opioid misuse among Florida justice-involved children*
M. Johnson, L. Cottler, University of Florida, Gainesville, FL
- 10:30 *Adolescent onset marijuana use and risk for opioid misuse in an urban cohort*
B. Reboussin¹, K. Green², D. Furr-Holden³, A. Milam⁴, J. Rabinowitz⁵, P. Matson⁶, B. Maher⁷, N. Ialongo⁷, ¹Wake Forest University School of Medicine, Winston-Salem, NC, ²University of Maryland, College Park, MD, ³Michigan State University, East Lansing, MI, ⁴Johns Hopkins University, LA, CA, ⁵Johns Hopkins Hospital, Baltimore, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 10:45 *A longitudinal study of prescription opioid use and misuse during adolescence and adult substance use disorder symptoms*
S. McCabe¹, P. Veliz¹, C. Boyd¹, T. Voepel-Lewis¹, T. Schepis², J. Ford³, V. McCabe⁴, J. Schulenberg¹, ¹University of Michigan, Ann Arbor, MI, ²Texas State University, San Marcos, TX, ³University of Central Florida, Orlando, FL, ⁴St. Joseph Mercy Hospital, Ann Arbor, MI
- 11:00 *Incidence of extra-medical oxycontin use after reformulation among youth, 2004-2017*
K. Sanchez¹, C. Thompson², J. Gryczynski³, ¹Baylor Scott and White Research Institute, Dallas, TX, ²Peds AI, Lansing, MI, ³Friends Research Institute, Baltimore, MD
- 11:15 *Opioid use and related socioeconomic and health outcomes among marginalized Mexican-American women*
T. Perdue, A. Cepeda, A. Valdez, University of Southern California, Los Angeles, CA
- 11:30 *Gender differences in adolescent risk and protective factors associated with opioid misuse from 2012 to 2016*
K. Polak, P. Dillon, J. Koch, W. Miller, E. Ngjelina, S. Kelpin, D. Pomm, J. Sadicario, A. Parlier-Ahmad, D. Svikis, Virginia Commonwealth University, Richmond, VA

Tuesday, June 18, 2019

- 11:45 *Adolescent sexual violence trajectories: Substance use and mental health correlates*
Q. Ngo¹, P. Veliz², Y. Kusunoki³, C. Boyd², ¹University of Michigan, Injury Prevention Center, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, School of Nursing, Ann Arbor, MI

SYMPOSIUM X TO SMOKE OR NOT TO SMOKE: THAT IS THE CUE-ESTION

**Grand Oaks I
10:00 - 12:00 PM**

Chairs: Yasmin Zakiniaieiz and Eric Woodcock

- 10:00 *Cue-reactivity among cigarette smokers and the importance of the insula from initiation to relapse*
A. Janes, McLean Hospital, Harvard Medical School, Belmont, MA
- 10:25 *Acute stress alters cue-evoked neural response and potentiates nicotine-seeking among cigarette smokers*
E. Woodcock, Yale University School of Medicine, New Haven, CT
- 10:50 *Further exploration into the influence of sex and hormones on cigarette smoking cue-reactivity*
T. Franklin, University of Pennsylvania, Philadelphia, PA
- 11:15 *The central role of smoking cues in reconsolidation-based interventions for cigarette smokers*
M. Saladin, Medical University of South Carolina, Charleston, SC
- 11:40 *Stress and cue-reactivity: Challenges and potential opportunities*
R. Sinha, Yale University School of Medicine, New Haven, CT

SYMPOSIUM XI STUDIES OF MEDICATIONS FOR ADDICTION TREATMENT IN CORRECTIONAL SETTINGS COOPERATIVE (SOMATICS): ADDRESSING THE OPIOID CRISIS IN VULNERABLE POPULATIONS

**Grand Oaks H
10:00 - 12:00 PM**

Chairs: David Farabee and Redonna Chandler

- 10:00 *SOMATICS research cooperative: The intersection between the justice system and the opioid epidemic*
R. Chandler, National Institutes of Health, Bethesda, MD
- 10:25 *Methadone treatment and patient navigation initiated in jail: A randomized trial*
R. Schwartz, Friends Research Institute, Baltimore, MD

Tuesday, June 18, 2019

- 10:50 *XOR: A randomized controlled trial of XR-naltrexone opioid treatment at jail-to-community re-entry*
J. Lee, New York University School of Medicine, New York, NY
- 11:15 *An experimental comparison of extended-release naltrexone alone and combined with patient navigation in a jail setting*
D. Farabee, New York University, New York, NY
- 11:40 *Economic analyses of pharmacotherapy for opioid treatment in criminal justice settings: Results from the SOMATICS collaborative*
G. Zarkin, RTI International, Durham, NC

POSTER SESSION III

Lunch

**Cibolo Ballroom
12:00 - 2:00 PM**

**Odd-numbered posters manned first hour; Even-numbered, second hour
Set-up time begins Monday, 3:00 PM; Must be removed by Tuesday 2:30 PM**

ALCOHOL

- Enhancement of a cue-exposure therapeutic approach with an alpha5GABA-A inverse agonist in rhesus monkeys*
T. Pareek¹, J. Overton¹, J. Rowlett¹, M. Rahman², J. Cook², D. Platt³, ¹University of Mississippi Medical Center, Jackson, MS, ²University of Wisconsin-Milwaukee, Milwaukee, WI, ³Division of Neurobiology and Behavior Research, Jackson, MS
- Varenicline reduces concurrent alcohol and nicotine self-administration in baboons*
E. Weerts, A. Holtyn, Johns Hopkins University School of Medicine, Baltimore, MD
- Paternal alcohol exposure reduces reinstatement of alcohol seeking in rat offspring*
S. Nieto¹, R. Meisch², T. Kosten³, ¹University of Houston, Los Angeles, CA, ²University of Texas Health Science Center, Houston, TX, ³University of Houston, Houston, TX
- Markers of inflammation, monocyte activation and intestinal permeability in patients with alcohol use disorder admitted for detoxification*
D. Fuster¹, X. Garcia-Calvo², F. Bolao², P. Zuluaga², A. Sanvisens², J. Tor², R. Muga³, ¹Hospital Universitari Germans Trias, Badalona, Spain, ²Internal Medicine Service, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ³Hospital Universitari Germans Trias i Pujol, Badalona, Spain
- From network medicine: Construction and analysis of protein-protein interaction network of alcohol use disorder*
S. Chen, Mackay Medical College, Taitung Taiwan, NP, Taiwan
- Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care*
M. Malone¹, A. Vittitow¹, R. McDonald¹, B. Tofighi¹, A. Garment¹, D. Schatz², E. Laska¹, K. Goldfeld¹, J. Rotrosen¹, J. Lee¹, ¹New York University School of Medicine, New York, NY, ²New York University, New York, NY

- 7 *Assessment of the safety and pharmacodynamic (PD) interaction of ANS-6637 and ethanol (EtOH) in male moderate drinkers*
M. Shram¹, N. Levy-Cooperman¹, B. Vince², S. O'Malley³, ¹Altreos Research Partners Inc., Toronto, ON, Canada, ²Vince and Associates, Malvern, PA, ³Yale University School of Medicine, New Haven, CT
- 8 *Improvements in working memory in problem alcohol drinkers during adaptive psychological treatment*
N. Vadhan¹, M. Wu², T. Lalwani², R. Vitale², K. Craft², G. Nitzburg², J. Morgenstern², ¹Zucker School of Medicine, Great Neck, NY, ²Feinstein Institute for Medical Research, Northwell Health, Great Neck, NY
- 9 *The associations between alcohol-related cognitions and substance use among young adult drinkers*
D. Litt, M. Lewis, A. Lowery, C. LoParco, M. Leon, A. Galvin, University of North Texas Health Science Center, Fort Worth, TX
- 10 *Can inhibitory control training produce reductions in drinking? Influence of the control condition*
L. Mewton¹, J. Smith², Q. Liu², L. Hu², ¹University of New South Wales, Woollahra, Australia, ²University of New South Wales, Sydney, Australia
- 11 *Poor inhibitory control predicts positive, stimulant-like subjective response to alcohol*
J. Weafer, H. de Wit, University of Chicago, Chicago, IL
- 12 *Externalizing symptom and trait trajectories of youth who become regular alcohol users*
K. Bagot¹, M. Infante², K. Cummins³, D. Clark⁴, S. Ebersson², S. Brown³, S. Tapert³, ¹University of California, La Jolla, CA, ²University of California, Department of Psychiatry, La Jolla, CA, ³University of California San Diego, La Jolla, CA, ⁴University of Pittsburgh, Pittsburgh, PA
- 13 *Applying multiple indicator, multiple cause models to understand changes in youth externalizing behaviors*
J. Borodovsky¹, R. Krueger², R. Grucza¹, ¹Washington University School of Medicine, St. Louis, MO, ²University of Minnesota, Minneapolis, MN
- 14 *Alexithymia, alcohol expectancies, drinking refusal self-efficacy expectancies and negative affect in alcohol-dependent treatment seekers*
F. Thorberg¹, R. Tyssen², A. Landheim¹, R. Young³, M. Lyvers⁴, P. Hasking⁵, J. Connor³, E. London⁶, Y. Huang⁷, G. Feeney⁸, ¹Innlandet Hospital Trust, Brumunddal, Norway, ²University of Oslo, Oslo, Norway, ³University of Queensland, Brisbane, ⁴Bond University, Robina, Australia, ⁵Curtin University, Perth, Australia, ⁶University of California Los Angeles, Los Angeles, CA, ⁷Department of Emergency Medicine & Department of Respiratory Medicine, Gold Coast Health, Southport, Australia, ⁸Princess Alexandra Hospital, Queensland, Australia

Tuesday, June 18, 2019

- 15 *Reduction in non-abstinent WHO drinking risk levels and psychiatric and drug use disorders: 3-year follow-up results in the US general population*
J. Knox, D. Hasin, Columbia University, New York, NY
- 16 *Alcohol use and alcohol use motives in women firefighters: The role of conformity to masculine norms*
L. Smith¹, M. Zegel¹, J. Tran², A. Vujanovic¹, ¹University of Houston, Houston, TX, ²Firefighter Support Network, Houston Fire Department, Houston, TX
- 17 *Occupational stress, alcohol use, and alcohol use coping motives among firefighters: The moderating role of distress tolerance*
B. Bartlett¹, A. Lebeaut¹, M. Zegel¹, L. Smith¹, J. Tran², A. Vujanovic¹, ¹University of Houston, Houston, TX, ²Firefighter Support Network, Houston Fire Department, Houston, TX
- 18 *Marijuana and alcohol use among National Guard soldiers across the urban-rural continuum*
L. Coughlin¹, R. McCormick², K. Haenchen¹, A. Bohnert¹, M. Ilgen¹, M. Valenstein¹, M. Walton³, F. Blow³, ¹University of Michigan, Ann Arbor, MI, ²Case Western Reserve University, Cleveland, OH, ³University of Michigan, Addiction Center, Ann Arbor, MI

DRUGS AND PREGNANCY

- 19 *Attitudes among pregnant and postpartum women in substance disorder treatment toward using technology-assisted treatment*
A. Hammond, E. Strain, R. Brooner, D. Antoine, Johns Hopkins University School of Medicine, Baltimore, MD
- 20 *Punitive approaches to pregnant women with opioid use disorder: Impact on health care utilization, outcomes and ethical implications*
T. Clemons¹, D. Muthulingam², R. Marcus², K. Yonkers³, J. Meyer², ¹Quinnipiac University, Westland, MI, ²Yale University School of Medicine, New Haven, CT, ³Yale University Department of Psychiatry, New Haven, CT
- 21 *Treatment for substance use disorder in pregnant women: Motivators and barriers*
Z. Frazer¹, L. Jansson², K. McConnell³, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins Bayview Medical Center, Baltimore, MD
- 22 *Predictors of success in pregnant women receiving medication treatment for opioid use disorder*
C. Struble¹, J. Ellis¹, M. Carr², M. Fodor¹, D. Ledgerwood¹, L. Lundahl¹, ¹Wayne State University, Detroit, MI, ²Eastern Michigan University, Detroit, MI
- 23 *Family planning among female syringe exchange clients*
G. Zollman, A. O'Meara, S. Heil, University of Vermont, Burlington, VT

Tuesday, June 18, 2019

- 24 *The detection of fentanyl in human umbilical cord tissue: Method validation and prevalence in a high-risk population*
J. Jones, L. Abbas, United States Drug Testing Laboratories, Des Plaines, IL
- 25 *Individual-level and neighborhood-level sociodemographic predictors of cigarette smoking during pregnancy using birth record and census data*
A. Houston-Ludlam¹, K. Bucholz², M. Waldron³, P. Madden¹, A. Heath¹, ¹Washington University in St. Louis, St. Louis, MO, ²Washington University School of Medicine, St. Louis, MO, ³Indiana University School of Education, Bloomington, IN
- 26 *Anticipated vs. actual postpartum contraception use among pregnant cigarette smokers*
R. Harfmann¹, S. Heil¹, I. Zvorsky², T. Nighbor¹, I. Bernstein¹, S. Higgins¹, ¹University of Vermont, Burlington, VT, ²Vermont Center on Behavior and Health, Burlington, VT
- 27 *Place matters: The role of population size and urbanicity in prenatal tobacco and cannabis use in the US*
Q. Brown¹, N. Peterson¹, S. Crystal², J. Goodwin¹, R. Raghavan¹, E. Bosk¹, D. Furr-Holden³, ¹School of Social Work, Rutgers, The State University of New Jersey, New Brunswick, NJ, ²Rutgers University, New Brunswick, NJ, ³Michigan State University, East Lansing, MI

PAIN

- 28 *Pain as an emerging risk factor for non-medical cannabis use and cannabis use disorders in US adults: 2001-2002 and 2012-2013*
D. Hasin, D. Shmulewitz, Columbia University, New York, NY
- 29 *Longitudinal associations between cannabis use motives and cannabis use, mental health functioning, and physical health functioning among a cohort of medical cannabis patients with chronic pain*
K. Bohnert¹, M. Ilgen², M. Jannausch², ¹University of Michigan and Department of Veterans Affairs, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI
- 30 *A single centre retrospective study comparing post-operative opioid prescribing practices between caesarean sections and open general surgery procedures*
M. Harris¹, T. Girard², N. Dayan³, A. El-Messidi⁴, S. Gosselin⁵, D. Fleischer⁶, T. Lee³, E. McDonald⁷, E. Villeneuve⁸, A. Bonnici⁸, ¹Boston University, Boston, MA, ²Department of Medicine, McGill University Health Centre, Montreal, QC, Canada, ³Clinical Practice Assessment Unit, McGill University Health Centre, Montreal, QC, Canada, ⁴Department of Obstetrics and Gynecology, McGill University Health Centre, Montreal, QC, Canada, ⁵Hôpital Charles-Lemoyne, Greenfield Park, Greenfield Park, QC, Canada, ⁶Department of Surgery, McGill University Health Centre, Montreal, QC, Canada, ⁷McGill University Health Centre, Montreal, QC, Canada, ⁸Department of Pharmacy, McGill University Health Centre, Montreal, QC, Canada

Tuesday, June 18, 2019

- 31 *Predicting opioid utilization following cesarean section*
K. Bartels¹, J. Carrico¹, K. Mahoney¹, K. Raymond¹, S. McWilliams², L. Mayes¹, S. Mikulich-Gilbertson², ¹University of Colorado, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO
- 32 *Continued opioid use and risk for misuse in a sample of post-injury surgical patients*
A. Heads¹, S. Kapoor², J. Schmitz², C. Green², A. Stotts², S. Lane¹, J. Yoon², J. Harvin², ¹University of Texas Health Science Center, McGovern Medical School, Houston, TX, ²University of Texas Health Science Center, Houston, TX
- 33 *Opioid misuse risk assessment in patients undergoing surgery following traumatic injury*
S. Kapoor¹, J. Schmitz¹, A. Heads², C. Green¹, A. Stotts¹, S. Lane², J. Harvin¹, ¹University of Texas Health Science Center, Houston, TX, ²University of Texas Health Science Center, McGovern Medical School, Houston, TX
- 34 *Differences between non-opioid and long-term opioid therapy in pain and health-related outcomes*
A. Coloma-Carmona¹, J. Carballo¹, J. Rodríguez-Marín¹, A. Pérez-Carbonell², C. Van-der Hofstadt Román¹, R. Secades Villa³, ¹Miguel Hernández University, Elche, Spain, ²General University Hospital of Elche, Elche, Spain, ³University of Oviedo, Oviedo, Spain
- 35 *Identifying predictors of pain intensity following discontinuation of long-term opioid therapy among patients with and without substance use disorders*
T. Lovejoy¹, C. Smith², B. Morasco¹, S. Dobscha¹, S. McPherson³, ¹VA Portland Health Care System, Portland, OR, ²Washington State University, Spokane, WA, ³Washington State University, Elson S. Floyd College of Medicine, Spokane, WA
- 36 *Effects of ascending buprenorphine doses on measures of experimental pain: A pilot study*
S. Nielsen¹, C. Rivas², A. Demirkol², N. Lintzeris², ¹Monash University, Melbourne, Australia, ²South Eastern Sydney Local Health District, Surry Hills, Australia

PRESCRIPTION DRUG ABUSE

- 37 *Abuse of pregabalin and gabapentin in the US*
K. Asomaning¹, G. Bau², S. Severtson³, K. Rockhill³, D. Martire¹, R. Dart³, ¹Pfizer, Inc., New York, NY, ²RADARS® System and Rocky Mountain Poison and Drug Center, Denver, CO, ³Rocky Mountain Poison & Drug Center, Denver, CO
- 38 *Pregabalin misuse: Identifying acute harms and misuse trends in Victoria, Australia through analysis of ambulance attendance data*
R. Crossin¹, D. Scott², S. Arunogiri¹, K. Smith³, P. Dietze⁴, D. Lubman², ¹Monash University, Melbourne, Australia, ²Turning Point, Fitzroy, Australia, ³Ambulance Victoria, Doncaster, Australia, ⁴Burnet Institute, Melbourne, Australia

- 39 *An ethnographic decision model of initiation of gabapentin misuse among opioid misusers*
M. Buttram, S. Kurtz, Nova Southeastern University, Miami, FL
- 40 *A brief point-of-prescription intervention to improve appropriate use of opioids*
E. Winstanley¹, A. Castracane², B. Manibusan³, E. Thacker², M. Bridwell⁴, B. Riley⁴,
¹West Virginia University, Morgantown, WV, ²West Virginia University School of Pharmacy, Morgantown, WV, ³West Virginia University School of Public Health, Morgantown, WV, ⁴Marshall University, School of Pharmacy, Huntington, WV
- 41 *Prescription opioid misuse among US Hispanics*
M. Cano, Boston College, Chestnut Hill, MA
- 42 *Patterns of non-prescribed buprenorphine and other opioid use among individuals with current opioid use disorder: A latent class analysis*
R. Daniulaityte¹, R. Nahhas¹, S. Silverstein², S. Martins³, R. Carlson¹, ¹Wright State University, Dayton, OH, ²Boonshoft School of Medicine Wright State University, Kettering, OH, ³Columbia University, New York, NY
- 43 *Patterns of prescription opioid use prior to self-reported heroin initiation*
D. Hartung¹, J. Geddes¹, G. Leichtling², K. Johnston³, S. Hallvik², C. Hildebran², P. Korthuis¹, ¹Oregon Health & Science University, Portland, OR, ²HealthInsight, Portland, OR, ³Oregon State University, Corvallis, OR
- 44 *Examining prescription opioid diversion cases and cases involving illicitly manufactured opioids in Canada*
M. Levi-Minzi¹, Z. Margolin², K. Wogenstahl², G. Martin¹, M. Buttram¹, S. Kurtz¹, ¹Nova Southeastern University, Miami, FL, ²Rocky Mountain Poison & Drug Center, Denver, CO
- 45 *Misclassification may contribute to overestimates of use of specific opioid products*
S. Severtson¹, J. Iwanicki¹, S. Kurtz², R. Dart¹, ¹Rocky Mountain Poison & Drug Center, Denver, CO, ²Nova Southeastern University, Miami, FL
- 46 *Non-medical use of codeine products in Canada*
B. Sproule¹, J. Black², R. Dart², ¹Centre for Addiction and Mental Health, Toronto, ON, Canada, ²Rocky Mountain Poison & Drug Center, Denver, CO
- 47 *Does medical and non-medical use of benzodiazepines and prescription opioids vary by insurance status?*
V. Tardelli¹, T. Fidalgo², J. Santaella-Tenorio³, S. Martins³, ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²Universidade Federal de São Paulo, São Paulo, ³Columbia University, New York, NY

Tuesday, June 18, 2019

- 48 *A recent six-city study of prescription stimulant use and misuse among 10- to 17- year-olds*
L. Cottler, M. Johnson, Y. Liu, N. Smith, K. Vaddiparti, C. Woodstock Striley, University of Florida, Gainesville, FL
- 49 *An exploratory study of decision factors for seeking medication-assisted treatment for prescription opioid use disorder*
P. Wright, A. Oliveto, M. Mancino, J. Jimmerson, J. Gernat, University of Arkansas for Medical Sciences, Little Rock, AR
- 50 *Sources of prescription opioids for misuse and dropping out of high school*
J. Ford¹, S. McCabe², T. Schepis³, ¹University of Central Florida, Orlando, FL, ²University of Michigan, Ann Arbor, MI, ³Texas State University, San Marcos, TX
- 51 *Providing an FDA-approved prescription opioid disposal method does not improve parental disposal intentions: The strong effect of past misuse and risk perception*
T. Voepel-Lewis, B. Zikmund-Fisher, A. Tait, S. McCabe, C. Boyd, E. Loescher, University of Michigan, Ann Arbor, MI

ADOLESCENT DRUG ABUSE

- 52 *A culturally adapted parenting intervention for Latino/a immigrant families: Testing implementation feasibility and initial efficacy*
R. Parra-Cardona¹, H. Yeh², J. Anthony³, ¹University of Texas at Austin, Austin, TX, ²Henry Ford Health System, Detroit, MI, ³Michigan State University, East Lansing, MI
- 53 *Family substance use, relationship problems and race/ethnicity among juvenile offenders*
C. Leukefeld¹, M. Dickson¹, C. Oser¹, M. Webster¹, H. Knudsen¹, J. Havens², ¹University of Kentucky, Lexington, KY, ²University of Kentucky, College of Medicine, Lexington, KY
- 54 *History of depression and past 30- day opioid misuse among justice-involved children*
G. Diaz, T. Hayes, M. Johnson, University of Florida, Gainesville, FL
- 55 *Netflix and pill: Antisocial romantic partners linked to past 30-day opioid misuse*
S. Lawrence, M. Johnson, University of Florida, Gainesville, FL
- 56 *School dropout predicts past 30-day opioid misuse among juveniles*
S. Bristol, M. Johnson, University of Florida, Gainesville, FL
- 57 *Associations between exposure to gangs and positive urine drug screens in Cape Town, South Africa among a sample of female adolescents who have dropped out of school*
F. Browne¹, T. Carney², J. Ndirangu³, B. Myers², W. Wechsberg¹, ¹RTI International, Research Triangle Park, NC, ²South African Medical Research Council, Tygerberg, South Africa, ³RTI International, Washington, DC

- 58 *Criminal behavior and arrest among opioid-dependent youth following residential rehabilitation*
L. Monico¹, S. Mitchell¹, J. Gryczynski¹, R. Schwartz¹, K. O'Grady², M. Fishman³, ¹Friends Research Institute, Baltimore, MD, ²University of Maryland, College Park, MD, ³Maryland Treatment Center, Baltimore, MD
- 59 *Data-driven subgroups of help-seeking youth based on patterns of substance use*
S. Malignaggi¹, N. Van Dam¹, J. Turnbull², R. Purcell³, P. McGorry³, I. Hickie⁴, A. Yung⁵, C. Pantelis⁶, P. Amminger⁷, G. Bedi¹, ¹The University of Melbourne, Parkville, Australia, ²Orygen, The National Centre of Excellence in Youth Mental Health, Parkville, ³The University of Melbourne, Victoria, Australia, ⁴The University of Sydney, Sydney, Australia, ⁵The University of Melbourne, Victoria, Australia, ⁶The University of Melbourne, Parkville, ⁷Orygen, The National Centre of Excellence in Youth Mental Health
- 60 *Gender differences in substance use, victimization and mental health among adolescents in therapeutic residential care*
S. Fernandez-Artamendi¹, A. Águila², J. Fernandez del Valle³, A. Bravo², ¹Universidad Loyola Andalucía, Seville, Spain, ²Universidad de Oviedo, Oviedo, Spain, ³Family and Childhood Research Group. Universidad de Oviedo, Oviedo, Spain
- 61 *Sex-specific bidirectional association between bullying perpetration and substance use among youth in the US: Findings from the PATH Study*
M. Azevedo Da Silva¹, S. Martins², ¹Columbia University Mailman School of Public Health, New York, NY, ²Columbia University, New York, NY
- 62 *Assessing cohort differences in the grade of onset and initiation sequence of e-cigarette, cigarette, and smokeless tobacco use among US adolescents*
V. McCabe¹, P. Veliz², R. Evans-Polce², C. Boyd², S. McCabe², ¹St. Joseph Mercy Hospital, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI
- 63 *Identifying patterns of poly-tobacco use to predict longitudinal changes in tobacco and substance use disorder symptoms among US adolescents*
P. Veliz¹, R. Evans-Polce¹, S. McCabe¹, V. McCabe², C. Boyd¹, ¹University of Michigan, Ann Arbor, MI, ²St. Joseph Mercy Hospital, Ann Arbor, MI
- 64 *Longitudinal associations between cannabis use and self-reported motivation among adolescents*
I. Pacheco-Colon, S. Coxe, S. Hawes, R. Gonzalez, Florida International University, Miami, FL
- 65 *The association of gender discrimination and cannabis use among adolescents and young adults*
M. Ahuja¹, K. Bucholz², ¹Washington University in St. Louis, St. Louis, MO, ²Washington University School of Medicine, St. Louis, MO
- 66 *Perceived discrimination and substance use among adolescents: Examining the moderating effect of distress tolerance and negative urgency*
A. Rowe, T. Zapolski, D. Banks, M. Faidley, Indiana University Purdue University Indianapolis, Indianapolis, IN

Tuesday, June 18, 2019

- 67 *Social influence and adolescent marijuana use: A latent space adjusted approach*
A. Burgess-Hull¹, J. Moody², ¹National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD, ²Duke University, Durham, NC
- 68 *Marijuana-related beliefs in adolescents: Moving beyond perceived riskiness of marijuana use*
N. Chadi, S. Levy, E. Weitzman, Boston Children's Hospital, Boston, MA
- 69 *Does legalization of recreational cannabis use increase substance use treatment admissions for youth?*
J. Stahler, J. Mennis, Temple University, Philadelphia, PA
- 70 *Health care providers asking adolescents about their marijuana or illegal drug use: Differences by state medical marijuana status, 2015-2017*
P. Mauro¹, M. Philbin², M. Askari¹, S. Martins¹, ¹Columbia University, New York, NY, ²Columbia University Mailman School of Public Health, New York, NY

HIV/HCV

- 71 *HIV testing practices and reasons for never-testing among men who have sex with men (MSM) in Malaysia*
R. Shrestha¹, Z. Ni², M. Copenhaver³, F. Altice⁴, S. Lim⁵, ¹Yale University, New Haven, CT, ²Duke University, Durham, NC, ³University of Connecticut, New Haven, CT, ⁴Yale University School of Medicine, New Haven, CT, ⁵University of Malaya, Kuala Lumpur, Malaysia
- 72 *Emotion regulation moderates the relationships between substance use and risky sexual behaviors*
A. Gilmore-Thomas¹, A. Heads², M. Hill¹, J. Hamilton³, J. Schmitz¹, ¹University of Texas Health Science Center, Houston, TX, ²University of Texas Health Science Center, McGovern Medical School, Houston, TX, ³University of Texas Health Science Center Houston, Houston, TX
- 73 *A brief intervention with mobile boosters for drug use and sexual risk behaviors among emerging adults in an urban emergency department*
E. Bonar¹, F. Blow², R. Cunningham¹, L. Drislane¹, M. Walton², ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Addiction Center, Ann Arbor, MI
- 74 *PrEP awareness and interest among people who inject drugs in rural West Virginia*
K. Schneider¹, R. White¹, A. O'Rourke², M. Kilkenny³, S. Sherman⁴, S. Allen⁵, ¹Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²George Washington University, Washington, DC, ³Cabell-Huntington Health Department, Huntington, WV, ⁴Johns Hopkins Hospital, Baltimore, MD, ⁵Johns Hopkins University, Baltimore, MD

Tuesday, June 18, 2019

- 75 *HIV pre-exposure prophylaxis (PrEP) prevention awareness, willingness and barriers among people who inject drugs (PWID) in Los Angeles and San Francisco, CA, 2016-2018*
R. Bluthenthal¹, S. Walters², L. Wenger³, K. Simpson¹, A. Kral³, ¹Keck School of Medicine, Los Angeles, CA, ²New York University, New York, NY, ³RTI International, San Francisco, CA
- 76 *Trajectories of self-reported illicit opioid use among people living with HIV*
E. Edelman¹, Y. Li², D. Barry¹, W. Becker³, J. Braden⁴, J. Chang⁵, S. Crystal⁶, J. Gaither⁷, K. Gordon⁸, R. Kerns¹, A. Manhapra¹, B. Moore¹, B. Oldfield¹, L. Park⁹, C. Rentsch⁸, M. Skanderson⁸, J. Tate³, A. Justice³, D. Fiellin¹, B. Marshall², ¹Yale University School of Medicine, New Haven, CT, ²Brown University School of Public Health, Providence, RI, ³Yale University, New Haven, CT, ⁴Behavioral Health Integration Program, Renton, WA, ⁵University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁶Rutgers University, New Brunswick, NJ, ⁷Yale Center for Medical Informatics, New Haven, CT, ⁸VA Connecticut Healthcare System, West Haven, CT, ⁹Stanford University, Palo Alto, CA
- 77 *Barriers and facilitators to recruiting patients with HIV for opioid use disorder research: Staff perspectives from the clinical trials network CHOICES study*
K. Hoffman, R. Baker, L. Kunkel, D. McCarty, P. Korthuis, Oregon Health & Science University, Portland, OR
- 78 *Exploring the role of family relationships on the decision to enter opioid agonist treatment among people who inject drugs in Ukraine*
R. Marcus¹, L. Madden², S. Farnum³, A. Meteliuk⁴, T. Fomenko⁴, I. Pykalo⁵, K. LaMonaca¹, F. Altice¹, ¹Yale University School of Medicine, New Haven, CT, ²Yale University, APT Foundation, New Haven, CT, ³APT Foundation, Inc., New Haven, CT, ⁴ICF Alliance for Public Health, Kyiv, Ukraine, ⁵Ukrainian Institute on Public Health Policy, Kiev, Ukraine
- 79 *The impact of expanding opioid agonist therapies on HIV epidemic and mortality in Ukraine: A modeling study*
J. Tan¹, F. Altice², L. Madden³, A. Zelenev², ¹Yale University AIDS Program, New Haven, CT, ²Yale University School of Medicine, New Haven, CT, ³Yale University, APT Foundation, New Haven, CT
- 80 *Interacting risks: High-risk network locations and risk behaviors during an HIV outbreak in Athens, Greece*
S. Friedman, L. Williams, T. Research Group, National Development and Research Institute, Inc., New York, NY

- 81 *Substance use and HIV care outcome trends among substance users in Puerto Rico*
Y. Pan¹, L. Metsch², J. Santana, P. Castellon², S. Miranda de Leon³, A. Rodriguez⁴, G. Dávila Torres⁵, Y. Iveth G², M. Maisonet-Alejandro⁶, L. Gooden², D. Feaster¹, ¹University of Miami Miller School of Medicine, Miami, FL, ²Columbia University, New York, NY, ³Departamento de Salud de Puerto Rico, San Juan, PR, ⁴University of Miami, Miami, FL, ⁵Departamento de Prevención y Educación Iniciativa Comunitaria, Inc., San Juan, PR, ⁶University of Puerto Rico, San Juan, PR
- 82 *Durable viral suppression among people with HIV and problem substance use in the era of universal antiretroviral treatment*
M. Paschen-Wolff¹, A. Campbell², S. Tross³, T. Choo⁴, M. Pavlicova⁴, D. Des Jarlais⁵, ¹New York State Psychiatric Institute at Columbia University Irving Medical Center, New York, NY, ²Columbia University and New York Psychiatric Institute, New York, NY, ³Columbia University, New York, NY, ⁴Columbia University Mailman School of Public Health, New York, NY, ⁵New York University College of Global Public Health, New York, NY
- 83 *A novel mathematical simulation to study the effect of naltrexone on CD4 cells, CD8 cells, and HIV viral load*
N. Thakor¹, S. Springer², G. Miller¹, ¹Northeastern University, Boston, MA, ²Yale University School of Medicine, New Haven, CT
- 84 *Evaluating the effect of extended-release naltrexone on HIV risk in patients presenting for opioid-use disorder treatment*
J. Fleuriscar¹, A. Bisaga², A. Campbell³, ¹City University of New York School of Medicine, New York, NY, ²Columbia University College of Physicians and Surgeons, New York, NY, ³Columbia University and New York Psychiatric Institute, New York, NY
- 85 *Uptake of new hepatitis C treatments among patients in opioid substitution therapy*
I. Rivas Puy¹, A. Sanvisens², E. Faure³, N. Espinach³, T. Muñoz³, M. Rubio³, N. Salgado³, R. Muga⁴, ¹Badalona Serveis Assistencials Plaza Pau Casals, Badalona, Spain, ²Internal Medicine Service. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ³Salut Mental i Addiccions. Badalona Serveis Assistencials (BSA), Badalona, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain
- 86 *Correlates of health care by HCV status among rural women at community re-entry from jail*
M. Staton¹, M. Dickson², C. Oser², M. Webster², C. Leukefeld², ¹University of Kentucky, College of Medicine, Lexington, KY, ²University of Kentucky, Lexington, KY
- 87 *Stakeholder perspectives on enhancing hepatitis C (HCV) screening, access, and linkage to care in the homeless population*
J. Fokuo¹, C. Masson¹, A. Andersen¹, B. Zevin², J. Powell³, M. Khalili¹, ¹University of California San Francisco, San Francisco, CA, ²San Francisco Department of Public Health, San Francisco, CA, ³Hennepin Healthcare, Minneapolis, MN

PROGRAM DESCRIPTION

- 88 *An environmental scan of service delivery models for injectable opioid agonist treatment in Canada*
C. Johnson¹, E. Eydt¹, C. Sutherland¹, K. Meador², M. Trew², M. Perreault³, M. Goyer⁴, B. Le Foll⁵, J. Turnbull⁶, N. Fairbairn⁷, ¹British Columbia Centre on Substance Use, Vancouver, BC, Canada, ²Alberta Health Services, Red Deer, AB, Canada, ³McGill University, Montreal, QC, Canada, ⁴University of Montreal, Montreal, QC, Canada, ⁵Centre for Addiction and Mental Health, Toronto, ON, Canada, ⁶Ottawa Inner City Health Inc., Ottawa, ON, Canada, ⁷BC Centre on Substance Use, Vancouver, BC, Canada
- 89 *Rapid initiation of buprenorphine/naloxone to optimize MAT utilization in Philadelphia*
D. Metzger¹, C. Denis², K. Kampman², J. Becher², K. Lynch², J. Benitez³, D. Barclay³, K. Dugosh⁴, D. Festinger², K. Viner⁵, ¹University of Pennsylvania, Department of Psychiatry, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Prevention Point Philadelphia, Philadelphia, PA, ⁴Treatment Research Institute, Philadelphia, PA, ⁵Philadelphia Department of Public Health, Philadelphia, PA
- 90 *Implementation of emergency-department-initiated buprenorphine induction for opioid use disorder*
C. Bogdon¹, L. Jennings¹, K. Barth¹, S. Goldsby², M. Oros³, L. Haynes¹, S. Lane¹, K. Brady¹, ¹Medical University of South Carolina, Charleston, SC, ²South Carolina Department of Alcohol and Other Drug Abuse Services, Columbia, SC, ³Mosaic Group, Towson, MD
- 91 *Get waived Texas: Expanding buprenorphine treatment capacity for medication-assisted treatment for opioid use disorder*
S. Schneegans¹, E. Finley², V. King³, A. Callen⁴, S. Schmidt⁴, J. Sharpe Potter¹, ¹University of Texas Health Science Center, San Antonio, TX, ²South Texas Veterans Health Care System, San Antonio, TX, ³University of Texas Health, San Antonio, San Antonio, TX, ⁴UT Health San Antonio, San Antonio, TX
- 92 *Design of the buprenorphine physician-pharmacist collaborative care of patients with opioid use disorder*
L. Wu¹, U. Ghitza², M. Lewis³, A. Matthews³, P. Mannelli¹, ¹Duke University School of Medicine, Durham, NC, ²National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD, ³The Emmes Corporation, Rockville, MD

- 93 *Understanding NSW long-acting opioids in custody-treatment (the UNLOC-T study)*
A. Dunlop¹, B. White², J. Roberts³, P. Haber⁴, J. Attia⁵, C. Oldmeadow⁵, A. Searles⁵, M. Cretikos⁶, J. Mackson⁷, D. Attalla³, T. Murrell⁸, M. Doyle⁹, E. McEntyre¹⁰, L. Brown¹¹, H. Hellal³, M. Howard¹², M. Sequeira¹, N. Lintzeris¹³, ¹Hunter New England Local Health District, Newcastle, Australia, ²Drug Health Services, Sydney Local Health District, Camperdown, Australia, ³Justice Health & Forensic Mental Health Network, Matraville, Australia, ⁴Sydney Local Health District, Sydney, Australia, ⁵Hunter Medical Research Institute, New Lambton Heights, Australia, ⁶Centre for Population Health, NSW Ministry of Health, North Sydney, Australia, ⁷Legal & Regulatory Services, NSW Ministry of Health, North Sydney, Australia, ⁸Corrective Services, NSW, Sydney, Australia, ⁹University of Sydney, Camperdown, Australia, ¹⁰Durri Aboriginal Corporation Medical Centre, Kempsey, Australia, ¹¹Aboriginal Health Unit, Nepean Blue Mountains Local Health District, Penrith, Australia, ¹²Corrections Research Evaluation and Statistics, Corrections Research Evaluation and Statistics, Sydney, Australia, ¹³South Eastern Sydney Local Health District, Surry Hills, Australia
- 94 *Treatment and care for people with drug use disorders in contact with the criminal justice system: Alternatives to conviction or punishment*
A. Busse, S. Pfeiffer, G. Gerra, G. Campello, E. Sáenz, V. Lebaux, J. Lee, United National Office on Drugs and Crime, Vienna, Austria
- 95 *Reducing risk of overdose after release from incarceration (ROAR): Protecting women released from prison in Oregon*
E. Waddell¹, C. Hildebran², G. Leichtling², R. Baker¹, D. Hartung¹, L. Kunkel¹, E. Stack², P. Korhuis¹, ¹Oregon Health & Science University, Portland, OR, ²HealthInsight, Portland, OR
- 96 *Peer supports at the intersection of opioid use disorder and disability*
J. Nicholson¹, S. Reif², M. Lee³, ¹Brandeis University, Waltham, MA, ²Brandeis University, Heller School for Social Policy and Management, Waltham, MA, ³Institute for Behavioral Health, Brandeis University, Waltham, MA
- 97 *Increasing identification and providing evidence-based treatment of opioid use disorder in VA primary care: The supporting primary care providers in opioid risk reduction and treatment (SUPPORT) center*
E. Williams¹, M. Frost¹, C. Achtmeyer², C. Malte², A. Saxon³, C. Hood⁴, A. Danner², A. Lott², E. Hawkins², ¹Veterans Affairs Puget Sound Health Services Research & Development, Seattle, WA, ²Center of Excellence in Substance Abuse Treatment and Education, Veterans Affairs Puget Sound Health Care System, Seattle, WA, ³Veterans Affairs Puget Sound Healthcare System, Seattle, WA, ⁴Veterans Affairs Puget Sound Health Care System, Seattle, WA
- 98 *Leveraging the emergency department visit to debunk myths on HIV risks among substance-using African American women*
S. Coker, M. Hill, A. Stotts, University of Texas Health Science Center, Houston, TX

- 99 *Testing an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among methadone-maintained patients: The CHRP-BB study*
R. Shrestha¹, F. Altice², J. Ssenyonjo³, B. Sibilio³, M. Copenhaver³, ¹Yale University, New Haven, CT, ²Yale University School of Medicine, New Haven, CT, ³University of Connecticut, New Haven, CT
- 100 *Implementing opioid agonist therapy scale-up for opioid use disorder in Ukraine*
L. Madden¹, D. Muthulingam², S. Farnum³, R. Marcus², K. LaMonaca², A. Meteliuk⁴, T. Fomenko⁴, I. Pykalo⁵, S. Dvoriak⁵, F. Altice², ¹Yale University, APT Foundation, New Haven, CT, ²Yale University School of Medicine, New Haven, CT, ³APT Foundation, Inc., New Haven, CT, ⁴ICF Alliance for Public Health, Kyiv, Ukraine, ⁵Ukrainian Institute on Public Health Policy, Kiev, Ukraine
- 101 *Using nominal group technique to inform strategic planning for integration of specialty and primary care among high-level administrators in Ukraine*
I. Pykalo¹, L. Madden², K. LaMonaca³, S. Farnum⁴, M. Filippovych¹, D. Barry³, S. Dvoriak¹, F. Altice³, ¹Ukrainian Institute on Public Health Policy, Kiev, Ukraine, ²Yale University, APT Foundation, New Haven, CT, ³Yale University School of Medicine, New Haven, CT, ⁴APT Foundation, Inc., New Haven, CT
- 102 *Innovative solutions to opioid overdose mortality crisis: Safe consumption sites*
A. Kral¹, L. Wenger¹, B. Lambdin¹, R. Bluthenthal², P. Davidson³, ¹RTI International, San Francisco, CA, ²Keck School of Medicine, Los Angeles, CA, ³University of California San Diego, La Jolla, CA
- 103 *A cohort study investigating and addressing morbidity, mortality and health care costs among substance use disorder patients in an acute care setting in Vancouver, Canada.*
S. Nolan¹, J. Morgan², J. Shoveller², E. Wood³, L. Ti³, ¹University of British Columbia, Vancouver, BC, Canada, ²BC Centre on Substance Use, Vancouver, BC, Canada, ³British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada
- 104 *Building an addiction care continuum model in North America: Lessons from an emerging integrated drug checking and supervised consumption system in Toronto, Canada*
N. Maghsoudi¹, D. Beriault², T. Watson³, L. Beletsky⁴, D. Werb⁵, ¹University of Toronto, Toronto, ON, Canada, ²St. Michael's Hospital, Toronto, ON, Canada, ³Centre for Addiction and Mental Health, Toronto, ON, Canada, ⁴Northeastern University, Boston, MA, ⁵University of California San Diego, La Jolla, CA

Tuesday, June 18, 2019

- 105 *Workforce development as a tool for strengthening OUID (opioid use disorder) treatment outcomes*
A. Skinstad¹, M. Dreyer Rossi², J. Ledolter³, C. McCoy⁴, ¹University of Iowa, Iowa City, IA, ²University of Iowa, Iowa City, ³National American Indian and Alaska Native Addiction Technology Transfer Center, Iowa City, IA, ⁴Comprehensive Drug Research Center, Miami, FL
- 106 *Direct dispensing laws: Status, trends and evidence*
C. Davie, A. Frazer, Legal Science, LLC, Philadelphia, PA
- 107 *Student-led initiatives to incorporate addiction medicine training into undergraduate medical education in Detroit, MI*
I. Lien¹, T. Moses², J. Chou¹, K. Shango¹, A. Szpytman², S. Dass², M. Greenwald², ¹Wayne State University School of Medicine, Detroit, MI, ²Wayne State University, Detroit, MI

LATE BREAKING II

Grand Oaks K/L
2:00 - 3:00 PM

Chair: Kelly Dunn

- 2:00 *Cocaine use is increasing. Are we prepared to confront the epidemic?*
J. Maxwell, Steve Hicks School of Social Work, Salisbury, NC
- 2:05 *How abusable is a slow-onset, longer duration dopamine reuptake inhibitor?*
M. Froimowitz¹, A. Moore², T. Buck², Z. You², E. Gardner³, ¹Consultant, Newton, MA, ²NIDA Intramural Research Program, Baltimore, MD, ³National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD
- 2:10 *An innovative approach for studying decision-making deficits in cocaine use disorder*
M. Wesley¹, J. Beckmann², J. Alcorn², B. Bolin², M. Ponder², C. Rush², A. Smith², W. Stoops², J. Strickland², J. Lile¹, ¹University of Kentucky, College of Medicine, Lexington, KY, ²University of Kentucky, Lexington, KY
- 2:15 *Neural correlates of stimulant use, gender, and risky sexual practices in sexual and monetary delay discounting*
M. Koffarnus¹, J. Lisinski², S. LaConte², T. Willson², W. Bickel³, M. Johnson⁴, ¹Virginia Tech, Roanoke, VA, ²Virginia Tech Carilion Research Institute, Roanoke, VA, ³Fralin Biomedical Research Institute at VTC, Roanoke, VA, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
- 2:20 *Relevance of methamphetamine and injection drug use in an ongoing outbreak of Hepatitis A in Kentucky*
J. Strickland, O. Vselvolozhskaya, A. Grigorian, University of Kentucky, Lexington, KY

Tuesday, June 18, 2019

- 2:25 *Pilot study of tolerability and safety of opioid receptor antagonists as novel therapies for pain among HIV-positive Russians with chronic pain and prior heavy drinking*
J. Tsui¹, S. Bendiks², D. Cheng³, E. Blokhina⁴, M. Vetrova⁴, E. Verbitskaya⁴, N. Gnatienco³, K. Bryant⁵, E. Krupitsky⁶, J. Samet³, ¹University of Washington, Seattle, WA, ²Boston Medical Center, Boston, MA, ³Boston University School of Medicine, Boston, MA, ⁴First Pavlov State Medical University, St. Petersburg, Russian Federation, ⁵National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD, ⁶V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, St. Petersburg, Russian Federation
- 2:30 *Syringe disposal practices among injection drug users before and after implementation of a syringe exchange program in Miami, FL*
H. Levine, T. Bartholomew, V. Rea-Wilson, D. Arriola, G. Cardenas, D. Feaster, D. Forrest, H. Tookes, University of Miami Miller School of Medicine, Miami, FL
- 2:35 *The relationship between pregnant women's interaction with the justice system and their admission of and continuation of use of cannabis*
K. Mark¹, E. Pierce¹, M. Terplan², ¹University of Maryland School of Medicine, Baltimore, MD, ²Virginia Commonwealth University, Richmond, VA
- 2:40 *Prenatal tobacco and marijuana co-use: Impact on infant stress response*
C. Vergara-Lopez¹, J. Metrik², G. Papandonatos¹, L. Stroud³, ¹Brown University, Providence, RI, ²Brown University School of Public Health, Providence, RI, ³Brown Medical School and The Miriam Hospital, Providence, RI
- 2:45 *High anxiety? Preliminary data from the first clinical trial of a novel high cannabidiol product for anxiety*
S. Gruber¹, A. Lambros², R. Smith², M. Dahlgren¹, K. Sagar², D. Olson², S. Lukas¹, ¹McLean Hospital, Harvard Medical School, Belmont, MA, ²McLean Hospital, Belmont, MA
- 2:50 *Does cannabis improve self-reported pain, sleep problems, and health-related quality of life among Individuals Living with chronic pain?*
N. Payakachat, W. Fantegrossi, University of Arkansas for Medical Sciences, Little Rock, AR
- 2:55 *A single, web-based episodic future thinking session may improve delay discounting, sunk cost propensity and readiness to change in cannabis users*
S. Lemley¹, M. Sofis², A. Budney¹, ¹Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Dartmouth College, Hanover, NH

ORAL COMMUNICATIONS 14 SLEEP IN THE HEART OF TEXAS

**Grand Oaks M
2:00 - 3:00 PM**

Chair: Lais Berro

- 2:00 *Acute effects of stimulant drugs on actigraphy-based sleep parameters in rhesus monkeys*
L. Berro, J. Rowlett, University of Mississippi Medical Center, Jackson, MS

Tuesday, June 18, 2019

- 2:15 *Prevalence and impact of PTSD symptoms on sleep and cannabis abstinence in an urban cannabis treatment trial*
R. Mayhugh¹, T. Spindle¹, M. Bonn-Miller², R. Vandrey¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Pennsylvania, Southmont, NC
- 2:30 *Are people with severe insomnia able to discontinue chronic hypnotic use?*
T. Roehrs, Henry Ford Health System, Detroit, MI
- 2:45 *The relationship between sleep apnea and substance abuse: Findings from the National Survey on Drug Use and Health*
S. Nayak¹, E. Strain², ¹Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD

**SYMPOSIUM VII
ETIOLOGY AND TREATMENT OF CO-OCCURRING
SUBSTANCE USE DISORDERS AND ATTENTION-DEFICIT
HYPERACTIVITY DISORDER: FROM PRECLINICAL
STUDIES TO BIG DATA ANALYTICS**

**Grand Oaks H
2:00 - 3:00 PM**

Chairs: Emily Hankosky and Linda Dwoskin

- 2:00 *Effects of ADHD medications on the developing brain: Impact on adult cocaine abuse risk in an animal model of ADHD*
K. Kantak, Boston University, Boston, MA
- 2:20 *Big data approaches exploring ADHD and substance use disorder*
J. Talbert, University of Kentucky, Lexington, KY
- 2:40 *Treating ADHD and substance use disorders: What does the current literature tell us?*
F. Levin, Columbia University and NYSPI, New York, NY

**SYMPOSIUM XIII
SELF-SUSTAINING STRATEGIES: VOLUNTARY
NONDRUG CHOICES TO REDUCE LONG-TERM
DRUG CRAVING AND RELAPSE: SEX DIFFERENCES**

**Grand Oaks G
2:00 - 3:00 PM**

Chairs: Marilyn Carroll

- 2:00 *Voluntary aerobic exercise reduces incubation of cocaine and nicotine craving and multi-triggered relapse in rats: Sex differences*
M. Carroll, University of Minnesota, Minneapolis, MN
- 2:20 *Operant social interaction inhibits drug self-administration and incubation of drug craving in rat addiction models*
M. Venniro, NIDA Intramural Research Program, Baltimore, MD

Tuesday, June 18, 2019

- 2:40 *Employment-based incentives to address interrelated problems of poverty and drug addiction*
K. Silverman, Johns Hopkins University, Baltimore, MD

SYMPOSIUM XIV

**THE USE OF TECHNOLOGY TO IMPROVE DETECTION
AND TREATMENT OF PERINATAL SUBSTANCE
USE DISORDERS**

**Grand Oaks I
2:00 - 3:00 PM**

Chairs: Constance Guille

- 2:00 *Electronic and clinician delivered screening, brief intervention and referral to treatment for women in reproductive healthcare centers: A randomized controlled trial*
K. Yonkers, Yale University Department of Psychiatry, New Haven, CT
- 2:20 *The use of telemedicine for the treatment of perinatal opioid use disorder*
C. Guille, Medical University of South Carolina, Charleston, SC
- 2:40 *Smartphone-delivered attentional bias modification for postpartum smoking relapse*
A. Forray, Yale University School of Medicine, New Haven, CT

BUSINESS MEETING

**Grand Oaks E/F
3:00 - 4:00 PM**

Members Only, MITs Welcome

COFFEE BREAK

**Cibolo Ballroom
3:00 - 4:00 PM**

**ORAL COMMUNICATIONS 17
MINI DRIVER**

**Grand Oaks H
4:00 - 5:00 PM**

Effects of therapeutic cannabis consumption on simulated driving and road safety

P. Di Ciano¹, H. Hamilton¹, A. Matamoros¹, J. Matheson¹, A. Fares¹,
C. Wickens¹, R. Mann¹, T. Watson¹, B. Le Foll¹, B. Brands², ¹Centre
for Addiction and Mental Health, Toronto, ON, Canada, ²Health
Canada, Toronto, ON, Canada

Tuesday, June 18, 2019

ORAL COMMUNICATIONS 18
TRUE GRIT: FIGHTING STRESS

Grand Oaks M
4:00 - 5:00 PM

Chair: Mark Greenwald

- 4:00 *Sex differences in life stress, morning cortisol levels, pain and risk of opioid use in a community sample*
N. Fogelman¹, R. Hart², R. Sinha¹, ¹Yale University School of Medicine, New Haven, CT, ²Yale University, New Haven, CT
- 4:15 *Modulation of stress-induced opioid seeking by hedonic sensitivity*
M. Greenwald, Wayne State University, Detroit, MI
- 4:30 *Wearable sensor-based detection of stress and craving in patients during treatment for substance use disorder*
K. Chintha¹, P. Indic¹, B. Chapman², S. Carreiro², ¹Department of Electrical Engineering, The University of Texas at Tyler, Tyler, TX, ²University of Massachusetts Medical School, Worcester, MA
- 4:45 *Stress, craving, and psychological flow during work in a therapeutic workplace*
J. Bertz¹, S. Stull¹, D. Epstein¹, A. Holtyn², K. Silverman³, K. Preston⁴, ¹NIDA Intramural Research Program, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴National Institute of Drug Abuse Intramural Research Program, Baltimore, MD

ORAL COMMUNICATIONS 15
ANIMAL HOUSE: OPIOIDS AND BEHAVIOR

Grand Oaks G
4:00 - 6:00 PM

Chairs: Francesco Leri and Chela Wallin

- 4:00 *Intermittent abstinence potentiates oxycodone self-administration and alters brain reward sensitivity*
J. Nguyen, Y. Grant, M. Taffè, The Scripps Research Institute, La Jolla, CA
- 4:15 *The effects of food restriction on the acquisition and persistence of responding for an opioid-associated stimulus*
S. Robertson, E. Jutkiewicz, University of Michigan, Ann Arbor, MI
- 4:30 *Sex differences in opioid reinforcement under a fentanyl vs. food choice procedure in rats*
D. Townsend¹, S. Negus¹, B. Caine², M. Thomsen³, M. Banks¹, ¹Virginia Commonwealth University, Richmond, VA, ²McGill University, Belmont, MA, ³University Hospital of Copenhagen, Copenhagen, Denmark
- 4:45 *Preconceptional, gestation, and postpartum buprenorphine exposure in rats: Litter outcomes, development, and adolescent behavior*
C. Wallin, C. Wiacek, K. Tilson, M. Saffar, L. Richardson, C. Roberge, S. Brummelte, S. Bowen, Wayne State University, Detroit, MI

Tuesday, June 18, 2019

- 5:00 *Quantification of observable behaviors induced by kappa agonists in rhesus monkeys: Effects of signaling bias*
S. Huskinson¹, D. Platt², M. Brasfield¹, M. Follett¹, T. Prisinzano³, B. Blough⁴, K. Freeman¹, ¹University of Mississippi Medical Center, Jackson, MS, ²Division of Neurobiology and Behavior Research, Jackson, MS, ³University of Kansas, Lawrence, KS, ⁴RTI International, Research Triangle Park, NC
- 5:15 *The memories that linger: The effect of opiate withdrawal and conditioned opiate withdrawal on memory consolidation*
F. Leri, N. Baidoo, M. Wolter, B. Winters, University of Guelph, Guelph, ON, Canada
- 5:30 *Comparison of mu-opioid and alpha2-adrenergic agonists: Scheduled-control responding, rectal temperature and hot-plate latency in rats*
T. Hiranita¹, J. Leon Oyola¹, L. Restrepo¹, S. Obeng², M. Reeves¹, A. Pennington¹, V. Taylor¹, A. Patel², C. McCurdy², L. McMahon², ¹University of Florida, College of Pharmacy, Gainesville, FL, ²University of Florida, Gainesville, FL
- 5:45 *Opioid, GABAB, and 5-HT1A receptor agonist combinations in a mouse model of neuropathic pain*
J. Wilkerson¹, J. Felix¹, M. Ansari², A. Coop², L. McMahon¹, ¹University of Florida, Gainesville, FL, ²University of Maryland, School of Pharmacy, Baltimore, MD

ORAL COMMUNICATIONS 16 SHINING SOME FRIDAY NIGHT LIGHTS ON THE BRAIN: IMAGING

**Grand Oaks I
4:00 - 6:00 PM**

Chairs: Stephen Kohut and Breno Sanvicente-Vieira

- 4:00 *Resting-state fMRI connectivity in awake nonhuman primates: Modulation by cocaine self-administration*
F. de Moura¹, M. Rohan², S. Kohut², ¹Harvard Medical School, Belmont, MA, ²McLean Hospital, Harvard Medical School, Belmont, MA
- 4:15 *Altered resting-state functional MRI connectivity following chronic cocaine self-administration in nonhuman primates*
S. Kohut¹, D. Mintzopoulos², B. Kangas³, R. Doyle⁴, T. Gillis⁵, J. Bergman⁶, M. Kaufman², ¹McLean Hospital, Harvard Medical School, Belmont, MA, ²McLean Hospital, Brain Imaging Center, Belmont, MA, ³Harvard Medical School, Belmont, MA, ⁴McGill University, Belmont, MA, ⁵ADARC - McLean Hospital, Belmont, MA, ⁶McLean Hospital, Belmont, MA

Tuesday, June 18, 2019

- 4:30 *Sex differences in implicit brain connectivity of cocaine users: Opposite patterns of connectivity for males and females in resting-state functional magnetic resonance imaging*
B. Sanvicente-Vieira¹, P. Ferreira¹, N. Bianchini¹, L. Rothmann¹, A. Buchweitz¹, A. Franco², R. Grassi-Oliveira¹, ¹Pontifca Universidade Catolica do Rio Grande do Sul, Porto Alegre, Brazil, ²The Nathan S. Kline Institute for Psychiatric Research, New York, NY
- 4:45 *Gray-matter structure in long-term abstinent methamphetamine users*
L. Nie¹, D. Ghahremani², J. Li³, E. London², ¹West China Medical School of Sichuan University; UCLA, Los Angeles, CA, ²University of California Los Angeles, Los Angeles, CA, ³West China Medical School of Sichuan University, Chengdu, China
- 5:00 *The performance of working memory and brain structural changes in chronic ketamine users*
Y. Liu¹, C. Hung², C. Huang¹, C. Li³, N. Muggleton⁴, T. Lee⁵, C. Lin¹, ¹National Yang Ming University, Taipei, Taiwan, ²Bali Psychiatric Center, New Taipei City, Taiwan, ³Yale University, New Haven, CT, ⁴National Central University, Jhongli City, Taiwan, ⁵National Taiwan Normal University, Taipei, Taiwan
- 5:00 *Frontoparietal connectivity as a potential EEG biomarker for substance use disorder: Interaction of stimulants and opioids*
R. Kuplicki¹, H. Ekhtiari¹, O. Al Zoubi¹, J. Bodurka¹, T. Investigators¹, M. Paulus², ¹Laureate Institute for Brain Research, Tulsa, OK, ²Tulsa 1000 Investigators, Tulsa, OK
- 5:15 *Neural correlates of decreased persistence behavior in treatment-seeking prescription opioid-dependent individuals*
S. Ray, J. Bhanji, M. Delgado, Rutgers University, Newark, NJ
- 5:30 *Imaging the dopamine system with [11C]PHNO PET in recently abstinent tobacco smokers compared to nonsmokers*
K. Calakos, A. Hillmer, J. Anderson, D. Matuskey, Y. Huang, K. Cosgrove, Yale University, New Haven, CT

SYMPOSIUM XV THE IMPLEMENTATION CHASM FOR HARM REDUCTION SERVICES IN RURAL AREAS

**Grand Oaks K/L
4:00 - 6:00 PM**

Chairs: Hannah Cooper and Richard Jenkins

- 4:00 *Implications of burgeoning methamphetamine co-use for the health of people who inject opioids and for harm reduction systems in rural Oregon*
G. Leichtling, HealthInsight, Portland, OR
- 4:25 *The role of anti-MAT stigma in shaping access to and utilization of MAT among people who misuse opioids in the Ohio Valley*
E. Richard, University of North Carolina, Bronx, NY

Tuesday, June 18, 2019

- 4:50 *Opportunities for pharmacies to serve as harm reduction sites in Appalachian Kentucky*
H. Cooper, Emory University, Atlanta, GA
- 5:15 *Experiences with overdose and Narcan among people who use opioids in 3 rural areas, and implications for harm reduction policy and practice*
D. Seal, Tulane University SPHTM, New Orleans, LA
- 5:40 *The effect of siloed harm reduction organizations on the health of people who misuse opioids in the Ohio Valley*
C. Schalkoff, University of North Carolina, Chapel Hill, NC

WORKSHOP XI
MANUSCRIPT REVIEW: TIPS AND TRAPS
FOR EMERGING INVESTIGATORS
IN DRUG DEPENDENCE

Grand Oaks M
5:15 - 7:15 PM

Chairs: James Sorensen and Joseph Guydish

Manuscript review: Tips and traps for emerging investigators in drug dependence research

J. Sorensen¹, L. Porrino², T. Lovejoy³, L. Montgomery⁴, A. Freda⁵, E. Strain⁶, ¹University of California San Francisco, San Francisco, CA, ²Wake Forest University School of Medicine, Winston-Salem, NC, ³VA Portland Health Care System, Portland, OR, ⁴University of Cincinnati, College of Medicine, Cincinnati, OH, ⁵Elsevier Health and Medical Sciences, Amsterdam, ⁶Johns Hopkins University School of Medicine, Baltimore, MD

Importance, benefits, & requirements for peer reviewing for young investigators

L. Porrino, Wake Forest University School of Medicine, Winston-Salem, NC
Pragmatic guidelines for reviewing: Aid to both authors and editors

T. Lovejoy, VA Portland Health Care System, Portland, OR

Ways to become and develop as a peer reviewer

L. Montgomery, University of Cincinnati, College of Medicine, Cincinnati, OH

Publisher resources for becoming a more skilled reviewer

A. Freda, Elsevier Health and Medical Sciences, Amsterdam, Netherlands

Discussant and moderator of participant issues

E. Strain, Johns Hopkins University School of Medicine, Baltimore, MD

Tuesday, June 18, 2019

**WORKSHOP XII
EXPANDING THE IMPACT OF SUBSTANCE
USE DISORDER RESEARCH: ECONOMIC ANALYSIS
FOR PROGRAM AND POLICY EVALUATION**

**Grand Oaks H
5:15 - 7:15 PM**

Chairs: Sean Murphy and Kathryn McCollister

Expanding the impact of substance use disorder research: Economic analysis for program and policy evaluation

S. Murphy¹, K. McCollister², ¹Weill Cornell Medical College, New York, NY, ²University of Miami Miller School of Medicine, Miami, FL

Economic evaluation in substance use disorder research: Defining approach, relevant data, and interpretation of results for stakeholders

K. McCollister, University of Miami Miller School of Medicine, Miami, FL

Is it cost-effective: Interpreting economic outcomes

S. Murphy, Weill Cornell Medical College, New York, NY

DESSERT/RECEPTION

**Grand Oaks Ballroom
8:00 - 10:00 PM**

DJ & DANCING

**Cibolo Ballroom
8:00 - 10:00 PM**

JAZZ

**Grand Oaks G
8:00 - 10:00 PM**

Wednesday, June 19, 2019

POSTER SESSION IV

Breakfast

**Cibolo Ballroom
8:00 - 10:00 AM**

**Odd-numbered posters manned first hour; Even-numbered, second hour
Set-up time begins Tuesday, 3:00 PM; Must be removed by Wednesday 2:30 PM**

HEALTH DISPARITIES

- 1 *Gender and racial/ethnic differences in heavy episodic drinking and non-medical use of prescription opioids by sexual identity in a nationally representative sample of US adults*
J. Diaz¹, E. Greene¹, M. Philbin², S. Martins¹, P. Mauro¹, ¹Columbia University, New York, NY, ²Columbia University Mailman School of Public Health, New York, NY

Wednesday, June 19, 2019

- 2 *Racial identity and substance use: The promotive and protective role of racial identity profiles*
R. Clifton, T. Zapolski, Indiana University Purdue University Indianapolis, Indianapolis, IN
- 3 *Culturally adapted motivational interviewing and community reinforcement for substance use disorders among treatment-seeking American Indian adults: Predictors of abstinence*
J. Herron¹, K. Hirschak², K. Venner¹, ¹University of New Mexico, Albuquerque, NM, ²Center on Alcoholism, Substance Abuse and Addictions, Albuquerque, NM
- 4 *Urban Native American adults participating in AA: Drinking outcomes by attendance at culturally adapted versus mainstream aa meetings*
K. Hirschak¹, K. Venner², J. Tonigan³, J. Herron², ¹Center on Alcoholism, Substance Abuse and Addictions, Albuquerque, NM, ²University of New Mexico, Albuquerque, NM, ³University of New Mexico, Albuquerque
- 5 *Cumulative trauma and drug use outcomes among a sample of Mexican-American women living in a marginalized community*
A. Cepeda¹, E. Ramirez¹, K. Nowotny², A. Valdez¹, ¹University of Southern California, Los Angeles, CA, ²University of Miami, Miami
- 6 *Racial differences in the SUD services cascade among justice-involved youth*
A. Elliott, M. Johnson, L. Cottler, University of Florida, Gainesville, FL
- 7 *Trends in smoking during pregnancy over time and by race/ethnicity in the Florida, 2012 to 2016 birth cohorts*
M. Maldonado-Molina, University of Florida, Gainesville, FL

LITERATURE REVIEW

- 8 *Substance use interventions for refugees in low- and middle-income countries: A review of the literature*
M. Greene¹, P. Ventevogel², J. Kane³, ¹Columbia University, New York, NY, ²United Nations High Commissioner for Refugees, ³Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 9 *An examination of binge eating disorder assessments for use in primary care settings: A systematic review*
J. Schueler, S. Engler, B. Harris, T. Regan, S. Fields, Texas A&M University, College Station, TX
- 10 *Physical health and gambling and gaming disorders: A critical and systematic review of the literature*
L. Benchebra¹, J. Alexandre², J. Dubernet², M. Fatseas³, M. Auriacombe⁴, ¹Addiction Psychiatry, University of Bordeaux, Bordeaux, France, ²Université de Bordeaux, Bordeaux, ³Centre Hospitalier Charles Perrens, Bordeaux, France, ⁴Université de Bordeaux, Bordeaux, France

Wednesday, June 19, 2019

- 11 *Risky decision making and delay discounting in concurrent cannabis and stimulant users: A literature review*
K. Cadet¹, L. Ruglass², ¹CUNY School of Medicine, New York, NY, ²The City University of New York, New York, NY
- 12 *Pharmacotherapies for methamphetamine/amphetamine use disorder: A systematic review*
B. Chan¹, K. Kondo², M. Freeman², C. Ayers², J. Montgomery³, R. Paynter², D. Kansagara², ¹Oregon Health & Science University, Portland, OR, ²VA Portland Health Care System, Portland, OR, ³VAPORCHS, Portland, OR
- 13 *Pharmacotherapies for cocaine use disorder: A systematic review*
B. Chan¹, K. Kondo², M. Freeman², C. Ayers², J. Montgomery³, R. Paynter², D. Kansagara², ¹Oregon Health & Science University, Portland, OR, ²VA Portland Health Care System, Portland, OR, ³VAPORCHS, Portland, OR
- 14 *Will this adult patient develop a prescription opioid addiction? Strategies for rational clinical examination*
J. Klimas¹, L. Gorfinkel², D. Simel³, E. Wood⁴, ¹BC Centre on Substance Use, Vancouver, BC, Canada, ²Columbia University, New York, NY, ³Duke University, Durham, NC, ⁴British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada
- 15 *Integrating care of hepatitis C virus infection and opioid use disorder: A systematic review of interventions in diverse clinical settings*
B. Oldfield¹, N. Munoz¹, M. McGovern², M. Funaro¹, M. Villanueva¹, E. Edelman¹, J. Tetrault³, ¹Yale University School of Medicine, New Haven, CT, ²Stanford University School of Medicine, Palo Alto, CA, ³Yale University, New Haven, CT
- 16 *Review of sex-based differences in clinical trials and treatment outcome studies for individuals with opioid use disorder*
A. Huhn¹, M. Berry², K. Dunn¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Florida, Gainesville, FL
- 17 *Nonpharmacological adjunct treatment for postpartum women with opioid use disorder: A review of the literature beyond pharmacology treatment*
A. Martinez¹, A. Allen², ¹University of Arizona College of Medicine Tucson, Tucson, AZ, ²University of Arizona, Tucson, AZ
- 18 *Characteristics, feasibility, and efficacy of technology-based interventions for opioid use disorder and aberrant opioid behavior: A systematic review*
K. Rosen¹, M. Curtis², B. Dempsey³, M. Acuff¹, T. Vo⁴, S. Kaghyan⁴, S. Morissette⁴, D. Akopian⁴, J. Sharpe Potter², ¹UT Health San Antonio, San Antonio, TX, ²University of Texas Health Science Center, San Antonio, TX, ³OPAL; UT Health, San Antonio, TX, ⁴The University of Texas, San Antonio, TX
- 19 *Intersecting research on opioid misuse, addiction, and disability: A critical review*
S. Reif¹, R. Adams¹, C. Thomas², M. Mitra², J. Nicholson², ¹Brandeis University, Heller School for Social Policy and Management, Waltham, MA, ²Brandeis University, Waltham, MA

- 20 *Buprenorphine in the US: Motives for abuse, misuse, and diversion*
H. Chilcoat¹, H. Amick², E. Wood³, K. Dunn⁴, ¹Indivior, Inc., Richmond, VA, ²Venebio Group, LLC, North Chesterfield, VA, ³British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada, ⁴Johns Hopkins University School of Medicine, Baltimore, MD

OPIOIDS - HUMAN STUDIES II

- 21 *Buprenorphine use and misuse among those with opioid use disorders with and without recent treatment*
A. DeVeugh-Geiss¹, H. Chilcoat², ¹Indivior, Inc., North Chesterfield, VA, ²Indivior, Inc., Richmond, VA
- 22 *Examining the impact of chronic non-cancer pain on buprenorphine treatment response for individuals with opioid use disorder*
K. Peck, T. Ochalek, C. Watson, S. Sigmon, University of Vermont, Burlington, VT
- 23 *Variations in healthcare expenditures associated with buprenorphine treatment retention among privately insured adults with opioid use disorder*
A. Manhapra¹, E. Agbese², D. Leslie², R. Rosenheck³, ¹Yale University School of Medicine, New Haven, CT, ²Penn State College of Medicine, Department of Public Health Sciences, Hershey, PA, ³Yale University Department of Psychiatry, New Haven, CT
- 24 *Risk-adjusted abstinence rates are higher with greater buprenorphine plasma exposure among patients who inject opioids*
N. Fox¹, C. Laffont², S. Zhao², F. Gray³, A. Andorn¹, S. Learned², C. Heidbreder², ¹Indivior, Inc., North Chesterfield, VA, ²Indivior, Inc., Richmond, VA, ³Indivior, Inc., Slough, United Kingdom
- 25 *Attenuated response to hydromorphone during buprenorphine stabilization associated with injection opioid use and quicker opioid lapse during buprenorphine dose tapering*
T. Moses, M. Greenwald, Wayne State University, Detroit, MI
- 26 *Patterns of opioid withdrawal in patients transitioning from opioid use or buprenorphine treatment to extended-release injectable naltrexone*
A. Douaihy¹, A. Zavod², S. Akerman², A. Legedza², M. Sullivan², ¹UPMC-Western Psychiatric Hospital, Pittsburgh, PA, ²Alkermes, Inc., Waltham, MA
- 27 *Retention on extended-release naltrexone for patients with opioid use disorder: Predictive value of an inter-dose evaluation after initial injection*
P. Mannelli¹, J. Fratantonio², A. Zavod², S. Akerman², A. Legedza², M. Sullivan², ¹Duke University School of Medicine, Durham, NC, ²Alkermes, Inc., Waltham, MA

Wednesday, June 19, 2019

- 28 *Preferences and perceptions of long-acting injectable and implantable medications for opioid use disorder*
E. Saunders¹, S. Moore², O. Walsh³, S. Metcalf⁴, L. Marsch⁴, ¹The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, ²Dartmouth College, Lebanon, NY, ³Dartmouth College, Hanover, NH, ⁴Geisel School of Medicine at Dartmouth, Lebanon, NH
- 29 *Initial treatment responses in opioid use disorder: A universal predictor of outcome*
S. Luo¹, J. Jin¹, Y. Hser², A. Saxon³, E. Nunes⁴, ¹Columbia University, New York, NY, ²UCLA Integrated Substance Abuse Programs, Los Angeles, CA, ³Veterans Affairs Puget Sound Healthcare System, Seattle, WA, ⁴Columbia University and New York State Psychiatric Institute, New York, NY
- 30 *Association between methadone use during detoxification and long-acting injectable naltrexone induction failure*
M. Shulman¹, M. Pavlicova², T. Choo², A. Campbell³, J. Scodes¹, J. Rotrosen⁴, E. Nunes⁵, ¹Columbia University and NYSPI, New York, NY, ²Columbia University Mailman School of Public Health, New York, NY, ³Columbia University and New York Psychiatric Institute, New York, NY, ⁴New York University School of Medicine, New York, NY, ⁵Columbia University and New York State Psychiatric Institute, New York, NY
- 31 *Survey of medication-assisted treatment side effects among methadone-and buprenorphine-treated patients*
M. Mancino, M. Addicott, J. Thostenson, A. Oliveto, University of Arkansas for Medical Sciences, Little Rock, AR
- 32 *Relationships between psychosocial characteristics and co-occurring emotional problems among methadone patients*
J. Lister, J. Ellis, M. Greenwald, D. Ledgerwood, Wayne State University, Detroit, MI
- 33 *Using nominal group technique to identify barriers, facilitators and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support*
S. Farnum¹, D. Muthulingam², J. Bia³, L. Madden⁴, D. Barry², F. Altice², ¹APT Foundation, Inc., New Haven, CT, ²Yale University School of Medicine, New Haven, CT, ³Frank H. Netter MD School of Medicine, North Haven, CT, ⁴Yale University, APT Foundation, New Haven, CT
- 34 *Influence of a low-barrier buprenorphine treatment program on illicit drug use and quality of life metrics among predominantly homeless, needle exchange clients in Seattle*
H. Whitney¹, C. Banta-Green², J. Duchin¹, J. Libbing¹, M. Hamblin¹, M. Shim¹, J. Hood¹, ¹Public Health- Seattle & King County, Seattle, WA, ²University of Washington, Seattle, WA

- 35 *Long-term opioid use trajectories in relation to opioid agonist therapy outcomes among people who use drugs in a Canadian setting: An application of latent class growth analysis*
H. Dong¹, N. Fairbairn², K. Hayashi³, M. Milloy², K. DeBeck¹, E. Wood⁴, T. Kerr²,
¹British Columbia Centre on Substance Use, Vancouver, BC, Canada, ²BC Centre on Substance Use, Vancouver, BC, Canada, ³Simon Fraser University, Vancouver, BC, Canada, ⁴British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada
- 36 *Heterogeneity in the cascade of OUD care: A retrospective study in British Columbia, Canada*
M. Piske¹, C. Zhou¹, F. Homayra¹, J. Min², M. Socias³, B. Nosyk⁴, ¹BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, ²BC Centre for Excellence in HIV/AIDS, Vancouver, ³University of British Columbia, Vancouver, BC, Canada, ⁴British Columbia Centre on Substance Use, Vancouver, BC, Canada
- 37 *Selection into alternative forms of opioid agonist treatment in British Columbia, Canada*
F. Homayra¹, N. Hongdilokkul¹, C. Zhou¹, J. Min², B. Nosyk³, ¹BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, ²BC Centre for Excellence in HIV/AIDS, Vancouver, ³British Columbia Centre on Substance Use, Vancouver, BC, Canada
- 38 *Towards a comprehensive performance measurement system for opioid use disorders in British Columbia, Canada*
B. Nosyk¹, J. Min², L. Pearce³, C. Zhou³, F. Homayra³, L. Wang³, M. Piske³, ¹British Columbia Centre on Substance Use, Vancouver, BC, Canada, ²BC Centre for Excellence in HIV/AIDS, Vancouver, ³BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
- 39 *Motivations for the initiation of injectable opioid agonist treatment: An ethnographic study of patient experiences in Vancouver, Canada*
S. Mayer¹, A. Fowler², J. Boyd², R. McNeil³, ¹BC Centre on Substance Use, Vancouver, BC, Canada, ²British Columbia Centre on Substance Use, Vancouver, BC, Canada, ³University of British Columbia, Vancouver, BC, Canada
- 40 *Patient characteristics associated with the provision of opioid agonist therapy during hospitalization in a cohort of people who use opioids in Vancouver, Canada*
K. Colizza¹, N. Fairbairn², E. Nosova², E. Wood³, K. Hayashi⁴, M. Milloy², ¹University of Calgary, Calgary, AB, Canada, ²BC Centre on Substance Use, Vancouver, BC, Canada, ³British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada, ⁴Simon Fraser University, Vancouver, BC, Canada
- 41 *Opioid addiction beliefs and attitudes of primary health care clinicians in Ukraine*
M. Filippovych¹, K. LaMonaca², I. Pykalo¹, L. Madden³, R. Marcus², S. Farnum⁴, D. Barry², K. Dumchev¹, S. Dvoriak¹, F. Altice², ¹Ukrainian Institute on Public Health Policy, Kiev, Ukraine, ²Yale University School of Medicine, New Haven, CT, ³Yale University, APT Foundation, New Haven, CT, ⁴APT Foundation, Inc., New Haven, CT

- 42 *PWID and provider perspectives on factors influencing MAT uptake among PWID in Ukraine: Highlights from HPTN 074 study*
T. Kiriazova¹, O. Makarenko¹, I. Zaviriukha¹, R. Hershow², E. Hamilton, K. Lancaster³, K. Dumchev¹, V. Go⁴, C. Latkin⁵, ¹Ukrainian Institute on Public Health Policy, Kiev, Ukraine, ²Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina-Chapel Hill, Chapel Hill, NC, ³The Ohio State University, Columbus, OH, ⁴University of North Carolina, Chapel hill, NC, ⁵Johns Hopkins School of Public Health, Baltimore, MD

SUBSTANCE ABUSE TREATMENT

- 43 *Departure against medical advice (AMA) among hospitalized medical patients with substance use disorder (SUD)*
J. Gryczynski¹, C. Nordeck¹, R. Schwartz¹, S. Mitchell¹, C. Welsh², K. O'Grady³, ¹Friends Research Institute, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD, ³University of Maryland, College Park, MD
- 44 *Primary care provider attitudes toward substance use: Results of the substance abuse attitudes survey (SAAS) among urban public hospital primary care physicians*
A. Warner¹, A. Polyn², S. Floyd³, C. Cleland¹, D. Shelley², J. McNeely², ¹NYU Rory Meyers College of Nursing, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU School of Medicine, New York, NY
- 45 *Stigma, discrimination, treatment effectiveness, and policy support: Comparing behavior analysts' views on substance use disorders and mental illness*
C. Rey¹, A. Kurti¹, G. Badger¹, A. Cohen², S. Heil¹, ¹University of Vermont, Burlington, VT, ²University of Vermont, Burlington
- 46 *Creating a digital platform to support an integrated system of care for youth substance use treatment and recovery supports*
K. Claborn¹, T. Cunningham², J. McElrath³, L. Sherman³, L. Holleran Steiker⁴, ¹University of Texas Dell Medical School, Austin, TX, ²The University of Texas at Austin, Austin, TX, ³Youth Recovery Network, Austin, TX, ⁴University of Texas at Austin, Austin, TX
- 47 *Utilization of web-based evidence-based program registers by state behavioral health departments*
S. Magura¹, M. Maranda¹, R. Gugerty², J. Landsverk³, J. Rolls-Reutz⁴, B. Green⁵, ¹Western Michigan University, Kalamazoo, MI, ²Ryan Gugerty, Santa Cruz, CA, ³Oregon Social Learning Center, Eugene, OR, ⁴Chadwick Center for Children and Families, San Diego, CA, ⁵DSG Inc, Bethesda, MD
- 48 *Urine drug screen trajectory as a universal outcome predictor: Overcoming limitations of logistic regression as a canonical technique for binary outcome modeling*
J. Jin¹, S. Luo¹, E. Nunes², A. Ciarleglio, ¹Columbia University, New York, NY, ²Columbia University and New York State Psychiatric Institute, New York, NY

SOCIAL NETWORKS

- 49 *Substance use in urban areas: Results from Chula HealthStreet surveys*
C. Areesantichai¹, U. Perngparn¹, L. Cottler², ¹Chulalongkorn University, Bangkok, Thailand, ²University of Florida, Gainesville, FL
- 50 *Risk and protective effects of social network characteristics on substance misuse among Army Reserve and National Guard soldiers*
E. Anderson Goodell¹, D. Homish², G. Homish², ¹Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²State University of New York at Buffalo, Buffalo, NY
- 51 *Engagement in opioid agonist therapy and drug use among network members*
K. Tormohlen¹, L. Dayton¹, K. Tobin¹, C. Latkin², ¹Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Johns Hopkins School of Public Health, Baltimore, MD
- 52 *Peer information and substance use decision making in street-involved youth*
E. Macdonald, A. Howard, Carleton University, Ottawa, ON, Canada
- 53 *Age as a moderator of the association between perceived vulnerability and the posting and deleting of alcohol-related content on social media*
C. LoParco, A. Lowery, A. Galvin, M. Leon, M. Lewis, D. Litt, University of North Texas Health Science Center, Fort Worth, TX
- 54 *Posting, texting, and related social risk behavior while high*
J. Palamar¹, A. Le², P. Acosta¹, ¹New York University School of Medicine, New York, NY, ²New York University College of Dentistry, New York, NY
- 55 *Nighttime social networking site use by platform and the associations with adolescent and young adult sleep quality, substance use, and anxiety*
A. Lowery, D. Litt, M. Leon, C. LoParco, A. Galvin, M. Lewis, University of North Texas Health Science Center, Fort Worth, TX

TECH

- 56 *Machine learning identifies common and specific markers of alcohol, cannabis, and nicotine dependence*
J. Vassileva¹, R. Shahidi¹, E. Long², Q. Wang³, B. Taylor¹, F. Moeller¹, G. Vasilev⁴, ¹Virginia Commonwealth University, Richmond, VA, ²Pennsylvania State University, University Park, PA, ³The University of Alabama, Tuscaloosa, AL, ⁴Bulgarian Addictions Institute, Sofia
- 57 *Feasibility and acceptability of a m-health APP to assess daily substance use and firearm behaviors among an urban emergency department sample*
P. Carter¹, M. Walton², K. Resnicow³, J. Cranford¹, M. Zimmerman¹, R. Cunningham¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Addiction Center, Ann Arbor, MI, ³University of Michigan School of Public Health, Ann Arbor, MI

Wednesday, June 19, 2019

- 58 *mHealth for opioid use disorder, HIV, and hepatitis C treatment support in primary care: A pilot randomized controlled trial*
B. Tofighi¹, C. Marini¹, M. Acosta², J. Lee¹, ¹New York University School of Medicine, New York, NY, ²National Development and Research Institute, Inc., New York, NY
- 59 *eDarkTrends: Analyzing illicit fentanyl and other novel synthetic opioid trends on cryptomarkets*
F. Lamy¹, R. Daniulaityte², U. Lokala², U. Kursuncu², A. Sheth², M. Barratt³, R. Nahhas², R. Carlson², ¹Mahidol University, Salaya, Thailand, ²Wright State University, Dayton, OH, ³National Drug and Alcohol Research Centre, Sydney, Australia
- 60 *Dillies, gas, butyr, piff: Finding opioid and marijuana drug terms on social media*
N. Adams¹, E. Artigiani¹, E. Wish², ¹University of Maryland, College Park, MD, ²University of Maryland, College Park
- 61 *Relations between smartphone use, smartphone addiction and delay discounting*
B. Harris, J. Schueler, T. Regan, S. Engler, S. Fields, Texas A&M University, College Station, TX

EDUCATION AND TRAINING

- 62 *Who gains the most from online training in addiction medicine? Development and evaluation of a free, open-access online certificate in addiction medicine*
L. Gorfinkel¹, J. Klimas², N. Fairbairn², A. Giesler³, H. Dong³, E. Wood⁴, ¹Columbia University Mailman School of Public Health, New York, NY, ²BC Centre on Substance Use, Vancouver, BC, Canada, ³British Columbia Centre on Substance Use, Vancouver, BC, Canada, ⁴British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada
- 63 *Does online substance use education improve nurses' knowledge in addiction medicine? An educational evaluation in a Canadian setting*
K. Lorenz¹, S. Robinson¹, C. Johnson², J. Klimas¹, ¹BC Centre on Substance Use, Vancouver, BC, Canada, ²British Columbia Centre on Substance Use, Vancouver, BC, Canada
- 64 *Training health sciences students to conduct screening, brief intervention and referral for treatment (SBIRT) for substance use problems*
M. Reynolds¹, A. Douaihy², A. Falk¹, N. Korach¹, J. Pringle¹, ¹University of Pittsburgh, Pittsburgh, PA, ²UPMC-Western Psychiatric Hospital, Pittsburgh, PA
- 65 *Current workforce development priorities for training and technical assistance concerning health services for persons with opioid use disorders*
B. Hartzler, D. Vandersloot, University of Washington, Seattle, WA

ABUSE POTENTIAL

- 66 *Analysis of the discriminant validity and psychometric performance of the misuse, abuse and diversion drug event reporting system (MADDERS) in phase II and III clinical trials of drugs with suspected abuse potential*
H. Elder, R. Lanier, N. Erpelding, N. Katz, Analgesic Solutions, Natick, MA
- 67 *Prospective assessment of potentially abuse-related events in two Phase 3 studies of NKTR-181, a novel opioid analgesic, using the misuse, abuse, and diversion drug event reporting system (MADDERS)*
R. Lanier¹, J. Gudin², R. Rauck³, H. Elder¹, N. Erpelding¹, J. Gimbel⁴, S. Doberstein⁵, M. Tagliaferri⁵, L. Lu⁵, S. Siddhanti⁵, S. Schnoll⁶, J. Henningfield⁶, N. Katz¹, ¹Analgesic Solutions, Natick, MA, ²Englewood Hospital and Medical Center, Englewood, NJ, ³Carolinas Pain Institute and The Center for Clinical Research, Winston-Salem, NC, ⁴Arizona Research Center, Phoenix, AZ, ⁵Nektar Therapeutics, San Francisco, CA, ⁶Pinney Associates, Inc., Bethesda, MD
- 68 *Human abuse potential study of laquinimod in recreational polydrug users*
K. Schoedel¹, A. Elgart², L. Erisson², A. Zur³, M. Gillespie⁴, S. Searle⁵, D. Kelsh⁶, R. Turncliff⁵, O. Spiegelstein², ¹Altreos Research Partners Inc., Toronto, ON, Canada, ²Teva Pharmaceuticals, Petah Tiqva, Israel, ³BioLineRx Ltd., Modi'in, Israel, ⁴Teva Pharmaceuticals, Inc., Malvern, PA, ⁵PRA Health Sciences, Salt Lake City, UT, ⁶Vince and Associates, Malvern, PA
- 69 *An investigation of the reinforcing potential of Blue-181 in rats trained to self-administer heroin*
S. Smith¹, M. Hallam¹, Z. Turnbull¹, D. Roberson², M. Painter², A. Yekkirala², D. Heal¹, ¹RenaSci Ltd, Nottingham, United Kingdom, ²Blue Therapeutics, Cambridge, MA
- 70 *Assessment of the antinociceptive effects and dependence liability of novel fentanyl analogues in CDI mice*
K. Urquhart¹, S. Fukuda¹, J. Gogoi¹, T. Hiranita², W. Fantegrossi¹, ¹University of Arkansas for Medical Sciences, Little Rock, AR, ²University of Florida, College of Pharmacy, Gainesville, FL
- 71 *CBI Agonist (CP-55940) decreases sign-tracking behavior in male rats*
A. Gheidi, University of Michigan Medical School, Ann Arbor, MI

FOOD REWARD

- 72 *The growth hormone secretagogue receptor 1a (GHS1aR) antagonist JMV2959 differentially impacts high fat food vs. drug reinforcement in male Sprague-Dawley rats*
E. Garcia, V. Brehm, R. Fox, N. Anastasio, K. Cunningham, University of Texas Medical Branch, Galveston, TX

- 73 *Cannabidiol decreases drug choice in rhesus monkeys responding under a food versus remifentanyl choice procedure*
D. Maguire, C. France, University of Texas Health Science Center, San Antonio, TX
- 74 *Blockade of orexin receptors in the paraventricular nucleus of the thalamus prevents stress-induced food-seeking behavior in rats with a history of alcohol dependence*
R. Martin-Fardon, A. Matzeu, The Scripps Research Institute, La Jolla, CA
- 75 *Phenotype of recovery: Valuation of delayed rewards mediates the relationship of substance use and hedonic value of food*
D. Pope¹, W. DeHart¹, A. Mellis¹, B. Kaplan¹, L. Athamneh¹, W. Bickel², ¹Virginia Tech Carilion Research Institute, Roanoke, VA, ²Fralin Biomedical Research Institute at VTC, Roanoke, VA
- 76 *Neural correlates of inhibitory control in adolescents with symptoms of food addiction*
C. Phaneuf, L. Cope, A. Gearhardt, M. Heitzeg, J. Hardee, University of Michigan, Ann Arbor, MI

IMAGING

- 77 *A positron emission tomography study of relationships between striatal dopamine function and individual differences in big five personality traits*
L. Oswald¹, G. Wand², H. Kuwabara², D. Wong³, J. Brasic², ¹University of Maryland School of Nursing, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins Hospital, Baltimore, MD
- 78 *Striatal dopamine release in response to morphine: A [¹¹C]-raclopride positron emission tomography study in healthy men*
P. Spagnolo¹, A. Kimes², M. Scwhandt², E. Shokri Kojori², S. Thada¹, K. Phillips², N. Diazgranados², K. Preston³, P. Herscovitch⁴, D. Tomasi², V. Ramchandani², M. Heilig⁵, ¹National Institutes of Health, Bethesda, MD, ²National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD, ³National Institute of Drug Abuse Intramural Research Program, Baltimore, MD, ⁴NIH, PET, CC, Bethesda, MD, ⁵Linköping University, Linköping, Sweden
- 79 *Cingulo-hippocampal effective connectivity and drug cue related attentional bias in opioid use disorder*
L. Ma¹, J. Steinberg¹, J. Bjork¹, B. Taylor¹, A. Arias¹, M. Terplan¹, E. Zuniga¹, M. Lennon¹, N. Anastasio², K. Cunningham², F. Moeller¹, ¹Virginia Commonwealth University, Richmond, VA, ²University of Texas Medical Branch, Galveston, TX

- 80 *More extensive gray matter volume reduction in fronto-temporal areas among individuals with cocaine + alcohol use disorder than cocaine only: A voxel-based morphometric study.*
P. Dib Gonçalves¹, C. de Melo¹, F. Duran¹, D. Lima², H. Oliveira¹, M. Serpa¹, L. de Menezes Sanchez², P. Rosa¹, T. Chaim-Avancini¹, L. Kobuti¹, M. Cavalett¹, N. Costa¹, M. Foigel², M. Ometto³, A. Malbergier⁴, R. Amaral³, S. Nicastr⁵, A. Andrade⁶, G. Busatto Filho⁶, P. Jannuzzi Cunha², ¹University of São Paulo, São Paulo, Brazil, ²University of Sao Paulo Medical School, São Paulo, Brazil, ³University of São Paulo Medical School, São Paulo, ⁴University of Sao Paulo Medical School, São Paulo, ⁵Hospital Israelita Albert Einstein, São Paulo, Brazil, ⁶University of São Paulo Medical School, São Paulo, Brazil
- 81 *Gray matter concentration of hippocampal and cerebellar regions associated with cocaine use severity and relapse: A follow-up voxel-based morphometric study*
C. de Melo¹, P. Goncalves¹, F. Duran¹, H. Oliveira¹, D. Lima², M. Serpa¹, M. Ometto³, R. Amaral³, M. Zanetti¹, T. Chaim-Avancini¹, L. Kobuti¹, M. Cavalett¹, A. Malbergier⁴, N. Costa¹, S. Nicastr⁵, A. Andrade⁶, G. Busatto Filho⁶, P. Jannuzzi Cunha², ¹University of São Paulo, São Paulo, Brazil, ²University of Sao Paulo Medical School, São Paulo, Brazil, ³University of São Paulo Medical School, São Paulo, ⁴University of Sao Paulo Medical School, São Paulo, ⁵Hospital Israelita Albert Einstein, São Paulo, Brazil, ⁶University of São Paulo Medical School, São Paulo, Brazil
- 82 *In vivo evidence of lower synaptic density in cocaine users vs. healthy controls using IIC-UCB-J PET, independent of gray matter volume changes*
G. Angarita¹, P. Worhunsky¹, M. Naganawa², T. Toyonaga², N. Nabulsi³, Y. Huang³, C. Li³, I. Esterlis³, P. Skosnik⁴, R. Radhakrishnan⁴, S. Finnema², R. Carson³, R. Malison¹, ¹Yale University School of Medicine, New Haven, CT, ²Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, ³Yale University, New Haven, CT, ⁴Department of Psychiatry, Yale School of Medicine, West Haven, CT
- 83 *Resource allocation index as a potential fMRI-based biomarker for substance use disorder: Negative findings in T1000 Cohort*
M. Moradi¹, H. Ekhtiari¹, R. Kuplicki¹, B. McKinney², J. Stewart¹, R. Aupperle¹, J. Bodurka¹, Y. Cha³, J. Feinstein³, S. Khalsa³, J. Savitz³, T. Victor³, M. Paulus³, ¹Laureate Institute for Brain Research, Tulsa, OK, ²University of Tulsa, Tulsa, Ok, ³Tulsa 1000 Investigators, Tulsa, OK
- 84 *Caudate volumes and cognition in primarily ketamine and poly-drug ketamine users*
H. Liang¹, W. Tang², T. Ernst³, R. Chen⁴, L. Chang⁵, ¹University of Maryland, Baltimore, MD, ²Department of Psychiatry, Chinese University of Hong Kong., Hong Kong, Hong Kong SAR, ³Department of Medicine, John A. Burns School of Medicine, University of Hawaii and Queen's Medical Center, Baltimore, MD, ⁴Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, ⁵University of Maryland School of Medicine, Baltimore, MD
- 85 *Gender differences in the impact of aerobic fitness and cannabis use on brain structure in adolescents and young adults*
R. Sullivan, A. Wallace, K. Lisdahl, University of Wisconsin-Milwaukee, Milwaukee, WI

CRIMINAL JUSTICE

- 86 *Are juvenile offenders with ADHD more likely to misuse opioids?*
K. Wilson, M. Cushion, M. Johnson, University of Florida, Gainesville, FL
- 87 *Family structure and past 30- day opioid misuse among justice involved children*
D. Shaw, T. Warren, M. Johnson, University of Florida, Gainesville, FL
- 88 *Factors associated with completion of substance use disorder treatment among adolescents in the justice system*
D. Tran¹, M. Johnson², ¹Stomp Lan, Gainesville, FL, ²University of Florida, Gainesville, FL
- 89 *Somatic complaints and past-30 day opioid misuse among justice-involved children*
S. Clerjoste, M. Johnson, University of Florida, Gainesville, FL
- 90 *Juvenile detention placements linked to past 30- day opioid misuse*
W. Dixon, M. Johnson, University of Florida, Gainesville, FL
- 91 *Felony recidivism and past 30- day opioid misuse among adolescents*
D. Peitit-Bois, M. Johnson, University of Florida, Gainesville, FL
- 92 *Medication for opioid use disorder before and after short-term incarceration in Massachusetts*
A. Walley¹, Y. Li², S. Lodi³, D. Bernson⁴, B. Linas¹, M. Laroche¹, ¹Boston University School of Medicine, Boston, MA, ²Boston Medical Center, Boston, MA, ³Boston University School of Public Health, Boston, MA, ⁴Massachusetts Department of Public Health, Boston, MA
- 93 *Opioid overdose death following justice involvement and hospitalization: Using multiple data sources to detect individuals at highest risk*
N. Krawczyk¹, K. Schneider¹, M. Eisenberg¹, T. Richards¹, L. Ferris¹, C. Lyons², K. Jackson², J. Weiner¹, B. Saloner¹, ¹Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Maryland Department of Health, Catonsville, MD
- 94 *Evaluating evidence-based treatment for OUD in a US correctional system: Program participant impressions*
R. Martin¹, S. Gresko¹, L. Hurley², L. Barber², J. Clarke³, ¹Brown University, Providence, RI, ²CODAC Behavioral Healthcare, Cranston, RI, ³Rhode Island Department of Corrections, Cranston, RI
- 95 *Correlates of perceived need for treatment of drug-using incarcerated African American men*
J. Dogan, D. Stevens-Watkins, S. Thrasher, D. Lewis, P. Wheeler, University of Kentucky, Lexington, KY
- 96 *Effectiveness of medication-assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review*
K. Moore¹, S. McKee², ¹East Tennessee State University, Johnson City, TN, ²Yale University School of Medicine, New Haven, CT

Wednesday, June 19, 2019

- 97 *Criminal justice history for individuals with opioid use disorder (OUD) presenting to a community substance use treatment center and intention for medication-assisted therapy (MAT)*
D. Muthulingam¹, L. Madden², D. Barry¹, F. Altice¹, ¹Yale University School of Medicine, New Haven, CT, ²Yale University, APT Foundation, New Haven, CT
- 98 *Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder*
E. Evans, University of Massachusetts Amherst School of Public Health and Health Sciences, Amherst, MA
- 99 *Feasibility and acceptability of take-home naloxone for people released from prisons in New South Wales, Australia*
S. Larney¹, B. Moradmand Badie¹, J. Roberts², S. Ward², S. Nielsen³, J. Bowman², M. Farrell¹, L. Degenhardt¹, ¹National Drug and Alcohol Research Centre, Sydney, Australia, ²Justice Health & Forensic Mental Health Network, Matraville, Australia, ³Monash University, Melbourne, Australia
- 100 *Changes in associations of prescription opioid use disorder and illegal behaviors over time*
C. Mintz, Washington University School of Medicine, St. Louis, MO
- 101 *Community methadone treatment entry among detainees initiating interim methadone treatment in jail: Impact of patient navigation*
S. Kelly¹, R. Schwartz¹, S. Mitchell¹, K. O'Grady², J. Jaffe¹, ¹Friends Research Institute, Baltimore, MD, ²University of Maryland, College Park, MD
- 102 *HIV risk behavior during a randomized trial of methadone treatment initiated in jail*
M. Mitchell¹, J. Gryczynski¹, S. Mitchell¹, S. Kelly¹, J. Jaffe¹, K. O'Grady², R. Schwartz¹, ¹Friends Research Institute, Baltimore, MD, ²University of Maryland, College Park, MD
- 103 *Improving knowledge of, attitudes toward, and referrals to medication-assisted treatment in Ohio courts*
H. Matusow¹, A. Rosenblum², ¹National Development and Research Institute, Inc., New York, NY, ²National Disease Research Institutes, New York, NY
- 104 *New Haven Law Enforcement Assisted Diversion (LEAD): Formative assessment of program implementation and adaptation*
P. Joudrey, C. Nelson, K. Morford, E. Wang, C. Crusto, Yale University School of Medicine, New Haven, CT
- 105 *The impact of drug of choice in community corrections*
R. Ewy¹, K. Akao¹, J. Armstrong¹, C. Clark¹, K. Cropsey², ¹Wichita State University, Wichita, KS, ²University of Alabama, Birmingham, AL
- 106 *Characteristics associated with different sexual orientations in a community corrections population*
K. Moroney¹, J. Armstrong¹, R. Ewy¹, C. Clark¹, K. Cropsey², ¹Wichita State University, Wichita, KS, ²University of Alabama, Birmingham, AL

Wednesday, June 19, 2019

- 107 *Exploring the characteristics associated with psychotic disorders in a community corrections setting*
M. Pena¹, K. Akao¹, R. Ewy¹, C. Clark¹, K. Cropsey², ¹Wichita State University, Wichita, KS, ²University of Alabama, Birmingham, AL
- 108 *Race-related stress, types of Illicit drug use, and years of lifetime drug use for incarcerated African American men nearing re-entry*
S. Thrasher, D. Stevens-Watkins, J. Dogan, D. Lewis, P. Wheeler, M. Moody, University of Kentucky, Lexington, KY
- 109 *Relationship between overdose experiences prior to incarceration and substance use treatment utilization following release in rural women*
E. Pike¹, M. Staton², ¹University of Kentucky, Lexington, KY, ²University of Kentucky, College of Medicine, Lexington, KY

ORAL COMMUNICATIONS 19 REMEMBER THE ALLELE! GENETICS

**Grand Oaks G
10:00 - 12:00 PM**

Chairs: Victoria Brehm and Philipp Mews

- 10:00 *Revealing dynamic epigenetic changes in the nucleus accumbens induced by methamphetamine overdose*
A. Moszczynska¹, S. Liu², X. Xing², A. Sharma¹, V. Bazyljanska³, B. Zhang⁴, ¹Wayne State University, Detroit, MI, ²Washington University School of Medicine, St. Louis, MO, ³Wayne State University, College of Pharmacy and Health Sciences, Detroit, MI, ⁴Washington University, School of Medicine, St. Louis, MO
- 10:15 *When agony fuels ecstasy: Cocaine patients carrying a genetic variant linked to over-response of the stress (cortisol) system demonstrate heightened limbic brain response to appetitive drug cues*
A. Childress¹, R. Crist², K. Jagannathan², P. Regier², J. Suh², S. Darnley², M. Taylor³, Z. Monge², T. Franklin², D. Langleben⁴, K. Young², M. Gawrysiak⁵, R. Szucs-Reed², K. Kampman², C. O'Brien⁶, ¹University of Pennsylvania Perelman School Medicine, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania Perelman School Medicine, Philadelphia, PA, ⁴Veterans Administration, Philadelphia, PA, ⁵West Chester University of Pennsylvania, West Grove, PA, ⁶University of Pennsylvania, VA Medical Center, Philadelphia, PA
- 10:30 *Epigenetic priming maintains transcriptional disruption caused by cocaine*
P. Mews¹, H. Kronman¹, A. Ramakrishnan¹, S. Sidoli², B. Garcia², E. Nestler³, ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²University of Pennsylvania, Philadelphia, PA, ³Mount Sinai School of Medicine, New York, NY

Wednesday, June 19, 2019

- 10:45 *Epigenetics of cocaine use disorder: A collaborative case-control initiative in blood and brain*
C. Walss-Bass¹, G. Fries¹, T. Wendt Viola², B. Sanvicente-Vieira³, J. Schmitz¹, T. Meyer¹, D. Rovaris³, C. Bau⁴, R. Grassi-Oliveira³, ¹University of Texas Health Science Center, Houston, TX, ²University of Rio Grande do Sul, Porto Alegre, Brazil, ³Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre, Brazil, ⁴Universidade Federal de Sao Paulo, São Paulo, Brazil
- 11:00 *Bromodomain-containing protein 4 (BRD4) as an emerging therapeutic target in opioid use disorder*
V. Brehm, C. Merritt, Z. Liu, S. Stafford, R. Fox, H. Chen, N. Anastasio, J. Zhou, K. Cunningham, University of Texas Medical Branch, Galveston, TX
- 11:15 *Effects of genetic polymorphism on ligand-biased signaling: Mu-opioid receptor*
X. Zhang, R. Gilmore, S. Hutchins, E. Vallender, University of Mississippi Medical Center, Jackson, MS
- 11:30 *Paternal morphine exposure causes maladaptive behavior in male progeny*
A. Toussaint¹, A. Ellis², A. Bongiovanni¹, S. Bhakta¹, M. Knouse¹, A. Thomas³, K. Peer¹, H. Mayberry¹, M. Wimmer¹, ¹Temple University, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Pennsylvania University, Philadelphia, PA

ORAL COMMUNICATIONS 20 TRAUMA AND INTERPERSONAL VIOLENCE

**Grand Oaks M
10:00 - 12:00 PM**

Chairs: Jeremy Kane and Angela Moreland

- 10:00 *Prior adversity is associated with a heightened limbic response to aversive cues in patients with opioid, cannabis, and cocaine use disorders*
P. Regier¹, Z. Shi², K. Jagannathan¹, R. Wetherill¹, D. Langleben³, T. Franklin¹, A. Childress⁴, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ³Veterans Administration, Philadelphia, PA, ⁴University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
- 10:15 *Sexual trauma history is associated with reduced orbitofrontal network strength in stimulant-dependent women*
T. Poppa¹, V. Droutman¹, I. Arnaudova¹, H. Amaro², D. Black¹, J. Monterosso¹, ¹University of Southern California, Los Angeles, CA, ²Florida International University, Miami, FL
- 10:30 *Comorbid PTSD among women with opioid use disorder: Prevalence of symptoms and utilization in trauma-focused treatment*
A. Moreland, K. Crum, A. Melkonian, C. Newman, Medical University of South Carolina, Charleston, SC

Wednesday, June 19, 2019

- 10:45 *Marijuana use modifies the association between post-traumatic stress disorder and non-fatal overdose: Results from the IMPACT study*
S. Fisher¹, A. Bennett², E. Goldmann¹, D. Ompad¹, ¹New York University College of Global Public Health, New York, NY, ²National Development and Research Institute, Inc., New York, NY
- 11:00 *Trauma onset and cumulative trauma exposure moderate integrated treatment for posttraumatic stress disorder and substance use disorders*
T. Saraiya¹, S. Fitzpatrick², T. Lopez-Castro³, L. Ruglass³, D. Hien⁴, ¹Adelphi University, Garden City, NY, ²Rutgers University, Piscataway, NJ, ³The City University of New York, New York, NY, ⁴Center of Alcohol Studies, Rutgers University-New Brunswick, Piscataway, NJ
- 11:15 *Intimate partner violence and couple conflict behaviors: The moderating effect of drug use problem severity*
A. Jarnecke, S. Back, K. Brady, J. Flanagan, Medical University of South Carolina, Charleston, SC
- 11:30 *Effectiveness of an evidence-based transdiagnostic treatment for substance misuse and intimate partner violence in Zambia: Results from a community randomized controlled trial*
J. Kane¹, P. Bolton¹, N. Glass², S. Skavenski van Wyk¹, F. Melendez¹, S. Murray¹, C. Danielson³, R. Paul⁴, L. Murray¹, ¹Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Johns Hopkins School of Nursing, Baltimore, MD, ³Medical University of South Carolina, Charleston, SC, ⁴University of Zambia Teaching Hospital, Lusaka, Zambia
- 11:45 *Intimate partner violence and current drug use in US Army Reserve/National Guard soldiers and their partners*
D. Homish, R. Hoopsick, B. Vest, G. Homish, State University of New York at Buffalo, Buffalo, NY

ORAL COMMUNICATIONS 21 CANNABINOIDS - TREATMENT

Grand Oaks H
10:00 - 12:00 PM

Chairs: Carol Paronis and Alexander Wallace

- 10:00 *Changes in sleep pattern in mice during and after daily cannabinoid treatment*
C. Paronis¹, G. Missig¹, S. Nikas², A. Makriyannis³, W. Carlezon¹, J. Bergman⁴, ¹McLean Hospital, Harvard Medical School, Belmont, MA, ²CDD/Northeastern University, Boston, MA, ³Northeastern University, Boston, MA, ⁴McLean Hospital, Belmont, MA
- 10:15 *Selective neuromorphometric changes and recovery in response to cannabinoid treatment in adolescent female rhesus macaques*
A. Maksimovskiy¹, B. Kangas², J. Bergman¹, S. Nikas³, A. Makriyannis⁴, S. Lukas⁵, B. Frederick⁵, S. Kohut⁵, ¹McLean Hospital, Belmont, MA, ²Harvard Medical School, Belmont, MA, ³CDD/Northeastern University, Boston, MA, ⁴Northeastern University, Boston, MA, ⁵McLean Hospital, Harvard Medical School, Belmont, MA

Wednesday, June 19, 2019

- 10:30 *Does gender moderate BOLD responses to inhibition in cannabis using adolescents and emerging adults?*
A. Wallace, K. Maple, K. Lisdahl, University of Wisconsin-Milwaukee, Milwaukee, WI
- 10:45 *Inhibitors of sterol carrier protein-2, a binding protein for endocannabinoids*
C. Cunningham¹, G. Martin², C. Vogt¹, B. Rodriguez¹, H. Huang², T. Neumann¹, D. Sem¹, F. Schroeder², C. Hillard³, ¹Concordia University Wisconsin, Mequon, WI, ²Texas A&M University, College Station, TX, ³Medical College of Wisconsin, Milwaukee, WI
- 11:00 *Tinkering with THC-to-CBD ratios in marijuana: Modulation of dopamine signaling*
B. Madras¹, J. Bergman², S. Kohut¹, S. George³, Z. Lin², ¹McLean Hospital, Harvard Medical School, Belmont, MA, ²McLean Hospital, Belmont, MA, ³University of Toronto, Toronto, ON, Canada
- 11:15 *Acute oral and vaporized cannabidiol in healthy adults*
R. Vandrey¹, T. Spindle¹, E. Cone², J. Mitchell³, G. Bigelow¹, R. Flegel⁴, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Pinney Associates, Inc., Bethesda, MD, ³RTI International, Research Triangle Park, NC, ⁴Substance Abuse and Mental Health Services Administration, Rockville, MD
- 11:30 *Can high-frequency deep rTMS to the dorsomedial prefrontal cortex/anterior cingulate cortex reduce cannabis self-administration in cannabis smokers?*
T. Kearney-Ramos¹, N. Urban², M. Haney¹, D. Martinez³, ¹Columbia University Medical Center, New York, NY, ²New York University Langone Medical Center, New York, NY, ³Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, NY
- 11:45 *Quetiapine treatment of cannabis dependence: A randomized placebo-controlled clinical trial*
J. Mariani¹, M. Pavlicova², C. Choi³, E. Nunes⁴, K. Carpenter³, D. Brooks⁵, A. Mahony⁵, C. Brezing⁶, N. Naqvi³, F. Levin⁶, ¹Columbia University and New York Psychiatric Institute, New York, NY, ²Columbia University Mailman School of Public Health, New York, NY, ³Columbia University, New York, NY, ⁴Columbia University and New York State Psychiatric Institute, New York, NY, ⁵New York State Psychiatric Institute, New York, NY, ⁶Columbia University and NYSPI, New York, NY

ORAL COMMUNICATIONS 22

RECOVERY IS NO BED OF YELLOW ROSES: RELAPSE/REINSTATEMENT

Grand Oaks I

10:00 - 12:00 PM

Chairs: Kathleen Kantak and Lynn Kirby

- 10:00 *Exploring sex differences in the prevention of ethanol drinking by naltrexone in dependent rats during early and protracted abstinence*
A. Matzeu¹, L. Terenius², R. Martin-Fardon¹, ¹The Scripps Research Institute, La Jolla, CA, ²Karolinska Institute, Stockholm, Sweden

Wednesday, June 19, 2019

- 10:15 *Outcome of drug- and alcohol-dependent users after in-patient treatment and effect of follow-up outpatient counseling*
M. Yang¹, H. Run¹, Y. Liao², T. Liu¹, S. Xiao³, W. Hao⁴, ¹Shenzhen Kangning Hospital, Shenzhen, China, ²Mental Health Institute, Second Xiangya Hospital, Central South University, Changsha, Changsha, China, ³School of Public Health, Central South University, Changsha, China, ⁴Central South University, Changsha, China
- 10:30 *Preliminary effectiveness of mindfulness-based relapse prevention among those in recovery from opioid use disorder receiving outpatient medication-assisted treatment*
K. Zullig¹, L. Lander², M. Tuscano¹, G. Hobbs¹, L. Faulkenberry³, ¹West Virginia University School of Public Health, Morgantown, WV, ²West Virginia University, Morgantown, WV, ³West Virginia University School of Medicine, Morgantown, WV
- 10:45 *Phase II efficacy of a mindfulness-based intervention on clinical progress and relapse among women in residential SUD treatment: A randomized controlled trial*
H. Amaro¹, D. Black², ¹Florida International University, Miami, FL, ²University of Southern California, Los Angeles, CA
- 11:00 *Molecular changes associated with extinction training for cocaine relapse prevention in rats: Role of environmental enrichment and extinction context*
M. Hastings¹, J. Gauthier², H. Man¹, K. Kantak¹, ¹Boston University, Boston, MA, ²Boston University School of Medicine, Boston, MA
- 11:15 *CRF-5-HT interactions and motivation for stress-induced opioid relapse*
L. Kirby, C. Li, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
- 11:30 *Escalation and reinstatement of fentanyl self-administration in rats*
S. Malone, L. Hammerslag, M. Bardo, University of Kentucky, Lexington, KY
- 11:45 *The orexin system in the attenuation of relapse-related mechanisms in cocaine use disorder*
R. Suchting¹, J. Yoon¹, G. San Miguel², J. Vincent¹, M. Wardle³, A. Heads², M. Weaver¹, C. Green¹, J. Schmitz¹, S. Lane², ¹University of Texas Health Science Center, Houston, TX, ²University of Texas Health Science Center, McGovern Medical School, Houston, TX, ³University of Illinois, Chicago, IL

SYMPOSIUM XVI NOVEL AND MEANINGFUL CLINICAL TRIAL ENDPOINTS IN SUBSTANCE USE DISORDER TREATMENT

**Grand Oaks K/L
10:00 - 12:00 PM**

Chairs: Brian Kiluk / Katie Witiewitz

- 10:00 *Beyond abstinence: Reductions in drinking as an endpoint for alcohol clinical trials*
K. Witkiewitz, University of New Mexico, Albuquerque, NM

Wednesday, June 19, 2019

- 10:25 *Identifying meaningful alternatives to abstinence for cocaine use*
B. Kiluk, Yale University School of Medicine, New Haven, CT
- 10:50 *Cutting down on cannabis, can that be enough?*
A. Budney, Geisel School of Medicine at Dartmouth, Lebanon, NH
- 11:15 *Reanalyzing opioid trials for non-abstinence-based endpoints*
K. Dunn, Johns Hopkins University School of Medicine, Baltimore, MD
- 11:40 *The point at the end: Where are we in the evolution of clinical trial endpoints, and where might we go?*
E. Strain, Johns Hopkins University School of Medicine, Baltimore, MD

BRUNCH WITH CHAMPIONS

Advance Registration Required

Begonia

12:00 - 1:30 PM

ORAL COMMUNICATIONS 23

INFECTIOUS DISEASE INNOVATIONS

Grand Oaks I

1:30 - 3:30 PM

Chairs: Cecile Denis and William Zule

- 1:30 *Substance use as a predictor of HIV testing among emergency department patients who initially decline testing offered by hospital staff*
I. Aronson¹, S. Rajan², C. Cleland³, L. Marsch⁴, T. Bania⁵, ¹Digital Health Empowerment, Brooklyn, NY, ²Columbia University, New York, NY, ³NYU Rory Meyers College of Nursing, New York, NY, ⁴Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁵Mount Sinai School of Medicine, New York, NY
- 1:45 *The effects of needle gauge and syringe barrel capacity on syringe cleaning and possible HIV/HCV transmission*
W. Zule, S. Rhea, D. Schley, G. Mitchell, G. Bobashev, RTI International, Research Triangle Park, NC
- 2:00 *Substance use and quality of life in an urban cohort of people living with HIV and substance dependence*
S. Rawlins-Pilgrim¹, M. Winter², T. Heeren², A. Walley³, T. Kim¹, S. Kim⁴, R. Saitz², ¹Boston Medical Center, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Boston University School of Medicine, Boston, MA, ⁴Boston University, Boston, MA
- 2:15 *Polysubstance use patterns and HIV disease severity among those with substance use disorder: Latent class analysis*
N. Bertholet¹, M. Winter², T. Heeren², A. Walley³, R. Saitz², ¹Lausanne University Hospital, Lausanne, Switzerland, ²Boston University School of Public Health, Boston, MA, ³Boston University School of Medicine, Boston, MA

Wednesday, June 19, 2019

- 2:30 *Combined substance use and HIV risk reduction intervention reduces depressive symptoms in rural African American female adolescents*
S. Engler¹, C. Lopez², T. Regan¹, J. Schueler¹, B. Harris¹, S. Fields¹, ¹Texas A&M University, College Station, TX, ²The Medical University of South Carolina, Charleston, SC
- 2:45 *Sex differences in physical and mental health among people living with HIV/AIDS who smoke tobacco*
M. Fodor, C. Struble, J. Ellis, L. Lundahl, D. Ledgerwood, Wayne State University, Detroit, MI
- 3:00 *Double dissociation of HIV and SUD effects on tasks dependent on striatal integrity*
E. Martin¹, R. Gonzalez², J. Fogel³, J. Vassileva⁴, A. Bechara⁵, ¹Rush University Medical Center, Chicago, IL, ²Florida International University, Miami, FL, ³The University of Illinois at Chicago, Chicago, IL, ⁴Virginia Commonwealth University, Richmond, VA, ⁵University of Southern California, Los Angeles, CA
- 3:15 *Association between diagnoses of chronic pain, substance use disorder and HIV-related outcomes in HIV-positive individuals*
C. Denis¹, D. Metzger², Q. Wu¹, J. Pena¹, K. Morales¹, M. Cheatlé³, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Department of Psychiatry, Philadelphia, PA, ³Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

ORAL COMMUNICATIONS 24 THE GOOD, THE BAD AND THE UGLY: POLYDRUG ABUSE

**Grand Oaks M
1:30 - 3:30 PM**

Chairs: Victor Martínez-Loredo and Erin McClure

- 1:30 *The DISSECTIV method uncovers hidden actions of complex psychoactive mixtures: Emergent polypharmacology in fenethylamine*
C. Wenthur¹, B. Zhou², K. Janda², ¹University of Wisconsin-Madison, Madison, WI, ²The Scripps Research Institute, La Jolla, CA
- 2:00 *Modeling ethanol and nicotine co-use in Sprague Dawley rats*
C. Chandler, S. Maggio, K. Nixon, M. Bardo, University of Kentucky, Lexington, KY
- 2:15 *Sedative effects of triazolam and pregnanolone combinations in female rhesus macaques*
J. Cook¹, D. Platt², D. Rüedi-Bettschen¹, B. Gunter³, J. Rowlett¹, ¹University of Mississippi Medical Center, Jackson, MS, ²Division of Neurobiology and Behavior Research, Jackson, MS, ³Vanderbilt University, Nashville, TN
- 2:30 *Tobacco and marijuana co-use in adolescents: Differences in impulsivity and gambling behavior*
V. Martínez-Loredo¹, A. Grande-Gosende¹, A. González-Roz², S. Fernandez-Artamendi³, S. Weidberg¹, J. Fernández-Hermida¹, D. Gaalema⁴, ¹University of Oviedo, Oviedo, Spain, ²University of Oviedo, Addictive Behaviors Group, Oviedo, Spain, ³Universidad Loyola Andalucía, Seville, Spain, ⁴University of Vermont, Burlington, VT

Wednesday, June 19, 2019

- 2:45 *Cannabis and alcohol co-use in a pharmacotherapy tobacco treatment trial for adolescent and emerging adult smokers*
E. McClure¹, N. Baker¹, C. Hood², R. Tomko¹, L. Squeglia¹, K. Gray¹, ¹Medical University of South Carolina, Charleston, SC, ²University of Kentucky, Lexington, KY
- 3:00 *Patterns of polysubstance use and anxiety sensitivity among adults with sedative misuse*
V. Votaw¹, R. McHugh², K. Vowles¹, R. Weiss², M. Griffin³, K. Witkiewitz¹, ¹University of New Mexico, Albuquerque, NM, ²McLean Hospital, Belmont, MA, ³McLean Hospital, Harvard Medical School, Belmont, MA
- 3:15 *Culturally relevant correlates of polysubstance use among frequent marijuana users: An examination of African American incarcerated men*
P. Wheeler, D. Stevens-Watkins, S. Thrasher, J. Dogan, D. Lewis, University of Kentucky, Lexington, KY

ORAL COMMUNICATIONS 25 THE CONTINUING CRISIS: OPIOIDS AND OVERDOSE

**Grand Oaks H
1:30 - 3:30 PM**

Chairs: Robert Carlson and Ju Nyeong Park

- 1:30 *Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose?*
R. Carlson¹, R. Daniulaityte¹, S. Silverstein², R. Nahhas¹, ¹Wright State University, Dayton, OH, ²Boonshoft School of Medicine Wright State University, Kettering, OH
- 1:45 *The geographic distribution of fentanyl-involved overdose deaths*
E. Nesoff, C. Branas, S. Martins, Columbia University, New York, NY
- 2:00 *Novel strategies for the treatment of opioid use disorder: Anti-fentanyl vaccine*
C. Haile¹, G. Cuny¹, A. Duddupudi¹, H. Walters¹, F. Orson², Y. Kogan³, T. Kosten¹, T. Kosten⁴, ¹University of Houston, Houston, TX, ²Baylor College of Medicine, Houston, TX, ³Kadvax Technologies Inc, Houston, TX, ⁴Baylor College of Medicine, Bellaire, TX
- 2:15 *Short-term effectiveness of a brief fentanyl test strip intervention in reducing overdose risk among women who use street drugs*
J. Park¹, C. Tomko¹, B. Silberzahn², B. Marshall³, K. Haney², S. Sherman⁴, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ³Brown University School of Public Health, Providence, RI, ⁴Johns Hopkins Hospital, Baltimore, MD
- 2:30 *Predictors of baseline and recent non-fatal opioid overdose among a cohort of people who inject drugs in Melbourne, Australia*
P. Hill, P. Dietze, M. Stooze, Burnet Institute, Melbourne, Australia

Wednesday, June 19, 2019

- 2:45 *Recent incarceration and opioid-related risk in rural areas: Opportunities for harm reduction in the criminal justice system*
E. Waddell¹, G. Leichtling², C. Hildebran², P. Korthuis¹, ¹Oregon Health & Science University, Portland, OR, ²HealthInsight, Portland, OR
- 3:00 *Safety and liability concerns and naloxone deployment in response to an opioid overdose among patrol officers*
M. Podolsky¹, S. Mital², P. Martinez¹, T. Green³, J. Wolff¹, R. Noonan¹, J. Carroll⁴, ¹Centers for Disease Control and Prevention, Atlanta, GA, ²Emory University, Atlanta, GA, ³Boston University School of Medicine, Boston, MA, ⁴Elon University, Elon, NC
- 3:15 *Opioid overdose in patients treated with extended-release naltrexone: Postmarketing data from 2006 to 2018*
G. Bloomgren, P. Jain, R. Marino, K. Marcopoul, M. Wenten, P. Vunnavu, M. Liles-Burden, A. Desai, S. Akerman, M. Sullivan, J. Fratantonio, Alkermes, Inc., Waltham, MA

SYMPOSIUM XVII MECHANISMS FOR SEX AND GENDER DIFFERENCES IN ADDICTION: IMPLICATIONS FOR PREVENTION AND TREATMENT

**Grand Oaks G
1:30 - 3:30 PM**

Chairs: Mark Smith and Mariangela Martini

- 1:30 *Role of sex chromosome complement in vulnerability to cocaine use*
M. Martini, North Carolina State University, Raleigh, NC
- 1:55 *Hormonal influences on the development of a cocaine-addicted phenotype in females*
A. Bakhti-Suroosh, University of Virginia, Charlottesville, VA
- 2:20 *Gonadal hormones and vulnerability to opioid use*
M. Smith, Davidson College, Davidson, NC
- 2:45 *Sex and gender differences in substance use disorder: Evidence from human studies*
K. Brady, Medical University of South Carolina, Charleston, SC
- 3:10 *Sex/gender-specific prevention and treatment strategies for addiction*
W. Lynch, University of Virginia, Charlottesville, VA

Wednesday, June 19, 2019

ORAL COMMUNICATIONS 26
SADDLED WITH PAIN

Grand Oaks H
3:45 - 4:45 PM

Chair: Caroline Arout

- 3:45 *Half of the pregabalin misuse among methadone maintenance patients is for pain relief*
E. Peles¹, A. Sason², S. Schreiber³, M. Adelson², ¹Tel Aviv Sourasky Medical Center & Sackler Faculty of Medicine, Tel Aviv University, Reut, Israel, ²Adelson Clinic, Tel Aviv Medical Center, Tel Aviv, ³Tel Aviv Medical Center, Tel Aviv, Israel
- 4:00 *Pain decreases after transition from chronic opioid therapy for pain to buprenorphine*
K. Barth, J. Borckardt, K. Brady, Medical University of South Carolina, Charleston, SC
- 4:15 *Minocycline does not affect experimental pain or addiction-related outcomes in opioid-maintained patients*
C. Arout¹, A. Waters², R. MacLean³, P. Compton⁴, M. Sofuoglu⁵, ¹Columbia University Medical Center, New York, NY, ²Full Professor & Director of Graduate Studies, Bethesda, MD, ³VA Connecticut Healthcare System, West Haven, CT, ⁴University of Pennsylvania, School of Nursing, Philadelphia, PA, ⁵Yale University, New Haven, CT
- 4:30 *A behavioral economic analysis of cannabis and opioid co-use for pain*
C. Bergeria, S. Dolan, M. Johnson, C. Campbell, K. Dunn, Johns Hopkins University School of Medicine, Baltimore, MD

SYMPOSIUM XIX
METHOCINNAMOX: A NOVEL ANTAGONIST FOR
TREATING OPIOID OVERDOSE AND ABUSE

Grand Oaks G
3:45 - 4:45 PM

Chairs: Charles France and James Woods

- 3:45 *MCAM: Not your run-of-the-mill irreversible opioid antagonist*
J. Woods, University of Texas Health Science Center, San Antonio, TX
- 4:05 *Pharmacological properties of MCAM at mu, kappa and delta opioid receptors in vitro*
W. Clarke, University of Texas Health Science Center, San Antonio, TX
- 4:25 *MCAM reverses and provides long-lasting protection against the effects of opioids in vivo*
L. Gerak, University of Texas Health Science Center, San Antonio, TX

Wednesday, June 19, 2019

**SYMPOSIUM XVIII
LEVERAGING TECHNOLOGY TO DEPLOY
INNOVATIVE SUBSTANCE ABUSE TREATMENTS**

**Grand Oaks I
3:45 - 4:45 PM**

Chairs: Allison Kurti and Stephen Higgins

- 3:45 *Smartphone-based financial incentives to promote smoking cessation among pregnant women*
A. Kurti, University of Vermont, Burlington, VT
- 4:05 *Using transdermal alcohol monitoring in a contingency management procedure to promote healthier drinking patterns*
D. Dougherty, University of Texas Health Science Center, San Antonio, TX
- 4:25 *Acceptability and willingness to pay for contingency management interventions among caregivers affected by an opioid use disorder*
S. Ryan-Pettes, Baylor University, Waco, TX

CPDD SWEEPSTAKES DRAWING

**Grand Oaks M
5:00 PM**

You must be seated in one of the afternoon sessions in order to have your badge collected.

*Have a safe trip home!
See you next year at the Diplomat Beach Resort
Hollywood, Florida, June 20th-24th, 2020*

Author Index

A

- Abagiu1,2, 56
Abatemarco, 18–19, 43
Abatemarco, Diane, 128
Abbas, 84
Abdelghani, 56
Aberal, 56
Abhängigkeitserkrankungen, 69
Abional, 56
Abraham2, 49
Abramovitz, 39
Absar, 33
Abyu1, 56
Accra, 68
Achtmeyer, 93
Acosta1, 26, 110
Acosta2, 111
Acri, 13
Acri, Jane, 50, 131
Acuff1, 105
Addis3, 13
Adegbohun, 60
Adelekan, 62
Adelson2, 126
Adeniyi-Jones, 43
Ades2, 22
Adorjan1,2,3, 53
Adorjan2,3,4, 56
Agbese2, 106
Agrawal, 57, 61
Aguascalientes, 70
Águila2, 57, 88
Ahuja1, 88
Ain1, 4, 56
Ajayi, 60
Ajay Manhapra, 18
Ajiro tutu, 60
Akao1, 35, 116–17
Akbarali, 20
Akbarali, Hamid, 20, 129
Akerman, 125
Akerman2, 106
Akopian4, 105
Akpabio, 56
AlAfifi1, 62
Alarcon2, 63
Alastrue, 8
Alcorn2, 29, 95
Alcover1, 8
Alcover2, 29–30
Alder1, 77
Aldridge, 6
Alexandre, 104
Alexandria, 13
Alfanek1, 34
Alger3, 48
Alhazmi, 54
Aliche, 60
Allen1, 43
Allen2, 51, 105
Allen5, 89
Allerton, 14
Allgaier, 74
Almiroll, 65
Alshaarawy, 43
Altice1, 65, 90, 116
Altice2, 67, 90, 94, 107–8
Altice3, 59, 94
Altice4, 89
Altice6, 59
Altice3,5, 67
Altice8,9,10, 67
Amankwaah, 66
Amaral, 53
Amaral3, 23, 114
Amaro1, 121
Amaro2, 7, 118
Ambekar, 12, 57, 61
Ames, 29
Amick2, 106
Amminger, 88
Ananthan, 41
Anastasio, 23, 78, 112–13, 118
Andersen, 18, 24, 91, 129
Anderson, 101
Andorn1, 106
Andrade, 53
Andrade6, 23, 114
Angarita, 114
Ansari2, 100
Anthenelli, 14
Anthony, 7, 12, 16, 27
Anthony3, 29, 87
Antoine, 83
Antoine1, 50
Anya2, 60
Aonso-Diego1, 34, 68
Arasteh3, 40
Arcadepani, 71
Ardelt1, 19
Areesantichai, 27, 110
Arellano, 7
Arfken, 31
Ariadna Forray, 133
Arias1, 113
Armistead, 9
Armstrong, 10, 116
Arnaudova, 118
Aronowitz, 18
Aronson1, 122
Arout, Caroline, 126
Arout1, 23, 126
Arredondo, 26, 36, 39, 58
Arria, 29
Arria2, 12

Author Index

- Arriola, 63, 96
Artamonova, 39
Arterberry, 29
Arthur1, 13
Artigiani, 111
Arunogiri, 85
Ashrafioun, 9
Ashton, 52
Ashworth, 13
Askari1, 89
Asomaning, 85
Assanangkornchai, 61
Aston2, 4
Ataiants, 30, 36
Ateneo, 52
Athamneh, 113
Attalla3, 67, 93
August Holtyn, 26, 137
Aunno3, 49
Aupperle, 114
Auriacombe, 31–32, 40, 104
Aurora, 5, 85
Austin, 4, 87, 109
Austin4, 19
Australia, 5–7, 67–68, 82, 85, 93
Ayana4, 53
Ayers, 30
Ayers1, 64
Ayers2, 105
Azbel3, 59
Azevedo, 88
- B**
Babuscio, 35
Bach1, 40
Bachireddy, 59
Badalona, 47, 81, 91
Bader1, 43
Badger1, 109
Bagley1, 36
Bagot1, 82
Bahir-Dar, 10
Baidoo, 100
Baidya3, 70
Bailey, 12
Bailey1, 14
Baker, 22, 90
Baker1, 13, 32, 39, 93, 124
Baker2, 23
Baker3, 39
Bakhireva, 43
Bakhromov, 63
Bakhshaie, 8
Bakhti-Suroosh, 42, 125
Balasingam, 65
Baldassarri, 32
Baldrige, 12
Baldwin3, 59
Ball3, 8
Ballbè1, 8
Balster, 52
Balster2, 52
Bania5, 122
Banks, 88
Banks, Devin, 51
Banks1, 28, 51, 99
Bansil, 12
Banta-Green2, 107
Bantjes2, 65
Banuelo5, 39
Barber, 43
Barber2, 115
Barclay3, 92
Bardo, 41, 121, 123
Bardo, Michael T., 141
Bardo1, 41
Bario5, 8
Barker, 12
Barker3, 57
Barker1,2, 56
Barnes1, 53
Barnes3, 40
Barrall, 29
Barratt2, 5, 39, 59
Barratt3, 111
Barrett2, 18
Barrett3, 27
Barrington-Trimis, 32
Barry1, 16, 47, 90, 116
Barry2, 5, 32, 107–8
Barry3, 5, 67, 94
Bart2, 69
Bartels1, 85
Barth, 4, 126
Barth1, 92
Bartholomew, 63, 96
Bartlett, 83
Basaraba, 31
Bassiony, 56
Bassir Nia1, 8
Basu4, 57
Batchelder, 38
Bath, 14, 54
Batki3, 23
Bau2, 85
Bau4, 118
Bauer3, 6, 66
Baum2, 9
Baumann1, 20, 22
Bautista-Pérez, 62
Bavle, 59
Bazylianska, 117
Beardsley, Patrick, 141
Beardsley, Patrick M., 1
Beavis1, 19
Becan, 73
Bechara5, 123
Becher2, 92
Beck2, 78
Becker3, 69, 90
Beckmann, 41, 95
B.Edet1, 60
Bedi1, 88
Bedi5, 35
Beitel2, 5, 47
Beitel3, 5, 32

Author Index

- Belenko, 73, 139
Belenko, Steven, 73, 139
Beletsky, 39, 94
Belgium, 68
Bello2, 51
Bellvitge, 8
Belmont, 15, 21, 119–20
Benchebra, 104
Bendiks2, 96
Benegal2, 57
Benitez3, 92
Bennett2, 119
Benowitz, 32
Berg4, 40
Bergeria, 25, 126
Bergeria, Cecilia, 25, 46, 136
Bergman, Jack, 1
Bergman1, 119
Bergman2, 120
Bergman3, 21, 41
Bergman4, 119
Bergman6, 100
Beriault, 94
Berman2, 10
Berman3, 10
Bernson4, 115
Bernstein, 5, 84
Berro, 96
Berry1, 33
Berry2, 9, 33, 105
Bertholet, 122
Bertz1, 6, 99
Berumen1, 35
Beselia1, 27, 60, 64
Bespalov, 55
Best research poster, 52
Bethesda, 5–6, 12–13, 78, 80, 112–13
BH, 139
Bhakta1, 14, 118
Bhanji, 101
Bharat2, 57
Bhargawa, 57
Bia3, 107
Bianchini, 54, 101
Bickel, 24
Bickel, Warren, 129
Bickel1, 34
Bickel2, 15, 113
Bickel3, 95
Bigall, 12
Bigelow1, 120
Bimonte-Nelson, 14
Binghamton, 42
Binswanger, 132
Bird4, 15
Birmingham, 4, 10, 19, 35, 116–17
Bisaga2, 91
Bisaga3, 71
Bishop, 9
Bjork, 26
Bjork1, 113
Bloomgren, 125
Bloomington, 84
Blosnich, 19
Blough1, 27
Blough2, 41
Blough4, 100
Blow2, 89
Blow3, 83
Blumberg, 5
Bluthenthal, 9, 38, 43, 90, 94
Bobashev, 7, 122
Bodurka1, 101, 114
Bogdon1, 92
Bogenschutz, 6, 15
Bohigas4, 71
Bohnert1, 83–84
Bohnert2, 37
Bolao2, 58, 81
Bolin2, 95
Bollampally, 32, 47
Bollen2, 62
Bolocan1,2, 56
Bolton1, 119
Bonar1, 89
Bonet4, 8
Bongiovanni, 14, 118
Bonn, 53
Bonney1,2, 58
Bonnici8, 84
Bonn-Miller2, 97
Bonn-Miller3, 29
Bonson1, 13
Booz, 25
Borckardt, 126
Borda1, 66
Borodovsky, 21, 45, 82
Borquez1, 39
Bosk1, 84
Bosomprah, 68
Boston, 5–7, 36–39, 115, 119
Bough, 26
Bowen, 41, 99
Bowles2, 37
Bowman2, 116
Boyd, 29, 42, 87
Boyd1, 42, 79, 88
Boyd2, 36, 80, 88, 108
Boyd3, 58
Boyd4, 40
Boyer6, 65
Bozgunov, 60–61

Author Index

- Brackbill, 9
Braden4, 90
Bradley, 30
Brady, 4, 22, 119, 125–26
Brady, Kathleen, 134
Brady1, 92
Brady3, 39
Brainsway, 46
Bramon8,9,11, 53
Branas, 124
Branas1, 4
Brands2, 98
Brandt1, 6, 66
Brar, 13
Brasfield, 100
Basic2, 113
Bravo2, 57, 88
Brehm, 112, 118
Brehm, Victoria, 117
Breno Sanvicente-Vieira, 100
Breslin, 51
Brezing6, 120
Bridwell, 86
Brigham, 65
Brighthaupt, 79
Brisbane, 5, 82
Brooks2, 9
Brooks3, 31
Brooks5, 120
Brooner, 83
Brown1, 84
Brown2, 13
Brown3, 82
Brown11, 67, 93
Browne1, 87
Browne3, 70
Bruguera, 8
Bruno3, 12
Bruzelius, 9
Bryant5, 96
- Brummelte, 99
Brummett, 9
Brumunddal, 82
Brunette, 75, 139
Bruno3, 12
Bruzelius, 9
Bryant5, 96
Bubser, 78
Bucharest, 56
Bucholz2, 84, 88
Buchweitz, 54, 101
Buck2, 95
Budilovsky-Kelley6, 17
Budney, 122
Budney, Alan, 141
Budney, Alan J., 1
Budney, Richard J. Bonnie Alan J., 141
Budney1, 96
Budney2, 21
Bueno, 57
Bugbee, 29
Bukusi7, 64
Bulgaria, 60–61
Burgess-Hull1, 89
Burlew, 16
Burlew, Kathleen, 75, 140
Burlington, 32–34, 37–38, 49, 83–84, 109
Burma, 60, 62
Burmeister, 4
Burnet Institute, 58, 124
Burns School, John A., 114
Burrowes, 44
Busatto, 53
Busatto Filho6, 23, 114
Busch3, 13
Bush1, 11
Bushara1, 69
Bushara3, 48
- Busse, 93
Busse1, 66
Butelman, 16, 34, 78
Butrus1, 4
Buttram, 86
Buttram1, 86
- C
Cai1, 61
Caine2, 99
Calabar, 60
Calakos, 101
Calcaterra, 5
Calderon, 13
Calipari, 20, 128
Calipari, Erin, 20, 128
Callen4, 92
Calma, 41
Camarini, 23
Camenga2, 32
Campbell, 66, 75, 91, 107, 126
Campbell, Aimee, 75, 140
Campello, 66, 93
Carlezon, 119
Carlson, Robert, 124
Carlson1, 86, 124
Carlson2, 5, 111
Carmines, 18
Carney2, 87
Carpenter, 23, 32, 120
Carr1, 12
Carr2, 83
Carreiro, 99
Carrell, 30
Carrico, 30
Carrico1, 85
Carroll, 24, 97, 133
Carroll, Ivy, 1
Carroll, Kathleen, 24, 129
Carroll, Kathleen M., 1
Carroll, Marilyn, 97, 132
Carroll, Marilyn E., 1
Carroll1, 35

Author Index

- Carroll4, 125
Carson, 73
Carson3, 114
Carter1, 110
Castaño3, 66
Castellon, 91
Castracane, 86
Cataño3, 71
Catherine Woodstock Striley, 3, 45
Cavalett, 23, 53, 114
111
Cepeda, 79
Cepeda1, 39, 57, 104
Cepeda3, 39
Cepeda-Benita1, 33
Cha3, 114
Chadi, 89
Chaim-Avancini, 53
Chaim-Avancini1, 23, 114
Chakrabarti, 57
Chamine, 12
Champaign, 28
Champion, 4
Chan1, 105
Chandler, 37, 80, 123
Chandra1, 16
Chang2, 39
Chang5, 90, 114
Changsha, 121
Chao1, 35, 67
Chapman2, 99
Chartoff, 15
Chatterjee, 57
Chaudhari, 11
Chavez3, 58
Chawarski, 55
Cheatle3, 123
Chela Wallin, 99
Chen, 13, 16, 23, 34, 61
Chen1, 27, 53
Chen2, 15, 59
Chen3, 27
Chen4, 114
Cheng, 61
Cheng3, 96
Chengdu, 101
Cheshun1, 61
Chestnut Hill, 86
Chiapperino, 13
Chidiebere, 58
Chilcoat, 25, 106
Chilcoat, Howard, 25, 136
Childress, 18, 48, 117–18
Chintha1, 99
Chisolm, Margaret, 73, 76, 138
Chisolm, Margaret S., 76
Chisolm1, 73
Choi1, 43
Choi2, 5
Choi3, 120
Choi4, 31
Chongsuivatwong, 61
Choo2, 107
Choo4, 91
Chooi2, 55
Chopra, 57
Chou1, 95
Christie, 39
Chuka, 60
Chung2, 69
Ciano1, 98
Ciarleglio, 109
Claborn1, 4, 109
Clairgue, 39
Clark1, 10, 35, 116–17
Clark4, 82
Clarke, 126
Clarke1, 66
Clarke3, 115
Cleland1, 109
Cleland3, 122
Clemons1, 83
Clerjuste, 115
Clifford, 12
Clifton, 104
Clifton1, 18
Cobbold2, 58
Cochran1, 17
Coffin, Phillip, 76
Coffin1, 23
Cohen2, 109
Coker, 93
Cole1, 18
Coleman, 32
Colfax1, 23
Colizza1, 108
Collins, 77
Collins, Gregory, 1
Collins1, 36
Collins2, 41
Collins3, 27, 40
Collins6, 77
Coloma-Carmona1, 85
Comer, Sandra, 77, 141
Comer, Sandra D., 1
Comer1, 16
Comer2, 17, 31, 77
Comer3, 13
Comer5, 21, 23
Cone2, 120
Conley, 32
Conn1, 22
Connor3, 82
Constantino, 15
Conybeare, 16, 34
Cook, 31
Cook1, 123
Cook2, 81
Coop2, 100
Cooper, 102
Cooper, Hannah, 101, 133
Cooper1, 12
Cooper2, 11, 23
Cope1, 14
Copenhagen, 99

Author Index

- Copenhaver, 65, 89, 94
Copulsky, 37
Corvallis, 86
Cosford2, 14
Cosgrove, 101
Costa, 53, 61
Costa1, 23, 114
Costa3, 8
Cottler, 11, 16, 35, 43, 79
Cottler, Linda, 3
Cottler, Linda B., 141
Cottler1, 8
Cottler2, 11, 27, 110
Cotton, 10
Coughlin, 83
Coupet1, 49
Coupet2, 17
Coupland, 7, 43
Cowley1, 38
Cox1, 33–34
Coxe, 88
Craft2, 82
Craig2, 17
Cranford, 110
Cranston, 115
Cretikos, 67, 93
Crichlow, 51
Crist2, 117
Criterion, 10
Cronkite, 30
Cropsey, 74, 139
Cropsey2, 10, 35, 116–17
Crossin1, 85
Crossin2, 37
Crowley, Thomas J., 141
Crowley2, 77
Crum, 118
Crusto, 116
Cruz2, 55, 58
Culbert2, 59
Culbert1,2, 67
Cummins3, 82
Cunha, 53
Cunningham, 78, 109–10,
Cunningham, Christopher, 141
Cuny1, 124
Curran1,3, 53
Curtis2, 105
Cushion, 115

Cutter3, 47
Cyprus, 65
Czechaczek, 36

D
Dagnew, 10
Dahar1, 56
Dahar2, 4
Dahlgren, 21, 29, 76, 96
Dallas, 57, 79
Danica Knight, 73, 139
Danielson, 119
Daniulaityte, 5, 86, 111, 124
Danner2, 93
Dao1, 11, 62, 70
Darlinghurst, 12
Darnley1, 23
Darnley2, 117
Dart1, 86
Dart2, 86
Dart3, 12, 85
Darwish, 68
Das1, 57
Dass2, 95
Daulouede, 32, 40
Davidson, 37, 41, 94, 125
Davidson, Cameron, 41
Davie, 95
Dávila Torres5, 91
Davis, 33, 42
Davis1, 29
Davis2, 21
Day3, 7, 43
Dayan3, 84
Dayton, 5–6, 86, 111, 124
Dayton1, 110
Dean2, 18
DeBeck1, 35, 108
DeBeck3, 36
DeBeck4, 17
DeBeck2,5, 56
DeFransosco, 8
Degenhardt, 6, 53, 116
DeHart1, 113
Delgado, 101
Delgado2, 49
Demirkol, 85
Dempsey3, 105
Denehy1, 41
Denis, Cecile, 122
Denis1, 123
Denis2, 92
Denis3, 31, 40
Denis4, 32
Desai, 125
DeSantis, 41
DeSarno, 33
Desrivieres, 57
DeVaugh-Geiss, 25
DeVaugh-Geiss1, 106
Dewey, William, 20, 77, 129
Dewey1, 77
Dewey3, 77
Dhanya2, 14
Dhawan, 57
Dhingra4, 32
Diagnosis code, 4
Diaz, 87
Diaz1, 103
Diazgranados, 113
Dib Gonçalves, 23, 114
Dickson1, 87
Dickson2, 91
DiClemente, 10
Dietze, 124
Dietze1, 37
Dietze4, 85
Dietze1,2, 58

Author Index

- Dillies, 111
Dillon, 79
Ding1, 59
Dios, 33
Dixon, 115
DJ, 103
Dobbins2, 6
Doberstein, 112
Dobscha1, 85
Dogan, 115, 117, 124
Doko1, 57
Dolan, 27, 126
Dolan1, 33–34
Dolan2, 27
Dolgorukova, 55
Domínguez, 58
Dominguez Gonzalez, 38
Dominguez Hills, 73
Doncaster, 37, 85
Dong1, 108
Dong3, 36, 111
Dong2,3, 56
Donis1, 18
Doogan2, 33
Dorotenko, 55
Doss1, 18, 27
Douaihy1, 106
Douaihy2, 111
Dougherty, 127
Dougherty, Donald, 135
Downey1, 14
Doyle, Michelle, 41
Doyle1, 41
Doyle4, 100
Doyle9, 67, 93
Dreyer Rossi2, 95
Drislane, 89
Drogas, 65
Droutman, 118
Drumheller, 14
Duarte2, 15
Dubernet, 104
Duchin1, 107
Duddupudi, 124 Dugosh4, 92
Dumchev1, 62–63, 108–9
Duna1, 56
Dunbar1, 4
Duncan, 25, 78
Dunlop1, 67, 93
Dunlop2, 12
Dunn, 122, 126
Dunn, Kelly, 1, 95
Dunn1, 105
Dunn2, 37
Dunn4, 106
Durable, 91
Duran, 8, 53
Duran1, 23, 114
Durham, 33, 81, 89, 92, 105–6
Dvoriak1, 62, 67, 94, 108
Dvoriak5, 94
Dwoskin, Linda, 97, 132
Dwoskin, Linda P., 141
Dwoskin1, 11, 41
Dykstra, Linda, 141
E
Eans2, 41
Eastwood, 43
Eberson2, 82
E.Contreras-Pérez1, 70
Edelman1, 31, 90, 105
Edelman2, 17
Edwards, Emmeline, 44, 130
Eisenberg, 115
Ekerete-Udofia3, 62
Ekhtiari, 48, 101, 114
Ekpe1, 60
Elaine McMillon Sheldon, 3
Elche, 85
El-Deen, 56
Elder, 112
Elder1, 112
Elgart2, 112
El-Gohari, 56
El-Gohary, 56
Elkashef, 37
Elliott, 104
Elliott1, 8
Ellis, 5, 37, 107, 123
Ellis1, 83
Ellis2, 14, 118
El-Messidi4, 84
Elon, 125
El-Shahawy1,2,3, 57
Elson, 8, 85
Elton2, 34
Engler, 104, 111
Engler1, 42, 123
Englewood, 112
Epstein1, 6, 99
Epstein2, 29, 48
Erisson2, 112
Ernst3, 114
Erpelding, 112
Espinach, 71, 91
Essa, 33
Essien, 60
Esterlis, 114
Esther, 70
Estonia, 40
Evans, 15, 116
Evans-Polce1, 42, 88
Evans-Polce2, 88
Evins2, 21

Author Index

- Evripidou, 65
Ewha, 69
Ewyl, 116–17
Eydt1, 92
Ezard1, 12
- F**
- Fairbairn, 17, 36, 40, 108, 111
Fairbairn1,5, 69
Fairchild, 48
Fairman, 47
Fairman, Brian, 47
Fakunle, 25
Falk1, 111
Fantegrossi, 96, 112
Farabee, 81
Farabee, David, 80, 132
Fares1, 98
Farfell, 9
Farkas1, 17
Farma, 30
- Farnum1, 107
Farnum2, 59, 67
Farnum3, 67, 90, 94
Farnum4, 94, 108
Farquhar1,2,6, 64
Farré1, 71
Farre4, 47
Farré3,6, 68
Farrell1, 116
Fatseas3, 104
Fatseas4, 31
Fatseas5, 32
Fatseas7, 40
Faulkenberry, 121
Faulkner, 18, 48
Faure1, 71
Faure3, 91
Feaster, 96
Feaster1, 91
- Feaster3, 15
Feaster4, 11, 62
Feder, 7
federal efforts, 134
Fedorko1, 20
Fedorova, 22, 29–30
Feelemyer, 40
Feeney8, 82
Feigl, 9
Feinstein, 114
Felicia Jody Bayer, 141
Feliu1, 8
Felix1, 100
Fengl, 59
Feng3, 39
Fernandez, 88
Fernández, 8, 57
Fernández-Artamendi, 64
Fernandez-Artamendi1, 57, 88
Fernández-Artamendi2, 68
Fernandez-Artamendi3, 34, 123
Fernández-Hermida, 64
Fernández-Hermida1, 123
Ferreira, 53–54, 101
Ferris1, 115
Ferris3, 5, 59
Festinger, 92
FHI, 63
Fidalgo1, 71
Fidalgo2, 86
Fiddian-Green, 15
Fields1, 42, 123
Fiellin1, 47, 90
Fiellin2, 17, 32
Fieo, 31
Fierbinteanu, 56
Filipino, 65
Filippovych, 67, 94, 108
Fingerhood, 7
Finley2, 92
Finnegan, Loretta, 3, 43
Finnegan, Loretta P., 1
Finnema2, 114
- Firbas2, 6, 66
Fischer, 61
Fischer2, 47
Fischer4, 6, 66
Fisher1, 119
Fishman3, 88
Fitch1, 38
Fitzpatrick, 119
Fitzroy, 37, 85
Flanagan, 23, 119
Flanigan, 58
Flegel4, 120
Fleischer, 84
Fleiz1, 58
Fleming2, 40, 59
Fleuriscar, 91
Flores4, 8
Floyd3, 109
Fodor, 37, 123
Fodor1, 83
Fogel3, 123
Fogelman, 99
Foigel, 53
Foigel2, 114
Fokuo1, 91
Foll1, 98
Foll5, 92
Follett1, 100
Foltin4, 23, 35
Fomenko1, 59, 67
Fomenko4, 90, 94
Fonseca1, 47
Fonseca1,2,3, 68
Ford1, 87
Ford2, 4
Ford3, 79
Fornis2, 94
Forray, 98
Forrest, 63, 96
Forson1,2, 58
Forster, 27
Forster1, 27

Author Index

- Fowler², 37, 108
Fox, 112, 118
Fox¹, 78, 106
France, 30–32, 40, 104, 113
Franco², 101
Franco³, 54
Frank, 7
Frankeberger, 57
Franklin, 23, 25, 80, 117–18
Franklin, Theresa, 1
Fratantonio, 106, 125
Frazer, 95
Frazer¹, 83
Freda, 102
Freda⁵, 102
Frederick, 119
Freels⁷, 67
Freeman, 30
Freeman, Kevin B., 1
Freeman¹, 11, 78, 100
Freeman², 105
Freeman^{1,2,4,5}, 53
Fricker⁶, 53
Friedman, 65–66, 71, 90
Friedmann, 49
Friend, 77
Fries¹, 118
Frimpong, 58
Froimowitz, 95
Frontera, 64
Frost¹, 93
Fucito¹, 32
Fuente, 58
Fuente Muñiz, 57
Fukuda¹, 112
Funada¹, 28
Funaro¹, 105
Furr-Holden³, 79, 84
Furr-Holden⁶, 13
Fuster¹, 58, 71, 81
Fwemba^{1,4}, 68
- G**
- Gaalema, 32
Gaalema, Diann, 26, 137
Gaalema¹, 22, 33
Gaalema², 33
Gaalema³, 68
Gaalema⁴, 34, 123
Gabrielian, 19
Gadient², 14
Gaines¹, 37
Gaither⁷, 90
Galan¹, 71
Gallo², 27
Galvin, 82, 110
Galynker, 8
Gannon¹, 19
Garavan, 44
Garcia, 23, 112
Garcia², 117
García-Calvo¹, 58
Garcia-Calvo², 81
García-Pérez¹, 34, 68
Garcia-Reid¹, 39
Garcia-Romeu¹, 29
Garcia-Romeu⁴, 13
Garden City, 119
Gardner¹, 53
Gardner³, 95
Garibay¹, 20
Garment¹, 81
Garnick², 13
Gastfriend, 77
Gatch, 27
Gatch¹, 27
Gattaz¹, 23
Gauthier, 17, 121
Gawrysiak, 117
Gay¹, 27
Gaza, 62
Gearhardt, 113
Geddes¹, 86
Gelberg¹, 33
Gelberg⁵, 19
Gelberg⁶, 38
Geller, Ellen B., 1
George³, 120
Gerak, 126
Gernat, 87
Gerra, 93
Gerra³, 66
Geyer¹, 37
Ghahremani, 18, 48, 101
Ghana, 58, 66, 68
Gheidi, 112
Gheidi², 14
Ghitza², 92
Giacomuzzi, 69
Giallourous, 65
Giancotti, 65
Giang¹, 35
Giesler³, 111
Gilbert, 25
Gillespie, 112
Gillis⁵, 100
Gilman², 21
Gilmore, 118
Gilmore-Thomas¹, 89
Gimbel⁴, 112
Gipson-Reichardt, 14
Gipson-Reichardt, Cassie, 1
Girard², 84
Girgis², 34
Giroud¹, 23
Gisev², 6
Glasner², 10

Author Index

- Glass², 119
Glisker¹, 6
Gnatienco, 96
Goeders², 28
Goeders⁵, 28
Gogoi¹, 112
Goldfeld, 81
Goldmann, 119
Goldsby², 92
Goldshear, 9, 38
Goldstick, 37
Gomez¹, 35
Gomez², 71
Gomez-Gomez³, 47
Gomez-Gomez⁵, 68
Goncalves, 53, 114
Gondar, 10
Gonzalez, 51, 88, 123
González-Roz, 64
González-Roz¹, 34, 68
González-Roz², 123
Goodell¹, Anderson, 110
Gooden², 91
Goodman⁵, 17
Goodwin, Renee, 16
Goodwin¹, 84
Goodwin², 8
Goodwin³, 40
Gordon¹, 17
Gordon², 19, 65
Gordon⁸, 90
Gorfinkel, 69, 105, 111
Gorodetzky, Charles W., 141
Gortari-Gallardo¹, 55
Gosden, 15
Gosselin, 84
Gould, 78
Gouya², 6, 66
Govule², 68
Goyer⁴, 92
Grabenauer, 21
Graduate Studies, 65, 126
Graham², 39
Grande-Gosende, 64
Grande-Gosende¹, 123
Grant, 74, 99
Grant², 36
Grasing, 23
Grassi-Oliveira¹, 101
Grassi-Oliveira², 54
Grassi-Oliveira³, 118
Gray¹, 32, 124
Gray², 23
Gray³, 106
Greco¹, 6
Greece, 64–65, 90
Green¹, 4, 35, 85, 121
Green², 79, 85
Green³, 7, 11, 35, 125
Green⁵, 109
Greene¹, 42, 103–4
Greene², 42
Greenfield, 15
Greenfield Park, 84
Greenville, 33
Greenwald, 4, 31, 95, 99, 106–7
Gregoire, 27
Grella², 10
Grelotti, 69
Gresko¹, 115
Griffin², 37
Griffin³, 124
Griffiths, 12, 18, 27
Grigorian, 95
Grisham², 43
GRIT, 99
Groom³, 57
Gross³, 69
Gross⁴, 48
Gruber¹, 21, 96
Gruber², 29
Grucza¹, 82
Grundmann, 65
Gryczynski, 5, 79, 88, 109, 116
Gubner¹, 33
Gudin², 112
Guelph, 100
Gueorguieva, 51
Guerin¹, 28
Gugerty, 109
Gugerty², 109
Guha¹, 15
Guille, 98
Guille, Constance, 98, 133
Guillot, 10
Guillot¹, 10
Guha¹, 15
Guille, 98
Guille, Constance, 98, 133
Guillot, 10
Guillot¹, 10
Gulley, 28
Gulley¹, 28
Gunn¹, 36
Gunter³, 123
Guo¹, 63, 70
Gurka, 16
Gust, Steven, 52
Guthrie³, 4
Guthrie^{1,2,3}, 64
Gutierrez, 14
Guure¹, 68
Guydish, 8
Guydish, Joseph, 102, 140
Guydish¹, 33
Gynecology, 70, 84
H
Haas, 11
Haber⁴, 43, 67, 93
Hacker, 45
Haenchen, 83
Haeny, 75
Haeny, Angela, 51
Haeny¹, 51
Haffajee, 37
Hager¹, 23
Hahn³, 42
Haile¹, 124
Hallam¹, 112
Hallvik², 86
Halpern-Felsher, 18
Hamblin¹, 107
Hamersky, 14
Hamidovic, 33

Author Index

- Hamblin¹, 107
Hamersky, 14
Hamidovic, 33
Hamilton, 25, 63, 89, 98, 109
Hammerslag, 41, 121
Hammond, 83
Hand⁴, 18
Haney, Margaret, 1, 16, 22, 141
Haney¹, 23, 120
Haney², 124
Hangzhou, 41
Hanif, 58
Hankosky, 11, 17
Hankosky, Emily, 97, 132
Hanks², 50
Hannigan, 41
Hanoi, 11, 62, 70
Hanover, 21, 96, 107
Hanu, 68
Hao¹, 64
Hao⁴, 121
Hao^{1,2,3,4,5}, 55
Hardee, 74, 113
Hardee, Jillian, 1
Harding³, 37
Harfmann, 84
Harriet De Wit, 141
Harris, 104, 111
Harris¹, 11, 42, 84, 123
Harris², 36
Harrogate, 14
Harryman, 14
Hart², 99
Hart^{3,4}, 57
Hartung, 12
Hartung¹, 86, 93
Hartzler, 111
Harvanko, 32
Harvey, 33
Harvin¹, 85
Harvin², 85
Hasin, 25, 83–84
Hasin, Deborah, 141
Hasin, President Deborah S., 1
Hasin², 32
Hasking⁵, 82
Hassaan, 68
Hassan, 56
Hastings, 121
Hatsukami, 13
Hatzakis, 65
Haut², 9
Havens², 22, 87
Hawes, 88
Hawk¹, 12
Hawk⁷, 17
Hawkins, 12–13
Hawkins², 93
Hayashi¹, 36
Hayashi², 17, 63
Hayashi³, 35, 40, 66, 108
Hayashi⁴, 108
Hayden², 6
Hayes, 87
Hayes², 59
Haynes¹, 92
HEART, 96
Heath¹, 84
Hebbar, 59
Heeren², 122
Heidbreder, 6, 106
Heidelberg, 53
Heil¹, 38, 84, 109
Heilig⁵, 113
Heitzeg, 113
Hella³, 67, 93
Hellemann, 18
Hendree Jones, 46
Hennessy, 37
Henningfield, 13, 112
Herbeck², 64
Hererra³, 43
Hermes¹, 16
Hern¹, 23
Hernández-Ribas⁶, 8
Herrera², 66
Herron¹, 104
Herron², 104
Herscovitch, 113
Hershey, 106
Hershow², 63, 109
Hertzel², 29
Hershow², 63, 109
Hertzel², 29
Hickie⁴, 88
Hien², 18
Hien³, 16
Hien⁴, 119
Higgins, 32–33, 75, 139
Higgins, Stephen, 127, 135
Higgins¹, 33, 38, 66, 84
Hildebran, 86, 93, 125
Hill, 93, 124
Hill¹, 89
Hill^{1,2}, 58
Hillard³, 120
Hillmer, 101
Himmelstein, 30
Hindocha^{1,2,3,6}, 53
hippocampal, 114
hippocampus, 23
Hiranita, 28, 100, 112
Hirchak¹, 104
Hirchak², 104
Hlaing^{1,2}, 62
Hobart, 12
Hobbs¹, 121
Hodder², 9
Hodgkin¹, 13
Hoffman, 90
Hoffman¹, 13
Hofmann^{6,7}, 53
Hoge¹, 19
Holcomb, 41
Holla², 57
Holleran Steiker⁴, 109
Holmes¹, 19
Holmes³, 42
Holter, 14
Holtyn, 81, 133
Holtyn¹, 7
Holtyn², 99
Hodayra¹, 36, 49, 108
Hodayra³, 108
Homish, 18, 119

Author Index

- Homish2, 38, 110
Hommel, 14
Hongdilokkul, 49, 108
Hong Kong, 114
Hong Kong SAR, 114
Hongta District, 64
Hood, Caitlyn, 22
Hood1, 23, 107
Hood2, 124
Hood4, 93
Hoopsick, 18, 119
Horgan1, 13
Horner, 12
Horton2, 38
Hospital Universitari Germans Trias, 58, 71, 81, 91
Houston-Ludlam1, 84
Howard, 110
Howard12, 67, 93
HPLC, 94
HPTN, 63, 109
HPTN058, 69
Hruschak, 17
Hser2, 107
Hsieh3, 39
Hsu1, 39
Htun2, 62
Hu1, 5
Hu2, 82
Huang, 54, 101
Huang1, 101
Huang2, 63, 70, 120
Huang3, 54, 114
Huang7, 69, 82
Hufford2, 13
Huggins1, 22, 50
Hughes2, 42
Huguet, 12
Huhn1, 105
Hulse1,2, 68
Humphreys, 49
Hunan Province, 55
Hung2, 101
Hung1,2, 54
Huntington, 86, 89
Huntley6, 17
Hurd, Yasmin, 24, 129
Hurd2, 8
Hurley2, 115
Huskinson, 100
Hutchins, 118
Hutchinson, 14
hydromorphone, 106
Hynes5, 65
- I**
- Ialongo7, 79
Ibadan, 56, 62
Ibáñez, 59
Ibe, 58
Ibiyokun, 60
Ibrahim, 44
Icahn School, 24, 70
Ickes1, 4
Ickowicz, 13
Iddi3, 68
Idrisov1,2, 58
Ifeagwazi, 60
Iguchi1, 77
Iigen1, 83
Iigen2, 84
Ijadi-Maghsoodi1, 38
I-K.Lyoo1, 69
Inan, 44
Inc, 12–13, 90–91, 94, 106–9, 111–12
Iskiwitch, 39
Islam1, 59, 67
Iverson1, 22
Iverson3, 29–30
Iveth G2, 91
Iwanicki, 86
Iwuagwu2, 71
Iyer1, 39
- J**
- Jackson, 14, 78, 81, 100, 123
Jackson2, 115
Jackson4, 29
Jackson Foundation, 78
Jacobs, 68
Jacobs-Elliott1, 8
Jacobson, 9, 78
Jadavpur University, 70
Jaffe1, 116
Jaffe2, 35
Jagannathan, 23, 117–18
jail, 80, 91, 116, 132
Jain, 125
Jain2, 66
Jakubiec, 31
Jamaica Plain, 38
James1, 34
Janda2, 123
Janes, 80
Janes, Amy, 141
Janes, Past-President Amy C., 1
Janes2, 33
Jankowski, 9
Jannausch, 84
Jannuzzi Cunha2, 23, 114
Jansson2, 83
Japan, 28
Jarlais2, 40
Jarlais5, 91
Jarnecke, 119
Jauffret-Roustide4, 40
Jayaweera, 30
Jelstrom, 13
Jenkins, Richard, 101
Jennings, 92
Jensen1, 35
Jeong2, 69
Jerusalem, 46
Jhongli City, 101
Jimma, 56
Jimma University, 53, 56
Jimmerson, 87
Jin1, 107, 109
Johnson, 11, 27, 79, 87, 115
Johnson, Micah, 79
Johnson, Mona, 52
Johnson, Trina, 49
Johnson1, 6, 33–34, 92
Johnson2, 34, 43, 51

Author Index

Johnston, 86
Jolla, 14, 37, 39, 82, 94
Jonbekov, 63
Jones, 43, 50, 78, 84
Jones, Jermaine, 141
Jones1, 6, 51, 70
Jones2, 16
Jones3, 19, 21, 31
Jordan, 75
Jordan1, 66
Jorgenson, 4
Joseph, 22, 30–31
Joudrey, 116
Junstine Larson, 24, 129
Ju Nyeong Park, 124
Jusko2, 12
Jutkiewicz, 78, 99

K

Kaelber2, 22
Kaghyan4, 105
Kahle, 42
Kaicher4, 21
Kalam, 58
Kalesan, 38
Kaloiya, 12
Kaltenbach, 19
Kampman2, 92, 117
Kane, Jeremy, 118
Kane1, 119
Kane3, 104
Kang2, 28
Kangas2, 21, 119
Kangas3, 100
Kansagara, 30, 105
Kantak, 97
Kantak, Kathleen, 120
Kantak1, 121
Kapil1, 12

Kaplan1, 113
Kapodistrian University, 65
Kapoor1, 85
Kapoor2, 85
Karachi, 58
Karavidha, 4
Karega, 52
Karno3, 10
Karolinska Institutet, 53
Karol Kaltenbach, 19, 128
Kasper, 5, 14
Kataoka4, 38
Kate, 76
Kathungu, 52
Katz, 112
Katz1, 112
Kaufman2, 100
Kearney-Ramos1, 120
Keith1, 33
Keller1, 28
Kelly, 10
Kelly1, 10, 29, 116
Kelpin, 79
Kelsh2, 18
Kelsh6, 112
Kempsey, 93
Kendall3, 14
Kenichi2, 28
Kennedy1, 63
Kenner, 141
Kerns1, 90
Kerr1, 7, 40
Kerr2, 36, 108
Kerr3, 17, 63
Kerr4, 39
Kerr2,4, 56
Kertesz1, 19
Kervran1, 32, 40
ketamine, 55, 114
Ketcherside, 23
Kettering, 5, 86, 124

Khalid, 54
Khalifa, 68
Khalil1, 14
Khalili1, 91
Khalsa3, 114
Khanlari, 43
Kharabsha, 58
Khazvand, 30
Kiev, 90, 94, 108–9
Kilkenny, 89
Killeen, 9
Kilts1, 34
Kiluk, 122
Kiluk, Brian, 1, 121, 134
Kiluk1, 35
Kim, 61
Kim1, 69, 122
Kim2, 65
Kim4, 69, 122
Kim6, 17
Kimble2, 9
Kimes2, 113
Kimmel1, 38
King3, 92
Kioumars, 30
Kiplamai, 62
Kirby, 121
Kirby, Lynn, 120
Kiriazova, 58, 62–63, 109
Kirisci1, 4
Kirtadze, 27, 60
Kirtadze1,2, 64
Kivell1, 77
Klevens2, 38
Kliewer, 52
Kliewer2, 52
Klimas1, 105, 111
Klimas2, 111
Klimas1,2, 69
Knight, 139
Knight4, 17
Knoblach, 10
Knouse1, 118

Author Index

- Knox, 83
Knudsen, 49
Knudsen1, 87
Kobuti1, 23, 114
Koch, 52, 79
Koch1, 53
Koch2, 52
Kodaira, 28
Koffarnus, 95
Kogan3, 124
Kohut, Stephen, 1, 3, 100
Kohut1, 100, 120
Kohut2, 100
Kohut4, 41
Kohut5, 119
Kolandaswamy, 59
Kolaric1, 6
Komaromy1,2, 69
Kondo, 12, 30
Kondo2, 105
Konstanz, 53
Koob, George F., 3
Korach1, 111
Kordzadze1,2, 63
Korth, 65
Korthuis, 13, 86, 90, 93, 125
Koslov2, 33
Kosten1, 124
Kosten2, 34
Kosten3, 81
Kosten4, 124
Koulosousas, 56
Koutsenok, 69
Kowalczyk, 6, 48
Kowalski, 71
Kraft, 43
Kral1, 94
Kral2, 9
Kral3, 38, 43, 90
Krawczyk, 115
Krebs2, 49
Kreek, 16, 34, 41
Kreek1, 78
Kriegell1, 8
Krishna6, 57
Krom1, 69
Kronman1, 117
Krueger2, 82
Krupitsky, 48, 96
Krupitsky1,2,3, 69
Ksinan Jiskrova, 32
Ku1,2, 69
Kühberger, 6, 66
Kulak1, 38
Kulis1, 63–64
Kulkarni, 59
Kumanalieva, 59
Kumasi, 58
Kungshamn, 14
Kunkel, 90
Kunkel1, 13, 93
Kunming, 61
Kunwar1,2, 70
Kuo1, 27, 59
Kuo3, 69
Kuplicki, 48, 101, 114
Kuppe1, 29
Kuppe2, 21
Kuppe3, 21
Kurpad5, 57
Kursuncu, 111
Kurti, 32, 127
Kurti, Allison, 127, 135
Kurti1, 33, 109
Kurtz, 86
Kurtz1, 86
Kurtz2, 86
Kusumoputri, 59
Kusunoki, 80
Kutelia1, 27, 60
Kuwabara, 113
- L**
- Lacy, 25
Lacy2, 15
Laffont2, 106
Lagisetty, 37
Lagos, 60
Laing1, 7
Lais Berro, 96
Lal3, 6
Lalanne5, 40
Lalwani2, 82
Lamb1, 38
Lamb2, 19, 43
Lambdin1, 94
Lambros1, 29
Lambros2, 21, 96
LaMonaca, 59, 67, 90, 94, 108
Lamy1, 111
Lan, 115
Lancaster, 15, 25, 63, 109
Lander2, 9, 121
Landheim, 82
Landsverk, 109
Lane1, 35, 85, 92
Lane2, 35, 85, 121
Lane3, 35
Langleben, 18, 48, 117–18
Langohr5, 47
Langohr7, 68
Lanier, 112
Lanier1, 112
Lankenau, 22, 29–30, 36
Lannach, 6
Lansing, 29, 42, 79
Lapham, 30
Lardier Jr, 39
Larkins5, 69
Larney1, 116
Larney2, 6
Larochelle, 37–38, 115
Larson, 24
las Fuerzas Armadas, 59
Laska1, 81

Author Index

- Latkin2, 62, 110
Latkin3, 63
Latkin5, 63, 109
Lausanne, 122
Lawn, 2
Lawrence, 20, 77–78, 87, 100
Lawson1, 12
Lazar2, 9
L.Cruz, 55
Le1, 11, 33, 62, 70
Le2, 110
Learned2, 6, 106
Lebaux, 93
Lebaux2, 66
Lebeaut, 10
Lebeaut1, 83
Ledgerwood, 24, 37, 83, 107, 123
Ledgerwood, David, 130
Ledolter, 95
Lee, 30, 61, 81, 93
Lee1, 4, 39, 81, 111
Lee2, 34, 66
Lee3, 58, 69, 84, 93
Lee5, 101
Leeds, 9
Leeman, 16
Legedza2, 106
Leggio, 50
Lehane5, 68
Lei2, 18
Leichtling, 86, 93, 101, 125
Lemley1, 96
Lenert, 4
Lennon1, 113
Leon, 82, 110
Leon3, 91
Leonchuk, 52
Leri, 100
Leri, Francesco, 99
Lesaffre, 68
Leslie2, 106
Lester5, 38
Leukefeld, 87, 91
Leventhal, 51
Levi-Minzi1, 86
Levin, 97
Levin1, 31
Levin2, 21
Levin5, 23
Levin6, 120
Levine, 63, 96
Levine, Amir, 16
Levy1, 15, 63
Levy2, 22, 42
Levy6, 67
Levy-Cooperman1, 18, 82
Lewis, 82, 110, 115, 117, 124
Lewis1, 5, 22
Lewis3, 92
Li, 4, 121
Li1, 14, 55
Li2, 11, 31, 70, 90, 115
Li3, 61, 101, 114
Li4,5, 54
Liang1, 28, 114
Liang2, 10
Liao, 72
Liao1, 63–64, 70
Liao2, 121
Liao1,2,3,4,5, 55
Libbing1, 107
Libuy, 59
Lichenstein, 44
Liebschutz, 6
Lien1, 95
Lile1, 29, 95
Lile2, 22, 49
Liles-Burden, 125
Lim4, 65
Lim5, 89
Lima, 53
Lima2, 23, 114
Lin1, 34–35, 53, 101
Lin2, 37, 120
Lin1,8, 54
Lin1,38, 115
Lindsley, 78
Ling1, 6
Ling4, 42
Linköping, 113
Lintzeris, 12, 67, 85, 93
Lioznov1, 69
Lioznov2, 48
Lipkind4, 47
Lisdahl, 50, 114, 120
Lisdahl, Krista, 50, 131
Lisinski, 95
Lister, 37, 107
Litschauer, 6, 66
Litt, 82, 110
Liu, 11, 87, 118
Liu1, 54–55, 61, 64, 101, 121
Liu2, 82, 117
Liu3, 72
Liu6, 17, 55
Liu1,2,3,4,5, 55
Lleida, 8
Lloyd, 11, 16
Lodi3, 115
Loescher, 87
Lofwall, Michelle, 46
Lofwall3, 17

Author Index

- Lokala2, 111
Lon2, 29
London1, 48
London2, 18, 101
London6, 82
Long2, 110
Long4, 77
LoParco, 82, 110
Lopez2, 123
Lopez3, 33
Lopez-Castro3, 119
Lopez-Guzman4, 66
Lopez-Quintero, 16
Lopez-Quintero1, 30
Lorenz1, 111
Loscalzo, 4
Lott2, 93
Louisville, 57
Lovejoy, 102
Lovejoy1, 85
Lovejoy3, 102
Lu5, 112
Lubman2, 85
Lubman3, 37
Luce, 30
Lucke, 10
Luckel, 10
Ludwig-Barron1,2, 64
Lukas, Scott, 3, 20
Lukas1, 21, 96
Lukas5, 119
Lund, 17
Lundahl, 123
Lundahl1, 83
Lunze2, 58
Luo, 46
Luo, Sean, 46
Luo1, 107, 109
Luo5, 3
Lusaka, 119
Lwin, 60
Lynch, 42, 125, 133
Lynch, Wendy, 132
Lynch2, 92
Lyons2, 115
Lyvers4, 82
- M**
- Ma1, 59, 113
Ma2, 64
Ma4, 69
Ma5, 69
Macafee1, 38
Macdonald, 110
MacFadden, 63
Mackenzie, 19
Mackesy1, 63
Mackson7, 67, 93
MacLean3, 126
Madden1, 84, 94
Madden2, 5, 16, 47, 90, 94
Madden3, 5, 32, 90, 108
Madden4, 107
Madden2,3, 67
Madison, 123
Madras, 73
Madras, Bertha, 141
Madras, Bertha K., 3
Madras1, 21, 120
Maduka, 70
Maggio, 123
Maghsoudi, 94
Magin2, 30
Maglior2, 33
Magri1, 59
Maguire, 113
Magura1, 109
Maher7, 79
Mahoney1, 9, 85
Mahony5, 120
Maier1, 5, 59
Maio3, 58
Maisonet-Alejandro6, 91
Majors1, 14
Makarenko, 58, 62–63, 109
Makriyannis, 119
Maksimovskiy, 119
Makunyane, 64
Malbergier, 23, 53, 114
Maldonado-Molina, 104
Malignaggi, 88
Malison1, 114
Malone, 121
Malone1, 81
Malte2, 93
Malvern, 18, 82, 112
Mamaru1, 56
Man1, 121
Manchester, 17
Mancino, 31, 87, 107
Manhapra, 19, 90, 106
Manibusan, 86
Mann, 43
Mann1, 98
Mann2, 8
Mannelli, 92, 106
Manresa, 8
Mantente, 64
Manubay1, 31
Maple, 120
Mar, 47
Maranda1, 109
Marckell1, 28
Marcopoul, 125

Author Index

- Marcos, San, 4, 79, 87
Marcus1, 90
Marcus2, 5, 67, 83, 94, 108
Marcus3, 5, 59, 67
Margolin, 86
MARIAN, 46
Mariangela Martini, 125, 134
Mariani1, 120
Mariani2, 31
marijuana, 16, 21, 83
 combined, 31
marijuana consumption, 59, 62
marijuana co-use, 64, 96, 123
marijuana drug terms, 111
marijuana users, 21
 frequent, 124
 medical, 30
Marini1, 111
Marino, 125
Mark1, 96
markers, 35, 58, 81, 110
Mark Gold, 141
Mark Greenwald, 99
Mark Smith, 45, 125, 134
Mar Medical Research Institute, 47, 68
Mar Medical Research Institute-IMIM, 47, 68
Marquez McKetchnie, 38
Mar Research Institute, 47, 68
Marsch3, 17
Marsch4, 107, 122
Marseille, 40
Marshalek, 9
Marshall, 90, 124
Marsiglia, 63–64
Martin, 15, 30–31, 124
Martin1, 21, 29, 86, 115, 123
Martin2, 120
Martinez, 16, 31, 34, 120, 125
Martínez, 8, 70
Martínez-Loredo, 64
Martínez-Loredo1, 68, 123
Martínez-Loredo2, 34
Martin-Fardon, 113
Martin-Fardon1, 120
Martini, 125
Martins, Silvia, 1
Martins1, 34, 39, 42, 89, 94
Martins2, 9, 42, 88
Martins3, 9, 15, 86
Martire1, 85
Martoy, 52
Maru4, 70
Marusich, 14, 27
Mary, 76
Masson1, 91
Matamoros, 98
Matei Bals, 56
Maternal Substance Use, 19, 128
mathematical simulation, novel, 91
Matheson, 23, 98
Matlab, 138
Matrville, 93, 116
Matson6, 79
Matta Chasin3, 65
Mattheisen17,18, 53
Matthews, 78, 92
MAT uptake, 109
Matusiewicz, 38
Matuskey, 101
Matusow1, 116
Matyas1, 78
Matzeu, 113
Matzeu1, 120
Mauro, 30
Mauro1, 42, 89, 103
Mauro2, 42
Maurya1, 57
Maxwell, 95
May3, 18
Mayberry, 14, 118
Mayer, 61
Mayer1, 47, 108
Mayer2, 40
Mayer4, 38
Mayes1, 43, 85
Mayhugh1, 29, 97
Maylen Perez Diaz, 48
Mbogo1, 64
MCAM, 126, 135
MCAM reverses, 126
MCAM to naloxone in vitro, 135
McCabe, 29, 42, 87
McCabe, Sean, 76
McCabe1, 42, 79, 88
McCabe2, 87–88
McCabe3, 4
McCabe4, 79
McCallum, 14
McCann2, 66
McCarty, 90
McCarty1, 13
McClure, 45
McClure, Erin, 123
McClure1, 32, 124
McClure2, 23
McCollister, 103
McCollister, Kathryn, 103, 140
McConnell, 83
McCormack, 6, 17
McCormick, 83
McCoy, 52
McCoy4, 95
McCrae, 26
McCrae1, 36
McCuistian, 16
McCurdy1, 28
McCurdy2, 100
McDonald, 81, 84
McDonell, 8
McElrath, 109
McElroy1, 78
McEntyre, 67, 93
McGill University Health Centre, 84
McGorry3, 88
McGovern, 105
McGovern Medical School, 35, 85, 89, 121
McHugh1, 37
McHugh2, 124
McKee2, 115
McKelvey, 18
McKinney, 114

Author Index

- McLaughlin, 41
McLean Hospital, 24, 36, 73, 80, 100
McMahon1, 28, 100
McMahon2, 100
Mc Master University, 68
McNeely2, 109
McNeil1, 40
McNeil2, 61
McNeil3, 108
McNeil4, 36
McPherson, 8, 85
McRae-Clark, 22
McWilliams, 85
MDPV self-administration, 41
Meador2, 92
Meg Chisolm, 3
Meier, 21
Meisch2, 81
Mekonnen, 53
Melborune, 88
Melbostad, 38
Melbourne, 35, 37, 85, 88, 124
Melendez, 119
Melgar, 52
Meli, 61
Melkonian, 118
Mellis1, 15, 113
Melo, 53
Melo1, 23, 114
Members, 98
memory, 24, 82, 100–101
memory consolidation, 100
memory impairment, 54
Mendez2, 22
Mendonca, 35
Menezes Sanchez2, 23, 114
Mennenga, 6, 15
Mennis, 89
Mequon, 120
Merlin4, 4
Merlin7, 19
Merritt, 118
Merritt, Christina, 77
Merritt1, 78
Mestre-Pintó2, 47
Metcalf4, 107
Meteliuk, 59, 67, 90, 94
Metrik2, 96
Metsch2, 91
Metsch3, 11, 62
Metzger1, 69, 92
Metzger2, 59, 123
Mews1, 117
Mewton1, 82
Meyer, Roger, 141
Meyer1, 59, 118
Meyer2, 83
Meyers-Ohki1, 6
Mgebrishvili, 27, 60, 64
M.Giang4, 69
Mhamdi2, 52
Michelo4, 68
Mielenz2, 4
Migrants, 63
Miguell1, San, 27
Miguel2, San, 35, 121
Mikulich-Gilbertson2, 85
Milam4, 79
Milivojevic, 16, 30
Mill1, 18
Miller, 79
Miller1, 91
Miller-Roenigk, 16
Milloy1, 7, 40
Milloy2, 35–36, 108
Milloy3, 17
Minocycline, 126
Mintz, 116
Mintzopoulos, 100
Miranda, 46, 91
Mishra, 12, 57, 61
gabapentin, 86
Mital2, 125
Mitchell, 5, 109, 116, 120, 122
Mitra2, 105
Mitragyna Speciosa, 65
Mittal, 66
Mittal1, 37
Mittal3, 39
Moeller, 26
Moeller, Gerard, 26, 137
Moeller1, 40, 110, 113
Moeller2, 78
Moensted, 7, 43
Molobe1, 60
Molokotos, 33
Momand1, 70
MOMMY, 43
Montazi, 71
Monaca2, 67
Monastir, 52
Móndon5, 8
Monge2, 117
Monico1, 88
Monlezun, 30
Monroe-Wise6, 64
Montclair, 39
Montebello, 6
Monterosso, 39, 118
Montgomery, 6–7, 19, 24
Montreal, 84, 92
Moody, 117
Moody2, 89
Moore1, 90, 115
Moore2, 95, 107
Moradi1, 114
Moradmand Badiel, 116
Morales1, 123
Morales2, 70
Morales3, 39
Moran1, 29
Morasco, 30
Morasco1, 85
Moreland, 118
Moreland, Angela, 118
Morford, 116
Morford1, 31
Morgan2, 94
Morgan1,12, 53
Morgenstern, 82
Moriceau, 31
Morie1, 43
Morissette, 105
Morley2, 49
Morochnik, 41
Moroney1, 10, 35, 116

Author Index

- Morrison, 9
Morrow¹, 14
Moser², 6, 66
Moses, 106
Moses², 95
Moszczynska, 117
Mott¹, 28
Mottinelli, 28
Moura¹, 100
Muench, 12
Muga¹, 58, 71
Muga², 71
Muga³, 81
Muga⁴, 91
Muggleton, 54, 101
Mumford, Geoffrey, 141
Mun³, 35
Mundt, 59
Munich, 53, 56
Muniu¹, 62
Munoz¹, 105
Muñoz¹, 71
Muñoz³, 91
Murphy, 103
Murphy, Sean, 103, 140
Murphy¹, 103
Murray, Douglas P., 141
Murray¹, 119
Murrell⁸, 67, 93
Musonda⁴, 68
Muthulingam, 5, 83, 94, 107
Mutisya¹, 62
Mwangi¹, 62
Mwangi², 62
Myers², 87
Myint, 60
Mykhalchuk, 61
N
Nabulsi³, 114
Nadai¹, 4
Naddaf, 41
Nadipelli, 6
Naganawa, 114
Nagayoshi, 9
Nahas¹, 86, 124
Nahas², 5, 111
Nairobi, 62, 64
Nakajima, 52
Napadow, 44
Napier, 41
Naqvi³, 120
Narayanan, 65
Natchitoches, 28
Natera-Rey⁴, 57
Nayak¹, 97
Ndemwa¹, 62
Ndirangu, 87
Nedelchev, 60–61
Negus¹, 99
Nelson, 60, 116
Nelson¹, 28
Nesil, 42
Nesoff, 124
Nesoff, Elizabeth, 76
Nesoff¹, 4
Nestler³, 117
Netter, 57, 107
Neumann¹, 120
Newton, 95
Ngan³, 69
Ngjelina, 79
Ngo¹, 80
Nguyen, 14, 99
Nguyen, Jacques D., 3
Nguyen¹, 11, 62, 70
Nguyen², 11, 42, 62
Nguyen³, 11
Niaz, 60
Nicastri, 23, 53, 114
Nichols¹, 13
Nicholson, 93, 105
Nicolette, 8
Nie¹, 101
Nielsen, 24, 129
Nielsen¹, 85
Nielsen³, 34, 116
Nielsen^{1,2}, 71
Nieto¹, 81
Nieva², 8
Nighbor, 32
Nighbor¹, 33, 84
Nighttime, 110
Nikas², 119
Nikas³, 119
Nikolopoulos, 65

Author Index

- Nitzburg, 82
Nixon, 123
Nnadozie, 60
Nogales, 64
Nolan, 13
Nolan1, 94
Noonan1, 125
Nordeck1, 5, 109
Norman1, 28
Norman2, 13, 28
Nosova1, 40
Nosova2, 7, 36, 108
Nosova3, 17, 63
Nosyk1, 108
Nosyk3, 36, 49, 108
Nosyk4, 108
Nottingham, 14–15, 112
Novak3, 61
Novo1, 17
Nowotny2, 104
Nowotny3, 57
NP, 81
Nsukka, 60
Nugent, 30
Nunes1, 17
Nunes2, 109
Nunes4, 34, 107, 120
Nunes5, 107
Nunn, 22
Nurius5, 58
Nursing Akure, 56
NV, 37, 39
- O**
- Oakland, 43, 49
- Obeng1, 28
Obeng2, 100
Oberleitner, 5
Obot, 56
O'Brien3, 48
O'Brien6, 117
- Ochalek, 106
Ochalek1, 37
O'Cleirigh1, 38
O'Connell6, 69
Odenwald8,9, 53
Odukoya2, 66
Oduro1,2, 58
Ofonakara, 66
O'Grady2, 88, 116
O'Grady3, 5, 109
O'Grady4, 70
O'Hara1, 66
Ojo, 60
Ok, 114
Okafor, 11
Okafor2, 11, 70
O'Keeffe, Charles, 3, 141
O'Keeffe2, 77
Okey, 21
Okonkwo, 60
Okuda Benavides, 15
Olavide, 63
Oldfield, 90, 105
Oldmeadow, 67, 93
Oliveira, 23, 114
Oliveira Junior, 53
Oliver, 30
Oliveto, 31, 45, 87, 107
Olson2, 96
Olusegun, 56
Oluwakemi, 60
Oluwoye2, 8
O'Malley, 12
O'Malley2, 51
O'Malley3, 82
O'Meara, 83
Ometto, 53
Ometto3, 23, 114
Omoregie, 62
Ompad1, 119
Oncology, 8
O'Neil, 30, 71
O'Neil13,4, 68
- O'Neill1, 66
O'Neill2, 48
Oneonta, 6, 48
Onofrio2, 17
Ontario, 76
Onukogu1, 60
Onyedibe, 60
Opara1, 39
Org1, 40
Orofuke3, 66
Oros3, 92
O'Rourke2, 89
Orson2, 124
Oser1, 87
Oser2, 91
Oslo, 82
Ostrender, 59
Oswald1, 113
Otachi1, 38
Otiashvili, 27, 60
Ottawa, 92, 110
Otufowora, 8
Oyola1, Leon, 100
- P**
- Pacek2, 33
Pacheco3, 58
Pacheco-Colon, 88
Padley2, 18
Palamar, 73
Palamar1, 26, 110
Palamar3, 73
Palandri, 14
Palatkin, 48, 69
Palfai, 61
Palmatier, 14
Pampaka2, 65
Pan1, 91
Panlilio, 6, 48
Pantavou, 65

Author Index

- Pantelis, 88
Papandonatos, 96
Papaseit, 68, 71
Papasseit, 47
Paraskevis, 65
Pareek1, 81
Park1, 124
Park2, 51
Park9, 90
Parker, Maria, 1, 25, 49, 136
Parker1, 33, 49
Parkville, 35, 88
Parlier-Ahmad, 39, 79
Parmar, 61
Paronis, Carol, 119
Paronis1, 119
Parra-Cardona1, 87
Partilla, 20, 22
Pascale1,2, 65
Paschen-Wolff1, 91
Patel1, 28, 78
Patel2, 100
Patriarca, 21, 29
Patriquin, 34
Paul3, 70
Paul4, 119
Paulo, 23, 65, 86, 114, 118
Paulus2, 48, 101
Paulus3, 114
Pavlicova, 31, 91, 107, 120
Pavlitina, 65
Payakachat, 96
Paynter, 30
Paynter2, 105
Paz, 35, 43
Pazdrak, 23
Pearce1, 36
Pearce3, 108
Peck, 106
Peck1, 37
Peechatka, 33
Peer1, 118
Peiper3, 6
Peitit-Bois, 115
Peles1, 126
Pena1, 10, 35, 117, 123
117–18
Penrith, 93
Peralta1, 42
Perdue, 79
Pérez2, 64
Pérez-Carbonell2, 85
Perez Diaz1, 48
Perez Diaz2, 18
Pérez-Mañá4, 47
Pérez-Mañá6, 68
Pericot-Valverde1, 33
Periyasamy, 20
Perkel2, 8
Perlmutter, 22, 30
Perngparn, 27, 110
Perreault, 92
Perrine1, 4
Perth, 82
Peteet, 16
Peterkin, 11
Peterson, 17, 84
Petry, 130
Petry, Nancy, 24, 129
Pfeiffer, 66, 93
Phaneuf, 113
Philbin, Morgan, 42
Philbin1, 42
Philbin2, 42, 89, 103
Philibert, 18
Philippines, 52
Philipp Mews, 117
Phillips, 10, 29, 48, 113
Philogene-Khalid1, 9
PHNO PET, 101
Phoenix, 112
Phone, 75
Phyo1, 12
PI, 141
Piazza4, 30
Picco1, 71
Pierce1, 96
Pierre1, 51
Pike1, 117
pilot, 58, 96, 111
Pina, 14
Pinet3, 8
Pinney1, 13
Pinto3, 39
Pir, 56, 67
Pirtle, 23
Piscataway, 16, 18, 119
Piske1, 36, 108
Piske3, 108
2University of, 4, 57
3University of, 6, 17
Pittsburgh School, 4, 19, 90
Pizzagalli, 33
Plaines, 84
platform, 110
digital, 109
Platt2, 40, 100, 123
Platt3, 81
Podolsky, 125
Poe1, 10
Poklis3, 54
Polak, 39, 79
Polak, Kathryn, 79
Pollini1, 7
Pollio4, 19

Author Index

- Polsky², 49
Polyn², 109
Pomm, 39, 79
Ponder², 95
Ponder-Cepeda¹, 14
Poole³, 69
Poole⁴, 48
Pope¹, 113
Poppa¹, 118
Porrino, 102
Porrino, Linda J., 141
Porrino², 102
Porto, 39, 94
Pose², 65
Potenza, Marc, 134, 141
Potenza², 43
Powell³, 91
Poznyak⁴, 64
Pozo³, 47
Pozo⁵, 68
Prabhu, 59
Praptoraharjo, 59
Pravetoni, Marco, 46
Preston¹, 48
Preston³, 29, 113
Preston⁴, 6, 99
Price¹, 5–6
Priest, 32
Priest¹, 33
Prince, 61
Pringle¹, 111
Prisinzano, 20, 77–78, 100
Prozialeck, 65
Psederska, 61
Psederska^{1,2}, 60
Psichogiou, 65
Pujol, 58, 68, 71, 81, 91
Purcell³, 88
Purushottam, 57Putri¹, 61
Pykalo¹, 67, 94, 108
Pykalo⁴, 59, 67
Pykalo⁵, 90, 94
Quito, 61
Quizon⁴, 41
- R**
- Raag¹, 40
Rabie², 65
Rabinowitz, 79
Rafful, 66
Raghavan, 84
Rahim¹, 55
Rahman², 81
Rai¹, 61
Raich⁴, 8
Raifman, 49
Rajan², 122
Raleigh, 125
Ramachandran, 55
Ramakrishnan, 32, 117
Ramanathan, 55
Ramchandani, 113
Ramey, 26
Ramey, Tanya, 137
Ramey, Tatiana, 26
Ramirez¹, 104
Ramnarine^{1,2}, 54
Ramos-Olazagasti², 15
Ramsey, 14
Randall-Thompson, 13
Rannazzisi, 4
Rao, 12, 61
Rao¹, 23
Rapp², 6
RARIN, 41
Rasaily², 61
Rash, 24
Rash, Carla, 130
Rasmussen, 13, 50
Rasmussen, Kurt, 50, 131
Rauck³, 112
Rawlins-Pilgrim¹, 122
Rawson³, 10, 49
Ray, 101
Ray¹, 18
Raymond¹, 85
R.Bruno^{2,3}, 71
Rea-Wilson, 63, 96
Reboussin, 79
Reboussin, Beth, 76
Redner⁵, 33
Redonna Chandler, 80, 132
Reed, 41, 55
Reed¹, 22, 39
Reed², 30
Reed³, 23
Reeves¹, 100
Reeves³, 28
Regan, 104, 111
Regan¹, 42, 123
Regier¹, 118
Regier², 117
Regis¹, 6

Author Index

- Reid1, 39
Reif1, 13, 105
Reif2, 93
Reis Lourenço, 57
Rengo2, 22
Renner, John A., 141
Reno, 37, 39
Renshaw, 12
Renshaw3, 69
Renton, 90
Rentsch8, 90
Reynals, 8
Reynolds, 4, 111
R.Gainetdinov2, 55
Rhea, 122
Riaz, 58
Rice, 141
Rice2, 22, 27, 78
Rice3, 41, 78
Richard De La Garza, 141
Richards, 101, 115
Richardson, 7, 35, 99
Rich Jenkins, 133
Rico1, 33
Riedke8,9, 53
Rietschel, 53
Riggs1, 19
Riley4, 86
Rivas2, 71, 85
Rivas Puy1, 71, 91
Riveral, 7
Roberge, 99
Roberson, 112
Roberts2, 33, 116
Roberts3, 67, 93
Robertson, 99
Robina, 82
Robinson, 29, 111
Rocha3, 39
Rockhill, 85
Rodriguez, 12, 33, 91, 120
Rodríguez-Manzo, 55
Rodríguez-Marín1, 85
Roehrs, 97
Rohan2, 100
Rohsenow, 31
Rojeab-Bravo, 61
Roll, 24
Roll, John, 129
Rolls-Reutz4, 109
Romero-Rodriguez, 61
Ronquest, 6
Roos1, 35
Rosa, 53
Rosa1, 114
Rosa2, 5
Rosario, 66
Rosen1, 105
Rosen2, 9
Rosenblum, 116
Rosenheck, 19, 106
Rosenthal, 43
Roth1, 29, 39
Rotheram, 65
Rothmann, 54, 101
Rotrosen, 15, 17, 81, 107
Roux4, 40
Rovaris3, 118
Rowe, 88
Rowlett, 96
Rowlett1, 81, 123
Rowton, 14
Roy, 20, 30
Roy1, 5, 57
Ru1, 72
Ruan4, 69
Rubio1, 71
Rubio3, 91
Ruckles4, 69
Rüedi-Bettschen1, 123
Ruglass2, 105
Ruglass3, 119
Rui5, 69
Run1, 121
Rush1, 22
Rush2, 29, 95
Russell, 30
Ryan, 29
Ryan, Stacy, 135
Ryan3, 38
Ryan-Pettes, 127
- ### S
- Sabuncu1, 21
Sadiculario, 79
Sadiku, 60
Sáenz, 93
Sáenz1, 66
Saffar, 99
Sagar1, 29
Sagar2, 21, 96
Saha2, 70
Sahajanand, 59
Saichuk1, 62
Saini, 61
Saitz, 61
Saitz2, 122
Saitz4, 10
Sakka2, 62
Saladin, 80
Saladin1, 32
Saladin2, 23
Salaya, 111
Salgado1, 71
Salgado3, 91
Salisbury, 95
Saloner1, 115
Salud, 66, 71, 91
Saluik1, 61
Samet, 61

Author Index

- Samet2, 58
Samet3, 96
Sampath1, 36
Sanchez, 53
Sanchez1, 79
Santa Creu, 8
Santaella-Tenorio1, 15
Santaella-Tenorio3, 86
Santana, 91
Santé, 40
Santos1, 23
Santos2, 23
Santos4, 23
Sant Pau, 8
Sanvicente-Vieira1, 54, 101
Sanvicente-Vieira3, 118
Sanvisens, 58, 71, 81, 91
Saraiya1, 119
Saref1, 65
Sarkar2, 6
Sason2, 126
Saúde, 72
Saunders, 107
Savage, 32
Savage2, 22
Savitz3, 114
Saxon3, 93, 107
Sazonova, 61
Schafer1, 53
Schalkoff, 102
Schatz2, 81
Scheinost, 74
Scheinost, Dustin, 74, 138
Schepis1, 4
Schepis2, 79
Schepis3, 87
Schindler, 22
Schley, 122
Schlienz, 22, 29
Schmidt4, 92
Schmitz, Joy, 74, 139
Schmitz1, 35, 85, 89, 118, 121
Schmitz2, 85
Schmitz3, 35
Schneegans, 92
Schneider, 51, 65, 79, 89, 115
Schnipper, 6
Schnoll1, 13
Schnoll2, 12
Schnoll6, 112
Schoedel, 112
Scholl, 12
3Perelman, 69, 123
Schottenfeld, 47
Schrager, 29
Schreiber, 126
Schroeder, 48, 120
Schueler, 42, 104, 111, 123
Schulenberg, 79
Schulze1, 53
Schumann, 57
Schwartz, 5, 80, 88, 109, 116
Scialli, 15
Scodes1, 107
Scott, 79
Scott2, 85
Scott3, 37
Scwhandt, 113
Seal, 102
Seaman Jr1, 27
Searle5, 112
Searles5, 67, 93
Secades-Villa1, 68
Secades Villa2, 34
Secades Villa3, 85
Seedat3, 52
Segura, 30
Segura, Luis, 21
Segura1, 22
Segura3, 15
Sequeira, 67, 93
Serdarevic, 16
Serpa, 53
Serpa1, 23, 114
Serre2, 31, 40
Serre3, 32
Sessler1, 12
Severtson, 85–86
Sevigny3, 62
Seville, 34, 88, 123
Seybert3, 17
Shahidi1, 110
Shaltout, 35
Shanahan, 6
Shango1, 95
Shao1, 59
Shao4, 69
Sharma, 71
Sharma1, 117
Sharma2, 57
Sharon3, 7, 43
Sharpe Potter1, 92
Sharpe Potter2, 105
Shaw, 9, 115
Shea, 30
Shedlin2, 26
Sheffler, 14
Shehada1, 62
Sheik-Rezaei2, 6
Sheik-Rezai2, 66
Shelley2, 109
Shen1, 55, 61
Shen2, 55
Shen4, 61
Shenzhen, 121
SShepard2, 38
Shepherd, 8
Sherman, 22
Shmulewitz, 32, 84

Author Index

- Shokri Kojori², 113
Sholler, 78
Sholler, Dennis, 77
Shoptaw, 11
Shoptaw², 11, 70
Short¹, 19
Shoveller, 94
Shoveller^{2,3}, 56
Shover¹, 49
Shram¹, 18, 82
Shrestha, 65, 89, 94
Shulman¹, 107
Shurtleff, 44
Shurtleff, David, 44, 130
Sibilio³, 94
Siciliano, 20, 128
Siciliano, Cody, 20, 128
Siddhanti, 112
Sidoli², 117
Siefried, 12
Sigmon, 106
Sigmon, Stacey C., 1, 141
Sigmon¹, 37–38, 49
Sikkim, 61
Silbernag, 61
Silbernagl, 47
Silberzahn, 124
Silva, 57
Silva¹, 88
Silverman, 7, 98–99, 133
Silverstein, 5, 86, 124
Simel³, 105
Simone¹, 13
Stafford, 118
Stahler, 89
Stairs, 14
Simoni^{2,4,5}, 64
Simpson, 4
Simpson¹, 9, 90
Singer¹, 7
Singh, 12
Singh¹, 55, 65
Singh⁷, 57
Singh Balhara², 6
Sinha, 80
Sinha¹, 16, 99
Sinha³, 30
Sinkele⁸, 64
Sistema Único, 72
Skanderson, 90
Skavenski, 119
Sloan, 7
Slough, 106
Smith, 1, 11, 15, 35, 43
Smith¹, 14, 29, 83, 112
Smith², 21, 82, 85, 95–96
Smith³, 85
Smith⁵, 37
Smyrnov¹, 61
Smyrnov⁸, 65
Smyth¹, 22
Snider¹, 34
Snow, John, 71
Soares Bispo Santos Silva, 55
Soares Tardelli^{1,2}, 71
Soberanes-Chavez¹, 55
Soboka¹, 56
Soboka¹¹, 53
Sociás^{1,5}, 69
Soder¹, 35
Soder³, 35
Soe, 71
Sofia, 110
Sofis¹, 21
Sofis², 96
Sofuoglu, 126
Solem⁴, 6
Sorensen, 30, 102
Sorensen, James, 102, 140
Sorensen, James L., 141
Souza¹, 23
Spealman, Roger, 141
Spear¹, 10
Spence², 28
Spiegelstein, 112
Spilka², 23
Spindle, Tory, 20
Spindle¹, 21, 97, 120
Sprague Dawley, 123
Spriggs², 8
Springer, 91
Springfield, 49
Sproule¹, 86
Spurbeck, 55
Squeglia, 124
Srivastava, 33
Ssenyonjo, 94
Stack², 93
Stacy², 41

Author Index

- Stanger¹, 21
Stanton⁴, 33
Staton¹, 91
Staton², 38, 117
Stefanovics, 19
Stegemann, 47, 61
Stein¹, 43
Stein³, 31
Steinberg, 113
Sterling, 4, 49
Sterling McPherson, 1
sterol carrier protein-2, 120
Sterzer, 61
Sterzer¹, 47
Stevens³, 28
Stevens-Watkins, 115, 117, 124
Stewart, 44
Stewart¹, 114
Stewart², 13, 27, 65
Stoner³, 37
Stoops, William, 17, 21, 141
Stoops, William W., 1
Stoops¹, 22, 49
Stoops², 29, 95
Stoove, 124
Stoove^{1,2}, 58
Stotts, 74, 93, 139
Stotts¹, 35, 85
Stotts², 85
Strain, 83, 102, 122
Strain, Eric, 3
Strain, Eric C., 141
Strain¹, 50
Strain², 97
Strain⁶, 102
Strasbourg, 40
Strasser, 62
Strathdee, 39
Strathearn, 24, 129
Strauss⁴, 41
Strickland, 22, 49, 95
Stroud³, 96
Struble, 37, 123
Struble¹, 83
Stull¹, 6, 99
Stull², 48
Stutz¹, 78
Subeliani, 27, 60
Subira⁷, 8
Suchting, 35, 121
Suelves⁹, 8
Sufka³, 78
Suh², 117
Sukhanov, 55
Sulaj², 57
Suleman, 53
Sulima², 27
Sulima³, 41, 78
Sullivan, 106, 114, 125
Sung, 12
Suraya², 65
Surineni, 23
Surratt¹, 38
Susser^{15,16}, 53
sustainability, 128, 140
Sutherland, 92
Suzuki¹, 6
Svikis, 39, 79
Swahn², 62
Sweden, 14, 17, 53, 113, 120
Sweeney¹, 12
Swinton-Jenkins¹, 19
Swogger⁴, 65
Syarif³, 67
Sypsa⁵, 65
Szpytman, 95
Szucs-Reed², 117
Szu-Hsien Lee¹, 67
Szu-Hsien Lee², 56
Szu-Hsien Lee⁷, 54
T
Taffe, 14, 20, 99, 128
Taffe, Michael, 3
Taghian¹, 37
Tagliaferri, 112
Taipei, 4, 27, 39, 101
Tait, 87
Taiwan Y-C, 59
Tajiks, 63
Takemoto, 9
Talbert, 17, 97
Talbert¹, 11
Talib², 23
Talu¹, 40
Tamanal, 65
Tamasdan, 57
Tan¹, 90
Tang¹, 61
Tang², 114
Tang^{1,2,3,4,5}, 55
Tapert³, 82
Tardelli, 86
Tarter², 4
Tarter³, 17
Tartu, 40
Tate³, 90

Author Index

- Tavitian-Exley^{2,3}, 62
Taylor¹, 100, 110, 113
Taylor³, 28, 117
Tbilisi, 27
Teal, 78
Tendler, 46
Terenius, 120
Terplan, 15
Terplan¹, 113
Terplan², 96
Teskaye, 53
Teskaye¹, 56
Tessema⁵, 53
Tetrault, 31, 105
Thacker², 86
Thada¹, 113
Thakor¹, 91
Thakur, 23
Thapa³, 70
Theobald, 22
Thomas², 105
Thomas³, 118
Thompson, 29, 42, 79
Thomsen³, 99
Thorberg, 82
Thorndike, 22
Thorpe¹, 15
Thostenson, 107
Thrasher, 115, 117, 124
Thrul, Johannes, 42
Thrul¹, 42
Ti¹, 36
Tiberg⁵, 17
Tidey, 31
Tidey, Jennifer, 16, 141
Tidey, Jennifer W., 1
Tillotson, 12
Tilson, 99
Tips, 102, 140
Tirado-Muñoz¹, 66
Toal Huynh, 141
Tobias, 26
Tobias¹, 36
Tobin¹, 110
Todman³, 35
Toennes, 53
Tofighi¹, 71, 81, 111
Tofighi⁵, 66
Tomasi², 113
Tomeo, Michele, 141
Tomko¹, 32, 124
Tomko², 23
Tomlinson, 65
Tonigan³, 104
Tonkin¹, 12
Tookes, 63, 96
Tor¹, 58
Tor², 81
Tormohlen, 110
Torre⁷, 47
Torre^{3,5,8}, 68
Torrens⁸, 47
Torrens^{1,2,3}, 68
Torres¹, 8
Torres², 78
Toussaint, 14, 118
Townsend, 99
Towson, 92
Toyonaga, 114
Trew², 92
Tross³, 91
Tross⁵, 40
Tsang³, 34
Tsibulsky, 28
Tsui¹, 96
Tuck², 23
Tunrayo², 62
Tupper, 26
Tupper¹, 36
Turnbull, 88, 92, 112
Turncliff, 112
Turner², 34
Tuscaloosa, 110
Tuscano¹, 121
Tygerberg, 87
Tyler, 99
Tyssen², 82
- ### U
- Ukhanova, 12
Ul Ain², 67
Ulangkaya, 14
Umbricht, 22
Urquhart, 112
Uuskula¹, 40
Uyo, 56, 60
- ### V
- Vaddiparti, 11, 87
Vadhan¹, 82
Vaidya², 57
Valdez, 79
Valdez¹, 57, 104
Valenstein, 83
Valente¹, 39, 94
Valiengo, 23
Valle², 57
Valle³, 88
Vallender, 118
Valverde, 47
Valverde^{8,9}, 68
Van Dam¹, 88
Vander Hofstadt Román¹, 85
Vandersloot, 111
Vanderziel, 12
Vandrey, 30
Vandrey, Ryan, 76
Vandrey¹, 21, 29, 97, 120
VanMeter, 11
van Wyk¹, 119
Varley⁴, 19
Varma, 11
Varshney, 6
Vasilev¹, 60–61
Vasilev⁴, 110

Author Index

- Vassileva, 60–61, 63, 110, 123
Velez1, 22
Velicelebi, 14
Veliz, 42
Veliz1, 42, 79, 88
Veliz2, 80, 88
Venner, 75
Venner1, 104
Venner2, 104
Venniuro, 97, 132
Ventevogel, 104
Ventura2, 94
Vera1, 39
Verbitskaya, 48, 69, 96
Verdugo1, 37
Vergara-Lopez1, 96
Versace2, 35
Vest, 18, 119
Vestal, 42
Vetrova1, 69
Vetrova3, 48
Vetrova4, 96
Vicens7, 8
Vicknasingam, 55
Victor, 37
Victor3, 114
Victoria, 85, 88
Victor Martínez-Loredo, 123
Vidot, 25, 30
Vidot, Denise, 25, 136
Vidrine, 74, 139
Vieira, 73
Vieira2, 73
Vienna, 6, 47, 61, 66, 93
Vilalta1, 8
Vilaplana, 8
Villalba, 63
Villanti, 49
Villanueva, 105
Villatoro, 58
Villeneuve, 84
Vince2, 18, 82
Vincent, 29
Vincent1, 35, 121
Vincent2, 12
Vincent3, 35
Viner5, 92
Violante-Soria, 55
violent injury, 4
Virginia, 42, 125, 134
Vitale2, 82
Vittinghoff, 23
Vittitow, 81
Vocci, Frank, 141
Voepel-Lewis, 87
Voepel-Lewis1, 79
Vogt1, 120
Volkow, Nora D., 3
Vora, 10
Voss, 12
Votaw, Victoria, 45
Votaw1, 124
Vowles1, 124
Vrana, 9
Vselvolozhskaya, 95
Vujanovic, 10, 35, 83
Vunnava, 125
- W**
- Waddell1, 93, 125
Wager2, 42
Wagner2, 39, 70
Wagner4, 37
Wai, 46
Wai1, 21
Wakim3, 5
Waldron3, 84
Walker1, 23
Walker3,4, 57
Wall2, 15
Wallace, 114, 120
Wallace, Alexander, 119
Walley1, 5, 36, 38, 115
Walley3, 7, 122
Wallin, 99
Walsh, 45
Walsh3, 107
Walsh4, 17
Walss-Bass1, 118
Walters1, 43, 124
Walters2, 38, 90
Waltham, 13, 38, 93, 105–6
Walton2, 89, 110
Walton3, 83
Waluyo2, 67
Wan1, 62
Wand2, 113
Wang, 31, 33, 116
Wang1, 59
Wang2, 18, 48
Wang3, 41, 108, 110
Wang4, 64
Wang2,3, 59
Wanjihia, 62
Ward2, 116
Wardle2, 35
Wardle3, 121
Warner1, 109
Warren, 115
Wasserman, 73
Waters2, 126
Watson, 106
Watson1, 98
Watson3, 94
Watts, 51
W.Cui2, 55

Author Index

- Weafer, 82
Weafer2, 48
Weaver1, 12, 35, 121
Weaver3, 35
Webster1, 87
Webster2, 91
Wechsberg, 87
Weerts, 81
Weerts, Elise, 1
Wei1, 64
Wei6, 69
Weidberg, 64, 123
Weinberger, 8
Weiner1, 115
Weir3, 51
Weiss, 36, 51
Weiss, Susan, 50, 131
Weiss1, 37
Weiss2, 124
Weiss4, 6
Weisshaar, 6, 66
Weitzman, 89
Wellington, 77
Welsh, 73
Welsh2, 5, 109
Wemm1, 30
Wendt Viola2, 118
Weng2, 27
Wenger1, 94
Wenger2, 9
Wenger3, 38, 43, 90
Wenten, 125
Wenthur1, 123
Werb5, 94
Werb1,4, 66
Werner2, 49
Wesley1, 29, 95
Westbrook, 28
Westgate, 29
West Grove, 117
Westland, 83
Wetherill, 23, 44, 118
Wetzell, 13, 28
Wetzel2, 28
Whalen1, 78
Wheeler, 115, 117, 124
White1, 43, 89
White2, 7, 38, 67, 93
Whites, 140
Whitfield-Gabrielli, 44
Whitfield-Gabrielli, Susan, 44, 130
Whitney1, 107
Wiacek, 99
Wickens1, 98
Widmann8,9, 53
Wien, 6, 47
Wiley, 73
Wilkerson, 100
Williams, 65, 71, 78, 90, 93
Williams4,5, 67
Williamson, 77
Willson2, 95
Wilson, 115
Wilson4, 28
Wimardhani, 61
Wimmer1, 14, 118
Winder, 78
Windisch, 41
Winfield, 18
Winhusen, 22
Winstanley, 9, 73–74, 86
Winstanley, Erin, 73, 76, 137–38
Winstanley, Erin L., 76
Winstock, 5, 59
Winter2, 122
Winters, 100
Wit, 82
Wit2, 27
Withey1, 21
Witiewitz, Katie, 121
Witkiewitz, 35, 121, 124
Wiwanitkit, 72
Wogenstahl, 86
Wold, 23
Wolf, 54
Wolf, Chris, 137
Wolff1, 125
Wolter, 100
Wolzt2, 6, 66
Wong1, 22
Wong3, 29–30, 113
Wood1, 36
Wood2, 40
Wood3, 7, 63, 94, 106, 108
Wood4, 36, 105, 108, 111
Wood5, 17
Wood1,5, 69
Woodcock, 80
Woodcock, Eric, 80, 131
Woods, 26, 126
Woods, James, 126, 135
Woodstock Striley, 11, 16, 87
Woody3, 69
Woody4, 48
Woollahra, 82
Worcester, 99
Worcman, 72
Worhunsky, 114
Wright, 12, 87
Wu1, 62, 92, 123
Wu2, 82
Wu1,2,3,4,5, 55
Wuerzburg, 53
X
Xiao3, 121
Xiao4, 72
Xie6, 55
Xing2, 117
Xu1, 59
Xu3, 34
Xuan2, 7

Author Index

Xu-bin Zhu1, 64
Xue1, 53
X. Wang1,2,3,4,5, 55

Y

Yadav1, 57
Yammine, 74, 139
Yang, 32
Yang1, 23, 72, 121
Yang2, 64
Yang3, 39, 64
Yaroslavtseva, 48, 69
Yawson1, 68
Ye1, 34
Yeh2, 87
Yekkiralala, 112
Yip, 74
Yip, Sarah, 44, 74, 130, 138
Yip1, 33
Yonkers, 98, 133
Yonkers, Kimberly, 133
Yonkers3, 83
Yoon1, 35, 69, 121
Yoon2, 85
Yoon3, 35, 58
Young1, 11, 17
Young2, 117
Young3, 82
Yuan1,2, 53
Yule, 10
Yung5, 88
Yurgelun-Todd, 12
Yurgelun-Todd3, 69
Yuxi, 64

Z

Zainal3, 55
Zakiniaeiz, 15
Zakiniaeiz, Yasmin, 80, 131
Zamarripa, 78
Zanetti, 53
Zanetti1, 23, 114

Zang1, 49
Zapolski, 30, 51, 88, 104
Zarkin, 81
Zaviriukha, 63, 109
Zavod2, 106
Zavodnick, 49
Zegel, 10
Zegel1, 83
Zelenev2, 90
Zevin2, 91
Zeziulin, 62
Zhan, 17
Zhang, 4, 118
Zhang1, 11, 55, 64
Zhang2, 55
Zhang3, 37, 57
Zhang4, 117
Zhao2, 64, 106
Zhao3, 64
Zhenhao Shi, 48
Zhong3, 64
Zhou, 23, 118
Zhou1, 36, 49, 55, 108
Zhou2, 31, 123
Zhou3, 108
Zhou1,2, 55
Zhu, 4
Zhu1, 21, 41, 55
Zhu2, 8
Ziegler1, 12
Zikmund-Fisher, 87
Zimmerman, 110
Zinani1, 28
Ziva Cooper, 1, 45, 141
Zmarowski, 55
Zollman, 83
Zoubi1, 101
Zule, 7, 122
Zule, William, 122
Zullig1, 121
Zuluaga1, 58, 71
Zuluaga2, 81
Zuniga1, 113
Zuo1, 21

Zur3, 112
Zvartau1, 55, 69
Zvolensky, 8
Zvorsky2, 84
Zweben3, 51

SYMPOSIA

Sunday, June 16

I.

Outcomes of Mindfulness-Based Interventions in the Treatment of Maternal Substance Use

Chairs: Diane Abatemarco and Karol Kaltenbach

Maternal substance use and treatment is a complex public health concern. Women with substance use disorders report high levels of depression, anxiety, parenting stress, and adverse childhood exposures/trauma. Trauma as a leading cause for addiction behavior has not been systematically addressed. The use of mindfulness practices to ameliorate the effects of early life trauma and prevent intergenerational trauma among new mothers and their children has shown promise. Mindfulness practice supports mothers to be present with their children when interacting, while simultaneously highlighting non-judgment, self-compassion, self-regulation, and emotional awareness. This symposium will present data from two studies with women in treatment for opioid use disorder who participated in mindfulness-based interventions; one intervention during pregnancy and the other postnatally. The symposium will provide a comprehensive overview of the trauma-informed intervention programs and how each was designed to reduce stress, improve pregnancy outcomes and parenting responsiveness. A comprehensive presentation of the results will include both quantitative and qualitative findings. The quantitative data demonstrate improvement in general stress, parenting stress, mindfulness, parenting, and anxiety. The qualitative results focus on systematic program evaluation using focus groups and Re-AIM methods. Presentations will also include a comprehensive discussion of what the current research findings suggest for future mindfulness research in this population and the role of parenting to comprehensive treatment and relapse-prevention. Implications, plans for sustainability, and lessons learned, including barriers and assets for including mindfulness in treatment programs for pregnant and parenting women with substance use disorders, will also be discussed.

II.

Developing and Utilizing Preclinical Models for Investigating Circuit-Based Mechanisms Controlling Behavioral Dysregulation in Addiction

Chairs: Cody Siciliano and Erin Calipari

Drug abuse results in over 600,000 deaths and costs over 500 billion dollars in the United States annually. Despite efforts to elucidate the precise mechanisms by which drug-induced cellular dysregulation can lead to addiction, there has been limited success in translating findings from preclinical models into efficacious treatments for human substance abusers. Recent technological advances allow for unprecedented insight into neural circuitry controlling behavior; however, the impact of these technologies on our understanding of human addiction is inherently limited by the validity of the animal models that they are used to investigate them. Being able to dissociate discrete aspects of behavior and understand how each is dysregulated to drive addiction is critical to our understanding of the disorder. All participating investigators are at the forefront of developing and investigating innovative rodent models of addictive behaviors, and examining synaptic and circuit dysregulation with cutting-edge techniques. First, Dr. Calipari will present her work developing rodent models to examine the effects of cues on motivated behaviors. Using these models, she has identified the critical role that cues play in enhancing female self-administration and defined the associated neurocircuitry involved in this process. Dr. Taffe will discuss the development of compulsive behaviors and their manifestation following oxycodone self-administration. Finally, Dr. Siciliano will present a novel model of compulsion vulnerability, and discuss how the activity of single neurons in the prefrontal cortex during animals' first drug experience can predict the development of compulsive behaviors. Together, this session will highlight the importance of developing translational addiction models and will showcase the most recent advances in applying novel technologies to advance our understanding of the mechanisms controlling these behaviors.

III.

Peripheral Mechanisms of Opioid Tolerances

Chairs: William Dewey and Hamid Akbarali

Tolerance develops to the many different effects of opioids in the same individual to various degrees and at very different rates. The fact that tolerance develops to the euphoric effects of opioids faster than to the respiratory depressant effects may well be the cause of many lethalties to these widely abused and important therapeutic agents. For years, the studies related to the mechanisms involved in the tolerances that develops to these drugs have concentrated on effects in the brain and at the cellular and receptor levels. It is now clear from the work of the speakers of the symposium that the chronic effects of opioids on the microbiota, the resultant increase in epithelial membrane permeability in the gastrointestinal tract and marked systemic inflammation contribute to the mechanism of antinociceptive tolerance. Inflammation caused by other mechanisms including HIV infections and others also affect tolerance to morphine and other opioids. The speakers in this symposium will present evidence that peripheral changes induced by chronic morphine as well as by other external elements alter the activity of opioids at both peripheral and central neuronal sites. These studies, for the first time suggest the hypothesis that an “endocrine-like phenomenon” from the periphery, especially the gastrointestinal tract, might well be involved in the tolerance that develops to these drugs in the brain. Speculation as to the possible involvement of these peripheral sites in the development of physical dependence to opioids will also be discussed

IV.

Developmental Factors Contributing to Opioid Use Disorder Vulnerability

Chairs: Yasmin Hurd and Junstine Larson

Evidence suggests that both genes and early environmental factors contribute to the future propensity to develop opioid use disorders (OUD). These factors may include early life (embryonic, fetal or after birth) exposure to opioids and other drugs, genomic predisposition for substance dependence, childhood trauma and maltreatment, and psychosocial adversities. Exactly how these environmental insults interact with the genome to alter the developmental trajectory of brain and behavior, and promote the propensity to develop OUD will be discussed at this symposium. Dr. Strathearn will present his studies on long term effects of child maltreatment on risk of substance abuse and dependence. Dr. Andersen will present data on how early life trauma and opiates interact to produce susceptibility to opioid dependence. Dr. Hurd will talk about her research on the effect of embryonic exposure to cannabinoids that heightens adult opioid sensitization and craving. Finally, Dr. Nielsen will discuss how genomic variations and epigenetic regulation that impact brain development and exacerbate vulnerability for OUD.

V.

*Application of Behavior Analysis to the Treatment of Addiction:
Reflections on a Short Career*

Chairs: Kathleen Carroll and Maxine Stitzer

Nancy Petry was a creative and highly productive investigator who made many important contributions during a career cut short by her recent untimely death. This symposium is in her honor to acknowledge and celebrate those many contributions. The title reflects the behavior analysis perspective that underpinned her work while the presentations highlight the major aspects of her contribution. In the first presentation, Warren Bickel will describe how Nancy began her career with work on behavioral economics and delay discounting, how that perspective informed her subsequent treatment development work and where the field has taken the early discounting work. John Roll will discuss Nancy's creative contribution to the development and advance of contingency management as a treatment for substance use disorders and the large body of research she generated with her colleagues that has helped to cement this approach as an evidence-based treatment intervention. Carla Rash will follow with a discussion of Nancy's substantial body of contingency management dissemination work, a valuable asset to clinicians. This work includes development of counselor training methods, research on efficacy of training interventions and dissemination of CM throughout the network of Veteran's Administration substance use disorder programs. The fourth presentation by David Ledgerwood highlights another independent line of research on gambling disorders in which Nancy stimulated advances through her assessment and intervention research. The symposium will conclude with remarks by the session chairs. Overall, the symposium will provide a valuable review of Petry's creative and productive career contributions while acknowledging her substantial impact.

Monday, June 17

VI.

Exploring Non-Opioid Approaches for the Treatment of Pain

Chairs: David Shurtleff and Emmeline Edwards

Over 25 million Americans suffer from chronic pain, a highly debilitating medical condition that is complex and difficult to manage. In recent decades, there has been an overreliance on prescription opioids for chronic pain, contributing to an epidemic of opioid overdose deaths, misuse, addiction, and other harms, such as fractures and myocardial infarction. Evidence further indicates there is an associated dose-dependent risk for these harms. At the same time, there is insufficient evidence to determine the effectiveness of long-term opioid therapy for improving chronic pain and function. Given the risk-benefit profile of opioids for the management of pain, there is an increased interest in, and need for exploring, developing and utilizing non-opioid (including non-pharmacologic) approaches to manage pain. This symposium will explore some of these emerging interventions, and their underlying mechanisms as alternatives for the treatment of pain. Symposium topics will focus on the neuromodulatory effects of acupuncture and its role in pain management; the neuroimmune system's role in modulating pain and analgesia, offering a novel target for medication development; the antinociceptive effects of green light therapy on chronic pain, highlighting possible mechanisms, and preliminary results from fibromyalgia and migraine clinical trials; and brain circuitry and neurochemistry associated with mindfulness-based meditation for the management of pain. Discussion will summarize key findings, and future directions including the NIH HEAL (Helping End Addiction Long-term) initiative goals in the discovery and pre-clinical development of pain treatments and advancing pain treatments through the clinical research pipeline.

VII.

Predictive Modeling in Addiction: Recent Findings and Implications for Precision Medicine

Chairs: Sarah Yip and Susan Whitfield-Gabrielli

Recent advances in predictive modeling and machine-learning methods enable data-driven prediction of complex behaviors, including substance use. By focusing on individual differences and generalization to novel subjects (i.e., cross-validation) these approaches overcome limitations of traditional approaches, increasing the likelihood of replication and potential translation to clinical settings. However, these methods are still relatively new to clinical research and have yet to be fully leveraged within the context of addictions. This symposium brings together junior and senior addiction researchers to demonstrate the potential of machine-learning methods to inform clinical and neurobiological understanding of substance-use disorders and their treatment. Research will be presented to demonstrate the ability of these approaches to (i) accurately classify substance-using versus non-substance-using individuals using resting state fMRI data; (ii) predict substance-use initiation in developmental cohorts; (iii) identify brain networks predictive of opioid and cocaine abstinence during treatment; and (iv) predict future relapse to methamphetamine. Presentations will cover findings from a range of machine-learning approaches, including support vector regression, elastic net, and connectome-based predictive modeling approaches. The discussant, a world-recognized expert in machine learning, will synthesize research findings and discuss implications for precision medicine. While the goal of this symposium is to showcase clinically relevant addiction findings derived from machine-learning methods, our paired Workshop ('Introduction to Machine Learning and Applications to Addiction Research') will provide a practical introduction to machine-learning methods to encourage future adoption of these methods in addiction research.

VIII.

What Predicts Early Alcohol Sipping, Caffeine Use, and Screen Media Activity in Youth? Two-year Findings from the Adolescent Brain Cognitive Development (ABCD) Study

Chairs: Susan Weiss and Krista Lisdahl

The Adolescent Brain Cognitive Development (ABCD) Study is a landmark multi-site 10-year longitudinal study that has now successfully enrolled over 11,800 youth. One aim of the ABCD Study is to examine the risk and protective factors influencing onset and trajectories of substance use (SU) outcomes. The symposium will begin by presenting updated SU patterns observed in the ABCD youth at baseline and year-1 follow up (estimated n=11,800). For example, current baseline data (n=11,199) demonstrated approximately 23% of youth aged 9-10 reported sipping alcohol in their lifetime. By year 1, 12.6% of the 4508 participants to date reported a new onset of sipping alcohol. The speakers will then present a series of studies examining risk and resilience factors associated with early alcohol sipping, caffeine and screen media usage behaviors. Thus far, findings suggest that personality (e.g., impulsivity, sensation seeking, planning, perseverance, prosocial behavior), cognitive (problem solving), culture and environment (school involvement, parental religiosity, familism, family conflict), and demographics (gender, ethnicity) were linked with alcohol sipping. Youth with more general screen media usage demonstrated higher family conflict and more sleep disturbance. The symposium will include late-breaking findings (full cohort) and will discuss future directions and implications. On-going longitudinal assessment of these domains over a period of ten years in a diverse, nationwide sample of youth presents an exceptional opportunity to examine the factors influencing the onset and sequela of substance use and its consequences in youth that live in the United States.

IX.

Enlarging the Toolbox: Using Preclinical Data to Identify New Targets for Medication-assisted Treatment of Opioid Use Disorder

Chairs: Jane Acri and Kurt Rasmussen

The CDC has reported that more than 42,000 Americans died of opioid overdose in 2016 and that over 2 million Americans live with opioid use disorder (OUD). In response to this public health crisis, the NIH has launched the HEAL (Helping to End Addiction Long-term) Initiative. Part of this initiative includes the development of new treatments for OUD to augment existing agonist/antagonist therapies. In this symposium, we will review preclinical data on several molecular targets that suggest their potential for the development of ligands as treatments for OUD. Dr. Kurt Rasmussen will then discuss how NIDA will help advance medication development efforts through interactions with the private sector, contract work, and new funding opportunities.

Tuesday, June 18

X.

To Smoke or Not to Smoke: That is the Cue-estion

Chairs: Yasmin Zakiniaez and Eric Woodcock

Cue-reactivity, physiological and/or subjective responses to drug-related stimuli, plays a critical role in maintaining drug use and precipitating relapse. Neuroimaging research has highlighted important neural structures and circuits that mediate physiological and subjective responses to cigarette-related cues, which have been linked to continued drug use. This symposium will showcase human neuroimaging and laboratory work to explore the specific brain regions involved in cue reactivity as well as the influence of (1) acute stress, (2) biological sex/hormones, and (3) novel interventions, on cue-reactivity and smoking behavior in cigarette smokers. Insight into factors that influence cue-reactivity are likely to provide new targets for smoking cessation. Novel interventions such as using nicotine-free electronic cigarettes as adjuvant therapy, timing quit dates to coincide with hormonal variation, and reconsolidation-based strategies will be discussed. The speakers, leaders in the field of cigarette smoking cue-reactivity, will present neuroimaging and behavioral findings that highlight the importance of cue-reactivity from drug craving to drug seeking to treatment outcomes. The discussant, an expert in neuroimaging stress and cue-reactivity of addictive disorders, will synthesize study findings and identify knowledge gaps to facilitate audience discussion on the challenges and opportunities of cue-reactivity in smokers.

XI.

Studies of Medications for Addiction Treatment in Correctional Settings Cooperative (SOMATICS): Addressing the Opioid Crisis in Vulnerable Populations

Chairs: David Farabee and Redonna Chandler

With more than one in ten inmates in the US reporting regular opioid use, correctional settings offer an excellent opportunity for early identification and treatment of individuals with opioid use disorder (OUD). The importance of initiating treatment in jail is underscored by the fact that the risk of death during the first two weeks following release from prison is nearly 13 times greater than among individuals of similar demographic background, with drug overdose being the leading cause (Binswanger et al., 2007). But the use of medications to treat OUD remains inadequate in US correctional settings, placing persons with OUD at high risk for relapse to drug use, overdose, and mortality immediately following release from incarceration. The Studies on Medications for Addiction Treatment in Correctional Settings (SOMATICS) Collaborative, funded by the National Institute on Drug Abuse (NIDA), was designed to shed light on this critical public health problem. SOMATICS includes three research centers, each conducting an individual randomized trial while sharing the control condition study arm (Enhanced Treatment as Usual [ETAU]) as well as core assessments across all sites. Specifically, the trials compare (1) the initiation of medication (extended-release naltrexone (XR-NTX)—in New York City and in Albuquerque, NM and methadone in Baltimore, MD with vs. without patient navigation compared to ETAU for adult inmates with OUD who are transitioning to the community. This presentation will provide preliminary opioid use outcomes and cost data.

XII.

Etiology and Treatment of Co-Occurring Substance Use Disorders and Attention-Deficit Hyperactivity Disorder: From Preclinical Studies to Big Data Analytics

Chairs: Emily Hankosky and Linda Dwoskin

Neuropsychiatric disorders are highly prevalent among individuals with substance use disorders (SUDs). Attention deficit hyperactivity disorder (ADHD) is one of the most prevalent neuropsychiatric disorders, and it is estimated that more than 20% of individuals with SUD have co-occurring ADHD. Emerging data analytics tools and resources provide opportunities for generating new insights into the mechanisms of SUD pathology and these discoveries are most robust in the context of multidisciplinary investigations. This symposium will seek to integrate evidence from multiple scientific domains to understand the most recent findings regarding the etiology and treatment of co-occurring SUD and ADHD. The goals of this symposium are to present evidence spanning the translational science spectrum from preclinical studies to big data analytics on the role of ADHD in the etiology and treatment of SUDs. Specifically, the symposium will cover the following topics: 1) preclinical studies on the impact of ADHD medication exposure on the developing brain and drug-seeking behavior, 2) big data analytics investigating adolescent-onset ADHD medication utilization and SUD risk, and 3) clinical trial evidence on the efficacy of ADHD medications to treat co-occurring ADHD and SUD. The symposium will culminate in a discussion of how future collaborations can most effectively leverage emerging data technologies with existing tools to advance our understanding of risk factors and treatments for SUDs.

XIII.

Self-sustaining Strategies Offering Nondrug Choices Reduce Long-term Drug Craving and Relapse: Sex Differences

Chairs: Marilyn Carroll and Wendy Lynch

Addiction to stimulant drugs such as nicotine, methamphetamine and cocaine costs millions of dollars to treat and still leads to millions of lives lost every year. This session explores the problem that after drug use stops through self-imposed abstinence or treatment, craving begins, incubates over weeks-months, and leads to relapse. This session will examine ways to treat “incubation of craving” and implement behavior change that can be self-maintained long after treatment ends. In animal studies this has been done by arranging for voluntary access to competing nondrug rewards that the user chooses in place of using drugs. In the four presentations, 1) Venniro et al. show that rats will choose social interaction with another rat rather over methamphetamine or heroin, and this corresponds with activation of central amygdala AKCo expressing inhibitory neurons; 2) Carroll et al. discusses incubation of cocaine and nicotine craving in rats, and multi-triggered relapse that were blocked by voluntary aerobic exercise during a 4-week period when incubation of craving occurred. Sex differences in incubation of craving will be reported. 3) Lynch et al. will discuss aerobic exercise as an intervention cocaine relapse, as well as the importance of considering sex differences and molecular mechanisms in addiction and its treatment. 4) Silverman and Holtyn will discuss their human work with the therapeutic workplace as a model anti-poverty program to reduce addiction. A common theme is voluntary, self-maintained treatments over long durations to block incubation of craving and relapse.

XIV.

***The Use of Technology to Improve Detection and Treatment
of Perinatal Substance Use Disorders***

Chairs: Constance Guille and Kimberly Yonkers

The prevalence of perinatal substance use is increasing and associated with significant maternal, fetal, and newborn morbidity and mortality. The 2017 National Survey on Drug Use and Health [NSDUH] demonstrates an increase in past month illicit substance, tobacco and alcohol use among pregnant women compared to NSDUH data collected in 2015 and 2016. According to the 2017 NSDUH survey, in the preceding month 14.7% of pregnant women used tobacco, 11.5% used alcohol and 8.5% used an illicit drug. Early identification and treatment of pregnant women with substance use disorders is vital to improving the health and well-being of mothers, their infants and children. Barriers to care, however prevent pregnant women from accessing treatment. Innovative solutions are needed to improve detection of perinatal substance use and facilitate access to evidence-based treatment. Dr. Kimberly Yonkers will present results from a NIH trial that screened women for substance use and provided a motivational interview to help participants reduce substance misuse (Screening, Brief Intervention and Referral to Treatment; SBIRT). The behavioral intervention was delivered either by a clinician or via a computerized avatar and was compared to usual care. Findings on the impact of the SBIRT intervention on substance misuse, compared to usual care, will be presented. Dr. Constance Guille will present results from a NIDA and Duke Endowment-sponsored trial delivering perinatal opioid use disorder treatment in-person, compared to telemedicine. Using propensity score matching between group (in-person vs. telemedicine) outcomes related to substance use, and obstetrics and newborn health will be presented. Dr. Ariadna Forray will present results from a trial that used hand-held computers to undo the attentional bias that perinatal women who smoked have toward smoking and tobacco-related products.

XV.

The Implementation Chasm for Harm Reduction Services in Rural Areas

Chairs: Hannah Cooper and Rich Jenkins

Epicenters of opioid misuse and related harms have expanded from urban centers to rural areas. This expansion is creating wide “implementation chasms” for harm reduction services in rural areas; IOM defines “implementation chasms” as gaps between advances in scientific knowledge and their programmatic applications. Syringe service programs, for example, are vital harm reduction services, and yet 98% of young adults living in rural areas who tested positive for HCV in 2015/2016 had to travel >10 miles to reach such programs, compared with 46% of their urban counterparts. The symposium will present qualitative findings from four rural sites funded through the Rural Opioid Initiative, an initiative supported by NIDA, SAMHSA, the CDC, and the Appalachian Regional Commission. Presentations will illustrate the nature of this implementation chasm; identify novel strategies used in rural areas to close it; and describe opportunities to improve rural harm reduction systems.

Wednesday, June 19

XVI.

***Novel and Meaningful Clinical Trial Endpoints
in Substance Use Disorder Treatment***

Chair: Brian Kiluk

Achievement of sustained abstinence from drugs is currently the only valid endpoint accepted by the US Food and Drug Administration (FDA) for evaluating pharmacotherapies for most substance use disorders (alcohol use disorder being the exception). However, sustained abstinence is increasingly regarded as an overly stringent and restrictive outcome that may be a factor contributing to the shortage of approved pharmacotherapies. As part of the federal efforts to combat the opioid crisis, the FDA has recently expressed commitment to the development and use of new non-abstinence-based endpoints as part of product development. Yet despite long-standing interest and rising urgency, the identification of an alternative to sustained abstinence as a clinically meaningful endpoint for clinical trials has been elusive. This symposium will highlight the latest efforts and potential future directions toward the identification of meaningful non-abstinence-based endpoints for various substances of abuse by leveraging data from completed clinical trials. This will include a presentation on novel, reduction-based endpoints for alcohol clinical trials, where is there precedent for regulators accepting outcomes other than abstinence ('no heavy drinking days') that may serve as a useful model for the development of alternative outcomes for other substances. Additional presentations in this symposium will review potential alternative endpoints in clinical trials for cocaine, cannabis, and opioids. The discussant will provide insight into the evolution of clinical trial endpoints and a vision for future directions.

XVII.

***Mechanisms for Sex and Gender Differences in Addiction:
Implications for Prevention and Treatment***

Chairs: Mark Smith and Mariangela Martini

Sex and gender differences have been described for multiple aspects of addiction/substance use disorder including rates of use, vulnerability to use, progression to addiction, relapse, and treatment. In this session, we will explore recent evidence from human and laboratory animals for mechanisms underlying sex and gender differences in addiction focusing on biologically and psychologically based mechanisms. Mariangela Martini (North Carolina State University) will discuss evidence in mice for a role of sex chromosome complement in vulnerability to cocaine use as a mechanism underlying the enhanced vulnerability observed in females. Anousheh Bakhti-Suroosh (University of Virginia) will discuss evidence in rats for the enhancing effects of estradiol on the development of motivational aspects of an addicted phenotype as a mechanism underlying the enhanced progression to addiction observed in females. Mark Smith (Davidson College) will present data in rats showing that estradiol, which is known to enhance vulnerability to stimulants in females, has a different, and sometimes opposite effect, on sensitivity to opioids. Kathleen Brady (Medical University of South Carolina) will present data in humans on sex and gender differences in psychiatric comorbidities and will discuss how differences in the temporal relationship between the first presentation of addiction and the first psychiatric symptoms impact the trajectory of addiction. She will also present data on sex differences in response to stress and discuss implications for prevention and treatment. Finally, Marc Potenza (Yale University) will synthesize the findings from these various research perspectives with a view toward implications for sex/gender-specific prevention and treatment strategies.

XVIII.

Leveraging Technology to Deploy Innovative Substance Abuse Treatments

Chairs: Allison Kurti and Stephen Higgins

Substance abuse disorders represent a source of premature morbidity and mortality for which evidence-based treatments exist. Unfortunately, access and utilization of these treatments are not equivalent across the general population, with certain subpopulations experiencing disproportionate geographic and socioeconomic barriers to receiving treatment. This mini-symposium will expose attendees to three novel innovative approaches to surmounting treatment barriers by leveraging technological advancements to deliver evidence-based interventions to populations that remain hard to reach or difficult to treat. Dr. Allison Kurti will describe the promising data that resulted from a pilot study examining the feasibility, efficacy, and cost-effectiveness of a smartphone-based financial incentives intervention to reduce smoking during pregnancy. Smoking monitoring and delivery of incentives in this study were completed using a mobile app developed by DynamiCare Health, Inc. Dr. Donald Dougherty will discuss results from a study using transdermal alcohol monitoring in the context of an incentives-based intervention to reduce risky alcohol consumption. Finally, Dr. Stacy Ryan will present results of an internet-based survey querying parents about their attitudes and expectations regarding a smartphone-based financial incentives program for supporting recovery from opioid use disorder among their adolescent and emerging adult offspring. Considered together, this mini-symposium will provide the audience with an exciting glimpse into the emerging field of mHealth, as well as an enhanced understanding of the feasibility, efficacy, and acceptability of existing technology-based substance abuse treatments.

XIX.

Methocinnamox: A Novel Antagonist for Treating Opioid Overdose and Abuse

Chairs: Charles France and James Woods

Deaths from opioid overdose continue to rise and are a major factor contributing to the decreasing life expectancy of Americans. Naloxone is the only antidote currently available to reverse opioid-induced respiratory depression; however, a very short duration of action and surmountability limit its effectiveness. Options that are currently available to treat opioid abuse include methadone and buprenorphine, which are used because they are agonists at the same receptors (μ) as, and therefore share many effects with, abused opioids; consequently, their primary advantage is the ability to mimic some effects of abused opioids. While effective in many patients, both drugs have limitations. For example, methadone and buprenorphine are diverted and abused, and both drugs can have serious unwanted effects, including respiratory depression and death, especially when combined with other drugs such as alcohol or benzodiazepines. A second strategy for treating opioid abuse uses the opioid receptor antagonist naltrexone to block the abuse-related effects of opioids. Naltrexone avoids the diversion, abuse, and serious adverse effects of methadone and buprenorphine; however, like naloxone, a short duration of action and surmountability limit its effectiveness. A medication with a longer duration of action that prevents and reverses the effects of opioid agonists in a manner that cannot be surmounted by increasing doses of agonist could improve significantly treatment of abuse, overdose, and provide extended protection from overdose. This symposium will provide a brief history and overview of the search for non-addictive analgesics and how that resulted in the discovery of methocinnamox (MCAM), a pseudoirreversible, μ opioid receptor selective antagonist. We will present results comparing MCAM to naloxone in vitro showing MCAM to be a non-competitive, non-surmountable antagonist selectively at μ receptors and demonstrate that in monkeys MCAM blocks, reverses, and protects against the respiratory-depressant effects of heroin as well as blocks the i.v. self-administration of heroin for a week or longer after a single administration. The symposium will propose that MCAM is a safe, effective, and long-acting treatment for opioid overdose and abuse that could be advantageous for many patients (e.g. compliance would be insured by an extended-release formulation of a pseudoirreversible antagonist) and in many treatment settings (e.g. where access to health care or treatment providers is not available or practical).

WORKSHOPS

Sunday, June 16

I.

Navigating a Career in Addiction Science

Chairs: Denise Vidot and Cecilia Bergeria

The traditional route toward academia within a career in addiction science does not appeal to everyone. If you are a budding addiction investigator with new ideas and eager to find your niche in the world of addiction science, but could use some guidance, then this workshop is for you. It will focus on navigating traditional and non-traditional career trajectories. The workshop will feature a diverse set of speakers who have ‘been there and done that’ and want to share their experiences. Speakers will focus on 1) Pre/Post-Doctoral Fellowships, 2) Early Career Faculty Experience at a Research Institution, 3) Early Career Faculty Experience at a Liberal Arts Institution, 4) Careers in Industry, and 5) Careers in Policy. Each presentation will outline steps that can be taken to maximize your career stage-specific experience and make you a competitive job applicant for the next stage of your career. Examples of topics that will be covered include, how to choose mentors; striking a balance between executing your mentor’s vision and growing as an independent scientist; how to narrow down an innovative and significant research question; publishing amidst other responsibilities; establishing your niche and conveying its importance to potential employers; collaborating and networking; deciding whether or not to teach; life-work balance; and crucial to it all – time management strategies. After the presentations, the remainder of the workshop will be spent in small groups led by each speaker for a more personalized experience to discuss attendee questions as well as an opportunity for networking.

II.

Epidemiology and Public Health Research Methods

Chairs: Howard Chilcoat and Maria Parker

This year’s workshop will focus on how epidemiology can be used to inform development of medications to treat substance use disorder and to address FDA regulatory commitments to assess risk of abuse, misuse, addiction, overdose, and death related to the use of opioids to treat chronic pain. The first talk will demonstrate how epidemiologic approaches can inform all stages of drug development ranging from identification of targets for medication development, clinical trial design, and post marketing research. The second talk will present methods, including use of natural language processing, to measure opioid abuse, overdose, and death and their link to prescribed opioid use using medical claims and electronic medical records data. The third speaker will discuss a study to validate measures of opioid addiction among patients with chronic pain. The final talk will present emerging practices for the use of social media data for pharmacovigilance.

WORKSHOPS

Sunday, June 16

III.

25th Annual Contingency Management Working Group

Chairs: Diann Gaalema and August Holtyn

The Contingency Management (CM) Working Group, held annually during the CPDD convention, is an opportunity for the discussion and dissemination of current research regarding the use of CM interventions to promote behavior change and reduce drug use. CM is a behavioral treatment strategy that has demonstrated consistent success in promoting abstinence from a wide range of drugs and across many different treatment populations. It is also being used to promote change in behaviors impacting the course of other chronic diseases (e.g., obesity, diabetes). At the 25th annual meeting of the CM Working Group, junior and senior researchers will present preliminary data from ongoing studies involving CM. The goal for this working group is to provide an informal outlet for discussion of ongoing CM research, with an emphasis on developing or improving research strategies by seeking audience input, and providing opportunities for junior and senior researchers to interact.

IV.

Deep Phenotyping, Drug Development Tools and -omics Biosignatures for SUDs

Chairs: Tanya Ramey and F. Gerard Moeller

There is a need to advance a composite endophenotypical characterization of substance use disorders clinical manifestations to enable SUDs successful drug development and speedy regulatory approvals. In the context of the current Opioid Crisis, new and expanded range of treatments are needed to address the public health needs. The advent of dimensional Research Domain Criteria (RDoC)-based approach to psychopathology conceptualized as neurofunctional domains, including those related to substance use disorders (SUDs), requires modification and compilation of psychometric measures and behavioral tasks to assess the SUDs phenotypes along key domains. Furthermore, corresponding to addiction-related domains, appropriate clinical outcomes assessments standardization and potential certification as Drug Development Tools could help to move addictions drug development forward. In alignment with the above, we will discuss a battery of clinical assessment measures along the key addiction domains -NIDA Phenotypical Assessments Battery (NIDA PhAB), neurocircuitry underpinning SUDs constructs and sub-constructs. We will also address the search for more elemental peripheral -omics derived components to progress creating potentially composite SUDs endophenotypes, biomarkers and biosignatures. This workshop will bring together efforts from clinical and translational and Big Data fields to continue on the path of addictions biomarkers development, discuss applications of NIDA PhAB in novel studies in SUDs populations.

V.

Social Media: Learning to Tweet Yourself Right

Chairs: Erin Winstanley and Chris Wolf

Social media facilitates the dissemination of researchers' work to audiences as broadly or selectively as they might wish. This workshop will provide timely, common-sense advice on how to navigate the world of social media for the purpose of promoting your science.

Monday, June 17

WORKSHOPS

VI.

Communicating Your Science

Chairs: Erin Winstanley and Margaret Chisolm

The advancement of addiction science relies on effective communication of scientific discoveries to scientists and other addiction research stakeholders including funders, policy makers, clinicians, learners, patients, and families. While publication of scientific findings in peer-reviewed journals is the gold standard, the reach of this communication medium is limited and increasingly scientists are sharing their findings in non-academic outlets (e.g., media, lay publications) and using Internet-based tools to increase reach. Scientists rarely receive training on how to improve communication of their research findings as part of their formal academic education and it is important to ensure that they have information on the key elements of successful communication, as well state-of-the-art strategies. The overall purpose of this workshop is to provide addiction scientists with knowledge and a set of tools that will help them to disseminate effectively their scientific results and to optimize the reach, relevance and impact of their discoveries.

VII.

Introduction to Machine Learning and Applications to Addiction Research

Chairs: Sarah Yip and Dustin Scheinost

This workshop brings together addiction researchers with expertise in data science, neuroimaging and biomedical engineering to provide a practical introduction to common machine learning methods. In a series of didactic presentations, workshop participants will be (i) introduced to commonly used machine-learning approaches (including pros and cons of different methods); (ii) presented with practical guidelines for incorporating these methods into their work and avoiding common methodological pitfalls; (iii) guided through an interactive analysis of a real-world clinical dataset; and (iv) provided with an overview of valuable resources for future analysis support (e.g., guides to machine learning in Matlab). Finally, the Discussant, a senior program officer at NIDA, will examine the potential of these approaches to inform future addiction research. The goal of this workshop is to provide a practical introduction to machine learning methods. However, our paired Symposium ('Predictive Modeling in Addiction: Recent Findings and Implications for Precision Medicine') will showcase cutting-edge addiction research findings derived from machine learning methods. By attending both sessions, participants will learn how categorical and dimensional machine learning models are generated, and how adoption of these methods can advance understanding of the pathophysiology of addictions and inform clinical decision-making.

WORKSHOPS

Monday, June 17

VIII.

Reaching Underserved Smokers: New Strategies and How to Implement Them

Chair: Joy Schmitz

Rates of tobacco smoking remain unacceptably and disproportionately high in subpopulations of smokers who are underserved. Compared to the general population, underserved smokers are less likely to receive evidence-based smoking cessation treatment, and more likely to face economic and other challenges that undermine motivation to quit and treatment adherence. Despite the disparate smoking rates, little attention has been placed on gaining access to and developing treatment models that meet the needs of underserved populations. The specific aims of this workshop are to (1) call attention to the major tobacco-related disparities among underserved populations; and (2) describe new and creative methods being used to identify “hidden” populations and address barriers to tobacco cessation in underserved smokers. Presentations of novel work will provide the audience with broad coverage of this topic. Dr. Yammine will describe how to use the mobile dental clinic as a teachable moment for tobacco intervention in rural counties. In her work with low-income mothers of preterm infants, Dr. Stotts will discuss the neonatal intensive care unit as a setting in which to identify young smokers and deliver smoking cessation interventions. Dr. Cropsey will describe a behavioral approach to improve adherence to smoking pharmacotherapy in low-income patients, while Dr. Vidrine will address strategies targeting health literacy to improve treatment adherence. Dr. Brunette will present data on the efficacy of web-based motivational education and abstinence-contingent monetary incentives for smoking cessation in patients with severe mental illness. Insights from Dr. Higgins, Discussant, will provide the audience with recommendations and research priorities.

IX.

Using Implementation Science Principles and Interventions to Improve Substance Use Services Linkage for Justice-Involved Adolescents: Findings from the NIDA JJ-TRIALS Cooperative Agreement and Treatment Effectiveness Society for Adolescent Substance Abuse

Chairs: Steven Belenko and Danica Knight

Substance use (SU) is common among justice-involved youth and a primary predictor of recidivism; 51% of youth have SU problems requiring treatment. Because of limited focus on SU and limited coordination across juvenile justice [JJ] and behavioral health [BH] systems, youth under community supervision often do not receive services that improve clinical outcomes. This workshop presents findings from the Juvenile Justice—Translational Research on Interventions for Adolescents in the Legal System (JJ-TRIALS) project, a NIDA-funded cooperative aiming to improve delivery of services for substance-involved delinquent youth (Knight et al., 2016) and testing the impacts of Core and Enhanced implementation interventions on SU service receipt along the Behavioral Health Services Cascade (Cascade; Belenko et al., 2017). Presentation 1 reports on findings on the characteristics of more than 25,000 youth in 34 counties in 7 states, and individual and contextual factors affecting service receipt along the Cascade. Presentation 2 provides findings from tests of the main hypotheses on the impact of JJ-TRIALS on service receipt, and the additive impact of facilitation in the enhanced condition. Presentation 3 examines the conceptualization and operationalization of the implementation science construct of *site engagement*, using a multidimensional approach to measuring and tracking site engagement. Presentation 4 examines the influence of individual and agency-level factors on interagency service coordination between JJ agencies and BH partners, using multi-level modeling based on staff survey data from 549 JJ and BH staff. The workshop concludes with a discussion of research and practice implications, and ends with a SASATE business meeting.

WORKSHOPS

Monday, June 17

X.

Opioid Use Disorder Impacts Diverse Communities Too!

Chairs: A. Kathleen Burlew and Aimee Campbell

Despite less media attention to the opioid epidemic among racial/ethnic minorities, the impact on the health and well-being of these individuals, families, and communities has been significant. Although Blacks and Hispanic/Latinos had lower opioid overdose rates than either Whites or Native Americans prior to 2016, the Centers for Disease Control and Prevention reports that the overdose death rates are rising faster among Latinos and Blacks than Whites. Given evidence of racial/ethnic differences in etiology, pathways to treatment, treatment response, and retention, research on specific racial/ethnic minorities is warranted.

Tuesday, June 18

XI.

Manuscript Review: Tips and Traps for Emerging Investigators in Drug Dependence Research

Chairs: James Sorensen and Joseph Gurdish

The substance use disorders field needs increasingly productive investigators who publish high-quality scientific reports. This workshop focuses on training emerging investigators to review manuscripts submitted to professional journals. Presenters are investigators in preclinical, clinical, and services research, and include current editors of scientific publications. All presenters suggest both conceptual and practical guidelines. While the workshop aims to assist young investigators in becoming proficient peer reviewers, both junior and senior colleagues can benefit and provide their perspective. In this interactive workshop, a third of the time is reserved for audience comments and discussion.

XII.

Expanding the Impact of Substance Use Disorder Research: Economic Analysis for Program and Policy Evaluation

Chairs: Sean Murphy and Kathryn McCollister

Access to evidence-based therapies for individuals with substance use disorders (SUD) continues to be a challenge, notably for residents of rural communities and among those without health insurance coverage. Economic evaluation studies can support broadening access to SUD treatment by informing stakeholders how best to allocate limited resources across competing public health initiatives, including SUD treatment. Convincing stakeholders to expand access to treatment or modify current behavioral health services delivery systems requires not only clinical evidence, but also consideration for the additional costs and reallocation of existing resources associated with these changes. Moreover, failure to account for all relevant costs and benefits/cost-offsets associated with an effective intervention can undermine its true value. This workshop introduces participants to economic evaluation methods tailored for the assessment of treatment interventions for SUDs using interactive exercises and group-based learning methods. Featured economic evaluation cases for the workshop are based on recent economic-evaluation studies conducted by our team. The specific aims of this workshop are to 1) provide an overview of economic evaluation methods, and discuss the relative merits of each approach with regard to SUD interventions; 2) promote audience engagement by working through key components to an economic evaluation, such as defining the most appropriate analysis perspective, selecting appropriate measures and data sources for each perspective, calculating and interpreting cost-effectiveness ratios, addressing analytic challenges; and 3) help participants understand how economic evaluations complement clinical effectiveness studies and can expand the impact of such research by addressing feasibility, budgetary, and sustainability concerns of multiple stakeholders.

Acknowledgements

Alkermes, Inc.
Apt Foundation
Lawrence Armour
Michael T. Bardo
Felicia Jody Bayer
Patrick Beardsley
Mr. and Mrs. Richard J. Bonnie
Alan J. Budney
Center for Substance Abuse Research,
 Lewis Katz School of Medicine at
 Temple University
Anna Rose Childress
Ziva Cooper
Dartmouth College, Alan Budney
PI Sandra Comer
Thomas J. Crowley
Christopher Cunningham
Richard De La Garza, II
Harriet De Wit
Linda P. Dwoskin
Linda Dykstra
Elsevier, Amsterdam
FDA/Office of Women's Health
Loretta P. Finnegan
Dr. and Mrs. Richard Frances
Anthony H. Gair
Joseph Gaspari
Mr. and Mrs. Mark Gold
Charles W. Gorodetzky
Margaret Haney
Deborah Hasin
Toal Huynh
Amy Janes
Jermaine Jones
Anne Burlock Lawver
Dr. and Mrs. David M. Leivy
La Jolla Alcohol Research, Inc.
Scott Lane
Scott Lukas
Bertha Madras
Roger Meyer
Geoffrey Mumford
Douglas P. Murray
Dr. & Mrs. John B. Neeld
NIDA T32 at University of Florida
 (Director, Linda B. Cottler)
Charles O'Keeffe
Linda J. Porrino
Marc Potenza
PRA Health Sciences
John A. Renner, Jr.
Kenner C. Rice
Stacey C. Sigmon
James L. Sorensen
Roger Spealman
Mr. and Mrs. David Steinman
Maxine Stitzer
William Stoops
Eric C. Strain
Tempest Technologies
Jennifer Tidey
Michele Tomeo
UAMS NIDA T32 Training Program
University of Vermont, Stephen Higgins
USDTL
Frank Vocci, Jr.
Washington University, Theodore Cicero
Elise Weerts

Contributions from June 2018 - May 15, 2019
Funding for this conference was made possible (in part) by
5 R13 DA 013192 - 15 from the National Institute on Drug Abuse

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government

